data_5n5b_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 5n5b _Structure_validation_residue.Date_analyzed 2017-12-22 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 293' ' ' SER . . . . . 0.464 ' O ' ' O ' ' A' ' 294' ' ' LYS . 97.5 p . . . . . 0 N--CA 1.461 0.115 0 CA-C-O 121.119 0.485 . . . . 0.0 111.272 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 294' ' ' LYS . . . . . 0.464 ' O ' ' O ' ' A' ' 293' ' ' SER . 57.7 mttp -55.19 -126.1 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.502 -0.772 . . . . 0.0 111.757 179.836 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 295' ' ' ASP . . . . . . . . . . . . . 89.5 m-20 -92.17 7.43 42.57 Favored 'General case' 0 N--CA 1.455 -0.224 0 CA-C-N 114.924 -1.035 . . . . 0.0 111.235 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 49.9 t30 60.26 52.13 5.1 Favored 'General case' 0 C--N 1.333 -0.119 0 C-N-CA 119.68 -0.808 . . . . 0.0 111.567 179.842 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 297' ' ' ILE . . . . . . . . . . . . . 80.9 mt -64.99 135.22 28.6 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 122.396 1.093 . . . . 0.0 111.779 -177.354 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 84.6 tttt -81.76 137.0 35.41 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 112.884 -1.962 . . . . 0.0 112.752 -179.085 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 74.4 t60 -124.53 136.36 53.92 Favored 'General case' 0 CA--C 1.543 0.711 0 N-CA-C 107.914 -1.143 . . . . 0.0 107.914 178.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -124.0 76.72 58.78 Favored Pre-proline 0 N--CA 1.481 1.09 0 N-CA-C 113.336 0.865 . . . . 0.0 113.336 -177.876 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -59.76 -26.1 81.19 Favored 'Trans proline' 0 N--CA 1.493 1.472 0 C-N-CA 121.221 1.28 . . . . 0.0 111.862 178.451 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -167.28 125.1 1.28 Allowed Glycine 0 CA--C 1.527 0.789 0 N-CA-C 110.89 -0.884 . . . . 0.0 110.89 -179.585 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -150.35 37.2 0.92 Allowed Glycine 0 N--CA 1.468 0.803 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 179.732 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 96.7 -4.72 63.85 Favored Glycine 0 C--N 1.317 -0.488 0 N-CA-C 106.262 -2.735 . . . . 0.0 106.262 -177.079 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 24.9 t -59.89 -27.76 66.99 Favored 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 112.827 -1.686 . . . . 0.0 109.121 176.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 306' ' ' VAL . . . . . 0.641 ' O ' ' CB ' ' A' ' 307' ' ' GLN . 73.5 t -55.41 -40.08 56.01 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.643 0 CA-C-N 114.081 -1.418 . . . . 0.0 112.038 -175.77 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 307' ' ' GLN . . . . . 0.641 ' CB ' ' O ' ' A' ' 306' ' ' VAL . 63.1 tp60 117.37 84.61 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.529 0 N-CA-C 113.921 1.082 . . . . 0.0 113.921 177.482 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 308' ' ' ILE . . . . . 0.445 HG13 ' CE2' ' A' ' 310' ' ' TYR . 18.6 tt 26.46 58.24 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 N-CA-C 113.16 0.8 . . . . 0.0 113.16 176.217 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 54.8 t -56.0 -39.23 56.64 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.605 0 C-N-CA 118.724 -1.19 . . . . 0.0 109.76 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 310' ' ' TYR . . . . . 0.695 ' O ' ' CD1' ' A' ' 310' ' ' TYR . 36.7 p90 -69.83 104.56 2.5 Favored 'General case' 0 N--CA 1.439 -1.0 0 C-N-CA 119.082 -1.047 . . . . 0.0 109.41 178.601 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 311' ' ' LYS . . . . . . . . . . . . . 38.6 mtpt -73.34 128.07 88.02 Favored Pre-proline 0 C--N 1.313 -1.016 0 C-N-CA 119.649 -0.82 . . . . 0.0 110.385 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 312' ' ' PRO . . . . . . . . . . . . . 85.3 Cg_exo -55.96 149.48 51.89 Favored 'Trans proline' 0 C--N 1.306 -1.66 0 N-CA-C 106.122 -2.299 . . . . 0.0 106.122 174.326 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 36.1 t -64.46 126.26 22.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 C-N-CA 116.284 -2.166 . . . . 0.0 110.775 -175.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 314' ' ' ASP . . . . . 0.43 ' O ' ' HB3' ' A' ' 317' ' ' LYS . 89.5 m-20 -95.59 -19.22 19.95 Favored 'General case' 0 N--CA 1.444 -0.762 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 175.509 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 315' ' ' LEU . . . . . . . . . . . . . 60.5 mt -62.22 -37.47 85.48 Favored 'General case' 0 C--O 1.232 0.141 0 CA-C-N 116.029 -0.532 . . . . 0.0 112.293 -178.324 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 82.9 p -63.03 -30.76 71.85 Favored 'General case' 0 CA--C 1.519 -0.22 0 CA-C-O 121.499 0.666 . . . . 0.0 109.886 179.877 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 317' ' ' LYS . . . . . 0.43 ' HB3' ' O ' ' A' ' 314' ' ' ASP . 18.8 tttt -59.38 -36.89 76.62 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 114.342 -1.299 . . . . 0.0 112.783 -178.824 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 318' ' ' VAL . . . . . 0.412 ' O ' ' OXT' ' A' ' 319' ' ' THR . 5.3 p -57.07 -33.98 44.0 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 N-CA-C 112.268 0.47 . . . . 0.0 112.268 -178.148 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 319' ' ' THR . . . . . 0.412 ' OXT' ' O ' ' A' ' 318' ' ' VAL . 1.3 m . . . . . 0 C--O 1.221 -0.443 0 CA-C-O 117.951 -1.023 . . . . 0.0 110.792 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 23.8 m . . . . . 0 C--O 1.231 0.121 0 CA-C-O 120.862 0.363 . . . . 0.0 110.137 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -96.27 148.32 22.86 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.716 179.298 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 295' ' ' ASP . . . . . 0.596 ' O ' ' CB ' ' A' ' 296' ' ' ASN . 91.6 m-20 -56.52 -36.4 69.16 Favored 'General case' 0 CA--C 1.492 -1.251 0 N-CA-C 107.382 -1.34 . . . . 0.0 107.382 177.659 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 296' ' ' ASN . . . . . 0.596 ' CB ' ' O ' ' A' ' 295' ' ' ASP . 48.2 t30 118.39 -128.61 0.0 OUTLIER 'General case' 0 CA--C 1.469 -2.16 0 O-C-N 125.581 1.801 . . . . 0.0 110.097 179.51 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 297' ' ' ILE . . . . . 0.497 ' O ' ' CG2' ' A' ' 297' ' ' ILE . 8.9 tp -122.44 133.35 68.93 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.111 0 CA-C-N 114.499 -1.228 . . . . 0.0 110.497 -178.781 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 43.4 tttm -132.71 120.19 21.35 Favored 'General case' 0 C--N 1.294 -1.84 0 CA-C-N 114.234 -1.348 . . . . 0.0 110.323 174.453 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 79.8 m-70 -139.81 145.04 37.65 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.36 -0.836 . . . . 0.0 112.251 174.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -124.8 72.71 62.6 Favored Pre-proline 0 C--N 1.322 -0.63 0 CA-C-N 115.473 -0.785 . . . . 0.0 108.952 177.282 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -59.1 -24.67 74.76 Favored 'Trans proline' 0 N--CA 1.492 1.44 0 C-N-CA 121.034 1.156 . . . . 0.0 111.098 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . 150.15 136.51 2.58 Favored Glycine 0 CA--C 1.52 0.365 0 CA-C-N 115.05 -0.977 . . . . 0.0 110.875 179.442 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -84.57 1.52 88.76 Favored Glycine 0 CA--C 1.519 0.311 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 179.009 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 95.74 -2.83 64.81 Favored Glycine 0 CA--C 1.519 0.329 0 N-CA-C 108.936 -1.666 . . . . 0.0 108.936 -179.021 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 73.9 m -84.53 4.28 32.67 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 114.774 -0.713 . . . . 0.0 109.902 178.619 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 306' ' ' VAL . . . . . . . . . . . . . 98.8 t -59.67 -41.78 86.34 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.662 0 CA-C-O 122.235 1.017 . . . . 0.0 111.179 -178.309 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 307' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 -141.84 168.5 19.6 Favored 'General case' 0 C--N 1.31 -1.119 0 CA-C-N 112.896 -1.956 . . . . 0.0 109.0 -177.498 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 308' ' ' ILE . . . . . 0.552 HG22 ' H ' ' A' ' 311' ' ' LYS . 31.8 mm -104.05 117.81 50.19 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 CA-C-N 115.418 -0.81 . . . . 0.0 113.162 -179.152 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 21.0 m -78.53 -30.11 15.09 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.483 0 CA-C-N 114.13 -1.395 . . . . 0.0 108.398 175.592 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 310' ' ' TYR . . . . . 0.485 ' CE1' HG23 ' A' ' 308' ' ' ILE 0.364 51.7 p90 -64.15 -28.29 69.66 Favored 'General case' 0 N--CA 1.447 -0.608 0 N-CA-C 116.311 1.967 . . . . 0.0 116.311 -179.197 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 311' ' ' LYS . . . . . 0.552 ' H ' HG22 ' A' ' 308' ' ' ILE . 37.3 mtpt 53.72 65.65 5.32 Favored Pre-proline 0 C--N 1.318 -0.78 0 C-N-CA 119.875 -0.73 . . . . 0.0 110.958 178.44 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 312' ' ' PRO . . . . . 0.492 ' C ' ' O ' ' A' ' 311' ' ' LYS . 91.0 Cg_exo 3.86 -128.87 0.0 OUTLIER 'Trans proline' 0 N--CA 1.487 1.141 0 C-N-CA 123.092 2.528 . . . . 0.0 115.771 -179.287 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 4.5 p -113.04 37.06 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.718 0 N-CA-C 112.955 0.724 . . . . 0.0 112.955 -177.234 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 54.6 t0 -54.13 -35.26 62.01 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 112.081 0.4 . . . . 0.0 112.081 -179.614 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 315' ' ' LEU . . . . . 0.689 ' CD2' ' H ' ' A' ' 315' ' ' LEU . 1.8 mm? -57.15 -35.18 69.21 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 120.299 -0.56 . . . . 0.0 111.074 -178.486 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 89.8 p -62.37 -23.59 66.89 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 121.135 0.493 . . . . 0.0 110.582 178.65 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 41.8 tttp -56.62 -35.4 68.26 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.137 -0.938 . . . . 0.0 111.855 -177.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 13.3 p -129.7 142.75 43.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.045 0.45 . . . . 0.0 110.439 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 117.939 -1.029 . . . . 0.0 110.693 -179.27 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 46.5 m . . . . . 0 N--CA 1.455 -0.222 0 CA-C-O 121.159 0.504 . . . . 0.0 110.775 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 11.6 mtpp -81.17 168.9 18.04 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.807 179.476 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 295' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -48.68 -31.88 7.5 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.974 -177.347 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 74.6 m-20 63.81 52.47 2.15 Favored 'General case' 0 CA--C 1.516 -0.355 0 C-N-CA 120.269 -0.572 . . . . 0.0 111.457 -179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 297' ' ' ILE . . . . . . . . . . . . . 82.1 mt -62.98 130.93 28.21 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.249 0 N-CA-C 107.66 -1.237 . . . . 0.0 107.66 -178.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 44.4 tttp -81.98 133.69 35.32 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 115.469 1.655 . . . . 0.0 115.469 -175.373 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -121.72 139.17 53.91 Favored 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 106.843 -1.54 . . . . 0.0 106.843 175.812 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 8.0 m -125.75 72.04 68.15 Favored Pre-proline 0 N--CA 1.472 0.651 0 C-N-CA 119.308 -0.957 . . . . 0.0 113.31 -178.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 79.3 Cg_exo -62.07 -23.62 75.82 Favored 'Trans proline' 0 C--N 1.302 -1.918 0 C-N-CA 122.281 1.987 . . . . 0.0 110.692 176.266 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -92.97 28.43 9.46 Favored Glycine 0 CA--C 1.526 0.745 0 CA-C-N 114.492 -1.231 . . . . 0.0 112.713 -178.383 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 303' ' ' GLY . . . . . 0.415 ' C ' ' N ' ' A' ' 305' ' ' SER . . . -84.4 -173.28 49.73 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.376 -0.916 . . . . 0.0 111.39 -178.556 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . -50.68 -23.88 7.21 Favored Glycine 0 N--CA 1.453 -0.221 0 N-CA-C 108.31 -1.916 . . . . 0.0 108.31 178.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 305' ' ' SER . . . . . 0.415 ' N ' ' C ' ' A' ' 303' ' ' GLY . 22.4 m -55.07 -34.56 63.7 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 114.751 -0.724 . . . . 0.0 111.881 -179.223 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 306' ' ' VAL . . . . . 0.862 ' O ' ' O ' ' A' ' 307' ' ' GLN . 79.0 t -60.88 -39.72 82.9 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.712 0 C-N-CA 121.096 -0.241 . . . . 0.0 110.55 179.772 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 307' ' ' GLN . . . . . 0.862 ' O ' ' O ' ' A' ' 306' ' ' VAL . 13.0 pt20 24.88 166.03 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.471 0 O-C-N 125.222 1.576 . . . . 0.0 113.138 -177.292 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 308' ' ' ILE . . . . . 0.715 ' O ' ' N ' ' A' ' 310' ' ' TYR . 8.5 tt -59.26 -26.86 34.96 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.011 0 CA-C-N 114.192 -1.367 . . . . 0.0 112.753 -176.529 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER 51.06 -42.14 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.204 0 N-CA-C 113.0 0.741 . . . . 0.0 113.0 179.454 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 310' ' ' TYR . . . . . 0.715 ' N ' ' O ' ' A' ' 308' ' ' ILE 0.485 52.5 p90 -65.06 -25.48 67.83 Favored 'General case' 0 CA--C 1.564 1.507 0 N-CA-C 119.69 3.219 . . . . 0.0 119.69 -178.074 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 311' ' ' LYS . . . . . 0.441 ' HB2' ' O ' ' A' ' 310' ' ' TYR . 11.3 mttp 74.15 77.25 0.19 Allowed Pre-proline 0 N--CA 1.509 2.516 0 CA-C-N 120.996 1.726 . . . . 0.0 112.13 177.914 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 312' ' ' PRO . . . . . . . . . . . . . 4.7 Cg_endo -54.26 -34.33 79.25 Favored 'Trans proline' 0 N--CA 1.522 3.165 0 C-N-CA 123.524 2.816 . . . . 0.0 117.447 -178.178 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 69.7 t -67.29 -38.64 81.3 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.004 0 N-CA-C 116.155 1.909 . . . . 0.0 116.155 -178.398 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 314' ' ' ASP . . . . . 0.519 ' O ' ' O ' ' A' ' 317' ' ' LYS . 91.1 m-20 -55.47 -39.99 71.08 Favored 'General case' 0 C--N 1.322 -0.62 0 C-N-CA 118.697 -1.201 . . . . 0.0 113.103 -174.074 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 315' ' ' LEU . . . . . 0.516 ' CD2' ' H ' ' A' ' 315' ' ' LEU . 2.0 mm? -65.22 -36.71 85.01 Favored 'General case' 0 C--N 1.326 -0.423 0 C-N-CA 118.918 -1.113 . . . . 0.0 108.892 176.932 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 22.5 m -60.39 -36.36 77.91 Favored 'General case' 0 CA--C 1.516 -0.364 0 N-CA-C 108.253 -1.017 . . . . 0.0 108.253 178.079 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 317' ' ' LYS . . . . . 0.519 ' O ' ' O ' ' A' ' 314' ' ' ASP . 35.7 ttmt -97.02 117.38 31.06 Favored 'General case' 0 N--CA 1.446 -0.668 0 CA-C-N 114.958 -1.019 . . . . 0.0 111.098 179.71 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 59.5 t -130.92 135.84 59.26 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.333 176.728 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.218 -0.604 0 CA-C-O 117.871 -1.061 . . . . 0.0 110.451 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 92.5 p . . . . . 0 N--CA 1.461 0.121 0 CA-C-O 120.921 0.391 . . . . 0.0 110.531 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 11.9 mtpt -91.8 158.47 16.32 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.702 0.763 . . . . 0.0 112.489 -179.206 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 295' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -53.7 -33.8 56.68 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 114.359 -1.291 . . . . 0.0 110.652 -179.594 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 50.8 t30 64.73 54.34 1.39 Allowed 'General case' 0 CA--C 1.521 -0.14 0 C-N-CA 119.746 -0.782 . . . . 0.0 111.871 -179.817 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 297' ' ' ILE . . . . . . . . . . . . . 75.8 mt -68.05 139.25 21.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.304 -179.024 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 11.5 pttp -77.47 147.71 35.75 Favored 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 114.293 1.22 . . . . 0.0 114.293 -176.391 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 77.3 m80 -120.16 139.32 52.79 Favored 'General case' 0 N--CA 1.454 -0.261 0 CA-C-N 114.032 -1.44 . . . . 0.0 108.455 176.749 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 3.3 m -122.84 73.7 45.49 Favored Pre-proline 0 C--N 1.327 -0.387 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 179.574 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -61.1 -25.15 80.72 Favored 'Trans proline' 0 C--N 1.31 -1.458 0 C-N-CA 122.766 2.311 . . . . 0.0 114.176 -179.353 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -138.14 58.47 0.63 Allowed Glycine 0 CA--C 1.525 0.67 0 C-N-CA 120.597 -0.811 . . . . 0.0 113.363 -177.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -57.2 -28.54 58.87 Favored Glycine 0 N--CA 1.445 -0.722 0 N-CA-C 105.901 -2.88 . . . . 0.0 105.901 176.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 98.91 -10.45 62.2 Favored Glycine 0 N--CA 1.442 -0.966 0 N-CA-C 104.077 -3.609 . . . . 0.0 104.077 -176.099 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 84.9 p -66.29 -27.74 68.16 Favored 'General case' 0 N--CA 1.432 -1.336 0 CA-C-N 112.024 -2.088 . . . . 0.0 111.875 177.877 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 306' ' ' VAL . . . . . . . . . . . . . 55.8 t -61.1 -46.54 96.45 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.331 0 CA-C-O 122.151 0.977 . . . . 0.0 111.382 -175.385 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 307' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -148.14 164.4 34.02 Favored 'General case' 0 N--CA 1.441 -0.89 0 CA-C-N 113.567 -1.652 . . . . 0.0 110.206 -179.175 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 308' ' ' ILE . . . . . 0.442 HG12 ' CZ ' ' A' ' 310' ' ' TYR . 7.2 tp -122.37 129.72 75.07 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 CA-C-O 122.027 0.918 . . . . 0.0 110.915 176.266 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 69.6 t -67.25 -31.68 54.15 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.494 0 CA-C-N 113.639 -1.619 . . . . 0.0 115.128 179.656 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 310' ' ' TYR . . . . . 0.506 ' HD1' ' N ' ' A' ' 311' ' ' LYS . 0.0 OUTLIER -52.38 -33.84 45.23 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 117.197 2.295 . . . . 0.0 117.197 -171.689 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 311' ' ' LYS . . . . . 0.542 ' O ' ' C ' ' A' ' 312' ' ' PRO . 1.1 mmtt 54.09 64.68 6.15 Favored Pre-proline 0 CA--C 1.549 0.911 0 CA-C-N 121.697 2.044 . . . . 0.0 109.441 -179.974 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 312' ' ' PRO . . . . . 0.542 ' C ' ' O ' ' A' ' 311' ' ' LYS . 81.6 Cg_exo 2.76 64.82 0.0 OUTLIER 'Trans proline' 0 N--CA 1.49 1.321 0 C-N-CA 122.706 2.271 . . . . 0.0 114.794 -179.513 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 313' ' ' VAL . . . . . 0.541 ' N ' ' O ' ' A' ' 311' ' ' LYS . 1.8 m 20.96 54.17 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 CA-C-N 115.46 -0.791 . . . . 0.0 111.973 179.14 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 314' ' ' ASP . . . . . 0.648 ' OD2' ' N ' ' A' ' 315' ' ' LEU . 49.6 p30 -60.44 -33.7 72.93 Favored 'General case' 0 C--N 1.322 -0.614 0 C-N-CA 120.611 -0.435 . . . . 0.0 110.858 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 315' ' ' LEU . . . . . 0.648 ' N ' ' OD2' ' A' ' 314' ' ' ASP . 6.1 mp -59.16 -37.48 77.41 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 118.833 -1.147 . . . . 0.0 109.591 179.44 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 316' ' ' SER . . . . . 0.482 ' OG ' ' O ' ' A' ' 313' ' ' VAL . 87.3 p -63.53 -28.04 69.67 Favored 'General case' 0 CA--C 1.509 -0.62 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 177.491 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 15.4 ttpt -82.8 133.14 35.15 Favored 'General case' 0 N--CA 1.446 -0.652 0 CA-C-N 114.434 -1.257 . . . . 0.0 108.828 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 13.3 p -130.55 142.28 44.1 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.751 0 C-N-CA 120.599 -0.441 . . . . 0.0 110.693 -179.761 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.22 -0.491 0 CA-C-O 117.851 -1.071 . . . . 0.0 110.967 -179.696 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 74.5 m . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.648 0.261 . . . . 0.0 110.865 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 294' ' ' LYS . . . . . 0.465 ' C ' ' H ' ' A' ' 296' ' ' ASN . 68.7 mttm -92.95 148.69 21.79 Favored 'General case' 0 N--CA 1.451 -0.39 0 CA-C-O 121.548 0.689 . . . . 0.0 112.099 -179.355 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 295' ' ' ASP . . . . . 0.478 ' C ' ' OD1' ' A' ' 295' ' ' ASP . 49.4 p30 -88.19 11.55 16.1 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 106.427 -1.694 . . . . 0.0 106.427 177.218 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 296' ' ' ASN . . . . . 0.465 ' H ' ' C ' ' A' ' 294' ' ' LYS . 21.1 m120 33.88 -115.14 0.07 Allowed 'General case' 0 CA--C 1.49 -1.347 0 CA-C-N 112.878 -1.965 . . . . 0.0 111.934 -177.335 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 297' ' ' ILE . . . . . 0.439 HG12 ' HD1' ' A' ' 299' ' ' HIS . 16.9 tt -120.53 133.03 68.54 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.355 0 C-N-CA 118.478 -1.289 . . . . 0.0 110.315 -178.474 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 44.6 tttm -123.97 119.84 30.73 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 113.996 -1.457 . . . . 0.0 111.549 177.271 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 299' ' ' HIS . . . . . 0.439 ' HD1' HG12 ' A' ' 297' ' ' ILE . 71.7 m80 -137.89 145.37 42.05 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 114.504 -1.225 . . . . 0.0 108.464 173.873 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -123.81 68.37 43.48 Favored Pre-proline 0 N--CA 1.468 0.464 0 C-N-CA 119.358 -0.937 . . . . 0.0 111.856 179.231 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 301' ' ' PRO . . . . . 0.422 ' C ' ' H ' ' A' ' 303' ' ' GLY . 37.3 Cg_endo -64.35 -23.12 65.75 Favored 'Trans proline' 0 C--N 1.312 -1.353 0 C-N-CA 122.232 1.955 . . . . 0.0 111.044 176.485 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -80.75 25.78 3.35 Favored Glycine 0 N--CA 1.471 0.982 0 CA-C-N 114.794 -1.094 . . . . 0.0 111.297 -178.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 303' ' ' GLY . . . . . 0.422 ' H ' ' C ' ' A' ' 301' ' ' PRO . . . -56.08 -25.23 46.04 Favored Glycine 0 C--N 1.317 -0.522 0 N-CA-C 110.588 -1.005 . . . . 0.0 110.588 -179.872 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 100.5 -2.77 56.17 Favored Glycine 0 C--N 1.319 -0.401 0 N-CA-C 104.651 -3.379 . . . . 0.0 104.651 -174.339 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 86.9 p -65.49 -17.41 64.53 Favored 'General case' 0 N--CA 1.444 -0.774 0 CA-C-N 111.755 -2.223 . . . . 0.0 107.484 175.325 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 306' ' ' VAL . . . . . 0.527 ' O ' ' CB ' ' A' ' 307' ' ' GLN . 93.9 t -54.98 -41.52 59.0 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.628 0 CA-C-N 113.231 -1.804 . . . . 0.0 109.513 -176.44 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 307' ' ' GLN . . . . . 0.527 ' CB ' ' O ' ' A' ' 306' ' ' VAL . 12.4 pt20 124.39 147.43 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.86 0 O-C-N 124.921 1.388 . . . . 0.0 110.743 177.67 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 308' ' ' ILE . . . . . 0.403 HD11 ' CE1' ' A' ' 310' ' ' TYR . 15.9 tt -61.55 -26.63 40.14 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.045 0 CA-C-N 114.406 -1.27 . . . . 0.0 113.893 -178.483 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . 0.417 HG22 HE21 ' A' ' 307' ' ' GLN . 75.4 t 57.33 -30.24 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.396 0 N-CA-C 116.346 1.98 . . . . 0.0 116.346 178.903 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 310' ' ' TYR . . . . . 0.474 ' CE1' ' HA ' ' A' ' 312' ' ' PRO . 0.0 OUTLIER -65.79 -14.23 60.99 Favored 'General case' 0 N--CA 1.479 1.001 0 N-CA-C 115.805 1.78 . . . . 0.0 115.805 -175.33 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 311' ' ' LYS . . . . . 0.493 ' O ' ' C ' ' A' ' 312' ' ' PRO . 0.6 OUTLIER 74.46 65.86 0.28 Allowed Pre-proline 0 N--CA 1.473 0.708 0 CA-C-N 118.805 0.73 . . . . 0.0 110.585 -179.909 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 312' ' ' PRO . . . . . 0.493 ' C ' ' O ' ' A' ' 311' ' ' LYS . 12.3 Cg_exo -10.2 -111.4 0.0 OUTLIER 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 123.255 2.636 . . . . 0.0 114.905 179.375 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 17.7 m -111.05 15.69 8.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 N-CA-C 111.954 0.353 . . . . 0.0 111.954 -178.253 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 93.2 m-20 -55.26 -38.76 68.97 Favored 'General case' 0 N--CA 1.451 -0.391 0 C-N-CA 119.436 -0.906 . . . . 0.0 111.096 -178.046 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 315' ' ' LEU . . . . . . . . . . . . . 27.8 tp -60.09 -38.72 83.8 Favored 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 119.904 -0.718 . . . . 0.0 110.258 178.475 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 21.2 m -59.57 -33.95 72.08 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 115.508 -0.769 . . . . 0.0 111.596 179.263 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 33.9 tttp -56.78 -36.34 69.73 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.267 -0.879 . . . . 0.0 112.301 -177.346 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 318' ' ' VAL . . . . . 0.445 ' O ' ' C ' ' A' ' 319' ' ' THR . 5.9 p -57.11 -34.35 45.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 C-N-CA 120.067 -0.653 . . . . 0.0 109.888 179.647 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 319' ' ' THR . . . . . 0.445 ' C ' ' O ' ' A' ' 318' ' ' VAL . 2.5 m . . . . . 0 C--O 1.219 -0.546 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.911 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 89.4 p . . . . . 0 N--CA 1.462 0.159 0 CA-C-O 121.309 0.576 . . . . 0.0 111.296 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 9.5 mtpm? -88.35 172.83 9.12 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.45 179.77 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 295' ' ' ASP . . . . . 0.446 ' OD2' ' C ' ' A' ' 295' ' ' ASP . 49.1 p30 -76.76 8.49 3.62 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 112.571 0.582 . . . . 0.0 112.571 -175.629 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 76.7 m-20 61.44 51.68 4.05 Favored 'General case' 0 N--CA 1.468 0.428 0 N-CA-C 115.74 1.755 . . . . 0.0 115.74 175.34 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 297' ' ' ILE . . . . . . . . . . . . . 16.2 mm -70.8 132.51 33.19 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.158 0 N-CA-C 106.975 -1.491 . . . . 0.0 106.975 179.559 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 3.6 ptmt -99.37 144.23 28.73 Favored 'General case' 0 N--CA 1.464 0.264 0 N-CA-C 115.592 1.701 . . . . 0.0 115.592 -175.446 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 299' ' ' HIS . . . . . 0.439 ' CE1' ' CG ' ' A' ' 301' ' ' PRO . 54.8 t-80 -126.75 119.09 26.05 Favored 'General case' 0 CA--C 1.536 0.439 0 N-CA-C 106.022 -1.844 . . . . 0.0 106.022 175.515 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -129.82 77.05 77.49 Favored Pre-proline 0 N--CA 1.477 0.904 0 N-CA-C 114.939 1.459 . . . . 0.0 114.939 -176.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 301' ' ' PRO . . . . . 0.529 ' C ' ' H ' ' A' ' 303' ' ' GLY . 75.2 Cg_exo -60.29 -22.76 72.0 Favored 'Trans proline' 0 N--CA 1.502 2.005 0 C-N-CA 121.705 1.604 . . . . 0.0 112.446 177.285 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -69.32 20.41 0.45 Allowed Glycine 0 CA--C 1.526 0.732 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.924 -178.757 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 303' ' ' GLY . . . . . 0.529 ' H ' ' C ' ' A' ' 301' ' ' PRO . . . -56.82 -28.16 57.0 Favored Glycine 0 N--CA 1.453 -0.202 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 179.732 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 98.31 -4.71 60.47 Favored Glycine 0 C--N 1.317 -0.486 0 N-CA-C 103.962 -3.655 . . . . 0.0 103.962 -174.603 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 83.8 p -65.88 -18.93 65.67 Favored 'General case' 0 N--CA 1.438 -1.047 0 CA-C-N 111.333 -2.434 . . . . 0.0 108.615 176.591 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 306' ' ' VAL . . . . . 0.422 ' CG2' ' O ' ' A' ' 301' ' ' PRO . 90.7 t -56.35 -40.77 68.65 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 CA-C-N 113.98 -1.463 . . . . 0.0 110.672 -175.677 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 307' ' ' GLN . . . . . 0.761 ' HG2' ' H ' ' A' ' 308' ' ' ILE . 6.2 tt0 -173.27 -151.02 0.05 Allowed 'General case' 0 CA--C 1.536 0.43 0 N-CA-C 107.691 -1.226 . . . . 0.0 107.691 179.126 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 308' ' ' ILE . . . . . 0.761 ' H ' ' HG2' ' A' ' 307' ' ' GLN . 64.9 mt -114.92 136.69 50.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 179.289 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 71.3 t -60.55 -39.64 81.95 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.089 0 N-CA-C 112.828 0.677 . . . . 0.0 112.828 -178.789 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 310' ' ' TYR . . . . . 0.57 ' N ' ' CD1' ' A' ' 310' ' ' TYR . 0.1 OUTLIER -148.62 23.25 1.01 Allowed 'General case' 0 N--CA 1.477 0.906 0 N-CA-C 115.931 1.826 . . . . 0.0 115.931 -176.623 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 311' ' ' LYS . . . . . 0.518 ' H ' HG22 ' A' ' 308' ' ' ILE . 0.1 OUTLIER 51.69 67.71 3.89 Favored Pre-proline 0 CA--C 1.546 0.807 0 C-N-CA 117.842 -1.543 . . . . 0.0 107.869 -179.253 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 312' ' ' PRO . . . . . 0.471 ' C ' ' O ' ' A' ' 311' ' ' LYS . 60.3 Cg_exo -6.33 -66.55 0.0 OUTLIER 'Trans proline' 0 N--CA 1.492 1.423 0 C-N-CA 123.109 2.539 . . . . 0.0 116.29 -176.356 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 20.2 m -129.78 156.97 42.43 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.687 0 N-CA-C 113.285 0.846 . . . . 0.0 113.285 -178.429 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 23.1 t70 -142.71 -61.73 0.43 Allowed 'General case' 0 CA--C 1.535 0.382 0 CA-C-N 114.912 -1.04 . . . . 0.0 110.525 178.612 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 315' ' ' LEU . . . . . 0.475 ' O ' ' O ' ' A' ' 318' ' ' VAL . 6.6 mp -61.25 -35.1 76.34 Favored 'General case' 0 N--CA 1.47 0.554 0 N-CA-C 112.357 0.503 . . . . 0.0 112.357 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 85.2 p -60.78 -26.06 66.98 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.287 0.565 . . . . 0.0 109.9 -179.446 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 85.9 tttt -57.4 -36.76 71.72 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.355 -0.839 . . . . 0.0 110.362 -179.67 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 318' ' ' VAL . . . . . 0.475 ' O ' ' O ' ' A' ' 315' ' ' LEU . 13.7 p -131.45 142.97 41.91 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.176 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.332 179.67 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 2.0 m . . . . . 0 C--O 1.22 -0.494 0 CA-C-O 118.024 -0.988 . . . . 0.0 110.598 179.986 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 86.2 p . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.835 0.35 . . . . 0.0 110.676 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 11.5 mtpp -89.45 162.65 15.63 Favored 'General case' 0 CA--C 1.515 -0.381 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.869 179.89 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 295' ' ' ASP . . . . . 0.653 ' OD1' ' N ' ' A' ' 296' ' ' ASN . 50.0 p30 -57.58 -33.47 68.21 Favored 'General case' 0 N--CA 1.449 -0.524 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.407 -178.501 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 296' ' ' ASN . . . . . 0.653 ' N ' ' OD1' ' A' ' 295' ' ' ASP . 16.4 t-20 58.44 56.54 4.31 Favored 'General case' 0 CA--C 1.516 -0.357 0 C-N-CA 118.38 -1.328 . . . . 0.0 110.558 177.388 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 297' ' ' ILE . . . . . 0.42 ' C ' ' O ' ' A' ' 296' ' ' ASN . 21.6 mm -42.63 137.25 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-O 122.659 1.219 . . . . 0.0 109.975 -175.932 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 83.1 tttt -57.38 -36.04 70.74 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 112.354 -2.203 . . . . 0.0 112.939 -176.744 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 299' ' ' HIS . . . . . 0.408 ' H ' HG22 ' A' ' 297' ' ' ILE . 1.2 m80 64.86 112.35 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 120.167 -0.613 . . . . 0.0 109.755 -179.14 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -122.21 78.32 43.51 Favored Pre-proline 0 C--N 1.325 -0.46 0 CA-C-N 115.82 -0.627 . . . . 0.0 109.885 -179.293 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -56.32 -23.65 47.34 Favored 'Trans proline' 0 C--N 1.315 -1.231 0 C-N-CA 120.904 1.069 . . . . 0.0 110.238 -179.426 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 302' ' ' GLY . . . . . 0.473 ' C ' ' H ' ' A' ' 304' ' ' GLY . . . -167.15 127.21 1.54 Allowed Glycine 0 CA--C 1.526 0.721 0 CA-C-N 114.965 -1.016 . . . . 0.0 110.882 179.002 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -78.85 10.87 30.26 Favored Glycine 0 N--CA 1.463 0.459 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 178.811 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 304' ' ' GLY . . . . . 0.473 ' H ' ' C ' ' A' ' 302' ' ' GLY . . . 98.39 -4.2 60.06 Favored Glycine 0 CA--C 1.519 0.334 0 N-CA-C 108.25 -1.94 . . . . 0.0 108.25 -177.483 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 305' ' ' SER . . . . . 0.524 ' O ' ' C ' ' A' ' 306' ' ' VAL . 23.9 m -59.2 -33.14 70.61 Favored 'General case' 0 C--O 1.233 0.193 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 177.259 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 306' ' ' VAL . . . . . 0.562 ' CG2' ' H ' ' A' ' 307' ' ' GLN . 4.9 m -7.04 -109.7 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 CA-C-N 114.626 -1.17 . . . . 0.0 111.81 -178.881 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 307' ' ' GLN . . . . . 0.562 ' H ' ' CG2' ' A' ' 306' ' ' VAL . 25.3 pt20 -138.08 154.84 49.22 Favored 'General case' 0 N--CA 1.451 -0.401 0 CA-C-O 121.466 0.65 . . . . 0.0 109.699 178.612 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 308' ' ' ILE . . . . . 1.002 ' O ' ' N ' ' A' ' 310' ' ' TYR . 16.3 pt -78.1 -25.15 14.09 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.779 0 N-CA-C 116.09 1.885 . . . . 0.0 116.09 -177.239 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . 0.575 ' O ' ' CG1' ' A' ' 309' ' ' VAL . 93.7 t 9.4 27.78 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.257 0 N-CA-C 113.989 1.107 . . . . 0.0 113.989 -178.814 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 310' ' ' TYR . . . . . 1.002 ' N ' ' O ' ' A' ' 308' ' ' ILE 0.253 0.4 OUTLIER -71.66 -19.98 62.01 Favored 'General case' 0 C--N 1.332 -0.175 0 N-CA-C 113.158 0.799 . . . . 0.0 113.158 -179.523 . . . . . . . . 4 4 . 1 . 007 nuclear orig core ' A' A ' 311' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 57.08 62.72 5.66 Favored Pre-proline 0 C--N 1.325 -0.49 0 CA-C-O 121.316 0.579 . . . . 0.0 109.786 179.718 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 312' ' ' PRO . . . . . 0.778 ' O ' ' N ' ' A' ' 314' ' ' ASP . 32.7 Cg_endo -58.88 143.54 99.31 Favored 'Trans proline' 0 C--N 1.303 -1.855 0 C-N-CA 122.648 2.232 . . . . 0.0 111.288 179.223 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 313' ' ' VAL . . . . . 0.494 ' O ' ' OG ' ' A' ' 316' ' ' SER . 18.9 m -6.58 59.29 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.645 0 O-C-N 124.224 0.953 . . . . 0.0 113.295 -179.452 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 314' ' ' ASP . . . . . 0.778 ' N ' ' O ' ' A' ' 312' ' ' PRO . 93.2 m-20 -56.89 -36.75 70.5 Favored 'General case' 0 C--O 1.223 -0.308 0 N-CA-C 111.66 0.244 . . . . 0.0 111.66 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 315' ' ' LEU . . . . . . . . . . . . . 61.7 mt -58.81 -36.42 74.46 Favored 'General case' 0 C--N 1.326 -0.424 0 C-N-CA 120.07 -0.652 . . . . 0.0 110.719 -178.609 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 316' ' ' SER . . . . . 0.494 ' OG ' ' O ' ' A' ' 313' ' ' VAL . 86.3 p -63.37 -23.74 67.54 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-O 121.227 0.537 . . . . 0.0 110.756 178.67 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 49.2 tttm -56.75 -35.8 69.03 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.303 -0.862 . . . . 0.0 112.535 -177.489 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 12.5 p -129.7 142.88 42.74 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 C-N-CA 120.263 -0.575 . . . . 0.0 111.829 -179.238 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.221 -0.418 0 CA-C-O 118.137 -0.935 . . . . 0.0 110.813 179.882 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 21.2 m . . . . . 0 C--O 1.232 0.153 0 CA-C-O 120.842 0.353 . . . . 0.0 110.688 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 67.4 mttt -57.45 -37.77 73.39 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.098 -178.419 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 295' ' ' ASP . . . . . 0.645 ' OD2' ' N ' ' A' ' 296' ' ' ASN . 50.3 p30 175.1 -24.6 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.652 179.401 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 296' ' ' ASN . . . . . 0.645 ' N ' ' OD2' ' A' ' 295' ' ' ASP . 18.7 t-20 56.54 48.22 17.08 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.627 -0.715 . . . . 0.0 111.071 179.751 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 297' ' ' ILE . . . . . 0.628 ' O ' ' O ' ' A' ' 296' ' ' ASN . 10.9 tp 15.46 111.04 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 CA-C-O 122.176 0.988 . . . . 0.0 111.602 -178.647 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 298' ' ' LYS . . . . . 0.584 ' O ' ' C ' ' A' ' 299' ' ' HIS . 56.4 tttp -57.86 -36.48 72.4 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 114.488 -1.233 . . . . 0.0 113.285 -178.1 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 299' ' ' HIS . . . . . 0.584 ' C ' ' O ' ' A' ' 298' ' ' LYS . 85.3 t60 1.42 102.25 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.358 0 N-CA-C 112.104 0.409 . . . . 0.0 112.104 -179.265 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.55 75.22 69.68 Favored Pre-proline 0 N--CA 1.469 0.513 0 N-CA-C 111.964 0.357 . . . . 0.0 111.964 -179.17 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -58.94 -21.67 59.23 Favored 'Trans proline' 0 C--N 1.306 -1.693 0 N-CA-C 109.788 -0.889 . . . . 0.0 109.788 177.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -79.42 25.21 2.85 Favored Glycine 0 CA--C 1.528 0.892 0 CA-C-N 114.386 -1.279 . . . . 0.0 111.767 -179.848 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -55.93 -26.13 47.3 Favored Glycine 0 CA--C 1.509 -0.296 0 N-CA-C 109.274 -1.53 . . . . 0.0 109.274 179.631 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 98.65 -3.27 59.1 Favored Glycine 0 N--CA 1.442 -0.906 0 N-CA-C 104.686 -3.366 . . . . 0.0 104.686 -175.315 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 305' ' ' SER . . . . . 0.503 ' O ' ' O ' ' A' ' 306' ' ' VAL . 24.7 m -59.46 -33.89 71.86 Favored 'General case' 0 N--CA 1.439 -0.998 0 CA-C-N 112.501 -1.849 . . . . 0.0 108.674 177.157 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 306' ' ' VAL . . . . . 0.531 ' CG2' ' H ' ' A' ' 307' ' ' GLN . 8.2 m -11.22 -113.37 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.233 0.186 0 CA-C-N 113.438 -1.71 . . . . 0.0 112.835 -178.364 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 307' ' ' GLN . . . . . 0.531 ' H ' ' CG2' ' A' ' 306' ' ' VAL . 21.7 pt20 -141.56 165.1 28.43 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.429 -0.805 . . . . 0.0 110.803 -178.684 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 308' ' ' ILE . . . . . 0.628 HG13 ' O ' ' A' ' 308' ' ' ILE . 19.9 pt -63.99 100.6 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 122.596 1.189 . . . . 0.0 109.778 179.96 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 81.4 t -63.87 -42.44 95.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 122.005 0.907 . . . . 0.0 109.167 179.829 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 310' ' ' TYR . . . . . . . . . . . . 0.321 54.9 p90 -66.21 -32.34 73.71 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 118.082 2.623 . . . . 0.0 118.082 179.542 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 311' ' ' LYS . . . . . 0.615 ' O ' ' N ' ' A' ' 313' ' ' VAL . 14.6 mtpp 51.02 63.99 8.9 Favored Pre-proline 0 C--N 1.313 -0.979 0 C-N-CA 118.633 -1.227 . . . . 0.0 109.781 179.362 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 312' ' ' PRO . . . . . 0.591 ' O ' ' N ' ' A' ' 314' ' ' ASP . 84.0 Cg_exo 6.33 58.26 0.0 OUTLIER 'Trans proline' 0 N--CA 1.492 1.382 0 C-N-CA 122.635 2.223 . . . . 0.0 113.41 -179.586 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 313' ' ' VAL . . . . . 0.615 ' N ' ' O ' ' A' ' 311' ' ' LYS . 9.5 p 4.56 62.61 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 O-C-N 124.082 0.864 . . . . 0.0 112.196 -179.704 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 314' ' ' ASP . . . . . 0.591 ' N ' ' O ' ' A' ' 312' ' ' PRO . 92.1 m-20 -56.08 -35.82 67.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.025 -0.989 . . . . 0.0 111.78 -179.369 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 315' ' ' LEU . . . . . 0.517 ' CD1' ' H ' ' A' ' 315' ' ' LEU . 6.4 mp -57.39 -36.02 70.74 Favored 'General case' 0 C--N 1.326 -0.45 0 C-N-CA 119.854 -0.738 . . . . 0.0 110.027 -178.33 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 24.4 m -58.45 -34.23 70.61 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 108.396 -0.965 . . . . 0.0 108.396 177.299 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 65.8 tttt -77.05 132.8 39.11 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.084 -0.962 . . . . 0.0 109.714 179.424 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 14.4 p -131.67 142.82 42.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.629 -179.716 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 33.5 p . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 118.049 -0.976 . . . . 0.0 110.845 -179.709 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 1.9 m . . . . . 0 CA--C 1.535 0.367 0 CA-C-O 120.988 0.423 . . . . 0.0 111.829 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 27.8 mttp -91.55 153.51 19.71 Favored 'General case' 0 CA--C 1.515 -0.397 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 178.225 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 295' ' ' ASP . . . . . 0.459 ' OD2' ' C ' ' A' ' 295' ' ' ASP . 48.4 p30 -83.88 8.0 16.36 Favored 'General case' 0 C--N 1.322 -0.626 0 C-N-CA 119.617 -0.833 . . . . 0.0 109.949 -178.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 45.5 t30 58.31 56.06 4.67 Favored 'General case' 0 N--CA 1.455 -0.183 0 C-N-CA 119.671 -0.812 . . . . 0.0 112.014 177.102 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 297' ' ' ILE . . . . . 0.402 HG13 ' OD2' ' A' ' 295' ' ' ASP . 70.7 mt -59.82 131.4 24.41 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.165 0 CA-C-O 122.197 0.999 . . . . 0.0 110.103 -175.932 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 298' ' ' LYS . . . . . 0.405 ' HZ3' ' HB2' ' A' ' 298' ' ' LYS . 2.0 ttmp? -84.15 136.99 33.76 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 113.419 -1.719 . . . . 0.0 113.958 -177.819 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 64.5 m170 -115.88 136.9 52.6 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 106.483 -1.673 . . . . 0.0 106.483 176.08 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 3.9 m -125.08 69.74 59.64 Favored Pre-proline 0 N--CA 1.466 0.349 0 C-N-CA 119.573 -0.851 . . . . 0.0 112.867 -178.566 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -62.46 -19.31 67.11 Favored 'Trans proline' 0 C--N 1.302 -1.892 0 N-CA-C 107.174 -1.894 . . . . 0.0 107.174 174.683 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -165.08 -169.55 28.85 Favored Glycine 0 CA--C 1.531 1.039 0 CA-C-N 112.91 -1.95 . . . . 0.0 110.233 -178.219 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . 126.25 29.59 0.92 Allowed Glycine 0 N--CA 1.466 0.698 0 N-CA-C 109.013 -1.635 . . . . 0.0 109.013 -178.371 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 97.07 -7.45 64.56 Favored Glycine 0 C--N 1.324 -0.116 0 N-CA-C 107.352 -2.299 . . . . 0.0 107.352 -178.493 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 23.2 t -59.96 -30.75 69.3 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 113.146 -1.527 . . . . 0.0 111.157 177.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 306' ' ' VAL . . . . . 0.564 ' O ' ' CB ' ' A' ' 307' ' ' GLN . 88.5 t -56.93 -42.99 79.73 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.48 0 CA-C-N 115.729 -0.669 . . . . 0.0 112.071 -175.373 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 307' ' ' GLN . . . . . 0.564 ' CB ' ' O ' ' A' ' 306' ' ' VAL . 21.3 pt20 125.46 178.49 0.0 OUTLIER 'General case' 0 N--CA 1.469 0.501 0 O-C-N 124.643 1.214 . . . . 0.0 110.201 179.42 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 308' ' ' ILE . . . . . 0.823 ' O ' ' N ' ' A' ' 310' ' ' TYR . 33.3 mm -54.88 -45.16 75.09 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.933 0 CA-C-N 113.952 -1.476 . . . . 0.0 113.852 177.259 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . 0.432 ' H ' ' HG3' ' A' ' 307' ' ' GLN . 0.3 OUTLIER 37.2 -0.94 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.693 0 O-C-N 123.939 0.774 . . . . 0.0 113.069 -179.212 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 310' ' ' TYR . . . . . 0.823 ' N ' ' O ' ' A' ' 308' ' ' ILE 0.329 0.0 OUTLIER -67.39 -22.3 65.56 Favored 'General case' 0 CA--C 1.503 -0.85 0 C-N-CA 119.056 -1.057 . . . . 0.0 110.681 -178.763 . . . . . . . . 4 4 . 1 . 009 nuclear orig core ' A' A ' 311' ' ' LYS . . . . . 0.583 ' O ' ' C ' ' A' ' 312' ' ' PRO . 32.3 tttp 56.4 63.55 5.61 Favored Pre-proline 0 N--CA 1.447 -0.61 0 CA-C-N 115.028 -0.987 . . . . 0.0 109.916 177.779 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 312' ' ' PRO . . . . . 0.583 ' C ' ' O ' ' A' ' 311' ' ' LYS . 75.8 Cg_exo 12.85 -127.08 0.0 OUTLIER 'Trans proline' 0 N--CA 1.492 1.414 0 C-N-CA 122.337 2.025 . . . . 0.0 110.888 -178.448 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 313' ' ' VAL . . . . . 0.405 HG12 ' H ' ' A' ' 315' ' ' LEU . 45.2 t -120.98 126.87 75.73 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.398 0 C-N-CA 118.336 -1.345 . . . . 0.0 109.509 176.193 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -63.93 -38.14 89.98 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.64 0.733 . . . . 0.0 111.282 177.102 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 315' ' ' LEU . . . . . 0.65 ' N ' ' CD2' ' A' ' 315' ' ' LEU . 0.2 OUTLIER -61.07 -36.97 81.04 Favored 'General case' 0 C--O 1.233 0.192 0 CA-C-N 114.453 -1.249 . . . . 0.0 113.29 -176.902 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 68.4 m -79.58 -5.55 55.22 Favored 'General case' 0 C--N 1.327 -0.404 0 C-N-CA 120.166 -0.614 . . . . 0.0 111.026 -179.857 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 57.2 tttp -58.42 -38.0 76.52 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.114 -179.333 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 43.4 t -120.65 135.45 60.83 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 CA-C-N 116.545 -0.298 . . . . 0.0 110.577 179.188 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 6.9 m . . . . . 0 C--O 1.221 -0.399 0 CA-C-O 118.018 -0.991 . . . . 0.0 110.422 179.459 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 86.6 p . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.798 0.332 . . . . 0.0 110.498 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 31.0 mttt -93.9 153.37 18.27 Favored 'General case' 0 N--CA 1.448 -0.566 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 178.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 295' ' ' ASP . . . . . 0.457 ' C ' ' OD1' ' A' ' 295' ' ' ASP . 49.2 p30 -84.12 7.66 18.1 Favored 'General case' 0 C--N 1.322 -0.591 0 C-N-CA 119.685 -0.806 . . . . 0.0 110.301 -178.653 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 16.6 t-20 58.57 55.91 4.56 Favored 'General case' 0 CA--C 1.535 0.391 0 C-N-CA 119.818 -0.753 . . . . 0.0 112.488 176.629 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 297' ' ' ILE . . . . . 0.426 HG13 ' OD1' ' A' ' 295' ' ' ASP . 71.2 mt -61.8 133.24 27.62 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.52 0 CA-C-O 122.258 1.028 . . . . 0.0 110.906 -175.967 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 15.6 tttt -82.79 137.83 34.21 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-N 113.328 -1.76 . . . . 0.0 114.209 -178.105 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 58.3 t-80 -119.41 132.42 55.82 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 106.75 -1.574 . . . . 0.0 106.75 176.425 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 4.4 m -124.79 79.01 64.25 Favored Pre-proline 0 N--CA 1.472 0.635 0 N-CA-C 113.865 1.061 . . . . 0.0 113.865 -177.033 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -58.53 -24.59 70.42 Favored 'Trans proline' 0 C--N 1.31 -1.471 0 C-N-CA 120.572 0.848 . . . . 0.0 110.963 178.043 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -111.82 48.21 0.96 Allowed Glycine 0 CA--C 1.525 0.694 0 N-CA-C 109.864 -1.294 . . . . 0.0 109.864 179.507 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -81.19 6.85 62.02 Favored Glycine 0 N--CA 1.466 0.638 0 N-CA-C 112.174 -0.37 . . . . 0.0 112.174 -178.398 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 94.52 2.04 63.72 Favored Glycine 0 C--N 1.321 -0.29 0 N-CA-C 107.962 -2.055 . . . . 0.0 107.962 -178.167 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 75.7 m -82.56 6.99 15.77 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 113.851 -1.174 . . . . 0.0 108.229 178.564 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 306' ' ' VAL . . . . . 0.502 ' O ' ' O ' ' A' ' 307' ' ' GLN . 20.7 m -67.25 -22.65 29.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 114.861 -1.063 . . . . 0.0 110.649 -178.845 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 307' ' ' GLN . . . . . 0.536 ' O ' ' O ' ' A' ' 308' ' ' ILE . 21.7 pt20 46.16 118.03 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 122.039 0.924 . . . . 0.0 113.358 179.697 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 308' ' ' ILE . . . . . 0.536 ' O ' ' O ' ' A' ' 307' ' ' GLN . 9.7 tp 25.42 120.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.676 0 CA-C-N 113.42 -1.718 . . . . 0.0 114.374 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -149.58 -42.94 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.366 0 CA-C-N 114.599 -1.182 . . . . 0.0 109.072 177.889 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 310' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -61.67 -31.88 72.02 Favored 'General case' 0 CA--C 1.538 0.519 0 N-CA-C 112.938 0.718 . . . . 0.0 112.938 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 311' ' ' LYS . . . . . 0.403 ' HB3' ' HZ1' ' A' ' 311' ' ' LYS . 8.2 mtpp 65.09 73.76 0.42 Allowed Pre-proline 0 N--CA 1.473 0.711 0 N-CA-C 113.116 0.784 . . . . 0.0 113.116 179.114 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 312' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_endo -53.17 -23.76 23.8 Favored 'Trans proline' 0 N--CA 1.498 1.738 0 C-N-CA 120.41 0.74 . . . . 0.0 111.374 179.691 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 313' ' ' VAL . . . . . 0.473 ' CG1' ' OG ' ' A' ' 316' ' ' SER . 60.3 t -117.16 132.37 67.14 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.273 0 CA-C-O 121.448 0.642 . . . . 0.0 111.589 178.339 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 58.2 t0 -160.17 -60.94 0.06 Allowed 'General case' 0 N--CA 1.449 -0.515 0 CA-C-N 114.98 -1.009 . . . . 0.0 108.921 178.308 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 315' ' ' LEU . . . . . . . . . . . . . 61.1 mt -61.65 -35.33 77.63 Favored 'General case' 0 C--O 1.226 -0.167 0 CA-C-N 114.78 -1.1 . . . . 0.0 111.723 179.295 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 316' ' ' SER . . . . . 0.473 ' OG ' ' CG1' ' A' ' 313' ' ' VAL . 80.2 p -61.21 -28.34 69.08 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.307 0.575 . . . . 0.0 110.241 -179.154 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 317' ' ' LYS . . . . . 0.426 ' N ' ' HG ' ' A' ' 316' ' ' SER . 29.3 tttm -58.24 -37.2 74.43 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.456 -0.793 . . . . 0.0 111.432 -179.421 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 318' ' ' VAL . . . . . 0.428 HG13 ' N ' ' A' ' 319' ' ' THR . 5.5 p -57.67 -34.21 46.96 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.152 0 CA-C-O 120.882 0.373 . . . . 0.0 110.62 -179.87 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 319' ' ' THR . . . . . 0.428 ' N ' HG13 ' A' ' 318' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--O 1.221 -0.447 0 CA-C-O 118.027 -0.987 . . . . 0.0 110.044 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 87.0 p . . . . . 0 N--CA 1.456 -0.141 0 CA-C-O 120.662 0.268 . . . . 0.0 110.679 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 294' ' ' LYS . . . . . 0.431 ' C ' ' H ' ' A' ' 296' ' ' ASN . 41.2 mtpt -95.7 150.94 19.83 Favored 'General case' 0 N--CA 1.452 -0.328 0 CA-C-O 120.907 0.384 . . . . 0.0 111.081 -179.621 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 295' ' ' ASP . . . . . 0.457 ' OD2' ' C ' ' A' ' 295' ' ' ASP . 48.8 p30 -85.98 10.53 13.84 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 107.43 -1.322 . . . . 0.0 107.43 178.709 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 296' ' ' ASN . . . . . 0.431 ' H ' ' C ' ' A' ' 294' ' ' LYS . 23.6 m120 30.5 -102.09 0.02 OUTLIER 'General case' 0 CA--C 1.511 -0.549 0 CA-C-N 113.301 -1.772 . . . . 0.0 113.294 -179.218 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 297' ' ' ILE . . . . . . . . . . . . . 70.1 mt -113.5 130.31 67.74 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.454 0 CA-C-O 122.297 1.046 . . . . 0.0 113.486 -177.119 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 41.8 tttp -87.5 132.13 34.12 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 113.107 -1.86 . . . . 0.0 108.613 177.037 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 299' ' ' HIS . . . . . 0.575 ' CE1' ' CD ' ' A' ' 301' ' ' PRO . 37.4 t-80 -125.09 113.39 17.67 Favored 'General case' 0 N--CA 1.468 0.461 0 N-CA-C 112.676 0.621 . . . . 0.0 112.676 -179.116 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 3.2 m -134.16 73.34 70.07 Favored Pre-proline 0 N--CA 1.471 0.585 0 CA-C-N 116.196 -0.457 . . . . 0.0 112.191 178.075 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 301' ' ' PRO . . . . . 0.575 ' CD ' ' CE1' ' A' ' 299' ' ' HIS . 5.9 Cg_endo -60.56 -23.82 76.56 Favored 'Trans proline' 0 N--CA 1.5 1.901 0 CA-C-N 119.914 1.005 . . . . 0.0 113.067 179.211 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -134.21 -105.29 0.87 Allowed Glycine 0 CA--C 1.525 0.709 0 N-CA-C 111.149 -0.78 . . . . 0.0 111.149 -178.508 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . 86.4 35.64 10.46 Favored Glycine 0 N--CA 1.462 0.386 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 -178.81 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 96.56 -0.25 61.26 Favored Glycine 0 N--CA 1.446 -0.686 0 N-CA-C 108.991 -1.643 . . . . 0.0 108.991 -179.165 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 73.8 m -82.96 1.65 38.68 Favored 'General case' 0 N--CA 1.446 -0.661 0 CA-C-O 121.382 0.611 . . . . 0.0 109.558 178.675 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 306' ' ' VAL . . . . . . . . . . . . . 73.6 t -61.64 -38.17 79.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 115.06 -0.973 . . . . 0.0 111.253 179.835 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 307' ' ' GLN . . . . . 0.628 ' O ' ' O ' ' A' ' 308' ' ' ILE . 50.3 tt0 79.87 103.03 0.07 Allowed 'General case' 0 CA--C 1.506 -0.729 0 O-C-N 123.6 0.562 . . . . 0.0 112.039 -178.663 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 308' ' ' ILE . . . . . 0.628 ' O ' ' O ' ' A' ' 307' ' ' GLN . 81.7 mt 51.24 149.68 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.443 -0.778 0 CA-C-O 122.256 1.027 . . . . 0.0 109.871 178.506 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . 0.657 ' CG1' ' CD1' ' A' ' 310' ' ' TYR . 6.3 p -56.34 -33.91 39.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 CA-C-N 114.886 -1.052 . . . . 0.0 111.777 -178.576 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 310' ' ' TYR . . . . . 0.808 ' CD1' ' N ' ' A' ' 311' ' ' LYS . 0.0 OUTLIER -161.55 -97.09 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.39 0 CA-C-O 123.896 1.808 . . . . 0.0 112.638 -178.37 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 311' ' ' LYS . . . . . 0.808 ' N ' ' CD1' ' A' ' 310' ' ' TYR . 32.6 mtmm -123.62 103.88 34.32 Favored Pre-proline 0 C--N 1.275 -2.667 0 CA-C-N 109.845 -3.343 . . . . 0.0 108.228 179.181 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 312' ' ' PRO . . . . . 0.496 ' C ' ' O ' ' A' ' 311' ' ' LYS . 9.7 Cg_endo -49.1 151.95 5.51 Favored 'Trans proline' 0 C--N 1.299 -2.038 0 N-CA-C 106.626 -2.106 . . . . 0.0 106.626 179.081 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 313' ' ' VAL . . . . . 0.438 HG12 ' H ' ' A' ' 315' ' ' LEU . 44.3 t -59.53 128.5 20.51 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.585 0 C-N-CA 117.671 -1.611 . . . . 0.0 111.948 -173.434 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 314' ' ' ASP . . . . . 0.473 ' O ' ' HG2' ' A' ' 317' ' ' LYS . 49.2 p30 -97.33 -0.63 46.15 Favored 'General case' 0 N--CA 1.438 -1.058 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 175.897 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 315' ' ' LEU . . . . . 0.438 ' H ' HG12 ' A' ' 313' ' ' VAL . 64.8 mt -64.85 -31.44 72.68 Favored 'General case' 0 N--CA 1.469 0.504 0 O-C-N 123.774 0.671 . . . . 0.0 110.735 178.319 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 89.9 p -58.19 -25.56 61.73 Favored 'General case' 0 N--CA 1.448 -0.545 0 CA-C-N 114.962 -1.017 . . . . 0.0 110.276 -177.453 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 317' ' ' LYS . . . . . 0.473 ' HG2' ' O ' ' A' ' 314' ' ' ASP . 52.2 pttt -59.6 -33.57 71.64 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.349 -0.612 . . . . 0.0 109.349 -179.319 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 318' ' ' VAL . . . . . 0.422 ' N ' ' CG ' ' A' ' 317' ' ' LYS . 74.7 t -60.37 -39.81 82.12 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.132 0 CA-C-N 115.099 -0.955 . . . . 0.0 111.501 -178.807 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 7.1 m . . . . . 0 C--O 1.22 -0.482 0 CA-C-O 117.935 -1.031 . . . . 0.0 110.529 -179.76 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 45.3 m . . . . . 0 N--CA 1.461 0.088 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 294' ' ' LYS . . . . . 0.464 ' C ' ' H ' ' A' ' 296' ' ' ASN . 88.2 mttt -103.75 145.81 29.54 Favored 'General case' 0 N--CA 1.449 -0.477 0 CA-C-O 121.442 0.639 . . . . 0.0 112.014 -179.156 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 295' ' ' ASP . . . . . 0.47 ' OD2' ' C ' ' A' ' 295' ' ' ASP . 49.2 p30 -89.52 12.76 15.66 Favored 'General case' 0 CA--C 1.49 -1.332 0 N-CA-C 106.35 -1.722 . . . . 0.0 106.35 176.68 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 296' ' ' ASN . . . . . 0.624 ' CG ' ' H ' ' A' ' 297' ' ' ILE . 49.4 t30 36.48 -147.95 0.01 OUTLIER 'General case' 0 N--CA 1.426 -1.626 0 CA-C-N 112.362 -2.199 . . . . 0.0 110.697 -178.717 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 297' ' ' ILE . . . . . 0.624 ' H ' ' CG ' ' A' ' 296' ' ' ASN . 8.8 tp -123.2 132.67 70.98 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 CA-C-O 122.642 1.21 . . . . 0.0 112.809 -177.446 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 75.8 tttt -94.48 130.16 40.97 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-N 112.323 -2.217 . . . . 0.0 109.702 177.014 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 39.0 t-80 -132.18 136.21 46.89 Favored 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 119.701 -0.8 . . . . 0.0 111.784 179.613 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -125.76 74.77 70.57 Favored Pre-proline 0 N--CA 1.477 0.893 0 CA-C-O 120.4 0.143 . . . . 0.0 111.368 178.987 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -59.94 -21.28 63.95 Favored 'Trans proline' 0 N--CA 1.494 1.523 0 C-N-CA 122.529 2.153 . . . . 0.0 112.089 178.734 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . 114.03 130.63 5.1 Favored Glycine 0 CA--C 1.52 0.355 0 N-CA-C 107.418 -2.273 . . . . 0.0 107.418 -177.279 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -96.44 -78.77 1.43 Allowed Glycine 0 CA--C 1.523 0.564 0 C-N-CA 119.457 -1.354 . . . . 0.0 113.219 -177.853 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . -86.16 -35.29 11.14 Favored Glycine 0 CA--C 1.522 0.486 0 C-N-CA 121.201 -0.524 . . . . 0.0 112.589 -179.778 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 305' ' ' SER . . . . . 0.504 ' O ' ' O ' ' A' ' 306' ' ' VAL . 93.9 p -61.63 -30.02 70.43 Favored 'General case' 0 CA--C 1.513 -0.476 0 N-CA-C 114.263 1.209 . . . . 0.0 114.263 -176.756 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 306' ' ' VAL . . . . . 0.504 ' O ' ' O ' ' A' ' 305' ' ' SER . 16.8 t -27.25 -99.88 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 O-C-N 123.57 0.544 . . . . 0.0 112.395 -177.615 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 307' ' ' GLN . . . . . 0.41 ' HG2' ' N ' ' A' ' 308' ' ' ILE . 51.6 tt0 -143.14 158.07 43.95 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.635 179.857 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 308' ' ' ILE . . . . . 0.559 ' CD1' ' CZ ' ' A' ' 310' ' ' TYR . 5.0 tp -120.96 127.86 76.0 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.673 0 C-N-CA 120.05 -0.66 . . . . 0.0 109.635 177.635 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 73.7 t -67.98 -42.91 85.83 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.565 0 N-CA-C 114.975 1.472 . . . . 0.0 114.975 -179.57 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 310' ' ' TYR . . . . . 0.559 ' CZ ' ' CD1' ' A' ' 308' ' ' ILE 0.312 2.7 p90 -66.27 -28.14 68.48 Favored 'General case' 0 N--CA 1.469 0.499 0 N-CA-C 116.931 2.197 . . . . 0.0 116.931 -177.019 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 311' ' ' LYS . . . . . 0.536 ' O ' ' O ' ' A' ' 312' ' ' PRO . 10.6 mtpt 56.17 63.23 6.06 Favored Pre-proline 0 C--N 1.307 -1.248 0 C-N-CA 118.74 -1.184 . . . . 0.0 108.534 -178.959 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 312' ' ' PRO . . . . . 0.573 ' O ' ' N ' ' A' ' 314' ' ' ASP . 32.6 Cg_exo 23.62 112.06 0.0 OUTLIER 'Trans proline' 0 C--N 1.316 -1.157 0 C-N-CA 122.752 2.301 . . . . 0.0 115.214 -179.339 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 313' ' ' VAL . . . . . 0.469 ' C ' ' O ' ' A' ' 312' ' ' PRO . 2.1 m 8.15 55.77 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.232 0.141 0 CA-C-N 113.519 -1.673 . . . . 0.0 113.27 179.185 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 314' ' ' ASP . . . . . 0.573 ' N ' ' O ' ' A' ' 312' ' ' PRO . 55.2 t0 -55.37 -36.11 66.0 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 109.962 -0.385 . . . . 0.0 109.962 178.757 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 315' ' ' LEU . . . . . 0.466 ' CD1' ' H ' ' A' ' 315' ' ' LEU . 6.5 mp -59.27 -35.69 74.19 Favored 'General case' 0 N--CA 1.464 0.254 0 C-N-CA 120.61 -0.436 . . . . 0.0 111.577 -179.344 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 85.4 p -61.71 -27.34 68.64 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.352 0.596 . . . . 0.0 110.038 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 38.9 tttp -57.37 -39.1 75.31 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.265 -0.879 . . . . 0.0 111.112 -178.656 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 70.6 t -63.21 -39.26 84.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 121.128 0.489 . . . . 0.0 110.323 178.747 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 1.9 m . . . . . 0 C--O 1.22 -0.493 0 CA-C-O 118.068 -0.968 . . . . 0.0 110.282 -178.836 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 30.8 t . . . . . 0 N--CA 1.463 0.198 0 CA-C-O 121.098 0.475 . . . . 0.0 111.242 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 25.5 mttm -99.32 152.18 20.22 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.749 179.186 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 295' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -55.29 -37.14 66.94 Favored 'General case' 0 CA--C 1.497 -1.086 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.424 -179.547 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 296' ' ' ASN . . . . . 0.696 HD21 ' N ' ' A' ' 296' ' ' ASN . 0.0 OUTLIER 175.5 -103.07 0.0 OUTLIER 'General case' 0 C--N 1.308 -1.219 0 CA-C-O 121.97 0.891 . . . . 0.0 111.0 179.907 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 297' ' ' ILE . . . . . 0.652 ' H ' ' CG ' ' A' ' 296' ' ' ASN . 19.2 tt 137.32 86.92 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 CA-C-N 111.977 -2.374 . . . . 0.0 106.722 -178.124 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 36.0 mttt -83.25 137.23 34.1 Favored 'General case' 0 C--N 1.317 -0.828 0 C-N-CA 119.39 -0.924 . . . . 0.0 112.374 -177.247 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 56.8 t-80 -130.76 117.81 19.94 Favored 'General case' 0 N--CA 1.441 -0.899 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 175.686 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -125.63 77.32 69.55 Favored Pre-proline 0 C--N 1.324 -0.526 0 C-N-CA 120.704 -0.398 . . . . 0.0 111.36 -179.625 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 85.5 Cg_endo -57.79 -23.66 59.75 Favored 'Trans proline' 0 C--N 1.313 -1.308 0 N-CA-C 109.99 -0.812 . . . . 0.0 109.99 179.224 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -173.43 128.15 1.46 Allowed Glycine 0 CA--C 1.523 0.563 0 CA-C-N 114.81 -1.086 . . . . 0.0 110.84 179.193 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -82.05 4.84 74.02 Favored Glycine 0 N--CA 1.462 0.397 0 N-CA-C 108.701 -1.76 . . . . 0.0 108.701 178.414 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 98.4 -8.08 62.14 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 109.845 -1.302 . . . . 0.0 109.845 -179.259 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 305' ' ' SER . . . . . 0.465 ' O ' ' C ' ' A' ' 306' ' ' VAL . 20.3 m -59.9 -34.93 73.83 Favored 'General case' 0 CA--C 1.521 -0.172 0 CA-C-O 121.953 0.882 . . . . 0.0 109.463 177.557 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 306' ' ' VAL . . . . . 0.465 ' C ' ' O ' ' A' ' 305' ' ' SER . 7.7 t -13.61 -104.0 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 CA-C-N 113.475 -1.693 . . . . 0.0 113.697 -177.902 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 307' ' ' GLN . . . . . . . . . . . . . 21.7 pt20 -145.16 170.71 15.7 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.177 -178.1 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 308' ' ' ILE . . . . . 0.579 HG21 ' CD2' ' A' ' 310' ' ' TYR . 71.8 mt -97.28 116.96 41.02 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.095 0 N-CA-C 115.677 1.732 . . . . 0.0 115.677 -178.529 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 5.9 p -69.86 -32.29 51.3 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.462 0 CA-C-N 113.59 -1.641 . . . . 0.0 108.731 172.751 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 310' ' ' TYR . . . . . 0.579 ' CD2' HG21 ' A' ' 308' ' ' ILE 0.412 51.6 p90 -62.44 -10.71 12.46 Favored 'General case' 0 C--N 1.346 0.435 0 N-CA-C 117.817 2.525 . . . . 0.0 117.817 -177.203 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 311' ' ' LYS . . . . . 0.472 ' O ' ' C ' ' A' ' 312' ' ' PRO . 9.3 mmtt 63.68 67.53 0.98 Allowed Pre-proline 0 N--CA 1.475 0.813 0 CA-C-N 118.853 0.751 . . . . 0.0 112.406 177.235 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 312' ' ' PRO . . . . . 0.472 ' C ' ' O ' ' A' ' 311' ' ' LYS . 61.2 Cg_exo -0.99 -114.3 0.0 OUTLIER 'Trans proline' 0 N--CA 1.489 1.244 0 C-N-CA 123.093 2.529 . . . . 0.0 116.361 179.598 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 16.1 m -111.31 21.03 5.97 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.478 0 N-CA-C 113.071 0.767 . . . . 0.0 113.071 -176.761 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 58.2 t0 -51.33 -36.86 44.75 Favored 'General case' 0 C--N 1.323 -0.568 0 C-N-CA 120.271 -0.572 . . . . 0.0 111.176 -178.105 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 315' ' ' LEU . . . . . 0.635 ' N ' ' CD2' ' A' ' 315' ' ' LEU . 0.2 OUTLIER -60.05 -36.93 78.38 Favored 'General case' 0 C--N 1.33 -0.241 0 C-N-CA 118.983 -1.087 . . . . 0.0 109.496 178.458 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 21.5 t -59.49 -31.36 69.29 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.886 178.36 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 7.7 ttpp -56.17 -35.34 67.1 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.087 -0.961 . . . . 0.0 111.416 -176.879 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 43.0 t -112.27 134.74 53.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 121.017 0.436 . . . . 0.0 110.491 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 1.1 m . . . . . 0 C--O 1.22 -0.457 0 CA-C-O 117.916 -1.04 . . . . 0.0 110.695 -179.671 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 74.7 m . . . . . 0 CA--C 1.527 0.081 0 CA-C-O 120.647 0.26 . . . . 0.0 110.69 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 64.8 mttp -91.65 144.42 25.55 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 179.443 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 295' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -57.93 -39.59 78.37 Favored 'General case' 0 CA--C 1.507 -0.691 0 C-N-CA 120.069 -0.652 . . . . 0.0 111.688 -178.857 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 46.7 t-20 177.92 -94.41 0.0 OUTLIER 'General case' 0 C--N 1.314 -0.978 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 179.1 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 297' ' ' ILE . . . . . . . . . . . . . 18.1 tt 174.62 3.82 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 113.715 -1.584 . . . . 0.0 109.808 179.431 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 29.1 mttt 64.69 47.59 2.76 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-O 120.856 0.36 . . . . 0.0 110.705 -179.693 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 299' ' ' HIS . . . . . 0.401 ' ND1' ' O ' ' A' ' 299' ' ' HIS . 58.4 t-80 -74.07 65.43 1.12 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.139 -179.389 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 4.8 t -124.87 75.13 65.89 Favored Pre-proline 0 N--CA 1.465 0.319 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.323 178.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -57.81 -24.74 65.47 Favored 'Trans proline' 0 C--N 1.311 -1.427 0 C-N-CA 121.29 1.327 . . . . 0.0 111.431 -179.385 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -163.05 121.8 1.05 Allowed Glycine 0 CA--C 1.524 0.64 0 C-N-CA 120.624 -0.798 . . . . 0.0 111.656 179.76 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -82.32 1.21 87.88 Favored Glycine 0 CA--C 1.527 0.836 0 N-CA-C 110.264 -1.134 . . . . 0.0 110.264 178.534 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 96.79 -7.62 65.33 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.061 -1.215 . . . . 0.0 110.061 -179.788 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 305' ' ' SER . . . . . 0.455 ' O ' ' C ' ' A' ' 306' ' ' VAL . 25.9 t -60.04 -32.62 71.08 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.537 0.684 . . . . 0.0 109.232 177.07 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 306' ' ' VAL . . . . . 0.455 ' C ' ' O ' ' A' ' 305' ' ' SER . 0.0 OUTLIER -20.45 -90.5 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 CA-C-N 113.999 -1.455 . . . . 0.0 112.962 -177.44 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 307' ' ' GLN . . . . . . . . . . . . . 2.6 pt20 -143.22 167.95 20.92 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.341 -0.845 . . . . 0.0 111.067 -177.329 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 308' ' ' ILE . . . . . 0.497 HG23 ' CE2' ' A' ' 310' ' ' TYR . 67.1 mt -107.4 120.89 59.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-O 121.751 0.786 . . . . 0.0 111.075 -179.699 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . 0.467 ' CG1' ' N ' ' A' ' 310' ' ' TYR . 8.0 p -66.04 -36.38 77.33 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.847 0 CA-C-O 122.206 1.003 . . . . 0.0 108.914 174.876 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 310' ' ' TYR . . . . . 0.497 ' CE2' HG23 ' A' ' 308' ' ' ILE 0.448 51.1 p90 -64.53 -32.12 73.62 Favored 'General case' 0 N--CA 1.451 -0.407 0 N-CA-C 118.194 2.665 . . . . 0.0 118.194 -177.996 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 311' ' ' LYS . . . . . 0.49 ' C ' ' O ' ' A' ' 310' ' ' TYR . 49.6 mtpt 47.98 72.23 1.33 Allowed Pre-proline 0 C--N 1.317 -0.805 0 C-N-CA 116.942 -1.903 . . . . 0.0 108.74 176.728 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 312' ' ' PRO . . . . . . . . . . . . . 7.0 Cg_endo -42.88 -37.54 6.14 Favored 'Trans proline' 0 N--CA 1.505 2.148 0 N-CA-C 114.364 0.871 . . . . 0.0 114.364 -173.754 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 71.6 t -62.95 -38.23 81.39 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.059 0 N-CA-C 116.417 2.006 . . . . 0.0 116.417 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 60.3 t0 -54.33 -43.84 71.57 Favored 'General case' 0 N--CA 1.467 0.416 0 O-C-N 120.589 -1.32 . . . . 0.0 114.415 -173.899 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 315' ' ' LEU . . . . . 0.651 ' N ' ' CD2' ' A' ' 315' ' ' LEU . 0.3 OUTLIER -66.8 -36.43 82.38 Favored 'General case' 0 C--N 1.319 -0.751 0 C-N-CA 118.308 -1.357 . . . . 0.0 109.068 176.628 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 32.8 m -59.7 -34.88 73.47 Favored 'General case' 0 N--CA 1.45 -0.47 0 CA-C-N 115.091 -0.959 . . . . 0.0 110.719 178.262 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 30.1 ttpt -80.12 125.63 30.06 Favored 'General case' 0 N--CA 1.45 -0.429 0 CA-C-O 121.697 0.761 . . . . 0.0 111.701 -177.25 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 318' ' ' VAL . . . . . 0.475 ' O ' ' OG1' ' A' ' 319' ' ' THR . 13.2 p -134.39 142.45 40.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 114.814 -1.084 . . . . 0.0 109.262 178.468 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 319' ' ' THR . . . . . 0.475 ' OG1' ' O ' ' A' ' 318' ' ' VAL . 0.7 OUTLIER . . . . . 0 C--O 1.219 -0.513 0 CA-C-O 117.962 -1.018 . . . . 0.0 111.227 179.314 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 29.9 t . . . . . 0 C--O 1.232 0.159 0 CA-C-O 121.335 0.588 . . . . 0.0 110.228 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 1.9 mtpt -133.45 -166.65 1.8 Allowed 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.117 -0.947 . . . . 0.0 111.427 -179.313 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 295' ' ' ASP . . . . . 0.48 ' C ' ' OD1' ' A' ' 295' ' ' ASP . 48.7 p30 -82.92 11.04 6.6 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.19 -0.913 . . . . 0.0 109.203 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 17.6 m120 46.17 -138.34 0.58 Allowed 'General case' 0 CA--C 1.497 -1.074 0 CA-C-N 114.407 -1.27 . . . . 0.0 111.613 179.818 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 297' ' ' ILE . . . . . 0.582 ' CD1' ' CD2' ' A' ' 299' ' ' HIS . 13.9 tt -121.23 126.79 75.48 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-O 122.357 1.075 . . . . 0.0 111.404 -177.979 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 298' ' ' LYS . . . . . 0.404 ' HZ3' HG22 ' A' ' 300' ' ' VAL . 6.1 mtpm? -61.09 -36.52 79.89 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-N 112.98 -1.918 . . . . 0.0 112.568 179.13 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 299' ' ' HIS . . . . . 0.582 ' CD2' ' CD1' ' A' ' 297' ' ' ILE . 1.4 m170 38.21 60.89 1.19 Allowed 'General case' 0 CA--C 1.537 0.473 0 CA-C-O 121.175 0.512 . . . . 0.0 112.266 -179.657 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . 0.415 ' C ' ' N ' ' A' ' 302' ' ' GLY . 3.1 m -123.47 72.65 49.81 Favored Pre-proline 0 N--CA 1.464 0.274 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.009 178.658 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 301' ' ' PRO . . . . . 0.441 ' CD ' ' H ' ' A' ' 302' ' ' GLY . 44.5 Cg_endo -58.34 -17.8 35.1 Favored 'Trans proline' 0 C--N 1.317 -1.127 0 N-CA-C 107.96 -1.592 . . . . 0.0 107.96 177.72 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 302' ' ' GLY . . . . . 0.441 ' H ' ' CD ' ' A' ' 301' ' ' PRO . . . 116.61 156.13 10.58 Favored Glycine 0 N--CA 1.443 -0.846 0 CA-C-N 112.801 -2.0 . . . . 0.0 109.788 -179.014 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 303' ' ' GLY . . . . . 0.661 ' O ' ' N ' ' A' ' 305' ' ' SER . . . -163.69 -178.96 37.74 Favored Glycine 0 N--CA 1.446 -0.688 0 N-CA-C 108.528 -1.829 . . . . 0.0 108.528 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 59.32 -70.43 0.01 OUTLIER Glycine 0 CA--C 1.529 0.926 0 N-CA-C 109.815 -1.314 . . . . 0.0 109.815 -179.11 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 305' ' ' SER . . . . . 0.661 ' N ' ' O ' ' A' ' 303' ' ' GLY . 23.0 t -58.0 -33.97 69.5 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 121.081 0.467 . . . . 0.0 111.578 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 306' ' ' VAL . . . . . 0.55 ' CG2' ' H ' ' A' ' 307' ' ' GLN . 2.3 m -36.84 -100.91 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 N-CA-C 114.251 1.204 . . . . 0.0 114.251 -178.256 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 307' ' ' GLN . . . . . 0.55 ' H ' ' CG2' ' A' ' 306' ' ' VAL . 54.8 mt-30 -113.35 160.3 18.52 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 114.429 -1.26 . . . . 0.0 111.776 -176.376 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 308' ' ' ILE . . . . . 0.553 ' CG2' ' H ' ' A' ' 311' ' ' LYS . 34.9 mm -103.12 119.11 51.1 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-O 122.006 0.907 . . . . 0.0 112.635 -179.506 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 77.4 t -67.81 -40.27 83.38 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 CA-C-N 113.51 -1.677 . . . . 0.0 107.481 174.549 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 310' ' ' TYR . . . . . 0.525 ' CZ ' HG23 ' A' ' 308' ' ' ILE 0.361 51.2 p90 -62.7 -31.05 71.89 Favored 'General case' 0 N--CA 1.446 -0.634 0 N-CA-C 117.467 2.395 . . . . 0.0 117.467 -178.676 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 311' ' ' LYS . . . . . 0.553 ' H ' ' CG2' ' A' ' 308' ' ' ILE . 19.4 mtpp 52.89 65.57 5.8 Favored Pre-proline 0 C--N 1.319 -0.731 0 CA-C-N 119.815 1.189 . . . . 0.0 110.223 178.773 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 312' ' ' PRO . . . . . 0.45 ' C ' ' O ' ' A' ' 311' ' ' LYS . 78.4 Cg_exo 7.67 -129.04 0.0 OUTLIER 'Trans proline' 0 C--N 1.316 -1.171 0 C-N-CA 123.264 2.643 . . . . 0.0 116.937 -179.216 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 313' ' ' VAL . . . . . 0.543 ' O ' ' OG ' ' A' ' 316' ' ' SER . 17.6 m -112.89 28.77 2.28 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 CA-C-N 114.775 -1.102 . . . . 0.0 113.542 -175.931 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 314' ' ' ASP . . . . . 0.4 ' O ' ' CB ' ' A' ' 317' ' ' LYS . 92.1 m-20 -51.51 -36.46 44.79 Favored 'General case' 0 C--N 1.319 -0.751 0 C-N-CA 119.66 -0.816 . . . . 0.0 111.17 -177.127 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 315' ' ' LEU . . . . . 0.633 ' CD2' ' N ' ' A' ' 315' ' ' LEU . 0.3 OUTLIER -59.81 -35.34 74.5 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 119.819 -0.752 . . . . 0.0 110.414 178.587 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 316' ' ' SER . . . . . 0.543 ' OG ' ' O ' ' A' ' 313' ' ' VAL . 82.6 p -62.44 -21.12 65.17 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-O 121.431 0.634 . . . . 0.0 110.364 179.373 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 317' ' ' LYS . . . . . 0.4 ' CB ' ' O ' ' A' ' 314' ' ' ASP . 82.0 tttt -55.29 -34.53 64.18 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.071 -0.968 . . . . 0.0 111.779 -177.399 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 13.1 p -129.08 142.55 43.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 C-N-CA 120.471 -0.492 . . . . 0.0 110.789 179.657 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.221 -0.439 0 CA-C-O 118.008 -0.996 . . . . 0.0 110.555 -179.644 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 97.6 p . . . . . 0 C--O 1.231 0.116 0 CA-C-O 121.117 0.484 . . . . 0.0 110.687 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -133.59 170.67 15.19 Favored 'General case' 0 CA--C 1.506 -0.728 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.673 -179.499 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 295' ' ' ASP . . . . . . . . . . . . . 86.0 m-20 -63.12 143.71 57.55 Favored 'General case' 0 N--CA 1.438 -1.063 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 -179.769 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 22.3 t-20 -64.77 130.5 43.74 Favored 'General case' 0 C--N 1.309 -1.174 0 CA-C-N 115.246 -0.888 . . . . 0.0 111.669 -177.595 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 297' ' ' ILE . . . . . 0.453 HD12 HG21 ' A' ' 297' ' ' ILE . 71.4 mt -115.18 132.12 65.41 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.09 0 CA-C-N 114.856 -1.065 . . . . 0.0 110.545 -179.762 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 73.1 tttt -105.66 135.62 46.74 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.85 179.184 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 99.3 m-70 -118.94 140.48 49.92 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.089 178.451 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 3.6 m -123.98 78.28 58.44 Favored Pre-proline 0 C--N 1.33 -0.255 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.358 -179.156 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -56.53 145.82 78.3 Favored 'Trans proline' 0 C--N 1.312 -1.371 0 N-CA-C 109.244 -1.099 . . . . 0.0 109.244 178.807 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -49.36 107.52 0.32 Allowed Glycine 0 CA--C 1.52 0.375 0 C-N-CA 118.92 -1.61 . . . . 0.0 109.769 -178.864 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -77.92 -2.13 81.01 Favored Glycine 0 C--N 1.33 0.23 0 N-CA-C 109.798 -1.321 . . . . 0.0 109.798 179.59 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 95.33 -1.93 64.94 Favored Glycine 0 N--CA 1.45 -0.402 0 N-CA-C 108.958 -1.657 . . . . 0.0 108.958 -178.883 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 73.9 m -83.24 1.83 38.85 Favored 'General case' 0 N--CA 1.453 -0.32 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 178.505 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 306' ' ' VAL . . . . . . . . . . . . . 71.6 t -61.08 -39.93 83.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.062 -0.972 . . . . 0.0 110.214 -179.467 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 307' ' ' GLN . . . . . 0.792 ' HG3' ' H ' ' A' ' 308' ' ' ILE . 21.2 pt20 -159.63 -88.24 0.03 OUTLIER 'General case' 0 CA--C 1.542 0.637 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.824 179.065 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 308' ' ' ILE . . . . . 0.792 ' H ' ' HG3' ' A' ' 307' ' ' GLN . 32.0 pt -125.22 160.94 30.24 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 CA-C-N 118.985 0.811 . . . . 0.0 111.305 179.525 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . 0.655 ' CG1' ' H ' ' A' ' 310' ' ' TYR . 3.9 p -136.65 -65.26 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 178.199 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 310' ' ' TYR . . . . . 0.655 ' H ' ' CG1' ' A' ' 309' ' ' VAL . 0.8 OUTLIER -66.31 -19.47 65.82 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.288 -0.869 . . . . 0.0 112.484 178.461 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 311' ' ' LYS . . . . . 0.534 ' O ' ' C ' ' A' ' 312' ' ' PRO . 43.9 tttt 67.55 65.21 0.66 Allowed Pre-proline 0 C--N 1.326 -0.439 0 C-N-CA 120.791 -0.364 . . . . 0.0 110.674 -179.358 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 312' ' ' PRO . . . . . 0.568 ' O ' ' C ' ' A' ' 313' ' ' VAL . 70.6 Cg_exo 3.9 75.75 0.0 OUTLIER 'Trans proline' 0 N--CA 1.488 1.152 0 C-N-CA 122.924 2.416 . . . . 0.0 114.016 179.812 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 313' ' ' VAL . . . . . 0.568 ' C ' ' O ' ' A' ' 312' ' ' PRO . 13.7 p 1.33 71.18 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 O-C-N 124.085 0.866 . . . . 0.0 111.434 179.643 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 314' ' ' ASP . . . . . 0.506 ' N ' ' O ' ' A' ' 312' ' ' PRO . 21.7 t70 -55.18 -36.56 66.02 Favored 'General case' 0 CA--C 1.536 0.416 0 CA-C-N 114.464 -1.244 . . . . 0.0 112.992 -178.586 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 315' ' ' LEU . . . . . 0.635 ' N ' ' CD2' ' A' ' 315' ' ' LEU . 0.2 OUTLIER -58.88 -35.25 72.68 Favored 'General case' 0 N--CA 1.465 0.291 0 C-N-CA 120.585 -0.446 . . . . 0.0 111.258 -178.65 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 84.1 p -61.83 -26.39 68.09 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.002 0.43 . . . . 0.0 110.91 179.873 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 32.0 mmtm -58.07 -36.18 72.44 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.892 -0.595 . . . . 0.0 111.784 -177.397 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 13.3 p -132.47 143.11 40.81 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.26 0 CA-C-O 120.607 0.241 . . . . 0.0 111.077 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 27.0 p . . . . . 0 C--O 1.221 -0.446 0 CA-C-O 117.83 -1.081 . . . . 0.0 110.422 179.443 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 74.3 m . . . . . 0 C--O 1.231 0.108 0 CA-C-O 120.858 0.361 . . . . 0.0 110.457 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 76.9 mttt -96.56 151.52 19.51 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.439 179.699 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 295' ' ' ASP . . . . . 0.469 ' C ' ' OD1' ' A' ' 295' ' ' ASP . 48.9 p30 -86.7 9.86 17.49 Favored 'General case' 0 CA--C 1.503 -0.852 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 178.844 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 296' ' ' ASN . . . . . 0.616 ' CG ' ' H ' ' A' ' 297' ' ' ILE . 37.3 t-20 58.78 -143.17 0.62 Allowed 'General case' 0 CA--C 1.49 -1.341 0 CA-C-N 114.369 -1.287 . . . . 0.0 110.598 179.579 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 297' ' ' ILE . . . . . 0.616 ' H ' ' CG ' ' A' ' 296' ' ' ASN . 14.4 tt -121.4 131.19 73.65 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 CA-C-O 122.482 1.134 . . . . 0.0 112.416 -177.899 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 83.6 tttt -93.88 131.17 39.56 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-N 112.66 -2.064 . . . . 0.0 109.447 177.475 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 49.7 t-80 -128.26 137.05 51.82 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 120.114 -0.635 . . . . 0.0 110.86 179.792 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -124.21 76.55 60.43 Favored Pre-proline 0 N--CA 1.469 0.505 0 CA-C-N 116.804 -0.18 . . . . 0.0 111.065 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 83.6 Cg_endo -58.97 -25.49 77.75 Favored 'Trans proline' 0 N--CA 1.489 1.254 0 C-N-CA 121.126 1.217 . . . . 0.0 111.009 179.193 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . 174.77 133.61 1.75 Allowed Glycine 0 CA--C 1.532 1.125 0 CA-C-N 115.309 -0.86 . . . . 0.0 111.444 179.785 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -117.37 48.16 0.97 Allowed Glycine 0 CA--C 1.533 1.207 0 N-CA-C 110.534 -1.026 . . . . 0.0 110.534 179.565 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 99.1 -7.72 60.53 Favored Glycine 0 N--CA 1.466 0.687 0 N-CA-C 109.01 -1.636 . . . . 0.0 109.01 -178.143 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 27.9 t -83.68 -0.55 51.2 Favored 'General case' 0 CA--C 1.516 -0.327 0 N-CA-C 107.03 -1.47 . . . . 0.0 107.03 175.816 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 306' ' ' VAL . . . . . 0.623 ' O ' ' CB ' ' A' ' 307' ' ' GLN . 99.5 t -58.77 -41.56 82.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 113.569 -1.651 . . . . 0.0 112.193 -175.683 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 307' ' ' GLN . . . . . 0.623 ' CB ' ' O ' ' A' ' 306' ' ' VAL . 63.0 tt0 122.86 172.36 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.792 0 O-C-N 124.631 1.207 . . . . 0.0 108.023 -179.298 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 308' ' ' ILE . . . . . 0.466 ' N ' ' HG2' ' A' ' 307' ' ' GLN . 29.4 pt -121.25 155.24 25.11 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 N-CA-C 110.11 -0.329 . . . . 0.0 110.11 179.384 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 58.9 t -133.74 -5.62 1.34 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.292 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.611 179.569 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 310' ' ' TYR . . . . . 0.506 ' CD1' ' HD3' ' A' ' 312' ' ' PRO . 2.0 p90 -65.87 -18.29 65.24 Favored 'General case' 0 CA--C 1.517 -0.298 0 N-CA-C 112.508 0.559 . . . . 0.0 112.508 -176.481 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 311' ' ' LYS . . . . . 0.49 ' O ' ' C ' ' A' ' 312' ' ' PRO . 1.9 mtmm 59.38 64.91 2.84 Favored Pre-proline 0 C--N 1.325 -0.461 0 N-CA-C 107.252 -1.388 . . . . 0.0 107.252 -179.411 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 312' ' ' PRO . . . . . 0.506 ' HD3' ' CD1' ' A' ' 310' ' ' TYR . 1.1 Cg_exo -14.06 -62.1 0.01 OUTLIER 'Trans proline' 0 C--N 1.305 -1.731 0 C-N-CA 123.065 2.51 . . . . 0.0 114.536 -178.517 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 2.6 p -176.18 27.07 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 C-N-CA 120.397 -0.521 . . . . 0.0 111.314 179.621 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 92.9 m-20 -57.85 -37.66 74.29 Favored 'General case' 0 C--N 1.32 -0.705 0 N-CA-C 112.135 0.421 . . . . 0.0 112.135 -179.027 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 315' ' ' LEU . . . . . 0.484 ' O ' ' CD1' ' A' ' 315' ' ' LEU . 0.1 OUTLIER -56.95 -39.49 74.66 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 120.203 -0.599 . . . . 0.0 109.806 -178.671 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 86.6 p -63.34 -27.2 69.15 Favored 'General case' 0 N--CA 1.471 0.601 0 O-C-N 122.057 -0.402 . . . . 0.0 111.976 178.595 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 57.2 tttp -58.2 -36.17 72.7 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.156 -0.475 . . . . 0.0 112.114 -177.858 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 27.9 m -76.0 136.75 24.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-O 121.213 0.53 . . . . 0.0 111.097 -179.21 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 43.6 m . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 118.044 -0.979 . . . . 0.0 110.31 -179.952 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 46.7 m . . . . . 0 N--CA 1.46 0.074 0 N-CA-C 110.322 -0.251 . . . . 0.0 110.322 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 294' ' ' LYS . . . . . 0.47 ' C ' ' H ' ' A' ' 296' ' ' ASN . 11.5 mtpp -98.99 148.47 23.96 Favored 'General case' 0 N--CA 1.448 -0.569 0 CA-C-O 120.989 0.423 . . . . 0.0 111.188 -179.56 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 295' ' ' ASP . . . . . 0.471 ' OD2' ' C ' ' A' ' 295' ' ' ASP . 49.7 p30 -86.85 10.82 14.88 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 107.079 -1.452 . . . . 0.0 107.079 178.37 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 296' ' ' ASN . . . . . 0.47 ' H ' ' C ' ' A' ' 294' ' ' LYS . 81.1 m-20 29.17 -127.51 0.03 OUTLIER 'General case' 0 CA--C 1.5 -0.953 0 CA-C-N 112.604 -2.089 . . . . 0.0 113.467 -178.348 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 297' ' ' ILE . . . . . . . . . . . . . 14.7 tt -121.86 130.47 74.56 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.709 0 CA-C-O 122.473 1.13 . . . . 0.0 113.024 -177.469 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 15.6 ttmm -100.84 127.63 47.21 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-N 112.715 -2.039 . . . . 0.0 109.675 176.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 50.6 t-80 -136.33 114.33 11.37 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 120.552 -0.459 . . . . 0.0 111.479 179.193 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 3.2 m -133.89 72.87 72.2 Favored Pre-proline 0 N--CA 1.476 0.858 0 N-CA-C 113.953 1.094 . . . . 0.0 113.953 179.269 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 8.4 Cg_endo -61.25 -23.41 77.0 Favored 'Trans proline' 0 N--CA 1.502 2.017 0 CA-C-N 119.978 1.028 . . . . 0.0 112.026 177.732 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -77.01 46.25 2.38 Favored Glycine 0 CA--C 1.528 0.883 0 CA-C-N 115.121 -0.945 . . . . 0.0 113.194 -178.171 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -57.7 -28.53 60.22 Favored Glycine 0 N--CA 1.445 -0.7 0 N-CA-C 107.397 -2.281 . . . . 0.0 107.397 178.122 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 95.94 -0.56 62.62 Favored Glycine 0 N--CA 1.44 -1.038 0 N-CA-C 104.355 -3.498 . . . . 0.0 104.355 -175.594 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 72.8 m -83.06 1.36 40.52 Favored 'General case' 0 N--CA 1.436 -1.155 0 CA-C-N 112.486 -1.857 . . . . 0.0 110.314 179.295 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 306' ' ' VAL . . . . . . . . . . . . . 92.6 t -61.79 -42.63 95.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 115.424 -0.807 . . . . 0.0 112.178 -178.233 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 307' ' ' GLN . . . . . . . . . . . . . 2.5 pt20 173.65 -159.63 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.254 0 O-C-N 123.705 0.628 . . . . 0.0 109.585 -179.312 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 308' ' ' ILE . . . . . 0.52 ' CG2' ' H ' ' A' ' 311' ' ' LYS . 65.5 mt -114.97 122.95 70.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.546 178.127 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . 0.491 ' CG1' ' N ' ' A' ' 310' ' ' TYR . 8.0 p -63.82 -39.6 86.01 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.311 0 C-N-CA 118.859 -1.136 . . . . 0.0 108.442 176.588 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 310' ' ' TYR . . . . . 0.491 ' N ' ' CG1' ' A' ' 309' ' ' VAL 0.331 55.2 p90 -67.49 -33.14 74.49 Favored 'General case' 0 N--CA 1.452 -0.352 0 N-CA-C 117.584 2.438 . . . . 0.0 117.584 178.89 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 311' ' ' LYS . . . . . 0.539 ' O ' ' C ' ' A' ' 312' ' ' PRO . 2.9 ttpm? 46.34 61.29 13.24 Favored Pre-proline 0 C--N 1.315 -0.924 0 C-N-CA 119.136 -1.025 . . . . 0.0 109.508 179.606 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 312' ' ' PRO . . . . . 0.539 ' C ' ' O ' ' A' ' 311' ' ' LYS . 83.8 Cg_exo 24.16 55.25 0.0 OUTLIER 'Trans proline' 0 N--CA 1.486 1.031 0 C-N-CA 120.801 1.001 . . . . 0.0 113.201 -179.209 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 313' ' ' VAL . . . . . 0.526 ' C ' ' O ' ' A' ' 312' ' ' PRO . 4.2 m 2.68 84.11 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 CA-C-N 115.181 -0.918 . . . . 0.0 112.467 -179.743 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 56.1 t0 -55.8 -36.62 67.62 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.956 -0.565 . . . . 0.0 111.146 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 315' ' ' LEU . . . . . . . . . . . . . 62.4 mt -58.82 -33.91 70.93 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.593 -178.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 95.3 p -60.43 -28.05 67.98 Favored 'General case' 0 CA--C 1.511 -0.55 0 C-N-CA 120.048 -0.661 . . . . 0.0 111.058 -179.285 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 38.1 mtpt -92.04 137.75 32.11 Favored 'General case' 0 N--CA 1.448 -0.539 0 C-N-CA 119.455 -0.898 . . . . 0.0 109.868 179.434 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 13.7 p -131.69 143.0 41.68 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 CA-C-N 114.977 -1.01 . . . . 0.0 110.765 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 41.6 p . . . . . 0 C--O 1.22 -0.488 0 CA-C-O 118.02 -0.991 . . . . 0.0 110.559 179.989 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 92.3 p . . . . . 0 N--CA 1.463 0.191 0 CA-C-O 120.596 0.236 . . . . 0.0 110.463 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 16.0 mtpp -93.91 149.7 21.0 Favored 'General case' 0 N--CA 1.446 -0.633 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.714 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 295' ' ' ASP . . . . . 0.679 ' OD1' ' N ' ' A' ' 296' ' ' ASN . 49.8 p30 -60.16 -31.94 70.58 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 108.107 -1.071 . . . . 0.0 108.107 178.929 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 296' ' ' ASN . . . . . 0.679 ' N ' ' OD1' ' A' ' 295' ' ' ASP . 0.4 OUTLIER 58.99 44.98 15.54 Favored 'General case' 0 N--CA 1.45 -0.467 0 CA-C-N 115.277 -0.874 . . . . 0.0 109.804 179.63 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 297' ' ' ILE . . . . . 0.582 ' CG2' ' H ' ' A' ' 298' ' ' LYS . 84.4 mt 36.57 -118.09 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.439 -0.801 . . . . 0.0 110.634 -178.696 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 298' ' ' LYS . . . . . 0.582 ' H ' ' CG2' ' A' ' 297' ' ' ILE . 83.6 tttt -158.09 -95.86 0.03 OUTLIER 'General case' 0 CA--C 1.538 0.481 0 C-N-CA 119.948 -0.701 . . . . 0.0 111.564 179.499 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 76.3 m80 73.87 88.58 0.09 Allowed 'General case' 0 N--CA 1.476 0.871 0 N-CA-C 113.176 0.806 . . . . 0.0 113.176 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 3.1 m -124.01 77.87 58.78 Favored Pre-proline 0 CA--C 1.537 0.477 0 CA-C-N 115.408 -0.814 . . . . 0.0 109.582 179.125 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 301' ' ' PRO . . . . . 0.644 ' C ' ' H ' ' A' ' 303' ' ' GLY . 8.1 Cg_exo -56.51 -24.49 53.42 Favored 'Trans proline' 0 N--CA 1.494 1.529 0 C-N-CA 121.694 1.596 . . . . 0.0 113.1 -178.285 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -73.02 17.54 1.68 Allowed Glycine 0 N--CA 1.463 0.452 0 N-CA-C 109.238 -1.545 . . . . 0.0 109.238 178.338 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 303' ' ' GLY . . . . . 0.644 ' H ' ' C ' ' A' ' 301' ' ' PRO . . . -56.04 -23.58 39.77 Favored Glycine 0 CA--C 1.516 0.147 0 CA-C-N 114.311 -0.944 . . . . 0.0 110.971 -179.814 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 98.1 -4.36 60.69 Favored Glycine 0 CA--C 1.505 -0.59 0 N-CA-C 104.349 -3.5 . . . . 0.0 104.349 -174.776 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 85.2 p -64.69 -20.72 66.48 Favored 'General case' 0 N--CA 1.428 -1.541 0 CA-C-N 111.331 -2.435 . . . . 0.0 106.139 175.649 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 306' ' ' VAL . . . . . 0.586 ' O ' ' CB ' ' A' ' 307' ' ' GLN . 80.8 t -57.48 -42.09 80.16 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 CA-C-N 113.259 -1.791 . . . . 0.0 110.9 -177.375 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 307' ' ' GLN . . . . . 0.586 ' CB ' ' O ' ' A' ' 306' ' ' VAL . 57.2 tt0 103.92 160.48 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.484 0 O-C-N 124.378 1.049 . . . . 0.0 109.019 179.72 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 308' ' ' ILE . . . . . 0.648 HG21 ' H ' ' A' ' 310' ' ' TYR . 70.2 mt -114.98 129.0 71.91 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.46 0 CA-C-O 121.43 0.634 . . . . 0.0 110.738 178.53 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 1.5 t -86.56 8.63 1.95 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.558 0 CA-C-N 114.648 -1.16 . . . . 0.0 111.763 179.296 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 310' ' ' TYR . . . . . 0.648 ' H ' HG21 ' A' ' 308' ' ' ILE . 0.0 OUTLIER -54.27 -32.43 56.21 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 113.886 1.069 . . . . 0.0 113.886 -174.962 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 311' ' ' LYS . . . . . 0.53 ' N ' ' CD ' ' A' ' 312' ' ' PRO . 12.1 mmmt 57.33 68.16 2.14 Favored Pre-proline 0 N--CA 1.475 0.798 0 CA-C-N 119.732 1.151 . . . . 0.0 112.019 177.345 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 312' ' ' PRO . . . . . 0.594 ' O ' ' N ' ' A' ' 314' ' ' ASP . 86.6 Cg_exo -54.78 148.55 45.22 Favored 'Trans proline' 0 C--N 1.304 -1.808 0 C-N-CA 124.978 3.785 . . . . 0.0 114.761 -179.067 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 313' ' ' VAL . . . . . 0.469 ' O ' ' OG ' ' A' ' 316' ' ' SER . 17.8 m 38.82 12.28 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 CA-C-N 114.313 -1.312 . . . . 0.0 113.093 -179.337 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 314' ' ' ASP . . . . . 0.594 ' N ' ' O ' ' A' ' 312' ' ' PRO . 20.9 t70 -55.11 -36.64 65.91 Favored 'General case' 0 C--N 1.319 -0.734 0 C-N-CA 120.237 -0.585 . . . . 0.0 109.557 179.126 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 315' ' ' LEU . . . . . 0.62 ' CD2' ' N ' ' A' ' 315' ' ' LEU . 0.2 OUTLIER -61.12 -35.24 76.53 Favored 'General case' 0 CA--C 1.541 0.615 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.027 179.4 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 316' ' ' SER . . . . . 0.469 ' OG ' ' O ' ' A' ' 313' ' ' VAL . 79.6 p -62.4 -25.93 68.21 Favored 'General case' 0 N--CA 1.471 0.579 0 CA-C-O 121.643 0.735 . . . . 0.0 110.862 179.942 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 62.6 mmtt -58.04 -26.29 62.27 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 114.49 -1.232 . . . . 0.0 113.598 -178.432 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 11.6 p -110.22 138.6 37.32 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 CA-C-O 122.142 0.972 . . . . 0.0 111.061 -176.41 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 3.6 m . . . . . 0 C--O 1.219 -0.526 0 CA-C-N 113.335 -1.757 . . . . 0.0 110.203 -178.14 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 98.6 p . . . . . 0 N--CA 1.462 0.173 0 CA-C-O 120.911 0.386 . . . . 0.0 110.215 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 294' ' ' LYS . . . . . 0.443 ' HD2' ' N ' ' A' ' 294' ' ' LYS . 1.0 OUTLIER -85.4 -74.06 0.42 Allowed 'General case' 0 CA--C 1.512 -0.504 0 CA-C-O 121.701 0.762 . . . . 0.0 112.101 -179.296 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 295' ' ' ASP . . . . . 0.467 ' OD2' ' C ' ' A' ' 295' ' ' ASP . 50.6 p30 -89.58 6.94 38.92 Favored 'General case' 0 N--CA 1.442 -0.869 0 CA-C-N 114.427 -1.261 . . . . 0.0 109.468 179.879 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 17.3 t-20 58.97 53.53 5.58 Favored 'General case' 0 N--CA 1.473 0.675 0 N-CA-C 114.531 1.308 . . . . 0.0 114.531 176.587 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 297' ' ' ILE . . . . . 0.436 HG12 ' OD2' ' A' ' 295' ' ' ASP . 15.7 mm -73.4 140.94 16.96 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.653 0 C-N-CA 119.524 -0.87 . . . . 0.0 110.172 -179.617 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 298' ' ' LYS . . . . . 0.496 ' HZ2' HG12 ' A' ' 300' ' ' VAL . 14.0 ptmm? -125.22 154.26 41.89 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 114.682 -1.145 . . . . 0.0 111.62 -178.002 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 56.6 t-80 -124.36 129.6 50.99 Favored 'General case' 0 CA--C 1.536 0.409 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 178.265 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 300' ' ' VAL . . . . . 0.496 HG12 ' HZ2' ' A' ' 298' ' ' LYS . 0.2 OUTLIER -124.14 77.35 59.95 Favored Pre-proline 0 N--CA 1.474 0.763 0 N-CA-C 112.406 0.521 . . . . 0.0 112.406 -179.147 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -59.01 -27.63 85.57 Favored 'Trans proline' 0 C--N 1.312 -1.373 0 N-CA-C 109.885 -0.852 . . . . 0.0 109.885 177.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -121.66 106.32 1.08 Allowed Glycine 0 CA--C 1.523 0.568 0 CA-C-N 115.039 -0.982 . . . . 0.0 110.788 179.302 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -141.56 33.38 1.98 Allowed Glycine 0 CA--C 1.523 0.579 0 N-CA-C 109.905 -1.278 . . . . 0.0 109.905 179.23 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 95.2 -0.43 63.96 Favored Glycine 0 CA--C 1.521 0.426 0 N-CA-C 107.963 -2.055 . . . . 0.0 107.963 -177.891 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 52.0 p -82.78 -0.14 46.42 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 113.896 -1.152 . . . . 0.0 109.541 178.547 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 306' ' ' VAL . . . . . 0.514 ' O ' ' CB ' ' A' ' 307' ' ' GLN . 92.3 t -58.27 -39.19 72.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.509 -0.769 . . . . 0.0 110.127 -177.633 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 307' ' ' GLN . . . . . 0.614 ' O ' ' N ' ' A' ' 309' ' ' VAL . 57.9 tt0 94.07 139.74 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.727 0 N-CA-C 114.602 1.334 . . . . 0.0 114.602 177.816 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 308' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER 16.23 36.76 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.543 0 CA-C-N 112.723 -2.035 . . . . 0.0 115.397 177.99 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 309' ' ' VAL . . . . . 0.614 ' N ' ' O ' ' A' ' 307' ' ' GLN . 62.9 t -55.54 -37.45 45.65 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 N-CA-C 107.943 -1.132 . . . . 0.0 107.943 179.425 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 310' ' ' TYR . . . . . 0.495 ' CE1' ' HD3' ' A' ' 312' ' ' PRO . 33.6 p90 -60.3 -28.04 67.79 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 114.226 1.195 . . . . 0.0 114.226 -179.789 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 311' ' ' LYS . . . . . . . . . . . . . 2.3 tmtp? 68.97 74.32 0.29 Allowed Pre-proline 0 N--CA 1.474 0.75 0 CA-C-N 119.337 0.971 . . . . 0.0 110.512 178.313 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 312' ' ' PRO . . . . . 0.495 ' HD3' ' CE1' ' A' ' 310' ' ' TYR . 13.4 Cg_exo -54.83 -31.07 70.95 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 C-N-CA 122.59 2.193 . . . . 0.0 114.803 -177.014 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 39.2 t -124.26 134.81 65.63 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.525 0 C-N-CA 120.184 -0.606 . . . . 0.0 111.308 179.765 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 61.2 t0 -149.12 -89.42 0.08 Allowed 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.516 -0.765 . . . . 0.0 109.061 178.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 315' ' ' LEU . . . . . 0.538 ' CD2' ' H ' ' A' ' 315' ' ' LEU . 2.0 mm? -59.61 -31.09 69.16 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.065 178.041 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 25.2 m -55.29 -33.17 63.03 Favored 'General case' 0 N--CA 1.455 -0.197 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.133 -178.025 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 65.4 mttm -57.82 -34.1 69.3 Favored 'General case' 0 C--N 1.326 -0.435 0 C-N-CA 120.461 -0.496 . . . . 0.0 110.44 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 42.1 t -115.77 135.8 54.71 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-O 120.825 0.345 . . . . 0.0 110.983 -179.449 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 37.4 p . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.333 179.684 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.663 0 N-CA-C 111.123 -0.791 . . . . 0.0 111.123 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 293' ' ' SER . . . . . 0.464 ' O ' ' O ' ' A' ' 294' ' ' LYS . 97.5 p -122.27 153.86 38.34 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 121.119 0.485 . . . . 0.0 111.272 -179.815 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 294' ' ' LYS . . . . . 0.464 ' O ' ' O ' ' A' ' 293' ' ' SER . 57.7 mttp -55.19 -126.1 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.502 -0.772 . . . . 0.0 111.757 179.836 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 295' ' ' ASP . . . . . . . . . . . . . 89.5 m-20 -92.17 7.43 42.57 Favored 'General case' 0 N--CA 1.455 -0.224 0 CA-C-N 114.924 -1.035 . . . . 0.0 111.235 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 49.9 t30 60.26 52.13 5.1 Favored 'General case' 0 C--N 1.333 -0.119 0 C-N-CA 119.68 -0.808 . . . . 0.0 111.567 179.842 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 297' ' ' ILE . . . . . . . . . . . . . 80.9 mt -64.99 135.22 28.6 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 122.396 1.093 . . . . 0.0 111.779 -177.354 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 84.6 tttt -81.76 137.0 35.41 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 112.884 -1.962 . . . . 0.0 112.752 -179.085 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 74.4 t60 -124.53 136.36 53.92 Favored 'General case' 0 CA--C 1.543 0.711 0 N-CA-C 107.914 -1.143 . . . . 0.0 107.914 178.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -124.0 76.72 58.78 Favored Pre-proline 0 N--CA 1.481 1.09 0 N-CA-C 113.336 0.865 . . . . 0.0 113.336 -177.876 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -59.76 -26.1 81.19 Favored 'Trans proline' 0 N--CA 1.493 1.472 0 C-N-CA 121.221 1.28 . . . . 0.0 111.862 178.451 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -167.28 125.1 1.28 Allowed Glycine 0 CA--C 1.527 0.789 0 N-CA-C 110.89 -0.884 . . . . 0.0 110.89 -179.585 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -150.35 37.2 0.92 Allowed Glycine 0 N--CA 1.468 0.803 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 179.732 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 96.7 -4.72 63.85 Favored Glycine 0 C--N 1.317 -0.488 0 N-CA-C 106.262 -2.735 . . . . 0.0 106.262 -177.079 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 24.9 t -59.89 -27.76 66.99 Favored 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 112.827 -1.686 . . . . 0.0 109.121 176.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 306' ' ' VAL . . . . . 0.641 ' O ' ' CB ' ' A' ' 307' ' ' GLN . 73.5 t -55.41 -40.08 56.01 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.643 0 CA-C-N 114.081 -1.418 . . . . 0.0 112.038 -175.77 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 307' ' ' GLN . . . . . 0.641 ' CB ' ' O ' ' A' ' 306' ' ' VAL . 63.1 tp60 117.37 84.61 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.529 0 N-CA-C 113.921 1.082 . . . . 0.0 113.921 177.482 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 308' ' ' ILE . . . . . 0.445 HG13 ' CE2' ' A' ' 310' ' ' TYR . 18.6 tt 26.46 58.24 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 N-CA-C 113.16 0.8 . . . . 0.0 113.16 176.217 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 54.8 t -56.0 -39.23 56.64 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.605 0 C-N-CA 118.724 -1.19 . . . . 0.0 109.76 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 310' ' ' TYR . . . . . 0.695 ' O ' ' CD1' ' A' ' 310' ' ' TYR . 36.7 p90 -69.83 104.56 2.5 Favored 'General case' 0 N--CA 1.439 -1.0 0 C-N-CA 119.082 -1.047 . . . . 0.0 109.41 178.601 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 311' ' ' LYS . . . . . . . . . . . . . 38.6 mtpt -73.34 128.07 88.02 Favored Pre-proline 0 C--N 1.313 -1.016 0 C-N-CA 119.649 -0.82 . . . . 0.0 110.385 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 312' ' ' PRO . . . . . . . . . . . . . 85.3 Cg_exo -55.96 149.48 51.89 Favored 'Trans proline' 0 C--N 1.306 -1.66 0 N-CA-C 106.122 -2.299 . . . . 0.0 106.122 174.326 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 36.1 t -64.46 126.26 22.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 C-N-CA 116.284 -2.166 . . . . 0.0 110.775 -175.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 314' ' ' ASP . . . . . 0.43 ' O ' ' HB3' ' A' ' 317' ' ' LYS . 89.5 m-20 -95.59 -19.22 19.95 Favored 'General case' 0 N--CA 1.444 -0.762 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 175.509 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 315' ' ' LEU . . . . . . . . . . . . . 60.5 mt -62.22 -37.47 85.48 Favored 'General case' 0 C--O 1.232 0.141 0 CA-C-N 116.029 -0.532 . . . . 0.0 112.293 -178.324 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 82.9 p -63.03 -30.76 71.85 Favored 'General case' 0 CA--C 1.519 -0.22 0 CA-C-O 121.499 0.666 . . . . 0.0 109.886 179.877 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 317' ' ' LYS . . . . . 0.43 ' HB3' ' O ' ' A' ' 314' ' ' ASP . 18.8 tttt -59.38 -36.89 76.62 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 114.342 -1.299 . . . . 0.0 112.783 -178.824 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 318' ' ' VAL . . . . . 0.412 ' O ' ' OXT' ' A' ' 319' ' ' THR . 5.3 p -57.07 -33.98 44.0 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 N-CA-C 112.268 0.47 . . . . 0.0 112.268 -178.148 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 319' ' ' THR . . . . . 0.412 ' OXT' ' O ' ' A' ' 318' ' ' VAL . 1.3 m . . . . . 0 C--O 1.221 -0.443 0 CA-C-O 117.951 -1.023 . . . . 0.0 110.792 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.632 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 23.8 m -57.9 -35.31 70.84 Favored 'General case' 0 C--N 1.332 -0.186 0 C-N-CA 120.77 -0.372 . . . . 0.0 110.137 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -96.27 148.32 22.86 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.716 179.298 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 295' ' ' ASP . . . . . 0.596 ' O ' ' CB ' ' A' ' 296' ' ' ASN . 91.6 m-20 -56.52 -36.4 69.16 Favored 'General case' 0 CA--C 1.492 -1.251 0 N-CA-C 107.382 -1.34 . . . . 0.0 107.382 177.659 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 296' ' ' ASN . . . . . 0.596 ' CB ' ' O ' ' A' ' 295' ' ' ASP . 48.2 t30 118.39 -128.61 0.0 OUTLIER 'General case' 0 CA--C 1.469 -2.16 0 O-C-N 125.581 1.801 . . . . 0.0 110.097 179.51 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 297' ' ' ILE . . . . . 0.497 ' O ' ' CG2' ' A' ' 297' ' ' ILE . 8.9 tp -122.44 133.35 68.93 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.111 0 CA-C-N 114.499 -1.228 . . . . 0.0 110.497 -178.781 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 43.4 tttm -132.71 120.19 21.35 Favored 'General case' 0 C--N 1.294 -1.84 0 CA-C-N 114.234 -1.348 . . . . 0.0 110.323 174.453 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 79.8 m-70 -139.81 145.04 37.65 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.36 -0.836 . . . . 0.0 112.251 174.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -124.8 72.71 62.6 Favored Pre-proline 0 C--N 1.322 -0.63 0 CA-C-N 115.473 -0.785 . . . . 0.0 108.952 177.282 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -59.1 -24.67 74.76 Favored 'Trans proline' 0 N--CA 1.492 1.44 0 C-N-CA 121.034 1.156 . . . . 0.0 111.098 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . 150.15 136.51 2.58 Favored Glycine 0 CA--C 1.52 0.365 0 CA-C-N 115.05 -0.977 . . . . 0.0 110.875 179.442 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -84.57 1.52 88.76 Favored Glycine 0 CA--C 1.519 0.311 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 179.009 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 95.74 -2.83 64.81 Favored Glycine 0 CA--C 1.519 0.329 0 N-CA-C 108.936 -1.666 . . . . 0.0 108.936 -179.021 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 73.9 m -84.53 4.28 32.67 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 114.774 -0.713 . . . . 0.0 109.902 178.619 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 306' ' ' VAL . . . . . . . . . . . . . 98.8 t -59.67 -41.78 86.34 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.662 0 CA-C-O 122.235 1.017 . . . . 0.0 111.179 -178.309 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 307' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 -141.84 168.5 19.6 Favored 'General case' 0 C--N 1.31 -1.119 0 CA-C-N 112.896 -1.956 . . . . 0.0 109.0 -177.498 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 308' ' ' ILE . . . . . 0.552 HG22 ' H ' ' A' ' 311' ' ' LYS . 31.8 mm -104.05 117.81 50.19 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 CA-C-N 115.418 -0.81 . . . . 0.0 113.162 -179.152 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 21.0 m -78.53 -30.11 15.09 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.483 0 CA-C-N 114.13 -1.395 . . . . 0.0 108.398 175.592 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 310' ' ' TYR . . . . . 0.485 ' CE1' HG23 ' A' ' 308' ' ' ILE 0.364 51.7 p90 -64.15 -28.29 69.66 Favored 'General case' 0 N--CA 1.447 -0.608 0 N-CA-C 116.311 1.967 . . . . 0.0 116.311 -179.197 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 311' ' ' LYS . . . . . 0.552 ' H ' HG22 ' A' ' 308' ' ' ILE . 37.3 mtpt 53.72 65.65 5.32 Favored Pre-proline 0 C--N 1.318 -0.78 0 C-N-CA 119.875 -0.73 . . . . 0.0 110.958 178.44 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 312' ' ' PRO . . . . . 0.492 ' C ' ' O ' ' A' ' 311' ' ' LYS . 91.0 Cg_exo 3.86 -128.87 0.0 OUTLIER 'Trans proline' 0 N--CA 1.487 1.141 0 C-N-CA 123.092 2.528 . . . . 0.0 115.771 -179.287 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 4.5 p -113.04 37.06 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.718 0 N-CA-C 112.955 0.724 . . . . 0.0 112.955 -177.234 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 54.6 t0 -54.13 -35.26 62.01 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 112.081 0.4 . . . . 0.0 112.081 -179.614 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 315' ' ' LEU . . . . . 0.689 ' CD2' ' H ' ' A' ' 315' ' ' LEU . 1.8 mm? -57.15 -35.18 69.21 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 120.299 -0.56 . . . . 0.0 111.074 -178.486 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 89.8 p -62.37 -23.59 66.89 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 121.135 0.493 . . . . 0.0 110.582 178.65 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 41.8 tttp -56.62 -35.4 68.26 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.137 -0.938 . . . . 0.0 111.855 -177.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 13.3 p -129.7 142.75 43.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.045 0.45 . . . . 0.0 110.439 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 117.939 -1.029 . . . . 0.0 110.693 -179.27 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.634 0 N-CA-C 110.786 -0.925 . . . . 0.0 110.786 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 46.5 m -63.39 156.79 24.9 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.159 0.504 . . . . 0.0 110.775 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 11.6 mtpp -81.17 168.9 18.04 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.807 179.476 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 295' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -48.68 -31.88 7.5 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.974 -177.347 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 74.6 m-20 63.81 52.47 2.15 Favored 'General case' 0 CA--C 1.516 -0.355 0 C-N-CA 120.269 -0.572 . . . . 0.0 111.457 -179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 297' ' ' ILE . . . . . . . . . . . . . 82.1 mt -62.98 130.93 28.21 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.249 0 N-CA-C 107.66 -1.237 . . . . 0.0 107.66 -178.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 44.4 tttp -81.98 133.69 35.32 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 115.469 1.655 . . . . 0.0 115.469 -175.373 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -121.72 139.17 53.91 Favored 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 106.843 -1.54 . . . . 0.0 106.843 175.812 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 8.0 m -125.75 72.04 68.15 Favored Pre-proline 0 N--CA 1.472 0.651 0 C-N-CA 119.308 -0.957 . . . . 0.0 113.31 -178.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 79.3 Cg_exo -62.07 -23.62 75.82 Favored 'Trans proline' 0 C--N 1.302 -1.918 0 C-N-CA 122.281 1.987 . . . . 0.0 110.692 176.266 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -92.97 28.43 9.46 Favored Glycine 0 CA--C 1.526 0.745 0 CA-C-N 114.492 -1.231 . . . . 0.0 112.713 -178.383 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 303' ' ' GLY . . . . . 0.415 ' C ' ' N ' ' A' ' 305' ' ' SER . . . -84.4 -173.28 49.73 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.376 -0.916 . . . . 0.0 111.39 -178.556 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . -50.68 -23.88 7.21 Favored Glycine 0 N--CA 1.453 -0.221 0 N-CA-C 108.31 -1.916 . . . . 0.0 108.31 178.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 305' ' ' SER . . . . . 0.415 ' N ' ' C ' ' A' ' 303' ' ' GLY . 22.4 m -55.07 -34.56 63.7 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 114.751 -0.724 . . . . 0.0 111.881 -179.223 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 306' ' ' VAL . . . . . 0.862 ' O ' ' O ' ' A' ' 307' ' ' GLN . 79.0 t -60.88 -39.72 82.9 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.712 0 C-N-CA 121.096 -0.241 . . . . 0.0 110.55 179.772 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 307' ' ' GLN . . . . . 0.862 ' O ' ' O ' ' A' ' 306' ' ' VAL . 13.0 pt20 24.88 166.03 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.471 0 O-C-N 125.222 1.576 . . . . 0.0 113.138 -177.292 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 308' ' ' ILE . . . . . 0.715 ' O ' ' N ' ' A' ' 310' ' ' TYR . 8.5 tt -59.26 -26.86 34.96 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.011 0 CA-C-N 114.192 -1.367 . . . . 0.0 112.753 -176.529 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER 51.06 -42.14 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.204 0 N-CA-C 113.0 0.741 . . . . 0.0 113.0 179.454 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 310' ' ' TYR . . . . . 0.715 ' N ' ' O ' ' A' ' 308' ' ' ILE 0.485 52.5 p90 -65.06 -25.48 67.83 Favored 'General case' 0 CA--C 1.564 1.507 0 N-CA-C 119.69 3.219 . . . . 0.0 119.69 -178.074 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 311' ' ' LYS . . . . . 0.441 ' HB2' ' O ' ' A' ' 310' ' ' TYR . 11.3 mttp 74.15 77.25 0.19 Allowed Pre-proline 0 N--CA 1.509 2.516 0 CA-C-N 120.996 1.726 . . . . 0.0 112.13 177.914 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 312' ' ' PRO . . . . . . . . . . . . . 4.7 Cg_endo -54.26 -34.33 79.25 Favored 'Trans proline' 0 N--CA 1.522 3.165 0 C-N-CA 123.524 2.816 . . . . 0.0 117.447 -178.178 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 69.7 t -67.29 -38.64 81.3 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.004 0 N-CA-C 116.155 1.909 . . . . 0.0 116.155 -178.398 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 314' ' ' ASP . . . . . 0.519 ' O ' ' O ' ' A' ' 317' ' ' LYS . 91.1 m-20 -55.47 -39.99 71.08 Favored 'General case' 0 C--N 1.322 -0.62 0 C-N-CA 118.697 -1.201 . . . . 0.0 113.103 -174.074 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 315' ' ' LEU . . . . . 0.516 ' CD2' ' H ' ' A' ' 315' ' ' LEU . 2.0 mm? -65.22 -36.71 85.01 Favored 'General case' 0 C--N 1.326 -0.423 0 C-N-CA 118.918 -1.113 . . . . 0.0 108.892 176.932 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 22.5 m -60.39 -36.36 77.91 Favored 'General case' 0 CA--C 1.516 -0.364 0 N-CA-C 108.253 -1.017 . . . . 0.0 108.253 178.079 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 317' ' ' LYS . . . . . 0.519 ' O ' ' O ' ' A' ' 314' ' ' ASP . 35.7 ttmt -97.02 117.38 31.06 Favored 'General case' 0 N--CA 1.446 -0.668 0 CA-C-N 114.958 -1.019 . . . . 0.0 111.098 179.71 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 59.5 t -130.92 135.84 59.26 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.333 176.728 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.218 -0.604 0 CA-C-O 117.871 -1.061 . . . . 0.0 110.451 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.728 0 N-CA-C 111.005 -0.838 . . . . 0.0 111.005 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 92.5 p -122.65 156.43 34.34 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.921 0.391 . . . . 0.0 110.531 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 11.9 mtpt -91.8 158.47 16.32 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.702 0.763 . . . . 0.0 112.489 -179.206 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 295' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -53.7 -33.8 56.68 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 114.359 -1.291 . . . . 0.0 110.652 -179.594 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 50.8 t30 64.73 54.34 1.39 Allowed 'General case' 0 CA--C 1.521 -0.14 0 C-N-CA 119.746 -0.782 . . . . 0.0 111.871 -179.817 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 297' ' ' ILE . . . . . . . . . . . . . 75.8 mt -68.05 139.25 21.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.304 -179.024 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 11.5 pttp -77.47 147.71 35.75 Favored 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 114.293 1.22 . . . . 0.0 114.293 -176.391 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 77.3 m80 -120.16 139.32 52.79 Favored 'General case' 0 N--CA 1.454 -0.261 0 CA-C-N 114.032 -1.44 . . . . 0.0 108.455 176.749 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 3.3 m -122.84 73.7 45.49 Favored Pre-proline 0 C--N 1.327 -0.387 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 179.574 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -61.1 -25.15 80.72 Favored 'Trans proline' 0 C--N 1.31 -1.458 0 C-N-CA 122.766 2.311 . . . . 0.0 114.176 -179.353 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -138.14 58.47 0.63 Allowed Glycine 0 CA--C 1.525 0.67 0 C-N-CA 120.597 -0.811 . . . . 0.0 113.363 -177.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -57.2 -28.54 58.87 Favored Glycine 0 N--CA 1.445 -0.722 0 N-CA-C 105.901 -2.88 . . . . 0.0 105.901 176.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 98.91 -10.45 62.2 Favored Glycine 0 N--CA 1.442 -0.966 0 N-CA-C 104.077 -3.609 . . . . 0.0 104.077 -176.099 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 84.9 p -66.29 -27.74 68.16 Favored 'General case' 0 N--CA 1.432 -1.336 0 CA-C-N 112.024 -2.088 . . . . 0.0 111.875 177.877 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 306' ' ' VAL . . . . . . . . . . . . . 55.8 t -61.1 -46.54 96.45 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.331 0 CA-C-O 122.151 0.977 . . . . 0.0 111.382 -175.385 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 307' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -148.14 164.4 34.02 Favored 'General case' 0 N--CA 1.441 -0.89 0 CA-C-N 113.567 -1.652 . . . . 0.0 110.206 -179.175 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 308' ' ' ILE . . . . . 0.442 HG12 ' CZ ' ' A' ' 310' ' ' TYR . 7.2 tp -122.37 129.72 75.07 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 CA-C-O 122.027 0.918 . . . . 0.0 110.915 176.266 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 69.6 t -67.25 -31.68 54.15 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.494 0 CA-C-N 113.639 -1.619 . . . . 0.0 115.128 179.656 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 310' ' ' TYR . . . . . 0.506 ' HD1' ' N ' ' A' ' 311' ' ' LYS . 0.0 OUTLIER -52.38 -33.84 45.23 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 117.197 2.295 . . . . 0.0 117.197 -171.689 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 311' ' ' LYS . . . . . 0.542 ' O ' ' C ' ' A' ' 312' ' ' PRO . 1.1 mmtt 54.09 64.68 6.15 Favored Pre-proline 0 CA--C 1.549 0.911 0 CA-C-N 121.697 2.044 . . . . 0.0 109.441 -179.974 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 312' ' ' PRO . . . . . 0.542 ' C ' ' O ' ' A' ' 311' ' ' LYS . 81.6 Cg_exo 2.76 64.82 0.0 OUTLIER 'Trans proline' 0 N--CA 1.49 1.321 0 C-N-CA 122.706 2.271 . . . . 0.0 114.794 -179.513 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 313' ' ' VAL . . . . . 0.541 ' N ' ' O ' ' A' ' 311' ' ' LYS . 1.8 m 20.96 54.17 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 CA-C-N 115.46 -0.791 . . . . 0.0 111.973 179.14 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 314' ' ' ASP . . . . . 0.648 ' OD2' ' N ' ' A' ' 315' ' ' LEU . 49.6 p30 -60.44 -33.7 72.93 Favored 'General case' 0 C--N 1.322 -0.614 0 C-N-CA 120.611 -0.435 . . . . 0.0 110.858 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 315' ' ' LEU . . . . . 0.648 ' N ' ' OD2' ' A' ' 314' ' ' ASP . 6.1 mp -59.16 -37.48 77.41 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 118.833 -1.147 . . . . 0.0 109.591 179.44 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 316' ' ' SER . . . . . 0.482 ' OG ' ' O ' ' A' ' 313' ' ' VAL . 87.3 p -63.53 -28.04 69.67 Favored 'General case' 0 CA--C 1.509 -0.62 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 177.491 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 15.4 ttpt -82.8 133.14 35.15 Favored 'General case' 0 N--CA 1.446 -0.652 0 CA-C-N 114.434 -1.257 . . . . 0.0 108.828 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 13.3 p -130.55 142.28 44.1 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.751 0 C-N-CA 120.599 -0.441 . . . . 0.0 110.693 -179.761 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.22 -0.491 0 CA-C-O 117.851 -1.071 . . . . 0.0 110.967 -179.696 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.635 0 N-CA-C 110.99 -0.844 . . . . 0.0 110.99 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 74.5 m -82.72 3.7 28.12 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.648 0.261 . . . . 0.0 110.865 -179.813 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 294' ' ' LYS . . . . . 0.465 ' C ' ' H ' ' A' ' 296' ' ' ASN . 68.7 mttm -92.95 148.69 21.79 Favored 'General case' 0 N--CA 1.451 -0.39 0 CA-C-O 121.548 0.689 . . . . 0.0 112.099 -179.355 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 295' ' ' ASP . . . . . 0.478 ' C ' ' OD1' ' A' ' 295' ' ' ASP . 49.4 p30 -88.19 11.55 16.1 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 106.427 -1.694 . . . . 0.0 106.427 177.218 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 296' ' ' ASN . . . . . 0.465 ' H ' ' C ' ' A' ' 294' ' ' LYS . 21.1 m120 33.88 -115.14 0.07 Allowed 'General case' 0 CA--C 1.49 -1.347 0 CA-C-N 112.878 -1.965 . . . . 0.0 111.934 -177.335 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 297' ' ' ILE . . . . . 0.439 HG12 ' HD1' ' A' ' 299' ' ' HIS . 16.9 tt -120.53 133.03 68.54 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.355 0 C-N-CA 118.478 -1.289 . . . . 0.0 110.315 -178.474 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 44.6 tttm -123.97 119.84 30.73 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 113.996 -1.457 . . . . 0.0 111.549 177.271 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 299' ' ' HIS . . . . . 0.439 ' HD1' HG12 ' A' ' 297' ' ' ILE . 71.7 m80 -137.89 145.37 42.05 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 114.504 -1.225 . . . . 0.0 108.464 173.873 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -123.81 68.37 43.48 Favored Pre-proline 0 N--CA 1.468 0.464 0 C-N-CA 119.358 -0.937 . . . . 0.0 111.856 179.231 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 301' ' ' PRO . . . . . 0.422 ' C ' ' H ' ' A' ' 303' ' ' GLY . 37.3 Cg_endo -64.35 -23.12 65.75 Favored 'Trans proline' 0 C--N 1.312 -1.353 0 C-N-CA 122.232 1.955 . . . . 0.0 111.044 176.485 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -80.75 25.78 3.35 Favored Glycine 0 N--CA 1.471 0.982 0 CA-C-N 114.794 -1.094 . . . . 0.0 111.297 -178.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 303' ' ' GLY . . . . . 0.422 ' H ' ' C ' ' A' ' 301' ' ' PRO . . . -56.08 -25.23 46.04 Favored Glycine 0 C--N 1.317 -0.522 0 N-CA-C 110.588 -1.005 . . . . 0.0 110.588 -179.872 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 100.5 -2.77 56.17 Favored Glycine 0 C--N 1.319 -0.401 0 N-CA-C 104.651 -3.379 . . . . 0.0 104.651 -174.339 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 86.9 p -65.49 -17.41 64.53 Favored 'General case' 0 N--CA 1.444 -0.774 0 CA-C-N 111.755 -2.223 . . . . 0.0 107.484 175.325 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 306' ' ' VAL . . . . . 0.527 ' O ' ' CB ' ' A' ' 307' ' ' GLN . 93.9 t -54.98 -41.52 59.0 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.628 0 CA-C-N 113.231 -1.804 . . . . 0.0 109.513 -176.44 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 307' ' ' GLN . . . . . 0.527 ' CB ' ' O ' ' A' ' 306' ' ' VAL . 12.4 pt20 124.39 147.43 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.86 0 O-C-N 124.921 1.388 . . . . 0.0 110.743 177.67 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 308' ' ' ILE . . . . . 0.403 HD11 ' CE1' ' A' ' 310' ' ' TYR . 15.9 tt -61.55 -26.63 40.14 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.045 0 CA-C-N 114.406 -1.27 . . . . 0.0 113.893 -178.483 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . 0.417 HG22 HE21 ' A' ' 307' ' ' GLN . 75.4 t 57.33 -30.24 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.396 0 N-CA-C 116.346 1.98 . . . . 0.0 116.346 178.903 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 310' ' ' TYR . . . . . 0.474 ' CE1' ' HA ' ' A' ' 312' ' ' PRO . 0.0 OUTLIER -65.79 -14.23 60.99 Favored 'General case' 0 N--CA 1.479 1.001 0 N-CA-C 115.805 1.78 . . . . 0.0 115.805 -175.33 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 311' ' ' LYS . . . . . 0.493 ' O ' ' C ' ' A' ' 312' ' ' PRO . 0.6 OUTLIER 74.46 65.86 0.28 Allowed Pre-proline 0 N--CA 1.473 0.708 0 CA-C-N 118.805 0.73 . . . . 0.0 110.585 -179.909 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 312' ' ' PRO . . . . . 0.493 ' C ' ' O ' ' A' ' 311' ' ' LYS . 12.3 Cg_exo -10.2 -111.4 0.0 OUTLIER 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 123.255 2.636 . . . . 0.0 114.905 179.375 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 17.7 m -111.05 15.69 8.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 N-CA-C 111.954 0.353 . . . . 0.0 111.954 -178.253 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 93.2 m-20 -55.26 -38.76 68.97 Favored 'General case' 0 N--CA 1.451 -0.391 0 C-N-CA 119.436 -0.906 . . . . 0.0 111.096 -178.046 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 315' ' ' LEU . . . . . . . . . . . . . 27.8 tp -60.09 -38.72 83.8 Favored 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 119.904 -0.718 . . . . 0.0 110.258 178.475 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 21.2 m -59.57 -33.95 72.08 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 115.508 -0.769 . . . . 0.0 111.596 179.263 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 33.9 tttp -56.78 -36.34 69.73 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.267 -0.879 . . . . 0.0 112.301 -177.346 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 318' ' ' VAL . . . . . 0.445 ' O ' ' C ' ' A' ' 319' ' ' THR . 5.9 p -57.11 -34.35 45.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 C-N-CA 120.067 -0.653 . . . . 0.0 109.888 179.647 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 319' ' ' THR . . . . . 0.445 ' C ' ' O ' ' A' ' 318' ' ' VAL . 2.5 m . . . . . 0 C--O 1.219 -0.546 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.911 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.65 0 N-CA-C 110.983 -0.847 . . . . 0.0 110.983 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 89.4 p -126.03 157.57 37.56 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 121.309 0.576 . . . . 0.0 111.296 -179.521 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 9.5 mtpm? -88.35 172.83 9.12 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.45 179.77 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 295' ' ' ASP . . . . . 0.446 ' OD2' ' C ' ' A' ' 295' ' ' ASP . 49.1 p30 -76.76 8.49 3.62 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 112.571 0.582 . . . . 0.0 112.571 -175.629 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 76.7 m-20 61.44 51.68 4.05 Favored 'General case' 0 N--CA 1.468 0.428 0 N-CA-C 115.74 1.755 . . . . 0.0 115.74 175.34 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 297' ' ' ILE . . . . . . . . . . . . . 16.2 mm -70.8 132.51 33.19 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.158 0 N-CA-C 106.975 -1.491 . . . . 0.0 106.975 179.559 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 3.6 ptmt -99.37 144.23 28.73 Favored 'General case' 0 N--CA 1.464 0.264 0 N-CA-C 115.592 1.701 . . . . 0.0 115.592 -175.446 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 299' ' ' HIS . . . . . 0.439 ' CE1' ' CG ' ' A' ' 301' ' ' PRO . 54.8 t-80 -126.75 119.09 26.05 Favored 'General case' 0 CA--C 1.536 0.439 0 N-CA-C 106.022 -1.844 . . . . 0.0 106.022 175.515 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -129.82 77.05 77.49 Favored Pre-proline 0 N--CA 1.477 0.904 0 N-CA-C 114.939 1.459 . . . . 0.0 114.939 -176.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 301' ' ' PRO . . . . . 0.529 ' C ' ' H ' ' A' ' 303' ' ' GLY . 75.2 Cg_exo -60.29 -22.76 72.0 Favored 'Trans proline' 0 N--CA 1.502 2.005 0 C-N-CA 121.705 1.604 . . . . 0.0 112.446 177.285 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -69.32 20.41 0.45 Allowed Glycine 0 CA--C 1.526 0.732 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.924 -178.757 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 303' ' ' GLY . . . . . 0.529 ' H ' ' C ' ' A' ' 301' ' ' PRO . . . -56.82 -28.16 57.0 Favored Glycine 0 N--CA 1.453 -0.202 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 179.732 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 98.31 -4.71 60.47 Favored Glycine 0 C--N 1.317 -0.486 0 N-CA-C 103.962 -3.655 . . . . 0.0 103.962 -174.603 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 83.8 p -65.88 -18.93 65.67 Favored 'General case' 0 N--CA 1.438 -1.047 0 CA-C-N 111.333 -2.434 . . . . 0.0 108.615 176.591 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 306' ' ' VAL . . . . . 0.422 ' CG2' ' O ' ' A' ' 301' ' ' PRO . 90.7 t -56.35 -40.77 68.65 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 CA-C-N 113.98 -1.463 . . . . 0.0 110.672 -175.677 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 307' ' ' GLN . . . . . 0.761 ' HG2' ' H ' ' A' ' 308' ' ' ILE . 6.2 tt0 -173.27 -151.02 0.05 Allowed 'General case' 0 CA--C 1.536 0.43 0 N-CA-C 107.691 -1.226 . . . . 0.0 107.691 179.126 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 308' ' ' ILE . . . . . 0.761 ' H ' ' HG2' ' A' ' 307' ' ' GLN . 64.9 mt -114.92 136.69 50.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 179.289 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 71.3 t -60.55 -39.64 81.95 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.089 0 N-CA-C 112.828 0.677 . . . . 0.0 112.828 -178.789 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 310' ' ' TYR . . . . . 0.57 ' N ' ' CD1' ' A' ' 310' ' ' TYR . 0.1 OUTLIER -148.62 23.25 1.01 Allowed 'General case' 0 N--CA 1.477 0.906 0 N-CA-C 115.931 1.826 . . . . 0.0 115.931 -176.623 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 311' ' ' LYS . . . . . 0.518 ' H ' HG22 ' A' ' 308' ' ' ILE . 0.1 OUTLIER 51.69 67.71 3.89 Favored Pre-proline 0 CA--C 1.546 0.807 0 C-N-CA 117.842 -1.543 . . . . 0.0 107.869 -179.253 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 312' ' ' PRO . . . . . 0.471 ' C ' ' O ' ' A' ' 311' ' ' LYS . 60.3 Cg_exo -6.33 -66.55 0.0 OUTLIER 'Trans proline' 0 N--CA 1.492 1.423 0 C-N-CA 123.109 2.539 . . . . 0.0 116.29 -176.356 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 20.2 m -129.78 156.97 42.43 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.687 0 N-CA-C 113.285 0.846 . . . . 0.0 113.285 -178.429 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 23.1 t70 -142.71 -61.73 0.43 Allowed 'General case' 0 CA--C 1.535 0.382 0 CA-C-N 114.912 -1.04 . . . . 0.0 110.525 178.612 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 315' ' ' LEU . . . . . 0.475 ' O ' ' O ' ' A' ' 318' ' ' VAL . 6.6 mp -61.25 -35.1 76.34 Favored 'General case' 0 N--CA 1.47 0.554 0 N-CA-C 112.357 0.503 . . . . 0.0 112.357 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 85.2 p -60.78 -26.06 66.98 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.287 0.565 . . . . 0.0 109.9 -179.446 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 85.9 tttt -57.4 -36.76 71.72 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.355 -0.839 . . . . 0.0 110.362 -179.67 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 318' ' ' VAL . . . . . 0.475 ' O ' ' O ' ' A' ' 315' ' ' LEU . 13.7 p -131.45 142.97 41.91 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.176 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.332 179.67 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 2.0 m . . . . . 0 C--O 1.22 -0.494 0 CA-C-O 118.024 -0.988 . . . . 0.0 110.598 179.986 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.702 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 86.2 p -62.25 -25.99 68.14 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.835 0.35 . . . . 0.0 110.676 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 11.5 mtpp -89.45 162.65 15.63 Favored 'General case' 0 CA--C 1.515 -0.381 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.869 179.89 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 295' ' ' ASP . . . . . 0.653 ' OD1' ' N ' ' A' ' 296' ' ' ASN . 50.0 p30 -57.58 -33.47 68.21 Favored 'General case' 0 N--CA 1.449 -0.524 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.407 -178.501 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 296' ' ' ASN . . . . . 0.653 ' N ' ' OD1' ' A' ' 295' ' ' ASP . 16.4 t-20 58.44 56.54 4.31 Favored 'General case' 0 CA--C 1.516 -0.357 0 C-N-CA 118.38 -1.328 . . . . 0.0 110.558 177.388 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 297' ' ' ILE . . . . . 0.42 ' C ' ' O ' ' A' ' 296' ' ' ASN . 21.6 mm -42.63 137.25 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-O 122.659 1.219 . . . . 0.0 109.975 -175.932 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 83.1 tttt -57.38 -36.04 70.74 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 112.354 -2.203 . . . . 0.0 112.939 -176.744 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 299' ' ' HIS . . . . . 0.408 ' H ' HG22 ' A' ' 297' ' ' ILE . 1.2 m80 64.86 112.35 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 120.167 -0.613 . . . . 0.0 109.755 -179.14 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -122.21 78.32 43.51 Favored Pre-proline 0 C--N 1.325 -0.46 0 CA-C-N 115.82 -0.627 . . . . 0.0 109.885 -179.293 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -56.32 -23.65 47.34 Favored 'Trans proline' 0 C--N 1.315 -1.231 0 C-N-CA 120.904 1.069 . . . . 0.0 110.238 -179.426 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 302' ' ' GLY . . . . . 0.473 ' C ' ' H ' ' A' ' 304' ' ' GLY . . . -167.15 127.21 1.54 Allowed Glycine 0 CA--C 1.526 0.721 0 CA-C-N 114.965 -1.016 . . . . 0.0 110.882 179.002 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -78.85 10.87 30.26 Favored Glycine 0 N--CA 1.463 0.459 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 178.811 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 304' ' ' GLY . . . . . 0.473 ' H ' ' C ' ' A' ' 302' ' ' GLY . . . 98.39 -4.2 60.06 Favored Glycine 0 CA--C 1.519 0.334 0 N-CA-C 108.25 -1.94 . . . . 0.0 108.25 -177.483 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 305' ' ' SER . . . . . 0.524 ' O ' ' C ' ' A' ' 306' ' ' VAL . 23.9 m -59.2 -33.14 70.61 Favored 'General case' 0 C--O 1.233 0.193 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 177.259 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 306' ' ' VAL . . . . . 0.562 ' CG2' ' H ' ' A' ' 307' ' ' GLN . 4.9 m -7.04 -109.7 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 CA-C-N 114.626 -1.17 . . . . 0.0 111.81 -178.881 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 307' ' ' GLN . . . . . 0.562 ' H ' ' CG2' ' A' ' 306' ' ' VAL . 25.3 pt20 -138.08 154.84 49.22 Favored 'General case' 0 N--CA 1.451 -0.401 0 CA-C-O 121.466 0.65 . . . . 0.0 109.699 178.612 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 308' ' ' ILE . . . . . 1.002 ' O ' ' N ' ' A' ' 310' ' ' TYR . 16.3 pt -78.1 -25.15 14.09 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.779 0 N-CA-C 116.09 1.885 . . . . 0.0 116.09 -177.239 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . 0.575 ' O ' ' CG1' ' A' ' 309' ' ' VAL . 93.7 t 9.4 27.78 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.257 0 N-CA-C 113.989 1.107 . . . . 0.0 113.989 -178.814 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 310' ' ' TYR . . . . . 1.002 ' N ' ' O ' ' A' ' 308' ' ' ILE 0.253 0.4 OUTLIER -71.66 -19.98 62.01 Favored 'General case' 0 C--N 1.332 -0.175 0 N-CA-C 113.158 0.799 . . . . 0.0 113.158 -179.523 . . . . . . . . 4 4 . 1 . 007 nuclear orig full ' A' A ' 311' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 57.08 62.72 5.66 Favored Pre-proline 0 C--N 1.325 -0.49 0 CA-C-O 121.316 0.579 . . . . 0.0 109.786 179.718 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 312' ' ' PRO . . . . . 0.778 ' O ' ' N ' ' A' ' 314' ' ' ASP . 32.7 Cg_endo -58.88 143.54 99.31 Favored 'Trans proline' 0 C--N 1.303 -1.855 0 C-N-CA 122.648 2.232 . . . . 0.0 111.288 179.223 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 313' ' ' VAL . . . . . 0.494 ' O ' ' OG ' ' A' ' 316' ' ' SER . 18.9 m -6.58 59.29 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.645 0 O-C-N 124.224 0.953 . . . . 0.0 113.295 -179.452 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 314' ' ' ASP . . . . . 0.778 ' N ' ' O ' ' A' ' 312' ' ' PRO . 93.2 m-20 -56.89 -36.75 70.5 Favored 'General case' 0 C--O 1.223 -0.308 0 N-CA-C 111.66 0.244 . . . . 0.0 111.66 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 315' ' ' LEU . . . . . . . . . . . . . 61.7 mt -58.81 -36.42 74.46 Favored 'General case' 0 C--N 1.326 -0.424 0 C-N-CA 120.07 -0.652 . . . . 0.0 110.719 -178.609 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 316' ' ' SER . . . . . 0.494 ' OG ' ' O ' ' A' ' 313' ' ' VAL . 86.3 p -63.37 -23.74 67.54 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-O 121.227 0.537 . . . . 0.0 110.756 178.67 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 49.2 tttm -56.75 -35.8 69.03 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.303 -0.862 . . . . 0.0 112.535 -177.489 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 12.5 p -129.7 142.88 42.74 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 C-N-CA 120.263 -0.575 . . . . 0.0 111.829 -179.238 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.221 -0.418 0 CA-C-O 118.137 -0.935 . . . . 0.0 110.813 179.882 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.875 0 N-CA-C 110.974 -0.85 . . . . 0.0 110.974 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 21.2 m -56.98 -33.6 67.26 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.842 0.353 . . . . 0.0 110.688 -179.922 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 67.4 mttt -57.45 -37.77 73.39 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.098 -178.419 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 295' ' ' ASP . . . . . 0.645 ' OD2' ' N ' ' A' ' 296' ' ' ASN . 50.3 p30 175.1 -24.6 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.652 179.401 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 296' ' ' ASN . . . . . 0.645 ' N ' ' OD2' ' A' ' 295' ' ' ASP . 18.7 t-20 56.54 48.22 17.08 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.627 -0.715 . . . . 0.0 111.071 179.751 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 297' ' ' ILE . . . . . 0.628 ' O ' ' O ' ' A' ' 296' ' ' ASN . 10.9 tp 15.46 111.04 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 CA-C-O 122.176 0.988 . . . . 0.0 111.602 -178.647 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 298' ' ' LYS . . . . . 0.584 ' O ' ' C ' ' A' ' 299' ' ' HIS . 56.4 tttp -57.86 -36.48 72.4 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 114.488 -1.233 . . . . 0.0 113.285 -178.1 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 299' ' ' HIS . . . . . 0.584 ' C ' ' O ' ' A' ' 298' ' ' LYS . 85.3 t60 1.42 102.25 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.358 0 N-CA-C 112.104 0.409 . . . . 0.0 112.104 -179.265 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.55 75.22 69.68 Favored Pre-proline 0 N--CA 1.469 0.513 0 N-CA-C 111.964 0.357 . . . . 0.0 111.964 -179.17 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -58.94 -21.67 59.23 Favored 'Trans proline' 0 C--N 1.306 -1.693 0 N-CA-C 109.788 -0.889 . . . . 0.0 109.788 177.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -79.42 25.21 2.85 Favored Glycine 0 CA--C 1.528 0.892 0 CA-C-N 114.386 -1.279 . . . . 0.0 111.767 -179.848 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -55.93 -26.13 47.3 Favored Glycine 0 CA--C 1.509 -0.296 0 N-CA-C 109.274 -1.53 . . . . 0.0 109.274 179.631 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 98.65 -3.27 59.1 Favored Glycine 0 N--CA 1.442 -0.906 0 N-CA-C 104.686 -3.366 . . . . 0.0 104.686 -175.315 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 305' ' ' SER . . . . . 0.503 ' O ' ' O ' ' A' ' 306' ' ' VAL . 24.7 m -59.46 -33.89 71.86 Favored 'General case' 0 N--CA 1.439 -0.998 0 CA-C-N 112.501 -1.849 . . . . 0.0 108.674 177.157 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 306' ' ' VAL . . . . . 0.531 ' CG2' ' H ' ' A' ' 307' ' ' GLN . 8.2 m -11.22 -113.37 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.233 0.186 0 CA-C-N 113.438 -1.71 . . . . 0.0 112.835 -178.364 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 307' ' ' GLN . . . . . 0.531 ' H ' ' CG2' ' A' ' 306' ' ' VAL . 21.7 pt20 -141.56 165.1 28.43 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.429 -0.805 . . . . 0.0 110.803 -178.684 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 308' ' ' ILE . . . . . 0.628 HG13 ' O ' ' A' ' 308' ' ' ILE . 19.9 pt -63.99 100.6 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 122.596 1.189 . . . . 0.0 109.778 179.96 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 81.4 t -63.87 -42.44 95.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 122.005 0.907 . . . . 0.0 109.167 179.829 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 310' ' ' TYR . . . . . . . . . . . . 0.321 54.9 p90 -66.21 -32.34 73.71 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 118.082 2.623 . . . . 0.0 118.082 179.542 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 311' ' ' LYS . . . . . 0.615 ' O ' ' N ' ' A' ' 313' ' ' VAL . 14.6 mtpp 51.02 63.99 8.9 Favored Pre-proline 0 C--N 1.313 -0.979 0 C-N-CA 118.633 -1.227 . . . . 0.0 109.781 179.362 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 312' ' ' PRO . . . . . 0.591 ' O ' ' N ' ' A' ' 314' ' ' ASP . 84.0 Cg_exo 6.33 58.26 0.0 OUTLIER 'Trans proline' 0 N--CA 1.492 1.382 0 C-N-CA 122.635 2.223 . . . . 0.0 113.41 -179.586 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 313' ' ' VAL . . . . . 0.615 ' N ' ' O ' ' A' ' 311' ' ' LYS . 9.5 p 4.56 62.61 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 O-C-N 124.082 0.864 . . . . 0.0 112.196 -179.704 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 314' ' ' ASP . . . . . 0.591 ' N ' ' O ' ' A' ' 312' ' ' PRO . 92.1 m-20 -56.08 -35.82 67.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.025 -0.989 . . . . 0.0 111.78 -179.369 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 315' ' ' LEU . . . . . 0.517 ' CD1' ' H ' ' A' ' 315' ' ' LEU . 6.4 mp -57.39 -36.02 70.74 Favored 'General case' 0 C--N 1.326 -0.45 0 C-N-CA 119.854 -0.738 . . . . 0.0 110.027 -178.33 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 24.4 m -58.45 -34.23 70.61 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 108.396 -0.965 . . . . 0.0 108.396 177.299 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 65.8 tttt -77.05 132.8 39.11 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.084 -0.962 . . . . 0.0 109.714 179.424 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 14.4 p -131.67 142.82 42.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.629 -179.716 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 33.5 p . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 118.049 -0.976 . . . . 0.0 110.845 -179.709 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 292' ' ' GLY . . . . . 0.52 ' O ' ' C ' ' A' ' 293' ' ' SER . . . . . . . . 0 CA--C 1.525 0.665 0 N-CA-C 111.034 -0.827 . . . . 0.0 111.034 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 293' ' ' SER . . . . . 0.52 ' C ' ' O ' ' A' ' 292' ' ' GLY . 1.9 m 21.26 55.82 0.02 OUTLIER 'General case' 0 CA--C 1.535 0.367 0 CA-C-O 120.988 0.423 . . . . 0.0 111.829 -179.568 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 27.8 mttp -91.55 153.51 19.71 Favored 'General case' 0 CA--C 1.515 -0.397 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 178.225 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 295' ' ' ASP . . . . . 0.459 ' OD2' ' C ' ' A' ' 295' ' ' ASP . 48.4 p30 -83.88 8.0 16.36 Favored 'General case' 0 C--N 1.322 -0.626 0 C-N-CA 119.617 -0.833 . . . . 0.0 109.949 -178.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 45.5 t30 58.31 56.06 4.67 Favored 'General case' 0 N--CA 1.455 -0.183 0 C-N-CA 119.671 -0.812 . . . . 0.0 112.014 177.102 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 297' ' ' ILE . . . . . 0.402 HG13 ' OD2' ' A' ' 295' ' ' ASP . 70.7 mt -59.82 131.4 24.41 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.165 0 CA-C-O 122.197 0.999 . . . . 0.0 110.103 -175.932 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 298' ' ' LYS . . . . . 0.405 ' HZ3' ' HB2' ' A' ' 298' ' ' LYS . 2.0 ttmp? -84.15 136.99 33.76 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 113.419 -1.719 . . . . 0.0 113.958 -177.819 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 64.5 m170 -115.88 136.9 52.6 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 106.483 -1.673 . . . . 0.0 106.483 176.08 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 3.9 m -125.08 69.74 59.64 Favored Pre-proline 0 N--CA 1.466 0.349 0 C-N-CA 119.573 -0.851 . . . . 0.0 112.867 -178.566 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -62.46 -19.31 67.11 Favored 'Trans proline' 0 C--N 1.302 -1.892 0 N-CA-C 107.174 -1.894 . . . . 0.0 107.174 174.683 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -165.08 -169.55 28.85 Favored Glycine 0 CA--C 1.531 1.039 0 CA-C-N 112.91 -1.95 . . . . 0.0 110.233 -178.219 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . 126.25 29.59 0.92 Allowed Glycine 0 N--CA 1.466 0.698 0 N-CA-C 109.013 -1.635 . . . . 0.0 109.013 -178.371 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 97.07 -7.45 64.56 Favored Glycine 0 C--N 1.324 -0.116 0 N-CA-C 107.352 -2.299 . . . . 0.0 107.352 -178.493 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 23.2 t -59.96 -30.75 69.3 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 113.146 -1.527 . . . . 0.0 111.157 177.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 306' ' ' VAL . . . . . 0.564 ' O ' ' CB ' ' A' ' 307' ' ' GLN . 88.5 t -56.93 -42.99 79.73 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.48 0 CA-C-N 115.729 -0.669 . . . . 0.0 112.071 -175.373 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 307' ' ' GLN . . . . . 0.564 ' CB ' ' O ' ' A' ' 306' ' ' VAL . 21.3 pt20 125.46 178.49 0.0 OUTLIER 'General case' 0 N--CA 1.469 0.501 0 O-C-N 124.643 1.214 . . . . 0.0 110.201 179.42 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 308' ' ' ILE . . . . . 0.823 ' O ' ' N ' ' A' ' 310' ' ' TYR . 33.3 mm -54.88 -45.16 75.09 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.933 0 CA-C-N 113.952 -1.476 . . . . 0.0 113.852 177.259 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . 0.432 ' H ' ' HG3' ' A' ' 307' ' ' GLN . 0.3 OUTLIER 37.2 -0.94 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.693 0 O-C-N 123.939 0.774 . . . . 0.0 113.069 -179.212 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 310' ' ' TYR . . . . . 0.823 ' N ' ' O ' ' A' ' 308' ' ' ILE 0.329 0.0 OUTLIER -67.39 -22.3 65.56 Favored 'General case' 0 CA--C 1.503 -0.85 0 C-N-CA 119.056 -1.057 . . . . 0.0 110.681 -178.763 . . . . . . . . 4 4 . 1 . 009 nuclear orig full ' A' A ' 311' ' ' LYS . . . . . 0.583 ' O ' ' C ' ' A' ' 312' ' ' PRO . 32.3 tttp 56.4 63.55 5.61 Favored Pre-proline 0 N--CA 1.447 -0.61 0 CA-C-N 115.028 -0.987 . . . . 0.0 109.916 177.779 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 312' ' ' PRO . . . . . 0.583 ' C ' ' O ' ' A' ' 311' ' ' LYS . 75.8 Cg_exo 12.85 -127.08 0.0 OUTLIER 'Trans proline' 0 N--CA 1.492 1.414 0 C-N-CA 122.337 2.025 . . . . 0.0 110.888 -178.448 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 313' ' ' VAL . . . . . 0.405 HG12 ' H ' ' A' ' 315' ' ' LEU . 45.2 t -120.98 126.87 75.73 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.398 0 C-N-CA 118.336 -1.345 . . . . 0.0 109.509 176.193 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -63.93 -38.14 89.98 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.64 0.733 . . . . 0.0 111.282 177.102 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 315' ' ' LEU . . . . . 0.65 ' N ' ' CD2' ' A' ' 315' ' ' LEU . 0.2 OUTLIER -61.07 -36.97 81.04 Favored 'General case' 0 C--O 1.233 0.192 0 CA-C-N 114.453 -1.249 . . . . 0.0 113.29 -176.902 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 68.4 m -79.58 -5.55 55.22 Favored 'General case' 0 C--N 1.327 -0.404 0 C-N-CA 120.166 -0.614 . . . . 0.0 111.026 -179.857 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 57.2 tttp -58.42 -38.0 76.52 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.114 -179.333 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 43.4 t -120.65 135.45 60.83 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 CA-C-N 116.545 -0.298 . . . . 0.0 110.577 179.188 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 6.9 m . . . . . 0 C--O 1.221 -0.399 0 CA-C-O 118.018 -0.991 . . . . 0.0 110.422 179.459 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.636 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 86.6 p -61.79 -27.58 68.85 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.798 0.332 . . . . 0.0 110.498 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 31.0 mttt -93.9 153.37 18.27 Favored 'General case' 0 N--CA 1.448 -0.566 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 178.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 295' ' ' ASP . . . . . 0.457 ' C ' ' OD1' ' A' ' 295' ' ' ASP . 49.2 p30 -84.12 7.66 18.1 Favored 'General case' 0 C--N 1.322 -0.591 0 C-N-CA 119.685 -0.806 . . . . 0.0 110.301 -178.653 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 16.6 t-20 58.57 55.91 4.56 Favored 'General case' 0 CA--C 1.535 0.391 0 C-N-CA 119.818 -0.753 . . . . 0.0 112.488 176.629 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 297' ' ' ILE . . . . . 0.426 HG13 ' OD1' ' A' ' 295' ' ' ASP . 71.2 mt -61.8 133.24 27.62 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.52 0 CA-C-O 122.258 1.028 . . . . 0.0 110.906 -175.967 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 15.6 tttt -82.79 137.83 34.21 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-N 113.328 -1.76 . . . . 0.0 114.209 -178.105 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 58.3 t-80 -119.41 132.42 55.82 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 106.75 -1.574 . . . . 0.0 106.75 176.425 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 4.4 m -124.79 79.01 64.25 Favored Pre-proline 0 N--CA 1.472 0.635 0 N-CA-C 113.865 1.061 . . . . 0.0 113.865 -177.033 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -58.53 -24.59 70.42 Favored 'Trans proline' 0 C--N 1.31 -1.471 0 C-N-CA 120.572 0.848 . . . . 0.0 110.963 178.043 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -111.82 48.21 0.96 Allowed Glycine 0 CA--C 1.525 0.694 0 N-CA-C 109.864 -1.294 . . . . 0.0 109.864 179.507 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -81.19 6.85 62.02 Favored Glycine 0 N--CA 1.466 0.638 0 N-CA-C 112.174 -0.37 . . . . 0.0 112.174 -178.398 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 94.52 2.04 63.72 Favored Glycine 0 C--N 1.321 -0.29 0 N-CA-C 107.962 -2.055 . . . . 0.0 107.962 -178.167 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 75.7 m -82.56 6.99 15.77 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 113.851 -1.174 . . . . 0.0 108.229 178.564 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 306' ' ' VAL . . . . . 0.502 ' O ' ' O ' ' A' ' 307' ' ' GLN . 20.7 m -67.25 -22.65 29.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 114.861 -1.063 . . . . 0.0 110.649 -178.845 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 307' ' ' GLN . . . . . 0.536 ' O ' ' O ' ' A' ' 308' ' ' ILE . 21.7 pt20 46.16 118.03 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 122.039 0.924 . . . . 0.0 113.358 179.697 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 308' ' ' ILE . . . . . 0.536 ' O ' ' O ' ' A' ' 307' ' ' GLN . 9.7 tp 25.42 120.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.676 0 CA-C-N 113.42 -1.718 . . . . 0.0 114.374 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -149.58 -42.94 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.366 0 CA-C-N 114.599 -1.182 . . . . 0.0 109.072 177.889 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 310' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -61.67 -31.88 72.02 Favored 'General case' 0 CA--C 1.538 0.519 0 N-CA-C 112.938 0.718 . . . . 0.0 112.938 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 311' ' ' LYS . . . . . 0.403 ' HB3' ' HZ1' ' A' ' 311' ' ' LYS . 8.2 mtpp 65.09 73.76 0.42 Allowed Pre-proline 0 N--CA 1.473 0.711 0 N-CA-C 113.116 0.784 . . . . 0.0 113.116 179.114 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 312' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_endo -53.17 -23.76 23.8 Favored 'Trans proline' 0 N--CA 1.498 1.738 0 C-N-CA 120.41 0.74 . . . . 0.0 111.374 179.691 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 313' ' ' VAL . . . . . 0.473 ' CG1' ' OG ' ' A' ' 316' ' ' SER . 60.3 t -117.16 132.37 67.14 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.273 0 CA-C-O 121.448 0.642 . . . . 0.0 111.589 178.339 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 58.2 t0 -160.17 -60.94 0.06 Allowed 'General case' 0 N--CA 1.449 -0.515 0 CA-C-N 114.98 -1.009 . . . . 0.0 108.921 178.308 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 315' ' ' LEU . . . . . . . . . . . . . 61.1 mt -61.65 -35.33 77.63 Favored 'General case' 0 C--O 1.226 -0.167 0 CA-C-N 114.78 -1.1 . . . . 0.0 111.723 179.295 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 316' ' ' SER . . . . . 0.473 ' OG ' ' CG1' ' A' ' 313' ' ' VAL . 80.2 p -61.21 -28.34 69.08 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.307 0.575 . . . . 0.0 110.241 -179.154 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 317' ' ' LYS . . . . . 0.426 ' N ' ' HG ' ' A' ' 316' ' ' SER . 29.3 tttm -58.24 -37.2 74.43 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.456 -0.793 . . . . 0.0 111.432 -179.421 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 318' ' ' VAL . . . . . 0.428 HG13 ' N ' ' A' ' 319' ' ' THR . 5.5 p -57.67 -34.21 46.96 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.152 0 CA-C-O 120.882 0.373 . . . . 0.0 110.62 -179.87 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 319' ' ' THR . . . . . 0.428 ' N ' HG13 ' A' ' 318' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--O 1.221 -0.447 0 CA-C-O 118.027 -0.987 . . . . 0.0 110.044 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.576 0 N-CA-C 110.969 -0.852 . . . . 0.0 110.969 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 87.0 p -61.68 -27.22 68.53 Favored 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 120.851 -0.34 . . . . 0.0 110.679 -179.845 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 294' ' ' LYS . . . . . 0.431 ' C ' ' H ' ' A' ' 296' ' ' ASN . 41.2 mtpt -95.7 150.94 19.83 Favored 'General case' 0 N--CA 1.452 -0.328 0 CA-C-O 120.907 0.384 . . . . 0.0 111.081 -179.621 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 295' ' ' ASP . . . . . 0.457 ' OD2' ' C ' ' A' ' 295' ' ' ASP . 48.8 p30 -85.98 10.53 13.84 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 107.43 -1.322 . . . . 0.0 107.43 178.709 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 296' ' ' ASN . . . . . 0.431 ' H ' ' C ' ' A' ' 294' ' ' LYS . 23.6 m120 30.5 -102.09 0.02 OUTLIER 'General case' 0 CA--C 1.511 -0.549 0 CA-C-N 113.301 -1.772 . . . . 0.0 113.294 -179.218 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 297' ' ' ILE . . . . . . . . . . . . . 70.1 mt -113.5 130.31 67.74 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.454 0 CA-C-O 122.297 1.046 . . . . 0.0 113.486 -177.119 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 41.8 tttp -87.5 132.13 34.12 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 113.107 -1.86 . . . . 0.0 108.613 177.037 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 299' ' ' HIS . . . . . 0.575 ' CE1' ' CD ' ' A' ' 301' ' ' PRO . 37.4 t-80 -125.09 113.39 17.67 Favored 'General case' 0 N--CA 1.468 0.461 0 N-CA-C 112.676 0.621 . . . . 0.0 112.676 -179.116 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 3.2 m -134.16 73.34 70.07 Favored Pre-proline 0 N--CA 1.471 0.585 0 CA-C-N 116.196 -0.457 . . . . 0.0 112.191 178.075 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 301' ' ' PRO . . . . . 0.575 ' CD ' ' CE1' ' A' ' 299' ' ' HIS . 5.9 Cg_endo -60.56 -23.82 76.56 Favored 'Trans proline' 0 N--CA 1.5 1.901 0 CA-C-N 119.914 1.005 . . . . 0.0 113.067 179.211 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -134.21 -105.29 0.87 Allowed Glycine 0 CA--C 1.525 0.709 0 N-CA-C 111.149 -0.78 . . . . 0.0 111.149 -178.508 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . 86.4 35.64 10.46 Favored Glycine 0 N--CA 1.462 0.386 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 -178.81 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 96.56 -0.25 61.26 Favored Glycine 0 N--CA 1.446 -0.686 0 N-CA-C 108.991 -1.643 . . . . 0.0 108.991 -179.165 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 73.8 m -82.96 1.65 38.68 Favored 'General case' 0 N--CA 1.446 -0.661 0 CA-C-O 121.382 0.611 . . . . 0.0 109.558 178.675 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 306' ' ' VAL . . . . . . . . . . . . . 73.6 t -61.64 -38.17 79.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 115.06 -0.973 . . . . 0.0 111.253 179.835 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 307' ' ' GLN . . . . . 0.628 ' O ' ' O ' ' A' ' 308' ' ' ILE . 50.3 tt0 79.87 103.03 0.07 Allowed 'General case' 0 CA--C 1.506 -0.729 0 O-C-N 123.6 0.562 . . . . 0.0 112.039 -178.663 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 308' ' ' ILE . . . . . 0.628 ' O ' ' O ' ' A' ' 307' ' ' GLN . 81.7 mt 51.24 149.68 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.443 -0.778 0 CA-C-O 122.256 1.027 . . . . 0.0 109.871 178.506 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . 0.657 ' CG1' ' CD1' ' A' ' 310' ' ' TYR . 6.3 p -56.34 -33.91 39.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 CA-C-N 114.886 -1.052 . . . . 0.0 111.777 -178.576 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 310' ' ' TYR . . . . . 0.808 ' CD1' ' N ' ' A' ' 311' ' ' LYS . 0.0 OUTLIER -161.55 -97.09 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.39 0 CA-C-O 123.896 1.808 . . . . 0.0 112.638 -178.37 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 311' ' ' LYS . . . . . 0.808 ' N ' ' CD1' ' A' ' 310' ' ' TYR . 32.6 mtmm -123.62 103.88 34.32 Favored Pre-proline 0 C--N 1.275 -2.667 0 CA-C-N 109.845 -3.343 . . . . 0.0 108.228 179.181 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 312' ' ' PRO . . . . . 0.496 ' C ' ' O ' ' A' ' 311' ' ' LYS . 9.7 Cg_endo -49.1 151.95 5.51 Favored 'Trans proline' 0 C--N 1.299 -2.038 0 N-CA-C 106.626 -2.106 . . . . 0.0 106.626 179.081 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 313' ' ' VAL . . . . . 0.438 HG12 ' H ' ' A' ' 315' ' ' LEU . 44.3 t -59.53 128.5 20.51 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.585 0 C-N-CA 117.671 -1.611 . . . . 0.0 111.948 -173.434 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 314' ' ' ASP . . . . . 0.473 ' O ' ' HG2' ' A' ' 317' ' ' LYS . 49.2 p30 -97.33 -0.63 46.15 Favored 'General case' 0 N--CA 1.438 -1.058 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 175.897 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 315' ' ' LEU . . . . . 0.438 ' H ' HG12 ' A' ' 313' ' ' VAL . 64.8 mt -64.85 -31.44 72.68 Favored 'General case' 0 N--CA 1.469 0.504 0 O-C-N 123.774 0.671 . . . . 0.0 110.735 178.319 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 89.9 p -58.19 -25.56 61.73 Favored 'General case' 0 N--CA 1.448 -0.545 0 CA-C-N 114.962 -1.017 . . . . 0.0 110.276 -177.453 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 317' ' ' LYS . . . . . 0.473 ' HG2' ' O ' ' A' ' 314' ' ' ASP . 52.2 pttt -59.6 -33.57 71.64 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.349 -0.612 . . . . 0.0 109.349 -179.319 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 318' ' ' VAL . . . . . 0.422 ' N ' ' CG ' ' A' ' 317' ' ' LYS . 74.7 t -60.37 -39.81 82.12 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.132 0 CA-C-N 115.099 -0.955 . . . . 0.0 111.501 -178.807 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 7.1 m . . . . . 0 C--O 1.22 -0.482 0 CA-C-O 117.935 -1.031 . . . . 0.0 110.529 -179.76 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.626 0 N-CA-C 111.038 -0.825 . . . . 0.0 111.038 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 45.3 m -64.02 153.69 36.57 Favored 'General case' 0 C--N 1.333 -0.145 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.857 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 294' ' ' LYS . . . . . 0.464 ' C ' ' H ' ' A' ' 296' ' ' ASN . 88.2 mttt -103.75 145.81 29.54 Favored 'General case' 0 N--CA 1.449 -0.477 0 CA-C-O 121.442 0.639 . . . . 0.0 112.014 -179.156 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 295' ' ' ASP . . . . . 0.47 ' OD2' ' C ' ' A' ' 295' ' ' ASP . 49.2 p30 -89.52 12.76 15.66 Favored 'General case' 0 CA--C 1.49 -1.332 0 N-CA-C 106.35 -1.722 . . . . 0.0 106.35 176.68 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 296' ' ' ASN . . . . . 0.624 ' CG ' ' H ' ' A' ' 297' ' ' ILE . 49.4 t30 36.48 -147.95 0.01 OUTLIER 'General case' 0 N--CA 1.426 -1.626 0 CA-C-N 112.362 -2.199 . . . . 0.0 110.697 -178.717 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 297' ' ' ILE . . . . . 0.624 ' H ' ' CG ' ' A' ' 296' ' ' ASN . 8.8 tp -123.2 132.67 70.98 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 CA-C-O 122.642 1.21 . . . . 0.0 112.809 -177.446 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 75.8 tttt -94.48 130.16 40.97 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-N 112.323 -2.217 . . . . 0.0 109.702 177.014 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 39.0 t-80 -132.18 136.21 46.89 Favored 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 119.701 -0.8 . . . . 0.0 111.784 179.613 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -125.76 74.77 70.57 Favored Pre-proline 0 N--CA 1.477 0.893 0 CA-C-O 120.4 0.143 . . . . 0.0 111.368 178.987 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -59.94 -21.28 63.95 Favored 'Trans proline' 0 N--CA 1.494 1.523 0 C-N-CA 122.529 2.153 . . . . 0.0 112.089 178.734 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . 114.03 130.63 5.1 Favored Glycine 0 CA--C 1.52 0.355 0 N-CA-C 107.418 -2.273 . . . . 0.0 107.418 -177.279 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -96.44 -78.77 1.43 Allowed Glycine 0 CA--C 1.523 0.564 0 C-N-CA 119.457 -1.354 . . . . 0.0 113.219 -177.853 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . -86.16 -35.29 11.14 Favored Glycine 0 CA--C 1.522 0.486 0 C-N-CA 121.201 -0.524 . . . . 0.0 112.589 -179.778 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 305' ' ' SER . . . . . 0.504 ' O ' ' O ' ' A' ' 306' ' ' VAL . 93.9 p -61.63 -30.02 70.43 Favored 'General case' 0 CA--C 1.513 -0.476 0 N-CA-C 114.263 1.209 . . . . 0.0 114.263 -176.756 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 306' ' ' VAL . . . . . 0.504 ' O ' ' O ' ' A' ' 305' ' ' SER . 16.8 t -27.25 -99.88 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 O-C-N 123.57 0.544 . . . . 0.0 112.395 -177.615 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 307' ' ' GLN . . . . . 0.41 ' HG2' ' N ' ' A' ' 308' ' ' ILE . 51.6 tt0 -143.14 158.07 43.95 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.635 179.857 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 308' ' ' ILE . . . . . 0.559 ' CD1' ' CZ ' ' A' ' 310' ' ' TYR . 5.0 tp -120.96 127.86 76.0 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.673 0 C-N-CA 120.05 -0.66 . . . . 0.0 109.635 177.635 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 73.7 t -67.98 -42.91 85.83 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.565 0 N-CA-C 114.975 1.472 . . . . 0.0 114.975 -179.57 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 310' ' ' TYR . . . . . 0.559 ' CZ ' ' CD1' ' A' ' 308' ' ' ILE 0.312 2.7 p90 -66.27 -28.14 68.48 Favored 'General case' 0 N--CA 1.469 0.499 0 N-CA-C 116.931 2.197 . . . . 0.0 116.931 -177.019 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 311' ' ' LYS . . . . . 0.536 ' O ' ' O ' ' A' ' 312' ' ' PRO . 10.6 mtpt 56.17 63.23 6.06 Favored Pre-proline 0 C--N 1.307 -1.248 0 C-N-CA 118.74 -1.184 . . . . 0.0 108.534 -178.959 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 312' ' ' PRO . . . . . 0.573 ' O ' ' N ' ' A' ' 314' ' ' ASP . 32.6 Cg_exo 23.62 112.06 0.0 OUTLIER 'Trans proline' 0 C--N 1.316 -1.157 0 C-N-CA 122.752 2.301 . . . . 0.0 115.214 -179.339 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 313' ' ' VAL . . . . . 0.469 ' C ' ' O ' ' A' ' 312' ' ' PRO . 2.1 m 8.15 55.77 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.232 0.141 0 CA-C-N 113.519 -1.673 . . . . 0.0 113.27 179.185 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 314' ' ' ASP . . . . . 0.573 ' N ' ' O ' ' A' ' 312' ' ' PRO . 55.2 t0 -55.37 -36.11 66.0 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 109.962 -0.385 . . . . 0.0 109.962 178.757 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 315' ' ' LEU . . . . . 0.466 ' CD1' ' H ' ' A' ' 315' ' ' LEU . 6.5 mp -59.27 -35.69 74.19 Favored 'General case' 0 N--CA 1.464 0.254 0 C-N-CA 120.61 -0.436 . . . . 0.0 111.577 -179.344 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 85.4 p -61.71 -27.34 68.64 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.352 0.596 . . . . 0.0 110.038 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 38.9 tttp -57.37 -39.1 75.31 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.265 -0.879 . . . . 0.0 111.112 -178.656 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 70.6 t -63.21 -39.26 84.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 121.128 0.489 . . . . 0.0 110.323 178.747 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 1.9 m . . . . . 0 C--O 1.22 -0.493 0 CA-C-O 118.068 -0.968 . . . . 0.0 110.282 -178.836 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.644 0 N-CA-C 110.929 -0.869 . . . . 0.0 110.929 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 30.8 t -118.98 142.42 47.81 Favored 'General case' 0 N--CA 1.463 0.198 0 CA-C-O 121.098 0.475 . . . . 0.0 111.242 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 25.5 mttm -99.32 152.18 20.22 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.749 179.186 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 295' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -55.29 -37.14 66.94 Favored 'General case' 0 CA--C 1.497 -1.086 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.424 -179.547 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 296' ' ' ASN . . . . . 0.696 HD21 ' N ' ' A' ' 296' ' ' ASN . 0.0 OUTLIER 175.5 -103.07 0.0 OUTLIER 'General case' 0 C--N 1.308 -1.219 0 CA-C-O 121.97 0.891 . . . . 0.0 111.0 179.907 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 297' ' ' ILE . . . . . 0.652 ' H ' ' CG ' ' A' ' 296' ' ' ASN . 19.2 tt 137.32 86.92 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 CA-C-N 111.977 -2.374 . . . . 0.0 106.722 -178.124 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 36.0 mttt -83.25 137.23 34.1 Favored 'General case' 0 C--N 1.317 -0.828 0 C-N-CA 119.39 -0.924 . . . . 0.0 112.374 -177.247 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 56.8 t-80 -130.76 117.81 19.94 Favored 'General case' 0 N--CA 1.441 -0.899 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 175.686 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -125.63 77.32 69.55 Favored Pre-proline 0 C--N 1.324 -0.526 0 C-N-CA 120.704 -0.398 . . . . 0.0 111.36 -179.625 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 85.5 Cg_endo -57.79 -23.66 59.75 Favored 'Trans proline' 0 C--N 1.313 -1.308 0 N-CA-C 109.99 -0.812 . . . . 0.0 109.99 179.224 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -173.43 128.15 1.46 Allowed Glycine 0 CA--C 1.523 0.563 0 CA-C-N 114.81 -1.086 . . . . 0.0 110.84 179.193 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -82.05 4.84 74.02 Favored Glycine 0 N--CA 1.462 0.397 0 N-CA-C 108.701 -1.76 . . . . 0.0 108.701 178.414 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 98.4 -8.08 62.14 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 109.845 -1.302 . . . . 0.0 109.845 -179.259 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 305' ' ' SER . . . . . 0.465 ' O ' ' C ' ' A' ' 306' ' ' VAL . 20.3 m -59.9 -34.93 73.83 Favored 'General case' 0 CA--C 1.521 -0.172 0 CA-C-O 121.953 0.882 . . . . 0.0 109.463 177.557 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 306' ' ' VAL . . . . . 0.465 ' C ' ' O ' ' A' ' 305' ' ' SER . 7.7 t -13.61 -104.0 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 CA-C-N 113.475 -1.693 . . . . 0.0 113.697 -177.902 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 307' ' ' GLN . . . . . . . . . . . . . 21.7 pt20 -145.16 170.71 15.7 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.177 -178.1 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 308' ' ' ILE . . . . . 0.579 HG21 ' CD2' ' A' ' 310' ' ' TYR . 71.8 mt -97.28 116.96 41.02 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.095 0 N-CA-C 115.677 1.732 . . . . 0.0 115.677 -178.529 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 5.9 p -69.86 -32.29 51.3 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.462 0 CA-C-N 113.59 -1.641 . . . . 0.0 108.731 172.751 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 310' ' ' TYR . . . . . 0.579 ' CD2' HG21 ' A' ' 308' ' ' ILE 0.412 51.6 p90 -62.44 -10.71 12.46 Favored 'General case' 0 C--N 1.346 0.435 0 N-CA-C 117.817 2.525 . . . . 0.0 117.817 -177.203 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 311' ' ' LYS . . . . . 0.472 ' O ' ' C ' ' A' ' 312' ' ' PRO . 9.3 mmtt 63.68 67.53 0.98 Allowed Pre-proline 0 N--CA 1.475 0.813 0 CA-C-N 118.853 0.751 . . . . 0.0 112.406 177.235 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 312' ' ' PRO . . . . . 0.472 ' C ' ' O ' ' A' ' 311' ' ' LYS . 61.2 Cg_exo -0.99 -114.3 0.0 OUTLIER 'Trans proline' 0 N--CA 1.489 1.244 0 C-N-CA 123.093 2.529 . . . . 0.0 116.361 179.598 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 16.1 m -111.31 21.03 5.97 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.478 0 N-CA-C 113.071 0.767 . . . . 0.0 113.071 -176.761 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 58.2 t0 -51.33 -36.86 44.75 Favored 'General case' 0 C--N 1.323 -0.568 0 C-N-CA 120.271 -0.572 . . . . 0.0 111.176 -178.105 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 315' ' ' LEU . . . . . 0.635 ' N ' ' CD2' ' A' ' 315' ' ' LEU . 0.2 OUTLIER -60.05 -36.93 78.38 Favored 'General case' 0 C--N 1.33 -0.241 0 C-N-CA 118.983 -1.087 . . . . 0.0 109.496 178.458 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 21.5 t -59.49 -31.36 69.29 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.886 178.36 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 7.7 ttpp -56.17 -35.34 67.1 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.087 -0.961 . . . . 0.0 111.416 -176.879 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 43.0 t -112.27 134.74 53.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 121.017 0.436 . . . . 0.0 110.491 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 1.1 m . . . . . 0 C--O 1.22 -0.457 0 CA-C-O 117.916 -1.04 . . . . 0.0 110.695 -179.671 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.666 0 N-CA-C 110.788 -0.925 . . . . 0.0 110.788 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 74.7 m -82.51 3.37 28.7 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 120.979 -0.288 . . . . 0.0 110.69 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 64.8 mttp -91.65 144.42 25.55 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 179.443 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 295' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -57.93 -39.59 78.37 Favored 'General case' 0 CA--C 1.507 -0.691 0 C-N-CA 120.069 -0.652 . . . . 0.0 111.688 -178.857 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 46.7 t-20 177.92 -94.41 0.0 OUTLIER 'General case' 0 C--N 1.314 -0.978 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 179.1 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 297' ' ' ILE . . . . . . . . . . . . . 18.1 tt 174.62 3.82 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 113.715 -1.584 . . . . 0.0 109.808 179.431 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 29.1 mttt 64.69 47.59 2.76 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-O 120.856 0.36 . . . . 0.0 110.705 -179.693 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 299' ' ' HIS . . . . . 0.401 ' ND1' ' O ' ' A' ' 299' ' ' HIS . 58.4 t-80 -74.07 65.43 1.12 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.139 -179.389 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 4.8 t -124.87 75.13 65.89 Favored Pre-proline 0 N--CA 1.465 0.319 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.323 178.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -57.81 -24.74 65.47 Favored 'Trans proline' 0 C--N 1.311 -1.427 0 C-N-CA 121.29 1.327 . . . . 0.0 111.431 -179.385 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -163.05 121.8 1.05 Allowed Glycine 0 CA--C 1.524 0.64 0 C-N-CA 120.624 -0.798 . . . . 0.0 111.656 179.76 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -82.32 1.21 87.88 Favored Glycine 0 CA--C 1.527 0.836 0 N-CA-C 110.264 -1.134 . . . . 0.0 110.264 178.534 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 96.79 -7.62 65.33 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.061 -1.215 . . . . 0.0 110.061 -179.788 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 305' ' ' SER . . . . . 0.455 ' O ' ' C ' ' A' ' 306' ' ' VAL . 25.9 t -60.04 -32.62 71.08 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.537 0.684 . . . . 0.0 109.232 177.07 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 306' ' ' VAL . . . . . 0.455 ' C ' ' O ' ' A' ' 305' ' ' SER . 0.0 OUTLIER -20.45 -90.5 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 CA-C-N 113.999 -1.455 . . . . 0.0 112.962 -177.44 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 307' ' ' GLN . . . . . . . . . . . . . 2.6 pt20 -143.22 167.95 20.92 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.341 -0.845 . . . . 0.0 111.067 -177.329 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 308' ' ' ILE . . . . . 0.497 HG23 ' CE2' ' A' ' 310' ' ' TYR . 67.1 mt -107.4 120.89 59.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-O 121.751 0.786 . . . . 0.0 111.075 -179.699 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . 0.467 ' CG1' ' N ' ' A' ' 310' ' ' TYR . 8.0 p -66.04 -36.38 77.33 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.847 0 CA-C-O 122.206 1.003 . . . . 0.0 108.914 174.876 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 310' ' ' TYR . . . . . 0.497 ' CE2' HG23 ' A' ' 308' ' ' ILE 0.448 51.1 p90 -64.53 -32.12 73.62 Favored 'General case' 0 N--CA 1.451 -0.407 0 N-CA-C 118.194 2.665 . . . . 0.0 118.194 -177.996 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 311' ' ' LYS . . . . . 0.49 ' C ' ' O ' ' A' ' 310' ' ' TYR . 49.6 mtpt 47.98 72.23 1.33 Allowed Pre-proline 0 C--N 1.317 -0.805 0 C-N-CA 116.942 -1.903 . . . . 0.0 108.74 176.728 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 312' ' ' PRO . . . . . . . . . . . . . 7.0 Cg_endo -42.88 -37.54 6.14 Favored 'Trans proline' 0 N--CA 1.505 2.148 0 N-CA-C 114.364 0.871 . . . . 0.0 114.364 -173.754 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 71.6 t -62.95 -38.23 81.39 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.059 0 N-CA-C 116.417 2.006 . . . . 0.0 116.417 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 60.3 t0 -54.33 -43.84 71.57 Favored 'General case' 0 N--CA 1.467 0.416 0 O-C-N 120.589 -1.32 . . . . 0.0 114.415 -173.899 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 315' ' ' LEU . . . . . 0.651 ' N ' ' CD2' ' A' ' 315' ' ' LEU . 0.3 OUTLIER -66.8 -36.43 82.38 Favored 'General case' 0 C--N 1.319 -0.751 0 C-N-CA 118.308 -1.357 . . . . 0.0 109.068 176.628 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 32.8 m -59.7 -34.88 73.47 Favored 'General case' 0 N--CA 1.45 -0.47 0 CA-C-N 115.091 -0.959 . . . . 0.0 110.719 178.262 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 30.1 ttpt -80.12 125.63 30.06 Favored 'General case' 0 N--CA 1.45 -0.429 0 CA-C-O 121.697 0.761 . . . . 0.0 111.701 -177.25 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 318' ' ' VAL . . . . . 0.475 ' O ' ' OG1' ' A' ' 319' ' ' THR . 13.2 p -134.39 142.45 40.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 114.814 -1.084 . . . . 0.0 109.262 178.468 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 319' ' ' THR . . . . . 0.475 ' OG1' ' O ' ' A' ' 318' ' ' VAL . 0.7 OUTLIER . . . . . 0 C--O 1.219 -0.513 0 CA-C-O 117.962 -1.018 . . . . 0.0 111.227 179.314 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.515 0 N-CA-C 110.931 -0.868 . . . . 0.0 110.931 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 29.9 t -116.65 138.65 51.28 Favored 'General case' 0 C--O 1.232 0.159 0 CA-C-O 121.335 0.588 . . . . 0.0 110.228 179.542 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 1.9 mtpt -133.45 -166.65 1.8 Allowed 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.117 -0.947 . . . . 0.0 111.427 -179.313 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 295' ' ' ASP . . . . . 0.48 ' C ' ' OD1' ' A' ' 295' ' ' ASP . 48.7 p30 -82.92 11.04 6.6 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.19 -0.913 . . . . 0.0 109.203 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 17.6 m120 46.17 -138.34 0.58 Allowed 'General case' 0 CA--C 1.497 -1.074 0 CA-C-N 114.407 -1.27 . . . . 0.0 111.613 179.818 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 297' ' ' ILE . . . . . 0.582 ' CD1' ' CD2' ' A' ' 299' ' ' HIS . 13.9 tt -121.23 126.79 75.48 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-O 122.357 1.075 . . . . 0.0 111.404 -177.979 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 298' ' ' LYS . . . . . 0.404 ' HZ3' HG22 ' A' ' 300' ' ' VAL . 6.1 mtpm? -61.09 -36.52 79.89 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-N 112.98 -1.918 . . . . 0.0 112.568 179.13 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 299' ' ' HIS . . . . . 0.582 ' CD2' ' CD1' ' A' ' 297' ' ' ILE . 1.4 m170 38.21 60.89 1.19 Allowed 'General case' 0 CA--C 1.537 0.473 0 CA-C-O 121.175 0.512 . . . . 0.0 112.266 -179.657 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . 0.415 ' C ' ' N ' ' A' ' 302' ' ' GLY . 3.1 m -123.47 72.65 49.81 Favored Pre-proline 0 N--CA 1.464 0.274 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.009 178.658 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 301' ' ' PRO . . . . . 0.441 ' CD ' ' H ' ' A' ' 302' ' ' GLY . 44.5 Cg_endo -58.34 -17.8 35.1 Favored 'Trans proline' 0 C--N 1.317 -1.127 0 N-CA-C 107.96 -1.592 . . . . 0.0 107.96 177.72 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 302' ' ' GLY . . . . . 0.441 ' H ' ' CD ' ' A' ' 301' ' ' PRO . . . 116.61 156.13 10.58 Favored Glycine 0 N--CA 1.443 -0.846 0 CA-C-N 112.801 -2.0 . . . . 0.0 109.788 -179.014 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 303' ' ' GLY . . . . . 0.661 ' O ' ' N ' ' A' ' 305' ' ' SER . . . -163.69 -178.96 37.74 Favored Glycine 0 N--CA 1.446 -0.688 0 N-CA-C 108.528 -1.829 . . . . 0.0 108.528 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 59.32 -70.43 0.01 OUTLIER Glycine 0 CA--C 1.529 0.926 0 N-CA-C 109.815 -1.314 . . . . 0.0 109.815 -179.11 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 305' ' ' SER . . . . . 0.661 ' N ' ' O ' ' A' ' 303' ' ' GLY . 23.0 t -58.0 -33.97 69.5 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 121.081 0.467 . . . . 0.0 111.578 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 306' ' ' VAL . . . . . 0.55 ' CG2' ' H ' ' A' ' 307' ' ' GLN . 2.3 m -36.84 -100.91 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 N-CA-C 114.251 1.204 . . . . 0.0 114.251 -178.256 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 307' ' ' GLN . . . . . 0.55 ' H ' ' CG2' ' A' ' 306' ' ' VAL . 54.8 mt-30 -113.35 160.3 18.52 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 114.429 -1.26 . . . . 0.0 111.776 -176.376 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 308' ' ' ILE . . . . . 0.553 ' CG2' ' H ' ' A' ' 311' ' ' LYS . 34.9 mm -103.12 119.11 51.1 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-O 122.006 0.907 . . . . 0.0 112.635 -179.506 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 77.4 t -67.81 -40.27 83.38 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 CA-C-N 113.51 -1.677 . . . . 0.0 107.481 174.549 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 310' ' ' TYR . . . . . 0.525 ' CZ ' HG23 ' A' ' 308' ' ' ILE 0.361 51.2 p90 -62.7 -31.05 71.89 Favored 'General case' 0 N--CA 1.446 -0.634 0 N-CA-C 117.467 2.395 . . . . 0.0 117.467 -178.676 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 311' ' ' LYS . . . . . 0.553 ' H ' ' CG2' ' A' ' 308' ' ' ILE . 19.4 mtpp 52.89 65.57 5.8 Favored Pre-proline 0 C--N 1.319 -0.731 0 CA-C-N 119.815 1.189 . . . . 0.0 110.223 178.773 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 312' ' ' PRO . . . . . 0.45 ' C ' ' O ' ' A' ' 311' ' ' LYS . 78.4 Cg_exo 7.67 -129.04 0.0 OUTLIER 'Trans proline' 0 C--N 1.316 -1.171 0 C-N-CA 123.264 2.643 . . . . 0.0 116.937 -179.216 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 313' ' ' VAL . . . . . 0.543 ' O ' ' OG ' ' A' ' 316' ' ' SER . 17.6 m -112.89 28.77 2.28 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 CA-C-N 114.775 -1.102 . . . . 0.0 113.542 -175.931 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 314' ' ' ASP . . . . . 0.4 ' O ' ' CB ' ' A' ' 317' ' ' LYS . 92.1 m-20 -51.51 -36.46 44.79 Favored 'General case' 0 C--N 1.319 -0.751 0 C-N-CA 119.66 -0.816 . . . . 0.0 111.17 -177.127 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 315' ' ' LEU . . . . . 0.633 ' CD2' ' N ' ' A' ' 315' ' ' LEU . 0.3 OUTLIER -59.81 -35.34 74.5 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 119.819 -0.752 . . . . 0.0 110.414 178.587 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 316' ' ' SER . . . . . 0.543 ' OG ' ' O ' ' A' ' 313' ' ' VAL . 82.6 p -62.44 -21.12 65.17 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-O 121.431 0.634 . . . . 0.0 110.364 179.373 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 317' ' ' LYS . . . . . 0.4 ' CB ' ' O ' ' A' ' 314' ' ' ASP . 82.0 tttt -55.29 -34.53 64.18 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.071 -0.968 . . . . 0.0 111.779 -177.399 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 13.1 p -129.08 142.55 43.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 C-N-CA 120.471 -0.492 . . . . 0.0 110.789 179.657 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.221 -0.439 0 CA-C-O 118.008 -0.996 . . . . 0.0 110.555 -179.644 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.409 0 N-CA-C 110.793 -0.923 . . . . 0.0 110.793 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 97.6 p -120.68 153.07 37.41 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.117 0.484 . . . . 0.0 110.687 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -133.59 170.67 15.19 Favored 'General case' 0 CA--C 1.506 -0.728 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.673 -179.499 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 295' ' ' ASP . . . . . . . . . . . . . 86.0 m-20 -63.12 143.71 57.55 Favored 'General case' 0 N--CA 1.438 -1.063 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 -179.769 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 22.3 t-20 -64.77 130.5 43.74 Favored 'General case' 0 C--N 1.309 -1.174 0 CA-C-N 115.246 -0.888 . . . . 0.0 111.669 -177.595 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 297' ' ' ILE . . . . . 0.453 HD12 HG21 ' A' ' 297' ' ' ILE . 71.4 mt -115.18 132.12 65.41 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.09 0 CA-C-N 114.856 -1.065 . . . . 0.0 110.545 -179.762 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 73.1 tttt -105.66 135.62 46.74 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.85 179.184 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 99.3 m-70 -118.94 140.48 49.92 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.089 178.451 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 3.6 m -123.98 78.28 58.44 Favored Pre-proline 0 C--N 1.33 -0.255 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.358 -179.156 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -56.53 145.82 78.3 Favored 'Trans proline' 0 C--N 1.312 -1.371 0 N-CA-C 109.244 -1.099 . . . . 0.0 109.244 178.807 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -49.36 107.52 0.32 Allowed Glycine 0 CA--C 1.52 0.375 0 C-N-CA 118.92 -1.61 . . . . 0.0 109.769 -178.864 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -77.92 -2.13 81.01 Favored Glycine 0 C--N 1.33 0.23 0 N-CA-C 109.798 -1.321 . . . . 0.0 109.798 179.59 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 95.33 -1.93 64.94 Favored Glycine 0 N--CA 1.45 -0.402 0 N-CA-C 108.958 -1.657 . . . . 0.0 108.958 -178.883 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 73.9 m -83.24 1.83 38.85 Favored 'General case' 0 N--CA 1.453 -0.32 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 178.505 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 306' ' ' VAL . . . . . . . . . . . . . 71.6 t -61.08 -39.93 83.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.062 -0.972 . . . . 0.0 110.214 -179.467 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 307' ' ' GLN . . . . . 0.792 ' HG3' ' H ' ' A' ' 308' ' ' ILE . 21.2 pt20 -159.63 -88.24 0.03 OUTLIER 'General case' 0 CA--C 1.542 0.637 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.824 179.065 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 308' ' ' ILE . . . . . 0.792 ' H ' ' HG3' ' A' ' 307' ' ' GLN . 32.0 pt -125.22 160.94 30.24 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 CA-C-N 118.985 0.811 . . . . 0.0 111.305 179.525 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . 0.655 ' CG1' ' H ' ' A' ' 310' ' ' TYR . 3.9 p -136.65 -65.26 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 178.199 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 310' ' ' TYR . . . . . 0.655 ' H ' ' CG1' ' A' ' 309' ' ' VAL . 0.8 OUTLIER -66.31 -19.47 65.82 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.288 -0.869 . . . . 0.0 112.484 178.461 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 311' ' ' LYS . . . . . 0.534 ' O ' ' C ' ' A' ' 312' ' ' PRO . 43.9 tttt 67.55 65.21 0.66 Allowed Pre-proline 0 C--N 1.326 -0.439 0 C-N-CA 120.791 -0.364 . . . . 0.0 110.674 -179.358 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 312' ' ' PRO . . . . . 0.568 ' O ' ' C ' ' A' ' 313' ' ' VAL . 70.6 Cg_exo 3.9 75.75 0.0 OUTLIER 'Trans proline' 0 N--CA 1.488 1.152 0 C-N-CA 122.924 2.416 . . . . 0.0 114.016 179.812 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 313' ' ' VAL . . . . . 0.568 ' C ' ' O ' ' A' ' 312' ' ' PRO . 13.7 p 1.33 71.18 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 O-C-N 124.085 0.866 . . . . 0.0 111.434 179.643 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 314' ' ' ASP . . . . . 0.506 ' N ' ' O ' ' A' ' 312' ' ' PRO . 21.7 t70 -55.18 -36.56 66.02 Favored 'General case' 0 CA--C 1.536 0.416 0 CA-C-N 114.464 -1.244 . . . . 0.0 112.992 -178.586 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 315' ' ' LEU . . . . . 0.635 ' N ' ' CD2' ' A' ' 315' ' ' LEU . 0.2 OUTLIER -58.88 -35.25 72.68 Favored 'General case' 0 N--CA 1.465 0.291 0 C-N-CA 120.585 -0.446 . . . . 0.0 111.258 -178.65 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 84.1 p -61.83 -26.39 68.09 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.002 0.43 . . . . 0.0 110.91 179.873 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 32.0 mmtm -58.07 -36.18 72.44 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.892 -0.595 . . . . 0.0 111.784 -177.397 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 13.3 p -132.47 143.11 40.81 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.26 0 CA-C-O 120.607 0.241 . . . . 0.0 111.077 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 27.0 p . . . . . 0 C--O 1.221 -0.446 0 CA-C-O 117.83 -1.081 . . . . 0.0 110.422 179.443 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.609 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 74.3 m -82.3 2.3 32.74 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.858 0.361 . . . . 0.0 110.457 -179.94 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 76.9 mttt -96.56 151.52 19.51 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.439 179.699 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 295' ' ' ASP . . . . . 0.469 ' C ' ' OD1' ' A' ' 295' ' ' ASP . 48.9 p30 -86.7 9.86 17.49 Favored 'General case' 0 CA--C 1.503 -0.852 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 178.844 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 296' ' ' ASN . . . . . 0.616 ' CG ' ' H ' ' A' ' 297' ' ' ILE . 37.3 t-20 58.78 -143.17 0.62 Allowed 'General case' 0 CA--C 1.49 -1.341 0 CA-C-N 114.369 -1.287 . . . . 0.0 110.598 179.579 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 297' ' ' ILE . . . . . 0.616 ' H ' ' CG ' ' A' ' 296' ' ' ASN . 14.4 tt -121.4 131.19 73.65 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 CA-C-O 122.482 1.134 . . . . 0.0 112.416 -177.899 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 83.6 tttt -93.88 131.17 39.56 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-N 112.66 -2.064 . . . . 0.0 109.447 177.475 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 49.7 t-80 -128.26 137.05 51.82 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 120.114 -0.635 . . . . 0.0 110.86 179.792 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -124.21 76.55 60.43 Favored Pre-proline 0 N--CA 1.469 0.505 0 CA-C-N 116.804 -0.18 . . . . 0.0 111.065 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 83.6 Cg_endo -58.97 -25.49 77.75 Favored 'Trans proline' 0 N--CA 1.489 1.254 0 C-N-CA 121.126 1.217 . . . . 0.0 111.009 179.193 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . 174.77 133.61 1.75 Allowed Glycine 0 CA--C 1.532 1.125 0 CA-C-N 115.309 -0.86 . . . . 0.0 111.444 179.785 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -117.37 48.16 0.97 Allowed Glycine 0 CA--C 1.533 1.207 0 N-CA-C 110.534 -1.026 . . . . 0.0 110.534 179.565 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 99.1 -7.72 60.53 Favored Glycine 0 N--CA 1.466 0.687 0 N-CA-C 109.01 -1.636 . . . . 0.0 109.01 -178.143 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 27.9 t -83.68 -0.55 51.2 Favored 'General case' 0 CA--C 1.516 -0.327 0 N-CA-C 107.03 -1.47 . . . . 0.0 107.03 175.816 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 306' ' ' VAL . . . . . 0.623 ' O ' ' CB ' ' A' ' 307' ' ' GLN . 99.5 t -58.77 -41.56 82.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 113.569 -1.651 . . . . 0.0 112.193 -175.683 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 307' ' ' GLN . . . . . 0.623 ' CB ' ' O ' ' A' ' 306' ' ' VAL . 63.0 tt0 122.86 172.36 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.792 0 O-C-N 124.631 1.207 . . . . 0.0 108.023 -179.298 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 308' ' ' ILE . . . . . 0.466 ' N ' ' HG2' ' A' ' 307' ' ' GLN . 29.4 pt -121.25 155.24 25.11 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 N-CA-C 110.11 -0.329 . . . . 0.0 110.11 179.384 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 58.9 t -133.74 -5.62 1.34 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.292 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.611 179.569 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 310' ' ' TYR . . . . . 0.506 ' CD1' ' HD3' ' A' ' 312' ' ' PRO . 2.0 p90 -65.87 -18.29 65.24 Favored 'General case' 0 CA--C 1.517 -0.298 0 N-CA-C 112.508 0.559 . . . . 0.0 112.508 -176.481 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 311' ' ' LYS . . . . . 0.49 ' O ' ' C ' ' A' ' 312' ' ' PRO . 1.9 mtmm 59.38 64.91 2.84 Favored Pre-proline 0 C--N 1.325 -0.461 0 N-CA-C 107.252 -1.388 . . . . 0.0 107.252 -179.411 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 312' ' ' PRO . . . . . 0.506 ' HD3' ' CD1' ' A' ' 310' ' ' TYR . 1.1 Cg_exo -14.06 -62.1 0.01 OUTLIER 'Trans proline' 0 C--N 1.305 -1.731 0 C-N-CA 123.065 2.51 . . . . 0.0 114.536 -178.517 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 2.6 p -176.18 27.07 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 C-N-CA 120.397 -0.521 . . . . 0.0 111.314 179.621 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 92.9 m-20 -57.85 -37.66 74.29 Favored 'General case' 0 C--N 1.32 -0.705 0 N-CA-C 112.135 0.421 . . . . 0.0 112.135 -179.027 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 315' ' ' LEU . . . . . 0.484 ' O ' ' CD1' ' A' ' 315' ' ' LEU . 0.1 OUTLIER -56.95 -39.49 74.66 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 120.203 -0.599 . . . . 0.0 109.806 -178.671 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 86.6 p -63.34 -27.2 69.15 Favored 'General case' 0 N--CA 1.471 0.601 0 O-C-N 122.057 -0.402 . . . . 0.0 111.976 178.595 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 57.2 tttp -58.2 -36.17 72.7 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.156 -0.475 . . . . 0.0 112.114 -177.858 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 27.9 m -76.0 136.75 24.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-O 121.213 0.53 . . . . 0.0 111.097 -179.21 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 43.6 m . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 118.044 -0.979 . . . . 0.0 110.31 -179.952 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.761 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 46.7 m -63.83 154.32 33.96 Favored 'General case' 0 C--N 1.33 -0.255 0 C-N-CA 121.061 -0.255 . . . . 0.0 110.322 -179.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 294' ' ' LYS . . . . . 0.47 ' C ' ' H ' ' A' ' 296' ' ' ASN . 11.5 mtpp -98.99 148.47 23.96 Favored 'General case' 0 N--CA 1.448 -0.569 0 CA-C-O 120.989 0.423 . . . . 0.0 111.188 -179.56 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 295' ' ' ASP . . . . . 0.471 ' OD2' ' C ' ' A' ' 295' ' ' ASP . 49.7 p30 -86.85 10.82 14.88 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 107.079 -1.452 . . . . 0.0 107.079 178.37 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 296' ' ' ASN . . . . . 0.47 ' H ' ' C ' ' A' ' 294' ' ' LYS . 81.1 m-20 29.17 -127.51 0.03 OUTLIER 'General case' 0 CA--C 1.5 -0.953 0 CA-C-N 112.604 -2.089 . . . . 0.0 113.467 -178.348 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 297' ' ' ILE . . . . . . . . . . . . . 14.7 tt -121.86 130.47 74.56 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.709 0 CA-C-O 122.473 1.13 . . . . 0.0 113.024 -177.469 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 15.6 ttmm -100.84 127.63 47.21 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-N 112.715 -2.039 . . . . 0.0 109.675 176.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 50.6 t-80 -136.33 114.33 11.37 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 120.552 -0.459 . . . . 0.0 111.479 179.193 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 3.2 m -133.89 72.87 72.2 Favored Pre-proline 0 N--CA 1.476 0.858 0 N-CA-C 113.953 1.094 . . . . 0.0 113.953 179.269 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 8.4 Cg_endo -61.25 -23.41 77.0 Favored 'Trans proline' 0 N--CA 1.502 2.017 0 CA-C-N 119.978 1.028 . . . . 0.0 112.026 177.732 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -77.01 46.25 2.38 Favored Glycine 0 CA--C 1.528 0.883 0 CA-C-N 115.121 -0.945 . . . . 0.0 113.194 -178.171 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -57.7 -28.53 60.22 Favored Glycine 0 N--CA 1.445 -0.7 0 N-CA-C 107.397 -2.281 . . . . 0.0 107.397 178.122 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 95.94 -0.56 62.62 Favored Glycine 0 N--CA 1.44 -1.038 0 N-CA-C 104.355 -3.498 . . . . 0.0 104.355 -175.594 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 72.8 m -83.06 1.36 40.52 Favored 'General case' 0 N--CA 1.436 -1.155 0 CA-C-N 112.486 -1.857 . . . . 0.0 110.314 179.295 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 306' ' ' VAL . . . . . . . . . . . . . 92.6 t -61.79 -42.63 95.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 115.424 -0.807 . . . . 0.0 112.178 -178.233 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 307' ' ' GLN . . . . . . . . . . . . . 2.5 pt20 173.65 -159.63 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.254 0 O-C-N 123.705 0.628 . . . . 0.0 109.585 -179.312 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 308' ' ' ILE . . . . . 0.52 ' CG2' ' H ' ' A' ' 311' ' ' LYS . 65.5 mt -114.97 122.95 70.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.546 178.127 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . 0.491 ' CG1' ' N ' ' A' ' 310' ' ' TYR . 8.0 p -63.82 -39.6 86.01 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.311 0 C-N-CA 118.859 -1.136 . . . . 0.0 108.442 176.588 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 310' ' ' TYR . . . . . 0.491 ' N ' ' CG1' ' A' ' 309' ' ' VAL 0.331 55.2 p90 -67.49 -33.14 74.49 Favored 'General case' 0 N--CA 1.452 -0.352 0 N-CA-C 117.584 2.438 . . . . 0.0 117.584 178.89 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 311' ' ' LYS . . . . . 0.539 ' O ' ' C ' ' A' ' 312' ' ' PRO . 2.9 ttpm? 46.34 61.29 13.24 Favored Pre-proline 0 C--N 1.315 -0.924 0 C-N-CA 119.136 -1.025 . . . . 0.0 109.508 179.606 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 312' ' ' PRO . . . . . 0.539 ' C ' ' O ' ' A' ' 311' ' ' LYS . 83.8 Cg_exo 24.16 55.25 0.0 OUTLIER 'Trans proline' 0 N--CA 1.486 1.031 0 C-N-CA 120.801 1.001 . . . . 0.0 113.201 -179.209 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 313' ' ' VAL . . . . . 0.526 ' C ' ' O ' ' A' ' 312' ' ' PRO . 4.2 m 2.68 84.11 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 CA-C-N 115.181 -0.918 . . . . 0.0 112.467 -179.743 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 56.1 t0 -55.8 -36.62 67.62 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.956 -0.565 . . . . 0.0 111.146 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 315' ' ' LEU . . . . . . . . . . . . . 62.4 mt -58.82 -33.91 70.93 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.593 -178.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 95.3 p -60.43 -28.05 67.98 Favored 'General case' 0 CA--C 1.511 -0.55 0 C-N-CA 120.048 -0.661 . . . . 0.0 111.058 -179.285 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 38.1 mtpt -92.04 137.75 32.11 Favored 'General case' 0 N--CA 1.448 -0.539 0 C-N-CA 119.455 -0.898 . . . . 0.0 109.868 179.434 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 13.7 p -131.69 143.0 41.68 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 CA-C-N 114.977 -1.01 . . . . 0.0 110.765 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 41.6 p . . . . . 0 C--O 1.22 -0.488 0 CA-C-O 118.02 -0.991 . . . . 0.0 110.559 179.989 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.737 0 N-CA-C 110.939 -0.864 . . . . 0.0 110.939 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 92.3 p -122.67 155.88 35.49 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.596 0.236 . . . . 0.0 110.463 -179.878 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 16.0 mtpp -93.91 149.7 21.0 Favored 'General case' 0 N--CA 1.446 -0.633 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.714 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 295' ' ' ASP . . . . . 0.679 ' OD1' ' N ' ' A' ' 296' ' ' ASN . 49.8 p30 -60.16 -31.94 70.58 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 108.107 -1.071 . . . . 0.0 108.107 178.929 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 296' ' ' ASN . . . . . 0.679 ' N ' ' OD1' ' A' ' 295' ' ' ASP . 0.4 OUTLIER 58.99 44.98 15.54 Favored 'General case' 0 N--CA 1.45 -0.467 0 CA-C-N 115.277 -0.874 . . . . 0.0 109.804 179.63 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 297' ' ' ILE . . . . . 0.582 ' CG2' ' H ' ' A' ' 298' ' ' LYS . 84.4 mt 36.57 -118.09 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.439 -0.801 . . . . 0.0 110.634 -178.696 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 298' ' ' LYS . . . . . 0.582 ' H ' ' CG2' ' A' ' 297' ' ' ILE . 83.6 tttt -158.09 -95.86 0.03 OUTLIER 'General case' 0 CA--C 1.538 0.481 0 C-N-CA 119.948 -0.701 . . . . 0.0 111.564 179.499 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 76.3 m80 73.87 88.58 0.09 Allowed 'General case' 0 N--CA 1.476 0.871 0 N-CA-C 113.176 0.806 . . . . 0.0 113.176 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 3.1 m -124.01 77.87 58.78 Favored Pre-proline 0 CA--C 1.537 0.477 0 CA-C-N 115.408 -0.814 . . . . 0.0 109.582 179.125 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 301' ' ' PRO . . . . . 0.644 ' C ' ' H ' ' A' ' 303' ' ' GLY . 8.1 Cg_exo -56.51 -24.49 53.42 Favored 'Trans proline' 0 N--CA 1.494 1.529 0 C-N-CA 121.694 1.596 . . . . 0.0 113.1 -178.285 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -73.02 17.54 1.68 Allowed Glycine 0 N--CA 1.463 0.452 0 N-CA-C 109.238 -1.545 . . . . 0.0 109.238 178.338 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 303' ' ' GLY . . . . . 0.644 ' H ' ' C ' ' A' ' 301' ' ' PRO . . . -56.04 -23.58 39.77 Favored Glycine 0 CA--C 1.516 0.147 0 CA-C-N 114.311 -0.944 . . . . 0.0 110.971 -179.814 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 98.1 -4.36 60.69 Favored Glycine 0 CA--C 1.505 -0.59 0 N-CA-C 104.349 -3.5 . . . . 0.0 104.349 -174.776 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 85.2 p -64.69 -20.72 66.48 Favored 'General case' 0 N--CA 1.428 -1.541 0 CA-C-N 111.331 -2.435 . . . . 0.0 106.139 175.649 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 306' ' ' VAL . . . . . 0.586 ' O ' ' CB ' ' A' ' 307' ' ' GLN . 80.8 t -57.48 -42.09 80.16 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 CA-C-N 113.259 -1.791 . . . . 0.0 110.9 -177.375 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 307' ' ' GLN . . . . . 0.586 ' CB ' ' O ' ' A' ' 306' ' ' VAL . 57.2 tt0 103.92 160.48 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.484 0 O-C-N 124.378 1.049 . . . . 0.0 109.019 179.72 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 308' ' ' ILE . . . . . 0.648 HG21 ' H ' ' A' ' 310' ' ' TYR . 70.2 mt -114.98 129.0 71.91 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.46 0 CA-C-O 121.43 0.634 . . . . 0.0 110.738 178.53 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 1.5 t -86.56 8.63 1.95 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.558 0 CA-C-N 114.648 -1.16 . . . . 0.0 111.763 179.296 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 310' ' ' TYR . . . . . 0.648 ' H ' HG21 ' A' ' 308' ' ' ILE . 0.0 OUTLIER -54.27 -32.43 56.21 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 113.886 1.069 . . . . 0.0 113.886 -174.962 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 311' ' ' LYS . . . . . 0.53 ' N ' ' CD ' ' A' ' 312' ' ' PRO . 12.1 mmmt 57.33 68.16 2.14 Favored Pre-proline 0 N--CA 1.475 0.798 0 CA-C-N 119.732 1.151 . . . . 0.0 112.019 177.345 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 312' ' ' PRO . . . . . 0.594 ' O ' ' N ' ' A' ' 314' ' ' ASP . 86.6 Cg_exo -54.78 148.55 45.22 Favored 'Trans proline' 0 C--N 1.304 -1.808 0 C-N-CA 124.978 3.785 . . . . 0.0 114.761 -179.067 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 313' ' ' VAL . . . . . 0.469 ' O ' ' OG ' ' A' ' 316' ' ' SER . 17.8 m 38.82 12.28 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 CA-C-N 114.313 -1.312 . . . . 0.0 113.093 -179.337 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 314' ' ' ASP . . . . . 0.594 ' N ' ' O ' ' A' ' 312' ' ' PRO . 20.9 t70 -55.11 -36.64 65.91 Favored 'General case' 0 C--N 1.319 -0.734 0 C-N-CA 120.237 -0.585 . . . . 0.0 109.557 179.126 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 315' ' ' LEU . . . . . 0.62 ' CD2' ' N ' ' A' ' 315' ' ' LEU . 0.2 OUTLIER -61.12 -35.24 76.53 Favored 'General case' 0 CA--C 1.541 0.615 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.027 179.4 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 316' ' ' SER . . . . . 0.469 ' OG ' ' O ' ' A' ' 313' ' ' VAL . 79.6 p -62.4 -25.93 68.21 Favored 'General case' 0 N--CA 1.471 0.579 0 CA-C-O 121.643 0.735 . . . . 0.0 110.862 179.942 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 62.6 mmtt -58.04 -26.29 62.27 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 114.49 -1.232 . . . . 0.0 113.598 -178.432 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 11.6 p -110.22 138.6 37.32 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 CA-C-O 122.142 0.972 . . . . 0.0 111.061 -176.41 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 3.6 m . . . . . 0 C--O 1.219 -0.526 0 CA-C-N 113.335 -1.757 . . . . 0.0 110.203 -178.14 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.642 0 N-CA-C 111.05 -0.82 . . . . 0.0 111.05 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 98.6 p -120.25 152.75 37.31 Favored 'General case' 0 N--CA 1.462 0.173 0 CA-C-O 120.911 0.386 . . . . 0.0 110.215 179.654 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 294' ' ' LYS . . . . . 0.443 ' HD2' ' N ' ' A' ' 294' ' ' LYS . 1.0 OUTLIER -85.4 -74.06 0.42 Allowed 'General case' 0 CA--C 1.512 -0.504 0 CA-C-O 121.701 0.762 . . . . 0.0 112.101 -179.296 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 295' ' ' ASP . . . . . 0.467 ' OD2' ' C ' ' A' ' 295' ' ' ASP . 50.6 p30 -89.58 6.94 38.92 Favored 'General case' 0 N--CA 1.442 -0.869 0 CA-C-N 114.427 -1.261 . . . . 0.0 109.468 179.879 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 17.3 t-20 58.97 53.53 5.58 Favored 'General case' 0 N--CA 1.473 0.675 0 N-CA-C 114.531 1.308 . . . . 0.0 114.531 176.587 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 297' ' ' ILE . . . . . 0.436 HG12 ' OD2' ' A' ' 295' ' ' ASP . 15.7 mm -73.4 140.94 16.96 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.653 0 C-N-CA 119.524 -0.87 . . . . 0.0 110.172 -179.617 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 298' ' ' LYS . . . . . 0.496 ' HZ2' HG12 ' A' ' 300' ' ' VAL . 14.0 ptmm? -125.22 154.26 41.89 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 114.682 -1.145 . . . . 0.0 111.62 -178.002 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 56.6 t-80 -124.36 129.6 50.99 Favored 'General case' 0 CA--C 1.536 0.409 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 178.265 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 300' ' ' VAL . . . . . 0.496 HG12 ' HZ2' ' A' ' 298' ' ' LYS . 0.2 OUTLIER -124.14 77.35 59.95 Favored Pre-proline 0 N--CA 1.474 0.763 0 N-CA-C 112.406 0.521 . . . . 0.0 112.406 -179.147 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -59.01 -27.63 85.57 Favored 'Trans proline' 0 C--N 1.312 -1.373 0 N-CA-C 109.885 -0.852 . . . . 0.0 109.885 177.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -121.66 106.32 1.08 Allowed Glycine 0 CA--C 1.523 0.568 0 CA-C-N 115.039 -0.982 . . . . 0.0 110.788 179.302 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -141.56 33.38 1.98 Allowed Glycine 0 CA--C 1.523 0.579 0 N-CA-C 109.905 -1.278 . . . . 0.0 109.905 179.23 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 95.2 -0.43 63.96 Favored Glycine 0 CA--C 1.521 0.426 0 N-CA-C 107.963 -2.055 . . . . 0.0 107.963 -177.891 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 52.0 p -82.78 -0.14 46.42 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 113.896 -1.152 . . . . 0.0 109.541 178.547 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 306' ' ' VAL . . . . . 0.514 ' O ' ' CB ' ' A' ' 307' ' ' GLN . 92.3 t -58.27 -39.19 72.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.509 -0.769 . . . . 0.0 110.127 -177.633 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 307' ' ' GLN . . . . . 0.614 ' O ' ' N ' ' A' ' 309' ' ' VAL . 57.9 tt0 94.07 139.74 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.727 0 N-CA-C 114.602 1.334 . . . . 0.0 114.602 177.816 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 308' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER 16.23 36.76 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.543 0 CA-C-N 112.723 -2.035 . . . . 0.0 115.397 177.99 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 309' ' ' VAL . . . . . 0.614 ' N ' ' O ' ' A' ' 307' ' ' GLN . 62.9 t -55.54 -37.45 45.65 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 N-CA-C 107.943 -1.132 . . . . 0.0 107.943 179.425 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 310' ' ' TYR . . . . . 0.495 ' CE1' ' HD3' ' A' ' 312' ' ' PRO . 33.6 p90 -60.3 -28.04 67.79 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 114.226 1.195 . . . . 0.0 114.226 -179.789 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 311' ' ' LYS . . . . . . . . . . . . . 2.3 tmtp? 68.97 74.32 0.29 Allowed Pre-proline 0 N--CA 1.474 0.75 0 CA-C-N 119.337 0.971 . . . . 0.0 110.512 178.313 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 312' ' ' PRO . . . . . 0.495 ' HD3' ' CE1' ' A' ' 310' ' ' TYR . 13.4 Cg_exo -54.83 -31.07 70.95 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 C-N-CA 122.59 2.193 . . . . 0.0 114.803 -177.014 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 39.2 t -124.26 134.81 65.63 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.525 0 C-N-CA 120.184 -0.606 . . . . 0.0 111.308 179.765 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 61.2 t0 -149.12 -89.42 0.08 Allowed 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.516 -0.765 . . . . 0.0 109.061 178.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 315' ' ' LEU . . . . . 0.538 ' CD2' ' H ' ' A' ' 315' ' ' LEU . 2.0 mm? -59.61 -31.09 69.16 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.065 178.041 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 25.2 m -55.29 -33.17 63.03 Favored 'General case' 0 N--CA 1.455 -0.197 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.133 -178.025 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 65.4 mttm -57.82 -34.1 69.3 Favored 'General case' 0 C--N 1.326 -0.435 0 C-N-CA 120.461 -0.496 . . . . 0.0 110.44 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 42.1 t -115.77 135.8 54.71 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-O 120.825 0.345 . . . . 0.0 110.983 -179.449 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 37.4 p . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.333 179.684 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 293' ' ' SER . . . . . 0.464 ' O ' ' O ' ' A' ' 294' ' ' LYS . 97.5 p . . . . . 0 N--CA 1.461 0.115 0 CA-C-O 121.119 0.485 . . . . 0.0 111.272 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 294' ' ' LYS . . . . . 0.464 ' O ' ' O ' ' A' ' 293' ' ' SER . 57.7 mttp -55.19 -126.1 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.502 -0.772 . . . . 0.0 111.757 179.836 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 295' ' ' ASP . . . . . . . . . . . . . 89.5 m-20 -92.17 7.43 42.57 Favored 'General case' 0 N--CA 1.455 -0.224 0 CA-C-N 114.924 -1.035 . . . . 0.0 111.235 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 49.9 t30 60.26 52.13 5.1 Favored 'General case' 0 C--N 1.333 -0.119 0 C-N-CA 119.68 -0.808 . . . . 0.0 111.567 179.842 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 297' ' ' ILE . . . . . . . . . . . . . 80.9 mt -64.99 135.22 28.6 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 122.396 1.093 . . . . 0.0 111.779 -177.354 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 84.6 tttt -81.76 137.0 35.41 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 112.884 -1.962 . . . . 0.0 112.752 -179.085 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 74.4 t60 -124.53 136.36 53.92 Favored 'General case' 0 CA--C 1.543 0.711 0 N-CA-C 107.914 -1.143 . . . . 0.0 107.914 178.97 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -124.0 76.72 58.78 Favored Pre-proline 0 N--CA 1.481 1.09 0 N-CA-C 113.336 0.865 . . . . 0.0 113.336 -177.876 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -59.76 -26.1 81.19 Favored 'Trans proline' 0 N--CA 1.493 1.472 0 C-N-CA 121.221 1.28 . . . . 0.0 111.862 178.451 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -167.28 125.1 1.28 Allowed Glycine 0 CA--C 1.527 0.789 0 N-CA-C 110.89 -0.884 . . . . 0.0 110.89 -179.585 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -150.35 37.2 0.92 Allowed Glycine 0 N--CA 1.468 0.803 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 179.732 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 96.7 -4.72 63.85 Favored Glycine 0 C--N 1.317 -0.488 0 N-CA-C 106.262 -2.735 . . . . 0.0 106.262 -177.079 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 24.9 t -59.89 -27.76 66.99 Favored 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 112.827 -1.686 . . . . 0.0 109.121 176.937 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 306' ' ' VAL . . . . . 0.641 ' O ' ' CB ' ' A' ' 307' ' ' GLN . 73.5 t -55.41 -40.08 56.01 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.643 0 CA-C-N 114.081 -1.418 . . . . 0.0 112.038 -175.77 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 307' ' ' GLN . . . . . 0.641 ' CB ' ' O ' ' A' ' 306' ' ' VAL . 63.1 tp60 117.37 84.61 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.529 0 N-CA-C 113.921 1.082 . . . . 0.0 113.921 177.482 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 308' ' ' ILE . . . . . 0.672 HG23 ' O ' ' A' ' 308' ' ' ILE . 18.6 tt 26.46 58.24 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 N-CA-C 113.16 0.8 . . . . 0.0 113.16 176.217 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 54.8 t -56.0 -39.23 56.64 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.605 0 C-N-CA 118.724 -1.19 . . . . 0.0 109.76 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 310' ' ' TYR . . . . . 0.695 ' O ' ' CD1' ' A' ' 310' ' ' TYR . 36.7 p90 -69.83 104.56 2.5 Favored 'General case' 0 N--CA 1.439 -1.0 0 C-N-CA 119.082 -1.047 . . . . 0.0 109.41 178.601 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 311' ' ' LYS . . . . . . . . . . . . . 38.6 mtpt -73.34 128.07 88.02 Favored Pre-proline 0 C--N 1.313 -1.016 0 C-N-CA 119.649 -0.82 . . . . 0.0 110.385 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 312' ' ' PRO . . . . . . . . . . . . . 85.3 Cg_exo -55.96 149.48 51.89 Favored 'Trans proline' 0 C--N 1.306 -1.66 0 N-CA-C 106.122 -2.299 . . . . 0.0 106.122 174.326 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 36.1 t -64.46 126.26 22.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 C-N-CA 116.284 -2.166 . . . . 0.0 110.775 -175.921 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 314' ' ' ASP . . . . . 0.466 ' O ' ' HB3' ' A' ' 317' ' ' LYS . 89.5 m-20 -95.59 -19.22 19.95 Favored 'General case' 0 N--CA 1.444 -0.762 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 175.509 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 315' ' ' LEU . . . . . 0.697 ' O ' HG12 ' A' ' 318' ' ' VAL . 60.5 mt -62.22 -37.47 85.48 Favored 'General case' 0 C--O 1.232 0.141 0 CA-C-N 116.029 -0.532 . . . . 0.0 112.293 -178.324 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 82.9 p -63.03 -30.76 71.85 Favored 'General case' 0 CA--C 1.519 -0.22 0 CA-C-O 121.499 0.666 . . . . 0.0 109.886 179.877 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 317' ' ' LYS . . . . . 0.466 ' HB3' ' O ' ' A' ' 314' ' ' ASP . 18.8 tttt -59.38 -36.89 76.62 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 114.342 -1.299 . . . . 0.0 112.783 -178.824 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 318' ' ' VAL . . . . . 0.697 HG12 ' O ' ' A' ' 315' ' ' LEU . 5.3 p -57.07 -33.98 44.0 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 N-CA-C 112.268 0.47 . . . . 0.0 112.268 -178.148 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 319' ' ' THR . . . . . 0.412 ' OXT' ' O ' ' A' ' 318' ' ' VAL . 1.3 m . . . . . 0 C--O 1.221 -0.443 0 CA-C-O 117.951 -1.023 . . . . 0.0 110.792 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 23.8 m . . . . . 0 C--O 1.231 0.121 0 CA-C-O 120.862 0.363 . . . . 0.0 110.137 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -96.27 148.32 22.86 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.716 179.298 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 295' ' ' ASP . . . . . 0.596 ' O ' ' CB ' ' A' ' 296' ' ' ASN . 91.6 m-20 -56.52 -36.4 69.16 Favored 'General case' 0 CA--C 1.492 -1.251 0 N-CA-C 107.382 -1.34 . . . . 0.0 107.382 177.659 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 296' ' ' ASN . . . . . 0.596 ' CB ' ' O ' ' A' ' 295' ' ' ASP . 48.2 t30 118.39 -128.61 0.0 OUTLIER 'General case' 0 CA--C 1.469 -2.16 0 O-C-N 125.581 1.801 . . . . 0.0 110.097 179.51 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 297' ' ' ILE . . . . . 0.651 ' O ' HG23 ' A' ' 297' ' ' ILE . 8.9 tp -122.44 133.35 68.93 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.111 0 CA-C-N 114.499 -1.228 . . . . 0.0 110.497 -178.781 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 43.4 tttm -132.71 120.19 21.35 Favored 'General case' 0 C--N 1.294 -1.84 0 CA-C-N 114.234 -1.348 . . . . 0.0 110.323 174.453 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 299' ' ' HIS . . . . . 0.407 ' CD2' HD11 ' A' ' 297' ' ' ILE . 79.8 m-70 -139.81 145.04 37.65 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.36 -0.836 . . . . 0.0 112.251 174.851 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -124.8 72.71 62.6 Favored Pre-proline 0 C--N 1.322 -0.63 0 CA-C-N 115.473 -0.785 . . . . 0.0 108.952 177.282 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -59.1 -24.67 74.76 Favored 'Trans proline' 0 N--CA 1.492 1.44 0 C-N-CA 121.034 1.156 . . . . 0.0 111.098 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . 150.15 136.51 2.58 Favored Glycine 0 CA--C 1.52 0.365 0 CA-C-N 115.05 -0.977 . . . . 0.0 110.875 179.442 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -84.57 1.52 88.76 Favored Glycine 0 CA--C 1.519 0.311 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 179.009 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 95.74 -2.83 64.81 Favored Glycine 0 CA--C 1.519 0.329 0 N-CA-C 108.936 -1.666 . . . . 0.0 108.936 -179.021 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 73.9 m -84.53 4.28 32.67 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 114.774 -0.713 . . . . 0.0 109.902 178.619 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 306' ' ' VAL . . . . . . . . . . . . . 98.8 t -59.67 -41.78 86.34 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.662 0 CA-C-O 122.235 1.017 . . . . 0.0 111.179 -178.309 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 307' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 -141.84 168.5 19.6 Favored 'General case' 0 C--N 1.31 -1.119 0 CA-C-N 112.896 -1.956 . . . . 0.0 109.0 -177.498 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 308' ' ' ILE . . . . . 0.732 HG22 ' H ' ' A' ' 311' ' ' LYS . 31.8 mm -104.05 117.81 50.19 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 CA-C-N 115.418 -0.81 . . . . 0.0 113.162 -179.152 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 21.0 m -78.53 -30.11 15.09 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.483 0 CA-C-N 114.13 -1.395 . . . . 0.0 108.398 175.592 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 310' ' ' TYR . . . . . 0.611 ' CE2' HG23 ' A' ' 308' ' ' ILE 0.364 51.7 p90 -64.15 -28.29 69.66 Favored 'General case' 0 N--CA 1.447 -0.608 0 N-CA-C 116.311 1.967 . . . . 0.0 116.311 -179.197 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 311' ' ' LYS . . . . . 0.732 ' H ' HG22 ' A' ' 308' ' ' ILE . 37.3 mtpt 53.72 65.65 5.32 Favored Pre-proline 0 C--N 1.318 -0.78 0 C-N-CA 119.875 -0.73 . . . . 0.0 110.958 178.44 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 312' ' ' PRO . . . . . 0.492 ' C ' ' O ' ' A' ' 311' ' ' LYS . 91.0 Cg_exo 3.86 -128.87 0.0 OUTLIER 'Trans proline' 0 N--CA 1.487 1.141 0 C-N-CA 123.092 2.528 . . . . 0.0 115.771 -179.287 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 313' ' ' VAL . . . . . 0.624 HG13 ' O ' ' A' ' 313' ' ' VAL . 4.5 p -113.04 37.06 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.718 0 N-CA-C 112.955 0.724 . . . . 0.0 112.955 -177.234 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 314' ' ' ASP . . . . . 0.402 ' O ' ' HB3' ' A' ' 317' ' ' LYS . 54.6 t0 -54.13 -35.26 62.01 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 112.081 0.4 . . . . 0.0 112.081 -179.614 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 315' ' ' LEU . . . . . 1.012 HD22 ' H ' ' A' ' 315' ' ' LEU . 1.8 mm? -57.15 -35.18 69.21 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 120.299 -0.56 . . . . 0.0 111.074 -178.486 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 316' ' ' SER . . . . . 0.412 ' HB3' HG22 ' A' ' 313' ' ' VAL . 89.8 p -62.37 -23.59 66.89 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 121.135 0.493 . . . . 0.0 110.582 178.65 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 317' ' ' LYS . . . . . 0.402 ' HB3' ' O ' ' A' ' 314' ' ' ASP . 41.8 tttp -56.62 -35.4 68.26 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.137 -0.938 . . . . 0.0 111.855 -177.947 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 13.3 p -129.7 142.75 43.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.045 0.45 . . . . 0.0 110.439 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 117.939 -1.029 . . . . 0.0 110.693 -179.27 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 46.5 m . . . . . 0 N--CA 1.455 -0.222 0 CA-C-O 121.159 0.504 . . . . 0.0 110.775 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 11.6 mtpp -81.17 168.9 18.04 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.807 179.476 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 295' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -48.68 -31.88 7.5 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.974 -177.347 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 74.6 m-20 63.81 52.47 2.15 Favored 'General case' 0 CA--C 1.516 -0.355 0 C-N-CA 120.269 -0.572 . . . . 0.0 111.457 -179.923 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 297' ' ' ILE . . . . . . . . . . . . . 82.1 mt -62.98 130.93 28.21 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.249 0 N-CA-C 107.66 -1.237 . . . . 0.0 107.66 -178.976 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 44.4 tttp -81.98 133.69 35.32 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 115.469 1.655 . . . . 0.0 115.469 -175.373 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -121.72 139.17 53.91 Favored 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 106.843 -1.54 . . . . 0.0 106.843 175.812 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 8.0 m -125.75 72.04 68.15 Favored Pre-proline 0 N--CA 1.472 0.651 0 C-N-CA 119.308 -0.957 . . . . 0.0 113.31 -178.917 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 79.3 Cg_exo -62.07 -23.62 75.82 Favored 'Trans proline' 0 C--N 1.302 -1.918 0 C-N-CA 122.281 1.987 . . . . 0.0 110.692 176.266 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -92.97 28.43 9.46 Favored Glycine 0 CA--C 1.526 0.745 0 CA-C-N 114.492 -1.231 . . . . 0.0 112.713 -178.383 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 303' ' ' GLY . . . . . 0.415 ' C ' ' N ' ' A' ' 305' ' ' SER . . . -84.4 -173.28 49.73 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.376 -0.916 . . . . 0.0 111.39 -178.556 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . -50.68 -23.88 7.21 Favored Glycine 0 N--CA 1.453 -0.221 0 N-CA-C 108.31 -1.916 . . . . 0.0 108.31 178.91 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 305' ' ' SER . . . . . 0.415 ' N ' ' C ' ' A' ' 303' ' ' GLY . 22.4 m -55.07 -34.56 63.7 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 114.751 -0.724 . . . . 0.0 111.881 -179.223 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 306' ' ' VAL . . . . . 0.862 ' O ' ' O ' ' A' ' 307' ' ' GLN . 79.0 t -60.88 -39.72 82.9 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.712 0 C-N-CA 121.096 -0.241 . . . . 0.0 110.55 179.772 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 307' ' ' GLN . . . . . 0.862 ' O ' ' O ' ' A' ' 306' ' ' VAL . 13.0 pt20 24.88 166.03 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.471 0 O-C-N 125.222 1.576 . . . . 0.0 113.138 -177.292 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 308' ' ' ILE . . . . . 0.715 ' O ' ' N ' ' A' ' 310' ' ' TYR . 8.5 tt -59.26 -26.86 34.96 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.011 0 CA-C-N 114.192 -1.367 . . . . 0.0 112.753 -176.529 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 309' ' ' VAL . . . . . 0.608 HG23 ' O ' ' A' ' 307' ' ' GLN . 1.0 OUTLIER 51.06 -42.14 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.204 0 N-CA-C 113.0 0.741 . . . . 0.0 113.0 179.454 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 310' ' ' TYR . . . . . 0.715 ' N ' ' O ' ' A' ' 308' ' ' ILE 0.485 52.5 p90 -65.06 -25.48 67.83 Favored 'General case' 0 CA--C 1.564 1.507 0 N-CA-C 119.69 3.219 . . . . 0.0 119.69 -178.074 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 311' ' ' LYS . . . . . 0.461 ' HB2' ' O ' ' A' ' 310' ' ' TYR . 11.3 mttp 74.15 77.25 0.19 Allowed Pre-proline 0 N--CA 1.509 2.516 0 CA-C-N 120.996 1.726 . . . . 0.0 112.13 177.914 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 312' ' ' PRO . . . . . . . . . . . . . 4.7 Cg_endo -54.26 -34.33 79.25 Favored 'Trans proline' 0 N--CA 1.522 3.165 0 C-N-CA 123.524 2.816 . . . . 0.0 117.447 -178.178 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 69.7 t -67.29 -38.64 81.3 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.004 0 N-CA-C 116.155 1.909 . . . . 0.0 116.155 -178.398 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 314' ' ' ASP . . . . . 0.519 ' O ' ' O ' ' A' ' 317' ' ' LYS . 91.1 m-20 -55.47 -39.99 71.08 Favored 'General case' 0 C--N 1.322 -0.62 0 C-N-CA 118.697 -1.201 . . . . 0.0 113.103 -174.074 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 315' ' ' LEU . . . . . 0.841 HD22 ' H ' ' A' ' 315' ' ' LEU . 2.0 mm? -65.22 -36.71 85.01 Favored 'General case' 0 C--N 1.326 -0.423 0 C-N-CA 118.918 -1.113 . . . . 0.0 108.892 176.932 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 22.5 m -60.39 -36.36 77.91 Favored 'General case' 0 CA--C 1.516 -0.364 0 N-CA-C 108.253 -1.017 . . . . 0.0 108.253 178.079 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 317' ' ' LYS . . . . . 0.519 ' O ' ' O ' ' A' ' 314' ' ' ASP . 35.7 ttmt -97.02 117.38 31.06 Favored 'General case' 0 N--CA 1.446 -0.668 0 CA-C-N 114.958 -1.019 . . . . 0.0 111.098 179.71 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 59.5 t -130.92 135.84 59.26 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.333 176.728 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.218 -0.604 0 CA-C-O 117.871 -1.061 . . . . 0.0 110.451 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 92.5 p . . . . . 0 N--CA 1.461 0.121 0 CA-C-O 120.921 0.391 . . . . 0.0 110.531 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 11.9 mtpt -91.8 158.47 16.32 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.702 0.763 . . . . 0.0 112.489 -179.206 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 295' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -53.7 -33.8 56.68 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 114.359 -1.291 . . . . 0.0 110.652 -179.594 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 50.8 t30 64.73 54.34 1.39 Allowed 'General case' 0 CA--C 1.521 -0.14 0 C-N-CA 119.746 -0.782 . . . . 0.0 111.871 -179.817 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 297' ' ' ILE . . . . . . . . . . . . . 75.8 mt -68.05 139.25 21.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.304 -179.024 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 11.5 pttp -77.47 147.71 35.75 Favored 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 114.293 1.22 . . . . 0.0 114.293 -176.391 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 77.3 m80 -120.16 139.32 52.79 Favored 'General case' 0 N--CA 1.454 -0.261 0 CA-C-N 114.032 -1.44 . . . . 0.0 108.455 176.749 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 3.3 m -122.84 73.7 45.49 Favored Pre-proline 0 C--N 1.327 -0.387 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 179.574 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -61.1 -25.15 80.72 Favored 'Trans proline' 0 C--N 1.31 -1.458 0 C-N-CA 122.766 2.311 . . . . 0.0 114.176 -179.353 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -138.14 58.47 0.63 Allowed Glycine 0 CA--C 1.525 0.67 0 C-N-CA 120.597 -0.811 . . . . 0.0 113.363 -177.942 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -57.2 -28.54 58.87 Favored Glycine 0 N--CA 1.445 -0.722 0 N-CA-C 105.901 -2.88 . . . . 0.0 105.901 176.965 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 98.91 -10.45 62.2 Favored Glycine 0 N--CA 1.442 -0.966 0 N-CA-C 104.077 -3.609 . . . . 0.0 104.077 -176.099 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 84.9 p -66.29 -27.74 68.16 Favored 'General case' 0 N--CA 1.432 -1.336 0 CA-C-N 112.024 -2.088 . . . . 0.0 111.875 177.877 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 306' ' ' VAL . . . . . . . . . . . . . 55.8 t -61.1 -46.54 96.45 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.331 0 CA-C-O 122.151 0.977 . . . . 0.0 111.382 -175.385 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 307' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -148.14 164.4 34.02 Favored 'General case' 0 N--CA 1.441 -0.89 0 CA-C-N 113.567 -1.652 . . . . 0.0 110.206 -179.175 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 308' ' ' ILE . . . . . 0.47 HG12 ' CZ ' ' A' ' 310' ' ' TYR . 7.2 tp -122.37 129.72 75.07 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 CA-C-O 122.027 0.918 . . . . 0.0 110.915 176.266 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 69.6 t -67.25 -31.68 54.15 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.494 0 CA-C-N 113.639 -1.619 . . . . 0.0 115.128 179.656 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 310' ' ' TYR . . . . . 0.536 ' HD1' ' N ' ' A' ' 311' ' ' LYS . 0.0 OUTLIER -52.38 -33.84 45.23 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 117.197 2.295 . . . . 0.0 117.197 -171.689 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 311' ' ' LYS . . . . . 0.542 ' O ' ' C ' ' A' ' 312' ' ' PRO . 1.1 mmtt 54.09 64.68 6.15 Favored Pre-proline 0 CA--C 1.549 0.911 0 CA-C-N 121.697 2.044 . . . . 0.0 109.441 -179.974 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 312' ' ' PRO . . . . . 0.542 ' C ' ' O ' ' A' ' 311' ' ' LYS . 81.6 Cg_exo 2.76 64.82 0.0 OUTLIER 'Trans proline' 0 N--CA 1.49 1.321 0 C-N-CA 122.706 2.271 . . . . 0.0 114.794 -179.513 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 313' ' ' VAL . . . . . 0.541 ' N ' ' O ' ' A' ' 311' ' ' LYS . 1.8 m 20.96 54.17 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 CA-C-N 115.46 -0.791 . . . . 0.0 111.973 179.14 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 314' ' ' ASP . . . . . 0.89 ' OD2' HD12 ' A' ' 315' ' ' LEU . 49.6 p30 -60.44 -33.7 72.93 Favored 'General case' 0 C--N 1.322 -0.614 0 C-N-CA 120.611 -0.435 . . . . 0.0 110.858 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 315' ' ' LEU . . . . . 0.89 HD12 ' OD2' ' A' ' 314' ' ' ASP . 6.1 mp -59.16 -37.48 77.41 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 118.833 -1.147 . . . . 0.0 109.591 179.44 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 87.3 p -63.53 -28.04 69.67 Favored 'General case' 0 CA--C 1.509 -0.62 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 177.491 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 15.4 ttpt -82.8 133.14 35.15 Favored 'General case' 0 N--CA 1.446 -0.652 0 CA-C-N 114.434 -1.257 . . . . 0.0 108.828 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 13.3 p -130.55 142.28 44.1 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.751 0 C-N-CA 120.599 -0.441 . . . . 0.0 110.693 -179.761 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.22 -0.491 0 CA-C-O 117.851 -1.071 . . . . 0.0 110.967 -179.696 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 74.5 m . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.648 0.261 . . . . 0.0 110.865 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 294' ' ' LYS . . . . . 0.452 ' C ' ' H ' ' A' ' 296' ' ' ASN . 68.7 mttm -92.95 148.69 21.79 Favored 'General case' 0 N--CA 1.451 -0.39 0 CA-C-O 121.548 0.689 . . . . 0.0 112.099 -179.355 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 295' ' ' ASP . . . . . 0.478 ' C ' ' OD1' ' A' ' 295' ' ' ASP . 49.4 p30 -88.19 11.55 16.1 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 106.427 -1.694 . . . . 0.0 106.427 177.218 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 296' ' ' ASN . . . . . 0.452 ' H ' ' C ' ' A' ' 294' ' ' LYS . 75.7 m-20 33.88 -115.14 0.07 Allowed 'General case' 0 CA--C 1.49 -1.347 0 CA-C-N 112.878 -1.965 . . . . 0.0 111.934 -177.335 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 297' ' ' ILE . . . . . 0.551 ' O ' HG23 ' A' ' 297' ' ' ILE . 16.9 tt -120.53 133.03 68.54 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.355 0 C-N-CA 118.478 -1.289 . . . . 0.0 110.315 -178.474 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 44.6 tttm -123.97 119.84 30.73 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 113.996 -1.457 . . . . 0.0 111.549 177.271 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 299' ' ' HIS . . . . . 0.503 ' CE1' HD11 ' A' ' 297' ' ' ILE . 71.7 m80 -137.89 145.37 42.05 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 114.504 -1.225 . . . . 0.0 108.464 173.873 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -123.81 68.37 43.48 Favored Pre-proline 0 N--CA 1.468 0.464 0 C-N-CA 119.358 -0.937 . . . . 0.0 111.856 179.231 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -64.35 -23.12 65.75 Favored 'Trans proline' 0 C--N 1.312 -1.353 0 C-N-CA 122.232 1.955 . . . . 0.0 111.044 176.485 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -80.75 25.78 3.35 Favored Glycine 0 N--CA 1.471 0.982 0 CA-C-N 114.794 -1.094 . . . . 0.0 111.297 -178.908 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -56.08 -25.23 46.04 Favored Glycine 0 C--N 1.317 -0.522 0 N-CA-C 110.588 -1.005 . . . . 0.0 110.588 -179.872 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 100.5 -2.77 56.17 Favored Glycine 0 C--N 1.319 -0.401 0 N-CA-C 104.651 -3.379 . . . . 0.0 104.651 -174.339 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 86.9 p -65.49 -17.41 64.53 Favored 'General case' 0 N--CA 1.444 -0.774 0 CA-C-N 111.755 -2.223 . . . . 0.0 107.484 175.325 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 306' ' ' VAL . . . . . 0.527 ' O ' ' CB ' ' A' ' 307' ' ' GLN . 93.9 t -54.98 -41.52 59.0 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.628 0 CA-C-N 113.231 -1.804 . . . . 0.0 109.513 -176.44 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 307' ' ' GLN . . . . . 0.527 ' CB ' ' O ' ' A' ' 306' ' ' VAL . 12.4 pt20 124.39 147.43 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.86 0 O-C-N 124.921 1.388 . . . . 0.0 110.743 177.67 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 308' ' ' ILE . . . . . 0.413 HG12 ' CD1' ' A' ' 310' ' ' TYR . 15.9 tt -61.55 -26.63 40.14 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.045 0 CA-C-N 114.406 -1.27 . . . . 0.0 113.893 -178.483 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 309' ' ' VAL . . . . . 0.443 HG23 ' HG3' ' A' ' 307' ' ' GLN . 75.4 t 57.33 -30.24 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.396 0 N-CA-C 116.346 1.98 . . . . 0.0 116.346 178.903 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 310' ' ' TYR . . . . . 0.442 ' CE1' ' HA ' ' A' ' 312' ' ' PRO . 0.0 OUTLIER -65.79 -14.23 60.99 Favored 'General case' 0 N--CA 1.479 1.001 0 N-CA-C 115.805 1.78 . . . . 0.0 115.805 -175.33 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 311' ' ' LYS . . . . . 0.493 ' O ' ' C ' ' A' ' 312' ' ' PRO . 0.6 OUTLIER 74.46 65.86 0.28 Allowed Pre-proline 0 N--CA 1.473 0.708 0 CA-C-N 118.805 0.73 . . . . 0.0 110.585 -179.909 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 312' ' ' PRO . . . . . 0.493 ' C ' ' O ' ' A' ' 311' ' ' LYS . 12.3 Cg_exo -10.2 -111.4 0.0 OUTLIER 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 123.255 2.636 . . . . 0.0 114.905 179.375 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 17.7 m -111.05 15.69 8.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 N-CA-C 111.954 0.353 . . . . 0.0 111.954 -178.253 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 93.2 m-20 -55.26 -38.76 68.97 Favored 'General case' 0 N--CA 1.451 -0.391 0 C-N-CA 119.436 -0.906 . . . . 0.0 111.096 -178.046 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 315' ' ' LEU . . . . . 0.624 ' O ' HG12 ' A' ' 318' ' ' VAL . 27.8 tp -60.09 -38.72 83.8 Favored 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 119.904 -0.718 . . . . 0.0 110.258 178.475 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 21.2 m -59.57 -33.95 72.08 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 115.508 -0.769 . . . . 0.0 111.596 179.263 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 33.9 tttp -56.78 -36.34 69.73 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.267 -0.879 . . . . 0.0 112.301 -177.346 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 318' ' ' VAL . . . . . 0.624 HG12 ' O ' ' A' ' 315' ' ' LEU . 5.9 p -57.11 -34.35 45.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 C-N-CA 120.067 -0.653 . . . . 0.0 109.888 179.647 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 319' ' ' THR . . . . . 0.445 ' C ' ' O ' ' A' ' 318' ' ' VAL . 2.5 m . . . . . 0 C--O 1.219 -0.546 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.911 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 89.4 p . . . . . 0 N--CA 1.462 0.159 0 CA-C-O 121.309 0.576 . . . . 0.0 111.296 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 294' ' ' LYS . . . . . 0.409 ' HB3' ' NZ ' ' A' ' 294' ' ' LYS . 9.5 mtpm? -88.35 172.83 9.12 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.45 179.77 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 295' ' ' ASP . . . . . 0.446 ' OD2' ' C ' ' A' ' 295' ' ' ASP . 49.1 p30 -76.76 8.49 3.62 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 112.571 0.582 . . . . 0.0 112.571 -175.629 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 76.7 m-20 61.44 51.68 4.05 Favored 'General case' 0 N--CA 1.468 0.428 0 N-CA-C 115.74 1.755 . . . . 0.0 115.74 175.34 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 297' ' ' ILE . . . . . . . . . . . . . 16.2 mm -70.8 132.51 33.19 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.158 0 N-CA-C 106.975 -1.491 . . . . 0.0 106.975 179.559 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 3.6 ptmt -99.37 144.23 28.73 Favored 'General case' 0 N--CA 1.464 0.264 0 N-CA-C 115.592 1.701 . . . . 0.0 115.592 -175.446 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 299' ' ' HIS . . . . . 0.439 ' CE1' ' CG ' ' A' ' 301' ' ' PRO . 54.8 t-80 -126.75 119.09 26.05 Favored 'General case' 0 CA--C 1.536 0.439 0 N-CA-C 106.022 -1.844 . . . . 0.0 106.022 175.515 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -129.82 77.05 77.49 Favored Pre-proline 0 N--CA 1.477 0.904 0 N-CA-C 114.939 1.459 . . . . 0.0 114.939 -176.944 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 301' ' ' PRO . . . . . 0.499 ' O ' HG23 ' A' ' 306' ' ' VAL . 75.2 Cg_exo -60.29 -22.76 72.0 Favored 'Trans proline' 0 N--CA 1.502 2.005 0 C-N-CA 121.705 1.604 . . . . 0.0 112.446 177.285 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -69.32 20.41 0.45 Allowed Glycine 0 CA--C 1.526 0.732 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.924 -178.757 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 303' ' ' GLY . . . . . 0.495 ' H ' ' C ' ' A' ' 301' ' ' PRO . . . -56.82 -28.16 57.0 Favored Glycine 0 N--CA 1.453 -0.202 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 179.732 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 98.31 -4.71 60.47 Favored Glycine 0 C--N 1.317 -0.486 0 N-CA-C 103.962 -3.655 . . . . 0.0 103.962 -174.603 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 83.8 p -65.88 -18.93 65.67 Favored 'General case' 0 N--CA 1.438 -1.047 0 CA-C-N 111.333 -2.434 . . . . 0.0 108.615 176.591 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 306' ' ' VAL . . . . . 0.499 HG23 ' O ' ' A' ' 301' ' ' PRO . 90.7 t -56.35 -40.77 68.65 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 CA-C-N 113.98 -1.463 . . . . 0.0 110.672 -175.677 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 307' ' ' GLN . . . . . 0.801 ' HG2' ' H ' ' A' ' 308' ' ' ILE . 46.3 tt0 -173.27 -151.02 0.05 Allowed 'General case' 0 CA--C 1.536 0.43 0 N-CA-C 107.691 -1.226 . . . . 0.0 107.691 179.126 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 308' ' ' ILE . . . . . 0.801 ' H ' ' HG2' ' A' ' 307' ' ' GLN . 64.9 mt -114.92 136.69 50.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 179.289 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 71.3 t -60.55 -39.64 81.95 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.089 0 N-CA-C 112.828 0.677 . . . . 0.0 112.828 -178.789 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 310' ' ' TYR . . . . . 0.57 ' N ' ' CD1' ' A' ' 310' ' ' TYR . 0.1 OUTLIER -148.62 23.25 1.01 Allowed 'General case' 0 N--CA 1.477 0.906 0 N-CA-C 115.931 1.826 . . . . 0.0 115.931 -176.623 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 311' ' ' LYS . . . . . 0.471 ' O ' ' C ' ' A' ' 312' ' ' PRO . 0.1 OUTLIER 51.69 67.71 3.89 Favored Pre-proline 0 CA--C 1.546 0.807 0 C-N-CA 117.842 -1.543 . . . . 0.0 107.869 -179.253 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 312' ' ' PRO . . . . . 0.615 ' HD2' HG21 ' A' ' 308' ' ' ILE . 60.3 Cg_exo -6.33 -66.55 0.0 OUTLIER 'Trans proline' 0 N--CA 1.492 1.423 0 C-N-CA 123.109 2.539 . . . . 0.0 116.29 -176.356 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 20.2 m -129.78 156.97 42.43 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.687 0 N-CA-C 113.285 0.846 . . . . 0.0 113.285 -178.429 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 23.1 t70 -142.71 -61.73 0.43 Allowed 'General case' 0 CA--C 1.535 0.382 0 CA-C-N 114.912 -1.04 . . . . 0.0 110.525 178.612 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 315' ' ' LEU . . . . . 0.599 HD12 ' H ' ' A' ' 315' ' ' LEU . 6.6 mp -61.25 -35.1 76.34 Favored 'General case' 0 N--CA 1.47 0.554 0 N-CA-C 112.357 0.503 . . . . 0.0 112.357 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 85.2 p -60.78 -26.06 66.98 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.287 0.565 . . . . 0.0 109.9 -179.446 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 85.9 tttt -57.4 -36.76 71.72 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.355 -0.839 . . . . 0.0 110.362 -179.67 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 318' ' ' VAL . . . . . 0.475 ' O ' ' O ' ' A' ' 315' ' ' LEU . 13.7 p -131.45 142.97 41.91 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.176 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.332 179.67 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 2.0 m . . . . . 0 C--O 1.22 -0.494 0 CA-C-O 118.024 -0.988 . . . . 0.0 110.598 179.986 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 86.2 p . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.835 0.35 . . . . 0.0 110.676 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 11.5 mtpp -89.45 162.65 15.63 Favored 'General case' 0 CA--C 1.515 -0.381 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.869 179.89 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 295' ' ' ASP . . . . . 0.653 ' OD1' ' N ' ' A' ' 296' ' ' ASN . 50.0 p30 -57.58 -33.47 68.21 Favored 'General case' 0 N--CA 1.449 -0.524 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.407 -178.501 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 296' ' ' ASN . . . . . 0.653 ' N ' ' OD1' ' A' ' 295' ' ' ASP . 16.4 t-20 58.44 56.54 4.31 Favored 'General case' 0 CA--C 1.516 -0.357 0 C-N-CA 118.38 -1.328 . . . . 0.0 110.558 177.388 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 297' ' ' ILE . . . . . 0.448 HG22 ' H ' ' A' ' 299' ' ' HIS . 21.6 mm -42.63 137.25 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-O 122.659 1.219 . . . . 0.0 109.975 -175.932 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 83.1 tttt -57.38 -36.04 70.74 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 112.354 -2.203 . . . . 0.0 112.939 -176.744 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 299' ' ' HIS . . . . . 0.448 ' H ' HG22 ' A' ' 297' ' ' ILE . 1.2 m80 64.86 112.35 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 120.167 -0.613 . . . . 0.0 109.755 -179.14 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -122.21 78.32 43.51 Favored Pre-proline 0 C--N 1.325 -0.46 0 CA-C-N 115.82 -0.627 . . . . 0.0 109.885 -179.293 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -56.32 -23.65 47.34 Favored 'Trans proline' 0 C--N 1.315 -1.231 0 C-N-CA 120.904 1.069 . . . . 0.0 110.238 -179.426 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 302' ' ' GLY . . . . . 0.451 ' C ' ' H ' ' A' ' 304' ' ' GLY . . . -167.15 127.21 1.54 Allowed Glycine 0 CA--C 1.526 0.721 0 CA-C-N 114.965 -1.016 . . . . 0.0 110.882 179.002 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -78.85 10.87 30.26 Favored Glycine 0 N--CA 1.463 0.459 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 178.811 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 304' ' ' GLY . . . . . 0.451 ' H ' ' C ' ' A' ' 302' ' ' GLY . . . 98.39 -4.2 60.06 Favored Glycine 0 CA--C 1.519 0.334 0 N-CA-C 108.25 -1.94 . . . . 0.0 108.25 -177.483 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 305' ' ' SER . . . . . 0.524 ' O ' ' C ' ' A' ' 306' ' ' VAL . 23.9 m -59.2 -33.14 70.61 Favored 'General case' 0 C--O 1.233 0.193 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 177.259 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 306' ' ' VAL . . . . . 0.571 HG23 ' H ' ' A' ' 307' ' ' GLN . 4.9 m -7.04 -109.7 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 CA-C-N 114.626 -1.17 . . . . 0.0 111.81 -178.881 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 307' ' ' GLN . . . . . 0.571 ' H ' HG23 ' A' ' 306' ' ' VAL . 25.3 pt20 -138.08 154.84 49.22 Favored 'General case' 0 N--CA 1.451 -0.401 0 CA-C-O 121.466 0.65 . . . . 0.0 109.699 178.612 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 308' ' ' ILE . . . . . 1.002 ' O ' ' N ' ' A' ' 310' ' ' TYR . 16.3 pt -78.1 -25.15 14.09 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.779 0 N-CA-C 116.09 1.885 . . . . 0.0 116.09 -177.239 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 309' ' ' VAL . . . . . 0.821 HG12 ' O ' ' A' ' 309' ' ' VAL . 93.7 t 9.4 27.78 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.257 0 N-CA-C 113.989 1.107 . . . . 0.0 113.989 -178.814 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 310' ' ' TYR . . . . . 1.002 ' N ' ' O ' ' A' ' 308' ' ' ILE 0.253 0.4 OUTLIER -71.66 -19.98 62.01 Favored 'General case' 0 C--N 1.332 -0.175 0 N-CA-C 113.158 0.799 . . . . 0.0 113.158 -179.523 . . . . . . . . 4 4 . 1 . 007 nuclear build core ' A' A ' 311' ' ' LYS . . . . . 0.417 ' HE3' ' H ' ' A' ' 311' ' ' LYS . 0.0 OUTLIER 57.08 62.72 5.66 Favored Pre-proline 0 C--N 1.325 -0.49 0 CA-C-O 121.316 0.579 . . . . 0.0 109.786 179.718 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 312' ' ' PRO . . . . . 0.778 ' O ' ' N ' ' A' ' 314' ' ' ASP . 32.7 Cg_endo -58.88 143.54 99.31 Favored 'Trans proline' 0 C--N 1.303 -1.855 0 C-N-CA 122.648 2.232 . . . . 0.0 111.288 179.223 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 313' ' ' VAL . . . . . 0.491 ' O ' ' OG ' ' A' ' 316' ' ' SER . 18.9 m -6.58 59.29 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.645 0 O-C-N 124.224 0.953 . . . . 0.0 113.295 -179.452 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 314' ' ' ASP . . . . . 0.778 ' N ' ' O ' ' A' ' 312' ' ' PRO . 93.2 m-20 -56.89 -36.75 70.5 Favored 'General case' 0 C--O 1.223 -0.308 0 N-CA-C 111.66 0.244 . . . . 0.0 111.66 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 315' ' ' LEU . . . . . . . . . . . . . 61.7 mt -58.81 -36.42 74.46 Favored 'General case' 0 C--N 1.326 -0.424 0 C-N-CA 120.07 -0.652 . . . . 0.0 110.719 -178.609 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 316' ' ' SER . . . . . 0.491 ' OG ' ' O ' ' A' ' 313' ' ' VAL . 86.3 p -63.37 -23.74 67.54 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-O 121.227 0.537 . . . . 0.0 110.756 178.67 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 49.2 tttm -56.75 -35.8 69.03 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.303 -0.862 . . . . 0.0 112.535 -177.489 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 12.5 p -129.7 142.88 42.74 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 C-N-CA 120.263 -0.575 . . . . 0.0 111.829 -179.238 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.221 -0.418 0 CA-C-O 118.137 -0.935 . . . . 0.0 110.813 179.882 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 21.2 m . . . . . 0 C--O 1.232 0.153 0 CA-C-O 120.842 0.353 . . . . 0.0 110.688 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 67.4 mttt -57.45 -37.77 73.39 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.098 -178.419 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 295' ' ' ASP . . . . . 0.645 ' OD2' ' N ' ' A' ' 296' ' ' ASN . 50.3 p30 175.1 -24.6 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.652 179.401 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 296' ' ' ASN . . . . . 0.645 ' N ' ' OD2' ' A' ' 295' ' ' ASP . 18.7 t-20 56.54 48.22 17.08 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.627 -0.715 . . . . 0.0 111.071 179.751 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 297' ' ' ILE . . . . . 0.672 HG23 ' O ' ' A' ' 297' ' ' ILE . 10.9 tp 15.46 111.04 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 CA-C-O 122.176 0.988 . . . . 0.0 111.602 -178.647 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 298' ' ' LYS . . . . . 0.584 ' O ' ' C ' ' A' ' 299' ' ' HIS . 56.4 tttp -57.86 -36.48 72.4 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 114.488 -1.233 . . . . 0.0 113.285 -178.1 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 299' ' ' HIS . . . . . 0.584 ' C ' ' O ' ' A' ' 298' ' ' LYS . 85.3 t60 1.42 102.25 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.358 0 N-CA-C 112.104 0.409 . . . . 0.0 112.104 -179.265 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.55 75.22 69.68 Favored Pre-proline 0 N--CA 1.469 0.513 0 N-CA-C 111.964 0.357 . . . . 0.0 111.964 -179.17 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -58.94 -21.67 59.23 Favored 'Trans proline' 0 C--N 1.306 -1.693 0 N-CA-C 109.788 -0.889 . . . . 0.0 109.788 177.898 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -79.42 25.21 2.85 Favored Glycine 0 CA--C 1.528 0.892 0 CA-C-N 114.386 -1.279 . . . . 0.0 111.767 -179.848 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -55.93 -26.13 47.3 Favored Glycine 0 CA--C 1.509 -0.296 0 N-CA-C 109.274 -1.53 . . . . 0.0 109.274 179.631 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 98.65 -3.27 59.1 Favored Glycine 0 N--CA 1.442 -0.906 0 N-CA-C 104.686 -3.366 . . . . 0.0 104.686 -175.315 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 305' ' ' SER . . . . . 0.503 ' O ' ' O ' ' A' ' 306' ' ' VAL . 24.7 m -59.46 -33.89 71.86 Favored 'General case' 0 N--CA 1.439 -0.998 0 CA-C-N 112.501 -1.849 . . . . 0.0 108.674 177.157 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 306' ' ' VAL . . . . . 0.552 HG23 ' H ' ' A' ' 307' ' ' GLN . 8.2 m -11.22 -113.37 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.233 0.186 0 CA-C-N 113.438 -1.71 . . . . 0.0 112.835 -178.364 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 307' ' ' GLN . . . . . 0.552 ' H ' HG23 ' A' ' 306' ' ' VAL . 21.7 pt20 -141.56 165.1 28.43 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.429 -0.805 . . . . 0.0 110.803 -178.684 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 308' ' ' ILE . . . . . 0.667 ' O ' HG13 ' A' ' 308' ' ' ILE . 19.9 pt -63.99 100.6 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 122.596 1.189 . . . . 0.0 109.778 179.96 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 81.4 t -63.87 -42.44 95.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 122.005 0.907 . . . . 0.0 109.167 179.829 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 310' ' ' TYR . . . . . 0.405 ' CE1' ' HD3' ' A' ' 312' ' ' PRO 0.321 54.9 p90 -66.21 -32.34 73.71 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 118.082 2.623 . . . . 0.0 118.082 179.542 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 311' ' ' LYS . . . . . 0.615 ' O ' ' N ' ' A' ' 313' ' ' VAL . 14.6 mtpp 51.02 63.99 8.9 Favored Pre-proline 0 C--N 1.313 -0.979 0 C-N-CA 118.633 -1.227 . . . . 0.0 109.781 179.362 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 312' ' ' PRO . . . . . 0.591 ' O ' ' N ' ' A' ' 314' ' ' ASP . 84.0 Cg_exo 6.33 58.26 0.0 OUTLIER 'Trans proline' 0 N--CA 1.492 1.382 0 C-N-CA 122.635 2.223 . . . . 0.0 113.41 -179.586 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 313' ' ' VAL . . . . . 0.748 ' O ' HG13 ' A' ' 313' ' ' VAL . 9.5 p 4.56 62.61 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 O-C-N 124.082 0.864 . . . . 0.0 112.196 -179.704 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 314' ' ' ASP . . . . . 0.591 ' N ' ' O ' ' A' ' 312' ' ' PRO . 92.1 m-20 -56.08 -35.82 67.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.025 -0.989 . . . . 0.0 111.78 -179.369 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 315' ' ' LEU . . . . . 0.743 ' H ' HD12 ' A' ' 315' ' ' LEU . 6.4 mp -57.39 -36.02 70.74 Favored 'General case' 0 C--N 1.326 -0.45 0 C-N-CA 119.854 -0.738 . . . . 0.0 110.027 -178.33 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 316' ' ' SER . . . . . 0.456 ' OG ' HG22 ' A' ' 313' ' ' VAL . 24.4 m -58.45 -34.23 70.61 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 108.396 -0.965 . . . . 0.0 108.396 177.299 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 65.8 tttt -77.05 132.8 39.11 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.084 -0.962 . . . . 0.0 109.714 179.424 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 318' ' ' VAL . . . . . 0.407 ' O ' HG23 ' A' ' 319' ' ' THR . 14.4 p -131.67 142.82 42.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.629 -179.716 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 319' ' ' THR . . . . . 0.407 HG23 ' O ' ' A' ' 318' ' ' VAL . 33.5 p . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 118.049 -0.976 . . . . 0.0 110.845 -179.709 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 1.9 m . . . . . 0 CA--C 1.535 0.367 0 CA-C-O 120.988 0.423 . . . . 0.0 111.829 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 27.8 mttp -91.55 153.51 19.71 Favored 'General case' 0 CA--C 1.515 -0.397 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 178.225 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 295' ' ' ASP . . . . . 0.459 ' OD2' ' C ' ' A' ' 295' ' ' ASP . 48.4 p30 -83.88 8.0 16.36 Favored 'General case' 0 C--N 1.322 -0.626 0 C-N-CA 119.617 -0.833 . . . . 0.0 109.949 -178.988 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 45.5 t30 58.31 56.06 4.67 Favored 'General case' 0 N--CA 1.455 -0.183 0 C-N-CA 119.671 -0.812 . . . . 0.0 112.014 177.102 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 297' ' ' ILE . . . . . 0.451 HG13 ' OD2' ' A' ' 295' ' ' ASP . 70.7 mt -59.82 131.4 24.41 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.165 0 CA-C-O 122.197 0.999 . . . . 0.0 110.103 -175.932 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 2.0 ttmp? -84.15 136.99 33.76 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 113.419 -1.719 . . . . 0.0 113.958 -177.819 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 64.5 m170 -115.88 136.9 52.6 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 106.483 -1.673 . . . . 0.0 106.483 176.08 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 3.9 m -125.08 69.74 59.64 Favored Pre-proline 0 N--CA 1.466 0.349 0 C-N-CA 119.573 -0.851 . . . . 0.0 112.867 -178.566 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -62.46 -19.31 67.11 Favored 'Trans proline' 0 C--N 1.302 -1.892 0 N-CA-C 107.174 -1.894 . . . . 0.0 107.174 174.683 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -165.08 -169.55 28.85 Favored Glycine 0 CA--C 1.531 1.039 0 CA-C-N 112.91 -1.95 . . . . 0.0 110.233 -178.219 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . 126.25 29.59 0.92 Allowed Glycine 0 N--CA 1.466 0.698 0 N-CA-C 109.013 -1.635 . . . . 0.0 109.013 -178.371 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 97.07 -7.45 64.56 Favored Glycine 0 C--N 1.324 -0.116 0 N-CA-C 107.352 -2.299 . . . . 0.0 107.352 -178.493 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 23.2 t -59.96 -30.75 69.3 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 113.146 -1.527 . . . . 0.0 111.157 177.999 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 306' ' ' VAL . . . . . 0.564 ' O ' ' CB ' ' A' ' 307' ' ' GLN . 88.5 t -56.93 -42.99 79.73 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.48 0 CA-C-N 115.729 -0.669 . . . . 0.0 112.071 -175.373 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 307' ' ' GLN . . . . . 0.564 ' CB ' ' O ' ' A' ' 306' ' ' VAL . 21.3 pt20 125.46 178.49 0.0 OUTLIER 'General case' 0 N--CA 1.469 0.501 0 O-C-N 124.643 1.214 . . . . 0.0 110.201 179.42 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 308' ' ' ILE . . . . . 0.823 ' O ' ' N ' ' A' ' 310' ' ' TYR . 33.3 mm -54.88 -45.16 75.09 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.933 0 CA-C-N 113.952 -1.476 . . . . 0.0 113.852 177.259 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 309' ' ' VAL . . . . . 0.455 ' H ' ' HG3' ' A' ' 307' ' ' GLN . 0.3 OUTLIER 37.2 -0.94 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.693 0 O-C-N 123.939 0.774 . . . . 0.0 113.069 -179.212 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 310' ' ' TYR . . . . . 0.823 ' N ' ' O ' ' A' ' 308' ' ' ILE 0.329 0.0 OUTLIER -67.39 -22.3 65.56 Favored 'General case' 0 CA--C 1.503 -0.85 0 C-N-CA 119.056 -1.057 . . . . 0.0 110.681 -178.763 . . . . . . . . 4 4 . 1 . 009 nuclear build core ' A' A ' 311' ' ' LYS . . . . . 0.583 ' O ' ' C ' ' A' ' 312' ' ' PRO . 32.3 tttp 56.4 63.55 5.61 Favored Pre-proline 0 N--CA 1.447 -0.61 0 CA-C-N 115.028 -0.987 . . . . 0.0 109.916 177.779 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 312' ' ' PRO . . . . . 0.583 ' C ' ' O ' ' A' ' 311' ' ' LYS . 75.8 Cg_exo 12.85 -127.08 0.0 OUTLIER 'Trans proline' 0 N--CA 1.492 1.414 0 C-N-CA 122.337 2.025 . . . . 0.0 110.888 -178.448 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 45.2 t -120.98 126.87 75.73 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.398 0 C-N-CA 118.336 -1.345 . . . . 0.0 109.509 176.193 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -63.93 -38.14 89.98 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.64 0.733 . . . . 0.0 111.282 177.102 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 315' ' ' LEU . . . . . 0.65 ' N ' ' CD2' ' A' ' 315' ' ' LEU . 0.2 OUTLIER -61.07 -36.97 81.04 Favored 'General case' 0 C--O 1.233 0.192 0 CA-C-N 114.453 -1.249 . . . . 0.0 113.29 -176.902 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 68.4 m -79.58 -5.55 55.22 Favored 'General case' 0 C--N 1.327 -0.404 0 C-N-CA 120.166 -0.614 . . . . 0.0 111.026 -179.857 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 57.2 tttp -58.42 -38.0 76.52 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.114 -179.333 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 43.4 t -120.65 135.45 60.83 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 CA-C-N 116.545 -0.298 . . . . 0.0 110.577 179.188 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 6.9 m . . . . . 0 C--O 1.221 -0.399 0 CA-C-O 118.018 -0.991 . . . . 0.0 110.422 179.459 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 86.6 p . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.798 0.332 . . . . 0.0 110.498 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 31.0 mttt -93.9 153.37 18.27 Favored 'General case' 0 N--CA 1.448 -0.566 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 178.99 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 295' ' ' ASP . . . . . 0.474 ' OD1' HG13 ' A' ' 297' ' ' ILE . 49.2 p30 -84.12 7.66 18.1 Favored 'General case' 0 C--N 1.322 -0.591 0 C-N-CA 119.685 -0.806 . . . . 0.0 110.301 -178.653 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 16.6 t-20 58.57 55.91 4.56 Favored 'General case' 0 CA--C 1.535 0.391 0 C-N-CA 119.818 -0.753 . . . . 0.0 112.488 176.629 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 297' ' ' ILE . . . . . 0.474 HG13 ' OD1' ' A' ' 295' ' ' ASP . 71.2 mt -61.8 133.24 27.62 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.52 0 CA-C-O 122.258 1.028 . . . . 0.0 110.906 -175.967 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 15.6 tttt -82.79 137.83 34.21 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-N 113.328 -1.76 . . . . 0.0 114.209 -178.105 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 58.3 t-80 -119.41 132.42 55.82 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 106.75 -1.574 . . . . 0.0 106.75 176.425 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 4.4 m -124.79 79.01 64.25 Favored Pre-proline 0 N--CA 1.472 0.635 0 N-CA-C 113.865 1.061 . . . . 0.0 113.865 -177.033 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -58.53 -24.59 70.42 Favored 'Trans proline' 0 C--N 1.31 -1.471 0 C-N-CA 120.572 0.848 . . . . 0.0 110.963 178.043 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -111.82 48.21 0.96 Allowed Glycine 0 CA--C 1.525 0.694 0 N-CA-C 109.864 -1.294 . . . . 0.0 109.864 179.507 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -81.19 6.85 62.02 Favored Glycine 0 N--CA 1.466 0.638 0 N-CA-C 112.174 -0.37 . . . . 0.0 112.174 -178.398 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 94.52 2.04 63.72 Favored Glycine 0 C--N 1.321 -0.29 0 N-CA-C 107.962 -2.055 . . . . 0.0 107.962 -178.167 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 75.7 m -82.56 6.99 15.77 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 113.851 -1.174 . . . . 0.0 108.229 178.564 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 306' ' ' VAL . . . . . 0.502 ' O ' ' O ' ' A' ' 307' ' ' GLN . 20.7 m -67.25 -22.65 29.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 114.861 -1.063 . . . . 0.0 110.649 -178.845 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 307' ' ' GLN . . . . . 0.536 ' O ' ' O ' ' A' ' 308' ' ' ILE . 21.7 pt20 46.16 118.03 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 122.039 0.924 . . . . 0.0 113.358 179.697 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 308' ' ' ILE . . . . . 0.638 HG23 ' O ' ' A' ' 308' ' ' ILE . 9.7 tp 25.42 120.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.676 0 CA-C-N 113.42 -1.718 . . . . 0.0 114.374 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -149.58 -42.94 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.366 0 CA-C-N 114.599 -1.182 . . . . 0.0 109.072 177.889 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 310' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -61.67 -31.88 72.02 Favored 'General case' 0 CA--C 1.538 0.519 0 N-CA-C 112.938 0.718 . . . . 0.0 112.938 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 311' ' ' LYS . . . . . 0.454 ' HZ2' ' HB3' ' A' ' 311' ' ' LYS . 8.2 mtpp 65.09 73.76 0.42 Allowed Pre-proline 0 N--CA 1.473 0.711 0 N-CA-C 113.116 0.784 . . . . 0.0 113.116 179.114 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 312' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_endo -53.17 -23.76 23.8 Favored 'Trans proline' 0 N--CA 1.498 1.738 0 C-N-CA 120.41 0.74 . . . . 0.0 111.374 179.691 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 313' ' ' VAL . . . . . 0.73 HG13 ' OG ' ' A' ' 316' ' ' SER . 60.3 t -117.16 132.37 67.14 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.273 0 CA-C-O 121.448 0.642 . . . . 0.0 111.589 178.339 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 58.2 t0 -160.17 -60.94 0.06 Allowed 'General case' 0 N--CA 1.449 -0.515 0 CA-C-N 114.98 -1.009 . . . . 0.0 108.921 178.308 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 315' ' ' LEU . . . . . 0.82 ' O ' HG12 ' A' ' 318' ' ' VAL . 61.1 mt -61.65 -35.33 77.63 Favored 'General case' 0 C--O 1.226 -0.167 0 CA-C-N 114.78 -1.1 . . . . 0.0 111.723 179.295 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 316' ' ' SER . . . . . 0.73 ' OG ' HG13 ' A' ' 313' ' ' VAL . 80.2 p -61.21 -28.34 69.08 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.307 0.575 . . . . 0.0 110.241 -179.154 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 29.3 tttm -58.24 -37.2 74.43 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.456 -0.793 . . . . 0.0 111.432 -179.421 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 318' ' ' VAL . . . . . 0.82 HG12 ' O ' ' A' ' 315' ' ' LEU . 5.5 p -57.67 -34.21 46.96 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.152 0 CA-C-O 120.882 0.373 . . . . 0.0 110.62 -179.87 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 319' ' ' THR . . . . . 0.599 ' OG1' HG13 ' A' ' 318' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--O 1.221 -0.447 0 CA-C-O 118.027 -0.987 . . . . 0.0 110.044 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 87.0 p . . . . . 0 N--CA 1.456 -0.141 0 CA-C-O 120.662 0.268 . . . . 0.0 110.679 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 294' ' ' LYS . . . . . 0.405 ' C ' ' H ' ' A' ' 296' ' ' ASN . 41.2 mtpt -95.7 150.94 19.83 Favored 'General case' 0 N--CA 1.452 -0.328 0 CA-C-O 120.907 0.384 . . . . 0.0 111.081 -179.621 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 295' ' ' ASP . . . . . 0.457 ' C ' ' OD2' ' A' ' 295' ' ' ASP . 48.8 p30 -85.98 10.53 13.84 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 107.43 -1.322 . . . . 0.0 107.43 178.709 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 296' ' ' ASN . . . . . 0.405 ' H ' ' C ' ' A' ' 294' ' ' LYS . 79.9 m-20 30.5 -102.09 0.02 OUTLIER 'General case' 0 CA--C 1.511 -0.549 0 CA-C-N 113.301 -1.772 . . . . 0.0 113.294 -179.218 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 297' ' ' ILE . . . . . . . . . . . . . 70.1 mt -113.5 130.31 67.74 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.454 0 CA-C-O 122.297 1.046 . . . . 0.0 113.486 -177.119 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 41.8 tttp -87.5 132.13 34.12 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 113.107 -1.86 . . . . 0.0 108.613 177.037 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 299' ' ' HIS . . . . . 0.557 ' CE1' ' HD3' ' A' ' 301' ' ' PRO . 71.7 t60 -125.09 113.39 17.67 Favored 'General case' 0 N--CA 1.468 0.461 0 N-CA-C 112.676 0.621 . . . . 0.0 112.676 -179.116 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 3.2 m -134.16 73.34 70.07 Favored Pre-proline 0 N--CA 1.471 0.585 0 CA-C-N 116.196 -0.457 . . . . 0.0 112.191 178.075 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 301' ' ' PRO . . . . . 0.557 ' HD3' ' CE1' ' A' ' 299' ' ' HIS . 5.9 Cg_endo -60.56 -23.82 76.56 Favored 'Trans proline' 0 N--CA 1.5 1.901 0 CA-C-N 119.914 1.005 . . . . 0.0 113.067 179.211 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -134.21 -105.29 0.87 Allowed Glycine 0 CA--C 1.525 0.709 0 N-CA-C 111.149 -0.78 . . . . 0.0 111.149 -178.508 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . 86.4 35.64 10.46 Favored Glycine 0 N--CA 1.462 0.386 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 -178.81 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 96.56 -0.25 61.26 Favored Glycine 0 N--CA 1.446 -0.686 0 N-CA-C 108.991 -1.643 . . . . 0.0 108.991 -179.165 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 73.8 m -82.96 1.65 38.68 Favored 'General case' 0 N--CA 1.446 -0.661 0 CA-C-O 121.382 0.611 . . . . 0.0 109.558 178.675 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 306' ' ' VAL . . . . . 0.427 ' O ' ' HB3' ' A' ' 307' ' ' GLN . 73.6 t -61.64 -38.17 79.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 115.06 -0.973 . . . . 0.0 111.253 179.835 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 307' ' ' GLN . . . . . 0.628 ' O ' ' O ' ' A' ' 308' ' ' ILE . 50.3 tt0 79.87 103.03 0.07 Allowed 'General case' 0 CA--C 1.506 -0.729 0 O-C-N 123.6 0.562 . . . . 0.0 112.039 -178.663 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 308' ' ' ILE . . . . . 0.703 HG21 ' HD3' ' A' ' 312' ' ' PRO . 81.7 mt 51.24 149.68 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.443 -0.778 0 CA-C-O 122.256 1.027 . . . . 0.0 109.871 178.506 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 309' ' ' VAL . . . . . 0.673 HG13 ' CD1' ' A' ' 310' ' ' TYR . 6.3 p -56.34 -33.91 39.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 CA-C-N 114.886 -1.052 . . . . 0.0 111.777 -178.576 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 310' ' ' TYR . . . . . 0.808 ' CD1' ' N ' ' A' ' 311' ' ' LYS . 0.0 OUTLIER -161.55 -97.09 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.39 0 CA-C-O 123.896 1.808 . . . . 0.0 112.638 -178.37 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 311' ' ' LYS . . . . . 0.808 ' N ' ' CD1' ' A' ' 310' ' ' TYR . 32.6 mtmm -123.62 103.88 34.32 Favored Pre-proline 0 C--N 1.275 -2.667 0 CA-C-N 109.845 -3.343 . . . . 0.0 108.228 179.181 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 312' ' ' PRO . . . . . 0.703 ' HD3' HG21 ' A' ' 308' ' ' ILE . 9.7 Cg_endo -49.1 151.95 5.51 Favored 'Trans proline' 0 C--N 1.299 -2.038 0 N-CA-C 106.626 -2.106 . . . . 0.0 106.626 179.081 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 313' ' ' VAL . . . . . 0.724 HG12 ' H ' ' A' ' 315' ' ' LEU . 44.3 t -59.53 128.5 20.51 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.585 0 C-N-CA 117.671 -1.611 . . . . 0.0 111.948 -173.434 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 314' ' ' ASP . . . . . 0.497 ' O ' ' HG2' ' A' ' 317' ' ' LYS . 49.2 p30 -97.33 -0.63 46.15 Favored 'General case' 0 N--CA 1.438 -1.058 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 175.897 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 315' ' ' LEU . . . . . 0.724 ' H ' HG12 ' A' ' 313' ' ' VAL . 64.8 mt -64.85 -31.44 72.68 Favored 'General case' 0 N--CA 1.469 0.504 0 O-C-N 123.774 0.671 . . . . 0.0 110.735 178.319 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 89.9 p -58.19 -25.56 61.73 Favored 'General case' 0 N--CA 1.448 -0.545 0 CA-C-N 114.962 -1.017 . . . . 0.0 110.276 -177.453 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 317' ' ' LYS . . . . . 0.497 ' HG2' ' O ' ' A' ' 314' ' ' ASP . 52.2 pttt -59.6 -33.57 71.64 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.349 -0.612 . . . . 0.0 109.349 -179.319 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 318' ' ' VAL . . . . . 0.422 ' N ' ' CG ' ' A' ' 317' ' ' LYS . 74.7 t -60.37 -39.81 82.12 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.132 0 CA-C-N 115.099 -0.955 . . . . 0.0 111.501 -178.807 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 7.1 m . . . . . 0 C--O 1.22 -0.482 0 CA-C-O 117.935 -1.031 . . . . 0.0 110.529 -179.76 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 45.3 m . . . . . 0 N--CA 1.461 0.088 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 294' ' ' LYS . . . . . 0.458 ' C ' ' H ' ' A' ' 296' ' ' ASN . 88.2 mttt -103.75 145.81 29.54 Favored 'General case' 0 N--CA 1.449 -0.477 0 CA-C-O 121.442 0.639 . . . . 0.0 112.014 -179.156 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 295' ' ' ASP . . . . . 0.47 ' C ' ' OD2' ' A' ' 295' ' ' ASP . 49.2 p30 -89.52 12.76 15.66 Favored 'General case' 0 CA--C 1.49 -1.332 0 N-CA-C 106.35 -1.722 . . . . 0.0 106.35 176.68 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 296' ' ' ASN . . . . . 0.609 ' CG ' ' H ' ' A' ' 297' ' ' ILE . 49.4 t30 36.48 -147.95 0.01 OUTLIER 'General case' 0 N--CA 1.426 -1.626 0 CA-C-N 112.362 -2.199 . . . . 0.0 110.697 -178.717 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 297' ' ' ILE . . . . . 0.609 ' H ' ' CG ' ' A' ' 296' ' ' ASN . 8.8 tp -123.2 132.67 70.98 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 CA-C-O 122.642 1.21 . . . . 0.0 112.809 -177.446 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 75.8 tttt -94.48 130.16 40.97 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-N 112.323 -2.217 . . . . 0.0 109.702 177.014 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 39.0 t-80 -132.18 136.21 46.89 Favored 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 119.701 -0.8 . . . . 0.0 111.784 179.613 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -125.76 74.77 70.57 Favored Pre-proline 0 N--CA 1.477 0.893 0 CA-C-O 120.4 0.143 . . . . 0.0 111.368 178.987 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -59.94 -21.28 63.95 Favored 'Trans proline' 0 N--CA 1.494 1.523 0 C-N-CA 122.529 2.153 . . . . 0.0 112.089 178.734 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . 114.03 130.63 5.1 Favored Glycine 0 CA--C 1.52 0.355 0 N-CA-C 107.418 -2.273 . . . . 0.0 107.418 -177.279 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -96.44 -78.77 1.43 Allowed Glycine 0 CA--C 1.523 0.564 0 C-N-CA 119.457 -1.354 . . . . 0.0 113.219 -177.853 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . -86.16 -35.29 11.14 Favored Glycine 0 CA--C 1.522 0.486 0 C-N-CA 121.201 -0.524 . . . . 0.0 112.589 -179.778 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 305' ' ' SER . . . . . 0.504 ' O ' ' O ' ' A' ' 306' ' ' VAL . 93.9 p -61.63 -30.02 70.43 Favored 'General case' 0 CA--C 1.513 -0.476 0 N-CA-C 114.263 1.209 . . . . 0.0 114.263 -176.756 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 306' ' ' VAL . . . . . 0.504 ' O ' ' O ' ' A' ' 305' ' ' SER . 16.8 t -27.25 -99.88 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 O-C-N 123.57 0.544 . . . . 0.0 112.395 -177.615 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 307' ' ' GLN . . . . . 0.425 ' HG2' ' N ' ' A' ' 308' ' ' ILE . 51.6 tt0 -143.14 158.07 43.95 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.635 179.857 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 308' ' ' ILE . . . . . 0.995 HD11 ' CZ ' ' A' ' 310' ' ' TYR . 5.0 tp -120.96 127.86 76.0 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.673 0 C-N-CA 120.05 -0.66 . . . . 0.0 109.635 177.635 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 73.7 t -67.98 -42.91 85.83 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.565 0 N-CA-C 114.975 1.472 . . . . 0.0 114.975 -179.57 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 310' ' ' TYR . . . . . 0.995 ' CZ ' HD11 ' A' ' 308' ' ' ILE 0.312 2.7 p90 -66.27 -28.14 68.48 Favored 'General case' 0 N--CA 1.469 0.499 0 N-CA-C 116.931 2.197 . . . . 0.0 116.931 -177.019 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 311' ' ' LYS . . . . . 0.536 ' O ' ' O ' ' A' ' 312' ' ' PRO . 10.6 mtpt 56.17 63.23 6.06 Favored Pre-proline 0 C--N 1.307 -1.248 0 C-N-CA 118.74 -1.184 . . . . 0.0 108.534 -178.959 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 312' ' ' PRO . . . . . 0.573 ' O ' ' N ' ' A' ' 314' ' ' ASP . 32.6 Cg_exo 23.62 112.06 0.0 OUTLIER 'Trans proline' 0 C--N 1.316 -1.157 0 C-N-CA 122.752 2.301 . . . . 0.0 115.214 -179.339 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 313' ' ' VAL . . . . . 0.469 ' C ' ' O ' ' A' ' 312' ' ' PRO . 2.1 m 8.15 55.77 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.232 0.141 0 CA-C-N 113.519 -1.673 . . . . 0.0 113.27 179.185 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 314' ' ' ASP . . . . . 0.573 ' N ' ' O ' ' A' ' 312' ' ' PRO . 55.2 t0 -55.37 -36.11 66.0 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 109.962 -0.385 . . . . 0.0 109.962 178.757 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 315' ' ' LEU . . . . . 0.714 ' H ' HD12 ' A' ' 315' ' ' LEU . 6.5 mp -59.27 -35.69 74.19 Favored 'General case' 0 N--CA 1.464 0.254 0 C-N-CA 120.61 -0.436 . . . . 0.0 111.577 -179.344 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 85.4 p -61.71 -27.34 68.64 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.352 0.596 . . . . 0.0 110.038 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 317' ' ' LYS . . . . . 0.42 ' HB3' ' O ' ' A' ' 314' ' ' ASP . 38.9 tttp -57.37 -39.1 75.31 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.265 -0.879 . . . . 0.0 111.112 -178.656 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 70.6 t -63.21 -39.26 84.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 121.128 0.489 . . . . 0.0 110.323 178.747 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 1.9 m . . . . . 0 C--O 1.22 -0.493 0 CA-C-O 118.068 -0.968 . . . . 0.0 110.282 -178.836 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 30.8 t . . . . . 0 N--CA 1.463 0.198 0 CA-C-O 121.098 0.475 . . . . 0.0 111.242 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 25.5 mttm -99.32 152.18 20.22 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.749 179.186 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 295' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -55.29 -37.14 66.94 Favored 'General case' 0 CA--C 1.497 -1.086 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.424 -179.547 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 296' ' ' ASN . . . . . 0.656 ' CG ' ' H ' ' A' ' 297' ' ' ILE . 10.7 p30 175.5 -103.07 0.0 OUTLIER 'General case' 0 C--N 1.308 -1.219 0 CA-C-O 121.97 0.891 . . . . 0.0 111.0 179.907 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 297' ' ' ILE . . . . . 0.807 ' O ' HG23 ' A' ' 297' ' ' ILE . 19.2 tt 137.32 86.92 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 CA-C-N 111.977 -2.374 . . . . 0.0 106.722 -178.124 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 36.0 mttt -83.25 137.23 34.1 Favored 'General case' 0 C--N 1.317 -0.828 0 C-N-CA 119.39 -0.924 . . . . 0.0 112.374 -177.247 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 56.8 t-80 -130.76 117.81 19.94 Favored 'General case' 0 N--CA 1.441 -0.899 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 175.686 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -125.63 77.32 69.55 Favored Pre-proline 0 C--N 1.324 -0.526 0 C-N-CA 120.704 -0.398 . . . . 0.0 111.36 -179.625 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 85.5 Cg_endo -57.79 -23.66 59.75 Favored 'Trans proline' 0 C--N 1.313 -1.308 0 N-CA-C 109.99 -0.812 . . . . 0.0 109.99 179.224 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -173.43 128.15 1.46 Allowed Glycine 0 CA--C 1.523 0.563 0 CA-C-N 114.81 -1.086 . . . . 0.0 110.84 179.193 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -82.05 4.84 74.02 Favored Glycine 0 N--CA 1.462 0.397 0 N-CA-C 108.701 -1.76 . . . . 0.0 108.701 178.414 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 98.4 -8.08 62.14 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 109.845 -1.302 . . . . 0.0 109.845 -179.259 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 305' ' ' SER . . . . . 0.465 ' O ' ' C ' ' A' ' 306' ' ' VAL . 20.3 m -59.9 -34.93 73.83 Favored 'General case' 0 CA--C 1.521 -0.172 0 CA-C-O 121.953 0.882 . . . . 0.0 109.463 177.557 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 306' ' ' VAL . . . . . 0.465 ' C ' ' O ' ' A' ' 305' ' ' SER . 7.7 t -13.61 -104.0 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 CA-C-N 113.475 -1.693 . . . . 0.0 113.697 -177.902 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 307' ' ' GLN . . . . . 0.412 ' H ' ' HB ' ' A' ' 306' ' ' VAL . 21.7 pt20 -145.16 170.71 15.7 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.177 -178.1 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 308' ' ' ILE . . . . . 0.921 HG23 ' CD2' ' A' ' 310' ' ' TYR . 71.8 mt -97.28 116.96 41.02 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.095 0 N-CA-C 115.677 1.732 . . . . 0.0 115.677 -178.529 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 5.9 p -69.86 -32.29 51.3 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.462 0 CA-C-N 113.59 -1.641 . . . . 0.0 108.731 172.751 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 310' ' ' TYR . . . . . 0.921 ' CD2' HG23 ' A' ' 308' ' ' ILE 0.412 51.6 p90 -62.44 -10.71 12.46 Favored 'General case' 0 C--N 1.346 0.435 0 N-CA-C 117.817 2.525 . . . . 0.0 117.817 -177.203 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 311' ' ' LYS . . . . . 0.472 ' O ' ' C ' ' A' ' 312' ' ' PRO . 9.3 mmtt 63.68 67.53 0.98 Allowed Pre-proline 0 N--CA 1.475 0.813 0 CA-C-N 118.853 0.751 . . . . 0.0 112.406 177.235 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 312' ' ' PRO . . . . . 0.602 ' HD3' HG21 ' A' ' 308' ' ' ILE . 61.2 Cg_exo -0.99 -114.3 0.0 OUTLIER 'Trans proline' 0 N--CA 1.489 1.244 0 C-N-CA 123.093 2.529 . . . . 0.0 116.361 179.598 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 16.1 m -111.31 21.03 5.97 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.478 0 N-CA-C 113.071 0.767 . . . . 0.0 113.071 -176.761 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 58.2 t0 -51.33 -36.86 44.75 Favored 'General case' 0 C--N 1.323 -0.568 0 C-N-CA 120.271 -0.572 . . . . 0.0 111.176 -178.105 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 315' ' ' LEU . . . . . 0.635 ' N ' ' CD2' ' A' ' 315' ' ' LEU . 0.2 OUTLIER -60.05 -36.93 78.38 Favored 'General case' 0 C--N 1.33 -0.241 0 C-N-CA 118.983 -1.087 . . . . 0.0 109.496 178.458 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 21.5 t -59.49 -31.36 69.29 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.886 178.36 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 7.7 ttpp -56.17 -35.34 67.1 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.087 -0.961 . . . . 0.0 111.416 -176.879 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 43.0 t -112.27 134.74 53.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 121.017 0.436 . . . . 0.0 110.491 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 1.1 m . . . . . 0 C--O 1.22 -0.457 0 CA-C-O 117.916 -1.04 . . . . 0.0 110.695 -179.671 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 74.7 m . . . . . 0 CA--C 1.527 0.081 0 CA-C-O 120.647 0.26 . . . . 0.0 110.69 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 64.8 mttp -91.65 144.42 25.55 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 179.443 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 295' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -57.93 -39.59 78.37 Favored 'General case' 0 CA--C 1.507 -0.691 0 C-N-CA 120.069 -0.652 . . . . 0.0 111.688 -178.857 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 296' ' ' ASN . . . . . 0.445 ' HB3' ' H ' ' A' ' 297' ' ' ILE . 46.7 t-20 177.92 -94.41 0.0 OUTLIER 'General case' 0 C--N 1.314 -0.978 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 179.1 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 297' ' ' ILE . . . . . 0.445 ' H ' ' HB3' ' A' ' 296' ' ' ASN . 18.1 tt 174.62 3.82 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 113.715 -1.584 . . . . 0.0 109.808 179.431 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 298' ' ' LYS . . . . . 0.428 ' H ' ' H ' ' A' ' 297' ' ' ILE . 29.1 mttt 64.69 47.59 2.76 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-O 120.856 0.36 . . . . 0.0 110.705 -179.693 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 299' ' ' HIS . . . . . 0.401 ' ND1' ' O ' ' A' ' 299' ' ' HIS . 58.4 t-80 -74.07 65.43 1.12 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.139 -179.389 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 4.8 t -124.87 75.13 65.89 Favored Pre-proline 0 N--CA 1.465 0.319 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.323 178.974 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -57.81 -24.74 65.47 Favored 'Trans proline' 0 C--N 1.311 -1.427 0 C-N-CA 121.29 1.327 . . . . 0.0 111.431 -179.385 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -163.05 121.8 1.05 Allowed Glycine 0 CA--C 1.524 0.64 0 C-N-CA 120.624 -0.798 . . . . 0.0 111.656 179.76 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -82.32 1.21 87.88 Favored Glycine 0 CA--C 1.527 0.836 0 N-CA-C 110.264 -1.134 . . . . 0.0 110.264 178.534 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 96.79 -7.62 65.33 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.061 -1.215 . . . . 0.0 110.061 -179.788 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 305' ' ' SER . . . . . 0.455 ' O ' ' C ' ' A' ' 306' ' ' VAL . 25.9 t -60.04 -32.62 71.08 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.537 0.684 . . . . 0.0 109.232 177.07 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 306' ' ' VAL . . . . . 0.458 HG23 ' H ' ' A' ' 307' ' ' GLN . 0.0 OUTLIER -20.45 -90.5 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 CA-C-N 113.999 -1.455 . . . . 0.0 112.962 -177.44 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 307' ' ' GLN . . . . . 0.458 ' H ' HG23 ' A' ' 306' ' ' VAL . 23.4 pt20 -143.22 167.95 20.92 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.341 -0.845 . . . . 0.0 111.067 -177.329 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 308' ' ' ILE . . . . . 0.543 HG23 ' CE2' ' A' ' 310' ' ' TYR . 67.1 mt -107.4 120.89 59.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-O 121.751 0.786 . . . . 0.0 111.075 -179.699 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 309' ' ' VAL . . . . . 0.467 ' CG1' ' N ' ' A' ' 310' ' ' TYR . 8.0 p -66.04 -36.38 77.33 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.847 0 CA-C-O 122.206 1.003 . . . . 0.0 108.914 174.876 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 310' ' ' TYR . . . . . 0.543 ' CE2' HG23 ' A' ' 308' ' ' ILE 0.448 51.1 p90 -64.53 -32.12 73.62 Favored 'General case' 0 N--CA 1.451 -0.407 0 N-CA-C 118.194 2.665 . . . . 0.0 118.194 -177.996 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 311' ' ' LYS . . . . . 0.49 ' C ' ' O ' ' A' ' 310' ' ' TYR . 49.6 mtpt 47.98 72.23 1.33 Allowed Pre-proline 0 C--N 1.317 -0.805 0 C-N-CA 116.942 -1.903 . . . . 0.0 108.74 176.728 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 312' ' ' PRO . . . . . . . . . . . . . 7.0 Cg_endo -42.88 -37.54 6.14 Favored 'Trans proline' 0 N--CA 1.505 2.148 0 N-CA-C 114.364 0.871 . . . . 0.0 114.364 -173.754 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 71.6 t -62.95 -38.23 81.39 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.059 0 N-CA-C 116.417 2.006 . . . . 0.0 116.417 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 60.3 t0 -54.33 -43.84 71.57 Favored 'General case' 0 N--CA 1.467 0.416 0 O-C-N 120.589 -1.32 . . . . 0.0 114.415 -173.899 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 315' ' ' LEU . . . . . 0.651 ' N ' ' CD2' ' A' ' 315' ' ' LEU . 0.3 OUTLIER -66.8 -36.43 82.38 Favored 'General case' 0 C--N 1.319 -0.751 0 C-N-CA 118.308 -1.357 . . . . 0.0 109.068 176.628 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 32.8 m -59.7 -34.88 73.47 Favored 'General case' 0 N--CA 1.45 -0.47 0 CA-C-N 115.091 -0.959 . . . . 0.0 110.719 178.262 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 30.1 ttpt -80.12 125.63 30.06 Favored 'General case' 0 N--CA 1.45 -0.429 0 CA-C-O 121.697 0.761 . . . . 0.0 111.701 -177.25 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 318' ' ' VAL . . . . . 0.445 ' O ' ' OG1' ' A' ' 319' ' ' THR . 13.2 p -134.39 142.45 40.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 114.814 -1.084 . . . . 0.0 109.262 178.468 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 319' ' ' THR . . . . . 0.445 ' OG1' ' O ' ' A' ' 318' ' ' VAL . 0.7 OUTLIER . . . . . 0 C--O 1.219 -0.513 0 CA-C-O 117.962 -1.018 . . . . 0.0 111.227 179.314 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 29.9 t . . . . . 0 C--O 1.232 0.159 0 CA-C-O 121.335 0.588 . . . . 0.0 110.228 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 1.9 mtpt -133.45 -166.65 1.8 Allowed 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.117 -0.947 . . . . 0.0 111.427 -179.313 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 295' ' ' ASP . . . . . 0.48 ' C ' ' OD1' ' A' ' 295' ' ' ASP . 48.7 p30 -82.92 11.04 6.6 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.19 -0.913 . . . . 0.0 109.203 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 17.6 m120 46.17 -138.34 0.58 Allowed 'General case' 0 CA--C 1.497 -1.074 0 CA-C-N 114.407 -1.27 . . . . 0.0 111.613 179.818 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 297' ' ' ILE . . . . . 0.512 HD11 ' CE1' ' A' ' 299' ' ' HIS . 13.9 tt -121.23 126.79 75.48 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-O 122.357 1.075 . . . . 0.0 111.404 -177.979 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 6.1 mtpm? -61.09 -36.52 79.89 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-N 112.98 -1.918 . . . . 0.0 112.568 179.13 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 299' ' ' HIS . . . . . 0.512 ' CE1' HD11 ' A' ' 297' ' ' ILE . 0.1 OUTLIER 38.21 60.89 1.19 Allowed 'General case' 0 CA--C 1.537 0.473 0 CA-C-O 121.175 0.512 . . . . 0.0 112.266 -179.657 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 300' ' ' VAL . . . . . 0.415 ' C ' ' N ' ' A' ' 302' ' ' GLY . 3.1 m -123.47 72.65 49.81 Favored Pre-proline 0 N--CA 1.464 0.274 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.009 178.658 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 301' ' ' PRO . . . . . 0.401 ' CD ' ' H ' ' A' ' 302' ' ' GLY . 44.5 Cg_endo -58.34 -17.8 35.1 Favored 'Trans proline' 0 C--N 1.317 -1.127 0 N-CA-C 107.96 -1.592 . . . . 0.0 107.96 177.72 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 302' ' ' GLY . . . . . 0.415 ' N ' ' C ' ' A' ' 300' ' ' VAL . . . 116.61 156.13 10.58 Favored Glycine 0 N--CA 1.443 -0.846 0 CA-C-N 112.801 -2.0 . . . . 0.0 109.788 -179.014 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 303' ' ' GLY . . . . . 0.661 ' O ' ' N ' ' A' ' 305' ' ' SER . . . -163.69 -178.96 37.74 Favored Glycine 0 N--CA 1.446 -0.688 0 N-CA-C 108.528 -1.829 . . . . 0.0 108.528 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 59.32 -70.43 0.01 OUTLIER Glycine 0 CA--C 1.529 0.926 0 N-CA-C 109.815 -1.314 . . . . 0.0 109.815 -179.11 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 305' ' ' SER . . . . . 0.661 ' N ' ' O ' ' A' ' 303' ' ' GLY . 23.0 t -58.0 -33.97 69.5 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 121.081 0.467 . . . . 0.0 111.578 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 306' ' ' VAL . . . . . 0.627 HG23 ' H ' ' A' ' 307' ' ' GLN . 2.3 m -36.84 -100.91 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 N-CA-C 114.251 1.204 . . . . 0.0 114.251 -178.256 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 307' ' ' GLN . . . . . 0.627 ' H ' HG23 ' A' ' 306' ' ' VAL . 54.8 mt-30 -113.35 160.3 18.52 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 114.429 -1.26 . . . . 0.0 111.776 -176.376 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 308' ' ' ILE . . . . . 0.875 HG22 ' H ' ' A' ' 311' ' ' LYS . 34.9 mm -103.12 119.11 51.1 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-O 122.006 0.907 . . . . 0.0 112.635 -179.506 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 77.4 t -67.81 -40.27 83.38 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 CA-C-N 113.51 -1.677 . . . . 0.0 107.481 174.549 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 310' ' ' TYR . . . . . 0.641 ' CD2' HG23 ' A' ' 308' ' ' ILE 0.361 51.2 p90 -62.7 -31.05 71.89 Favored 'General case' 0 N--CA 1.446 -0.634 0 N-CA-C 117.467 2.395 . . . . 0.0 117.467 -178.676 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 311' ' ' LYS . . . . . 0.875 ' H ' HG22 ' A' ' 308' ' ' ILE . 19.4 mtpp 52.89 65.57 5.8 Favored Pre-proline 0 C--N 1.319 -0.731 0 CA-C-N 119.815 1.189 . . . . 0.0 110.223 178.773 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 312' ' ' PRO . . . . . 0.45 ' C ' ' O ' ' A' ' 311' ' ' LYS . 78.4 Cg_exo 7.67 -129.04 0.0 OUTLIER 'Trans proline' 0 C--N 1.316 -1.171 0 C-N-CA 123.264 2.643 . . . . 0.0 116.937 -179.216 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 313' ' ' VAL . . . . . 0.47 ' O ' ' OG ' ' A' ' 316' ' ' SER . 17.6 m -112.89 28.77 2.28 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 CA-C-N 114.775 -1.102 . . . . 0.0 113.542 -175.931 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 314' ' ' ASP . . . . . 0.4 ' O ' ' CB ' ' A' ' 317' ' ' LYS . 92.1 m-20 -51.51 -36.46 44.79 Favored 'General case' 0 C--N 1.319 -0.751 0 C-N-CA 119.66 -0.816 . . . . 0.0 111.17 -177.127 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 315' ' ' LEU . . . . . 0.633 ' CD2' ' N ' ' A' ' 315' ' ' LEU . 0.3 OUTLIER -59.81 -35.34 74.5 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 119.819 -0.752 . . . . 0.0 110.414 178.587 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 316' ' ' SER . . . . . 0.47 ' OG ' ' O ' ' A' ' 313' ' ' VAL . 82.6 p -62.44 -21.12 65.17 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-O 121.431 0.634 . . . . 0.0 110.364 179.373 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 317' ' ' LYS . . . . . 0.4 ' CB ' ' O ' ' A' ' 314' ' ' ASP . 82.0 tttt -55.29 -34.53 64.18 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.071 -0.968 . . . . 0.0 111.779 -177.399 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 13.1 p -129.08 142.55 43.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 C-N-CA 120.471 -0.492 . . . . 0.0 110.789 179.657 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.221 -0.439 0 CA-C-O 118.008 -0.996 . . . . 0.0 110.555 -179.644 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 97.6 p . . . . . 0 C--O 1.231 0.116 0 CA-C-O 121.117 0.484 . . . . 0.0 110.687 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -133.59 170.67 15.19 Favored 'General case' 0 CA--C 1.506 -0.728 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.673 -179.499 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 295' ' ' ASP . . . . . . . . . . . . . 86.0 m-20 -63.12 143.71 57.55 Favored 'General case' 0 N--CA 1.438 -1.063 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 -179.769 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 22.3 t-20 -64.77 130.5 43.74 Favored 'General case' 0 C--N 1.309 -1.174 0 CA-C-N 115.246 -0.888 . . . . 0.0 111.669 -177.595 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 297' ' ' ILE . . . . . . . . . . . . . 71.4 mt -115.18 132.12 65.41 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.09 0 CA-C-N 114.856 -1.065 . . . . 0.0 110.545 -179.762 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 73.1 tttt -105.66 135.62 46.74 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.85 179.184 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 99.3 m-70 -118.94 140.48 49.92 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.089 178.451 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 3.6 m -123.98 78.28 58.44 Favored Pre-proline 0 C--N 1.33 -0.255 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.358 -179.156 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -56.53 145.82 78.3 Favored 'Trans proline' 0 C--N 1.312 -1.371 0 N-CA-C 109.244 -1.099 . . . . 0.0 109.244 178.807 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -49.36 107.52 0.32 Allowed Glycine 0 CA--C 1.52 0.375 0 C-N-CA 118.92 -1.61 . . . . 0.0 109.769 -178.864 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -77.92 -2.13 81.01 Favored Glycine 0 C--N 1.33 0.23 0 N-CA-C 109.798 -1.321 . . . . 0.0 109.798 179.59 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 95.33 -1.93 64.94 Favored Glycine 0 N--CA 1.45 -0.402 0 N-CA-C 108.958 -1.657 . . . . 0.0 108.958 -178.883 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 73.9 m -83.24 1.83 38.85 Favored 'General case' 0 N--CA 1.453 -0.32 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 178.505 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 306' ' ' VAL . . . . . . . . . . . . . 71.6 t -61.08 -39.93 83.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.062 -0.972 . . . . 0.0 110.214 -179.467 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 307' ' ' GLN . . . . . 0.855 ' HG3' ' H ' ' A' ' 308' ' ' ILE . 21.2 pt20 -159.63 -88.24 0.03 OUTLIER 'General case' 0 CA--C 1.542 0.637 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.824 179.065 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 308' ' ' ILE . . . . . 0.855 ' H ' ' HG3' ' A' ' 307' ' ' GLN . 32.0 pt -125.22 160.94 30.24 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 CA-C-N 118.985 0.811 . . . . 0.0 111.305 179.525 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 309' ' ' VAL . . . . . 0.926 HG13 ' H ' ' A' ' 310' ' ' TYR . 3.9 p -136.65 -65.26 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 178.199 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 310' ' ' TYR . . . . . 0.926 ' H ' HG13 ' A' ' 309' ' ' VAL . 0.8 OUTLIER -66.31 -19.47 65.82 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.288 -0.869 . . . . 0.0 112.484 178.461 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 311' ' ' LYS . . . . . 0.534 ' O ' ' C ' ' A' ' 312' ' ' PRO . 43.9 tttt 67.55 65.21 0.66 Allowed Pre-proline 0 C--N 1.326 -0.439 0 C-N-CA 120.791 -0.364 . . . . 0.0 110.674 -179.358 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 312' ' ' PRO . . . . . 0.568 ' O ' ' C ' ' A' ' 313' ' ' VAL . 70.6 Cg_exo 3.9 75.75 0.0 OUTLIER 'Trans proline' 0 N--CA 1.488 1.152 0 C-N-CA 122.924 2.416 . . . . 0.0 114.016 179.812 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 313' ' ' VAL . . . . . 0.601 HG13 ' O ' ' A' ' 313' ' ' VAL . 13.7 p 1.33 71.18 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 O-C-N 124.085 0.866 . . . . 0.0 111.434 179.643 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 314' ' ' ASP . . . . . 0.506 ' N ' ' O ' ' A' ' 312' ' ' PRO . 21.7 t70 -55.18 -36.56 66.02 Favored 'General case' 0 CA--C 1.536 0.416 0 CA-C-N 114.464 -1.244 . . . . 0.0 112.992 -178.586 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 315' ' ' LEU . . . . . 0.635 ' N ' ' CD2' ' A' ' 315' ' ' LEU . 0.2 OUTLIER -58.88 -35.25 72.68 Favored 'General case' 0 N--CA 1.465 0.291 0 C-N-CA 120.585 -0.446 . . . . 0.0 111.258 -178.65 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 316' ' ' SER . . . . . 0.435 ' OG ' HG13 ' A' ' 313' ' ' VAL . 84.1 p -61.83 -26.39 68.09 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.002 0.43 . . . . 0.0 110.91 179.873 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 32.0 mmtm -58.07 -36.18 72.44 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.892 -0.595 . . . . 0.0 111.784 -177.397 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 13.3 p -132.47 143.11 40.81 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.26 0 CA-C-O 120.607 0.241 . . . . 0.0 111.077 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 27.0 p . . . . . 0 C--O 1.221 -0.446 0 CA-C-O 117.83 -1.081 . . . . 0.0 110.422 179.443 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 74.3 m . . . . . 0 C--O 1.231 0.108 0 CA-C-O 120.858 0.361 . . . . 0.0 110.457 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 76.9 mttt -96.56 151.52 19.51 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.439 179.699 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 295' ' ' ASP . . . . . 0.469 ' C ' ' OD1' ' A' ' 295' ' ' ASP . 48.9 p30 -86.7 9.86 17.49 Favored 'General case' 0 CA--C 1.503 -0.852 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 178.844 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 296' ' ' ASN . . . . . 0.565 ' CG ' ' H ' ' A' ' 297' ' ' ILE . 37.3 t-20 58.78 -143.17 0.62 Allowed 'General case' 0 CA--C 1.49 -1.341 0 CA-C-N 114.369 -1.287 . . . . 0.0 110.598 179.579 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 297' ' ' ILE . . . . . 0.565 ' H ' ' CG ' ' A' ' 296' ' ' ASN . 14.4 tt -121.4 131.19 73.65 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 CA-C-O 122.482 1.134 . . . . 0.0 112.416 -177.899 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 83.6 tttt -93.88 131.17 39.56 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-N 112.66 -2.064 . . . . 0.0 109.447 177.475 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 49.7 t-80 -128.26 137.05 51.82 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 120.114 -0.635 . . . . 0.0 110.86 179.792 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -124.21 76.55 60.43 Favored Pre-proline 0 N--CA 1.469 0.505 0 CA-C-N 116.804 -0.18 . . . . 0.0 111.065 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 83.6 Cg_endo -58.97 -25.49 77.75 Favored 'Trans proline' 0 N--CA 1.489 1.254 0 C-N-CA 121.126 1.217 . . . . 0.0 111.009 179.193 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . 174.77 133.61 1.75 Allowed Glycine 0 CA--C 1.532 1.125 0 CA-C-N 115.309 -0.86 . . . . 0.0 111.444 179.785 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -117.37 48.16 0.97 Allowed Glycine 0 CA--C 1.533 1.207 0 N-CA-C 110.534 -1.026 . . . . 0.0 110.534 179.565 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 99.1 -7.72 60.53 Favored Glycine 0 N--CA 1.466 0.687 0 N-CA-C 109.01 -1.636 . . . . 0.0 109.01 -178.143 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 27.9 t -83.68 -0.55 51.2 Favored 'General case' 0 CA--C 1.516 -0.327 0 N-CA-C 107.03 -1.47 . . . . 0.0 107.03 175.816 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 306' ' ' VAL . . . . . 0.623 ' O ' ' CB ' ' A' ' 307' ' ' GLN . 99.5 t -58.77 -41.56 82.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 113.569 -1.651 . . . . 0.0 112.193 -175.683 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 307' ' ' GLN . . . . . 0.623 ' CB ' ' O ' ' A' ' 306' ' ' VAL . 63.0 tt0 122.86 172.36 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.792 0 O-C-N 124.631 1.207 . . . . 0.0 108.023 -179.298 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 308' ' ' ILE . . . . . 0.494 ' N ' ' HG2' ' A' ' 307' ' ' GLN . 29.4 pt -121.25 155.24 25.11 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 N-CA-C 110.11 -0.329 . . . . 0.0 110.11 179.384 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 309' ' ' VAL . . . . . 0.59 ' O ' HG12 ' A' ' 309' ' ' VAL . 58.9 t -133.74 -5.62 1.34 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.292 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.611 179.569 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 310' ' ' TYR . . . . . 0.511 ' CD1' ' HD3' ' A' ' 312' ' ' PRO . 2.0 p90 -65.87 -18.29 65.24 Favored 'General case' 0 CA--C 1.517 -0.298 0 N-CA-C 112.508 0.559 . . . . 0.0 112.508 -176.481 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 311' ' ' LYS . . . . . 0.49 ' O ' ' C ' ' A' ' 312' ' ' PRO . 1.9 mtmm 59.38 64.91 2.84 Favored Pre-proline 0 C--N 1.325 -0.461 0 N-CA-C 107.252 -1.388 . . . . 0.0 107.252 -179.411 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 312' ' ' PRO . . . . . 0.511 ' HD3' ' CD1' ' A' ' 310' ' ' TYR . 1.1 Cg_exo -14.06 -62.1 0.01 OUTLIER 'Trans proline' 0 C--N 1.305 -1.731 0 C-N-CA 123.065 2.51 . . . . 0.0 114.536 -178.517 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 313' ' ' VAL . . . . . 0.768 HG22 ' OG ' ' A' ' 316' ' ' SER . 2.6 p -176.18 27.07 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 C-N-CA 120.397 -0.521 . . . . 0.0 111.314 179.621 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 92.9 m-20 -57.85 -37.66 74.29 Favored 'General case' 0 C--N 1.32 -0.705 0 N-CA-C 112.135 0.421 . . . . 0.0 112.135 -179.027 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 315' ' ' LEU . . . . . 0.741 ' O ' HG22 ' A' ' 318' ' ' VAL . 0.1 OUTLIER -56.95 -39.49 74.66 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 120.203 -0.599 . . . . 0.0 109.806 -178.671 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 316' ' ' SER . . . . . 0.768 ' OG ' HG22 ' A' ' 313' ' ' VAL . 86.6 p -63.34 -27.2 69.15 Favored 'General case' 0 N--CA 1.471 0.601 0 O-C-N 122.057 -0.402 . . . . 0.0 111.976 178.595 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 57.2 tttp -58.2 -36.17 72.7 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.156 -0.475 . . . . 0.0 112.114 -177.858 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 318' ' ' VAL . . . . . 0.741 HG22 ' O ' ' A' ' 315' ' ' LEU . 27.9 m -76.0 136.75 24.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-O 121.213 0.53 . . . . 0.0 111.097 -179.21 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 43.6 m . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 118.044 -0.979 . . . . 0.0 110.31 -179.952 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 46.7 m . . . . . 0 N--CA 1.46 0.074 0 N-CA-C 110.322 -0.251 . . . . 0.0 110.322 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 294' ' ' LYS . . . . . 0.445 ' C ' ' H ' ' A' ' 296' ' ' ASN . 11.5 mtpp -98.99 148.47 23.96 Favored 'General case' 0 N--CA 1.448 -0.569 0 CA-C-O 120.989 0.423 . . . . 0.0 111.188 -179.56 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 295' ' ' ASP . . . . . 0.471 ' OD2' ' C ' ' A' ' 295' ' ' ASP . 49.7 p30 -86.85 10.82 14.88 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 107.079 -1.452 . . . . 0.0 107.079 178.37 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 296' ' ' ASN . . . . . 0.445 ' H ' ' C ' ' A' ' 294' ' ' LYS . 81.1 m-20 29.17 -127.51 0.03 OUTLIER 'General case' 0 CA--C 1.5 -0.953 0 CA-C-N 112.604 -2.089 . . . . 0.0 113.467 -178.348 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 297' ' ' ILE . . . . . 0.448 ' O ' HG23 ' A' ' 297' ' ' ILE . 14.7 tt -121.86 130.47 74.56 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.709 0 CA-C-O 122.473 1.13 . . . . 0.0 113.024 -177.469 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 15.6 ttmm -100.84 127.63 47.21 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-N 112.715 -2.039 . . . . 0.0 109.675 176.933 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 81.4 t60 -136.33 114.33 11.37 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 120.552 -0.459 . . . . 0.0 111.479 179.193 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 3.2 m -133.89 72.87 72.2 Favored Pre-proline 0 N--CA 1.476 0.858 0 N-CA-C 113.953 1.094 . . . . 0.0 113.953 179.269 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 8.4 Cg_endo -61.25 -23.41 77.0 Favored 'Trans proline' 0 N--CA 1.502 2.017 0 CA-C-N 119.978 1.028 . . . . 0.0 112.026 177.732 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -77.01 46.25 2.38 Favored Glycine 0 CA--C 1.528 0.883 0 CA-C-N 115.121 -0.945 . . . . 0.0 113.194 -178.171 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -57.7 -28.53 60.22 Favored Glycine 0 N--CA 1.445 -0.7 0 N-CA-C 107.397 -2.281 . . . . 0.0 107.397 178.122 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 95.94 -0.56 62.62 Favored Glycine 0 N--CA 1.44 -1.038 0 N-CA-C 104.355 -3.498 . . . . 0.0 104.355 -175.594 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 72.8 m -83.06 1.36 40.52 Favored 'General case' 0 N--CA 1.436 -1.155 0 CA-C-N 112.486 -1.857 . . . . 0.0 110.314 179.295 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 306' ' ' VAL . . . . . . . . . . . . . 92.6 t -61.79 -42.63 95.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 115.424 -0.807 . . . . 0.0 112.178 -178.233 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 307' ' ' GLN . . . . . . . . . . . . . 23.2 pt20 173.65 -159.63 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.254 0 O-C-N 123.705 0.628 . . . . 0.0 109.585 -179.312 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 308' ' ' ILE . . . . . 0.626 HG22 ' H ' ' A' ' 311' ' ' LYS . 65.5 mt -114.97 122.95 70.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.546 178.127 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 309' ' ' VAL . . . . . 0.491 ' CG1' ' N ' ' A' ' 310' ' ' TYR . 8.0 p -63.82 -39.6 86.01 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.311 0 C-N-CA 118.859 -1.136 . . . . 0.0 108.442 176.588 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 310' ' ' TYR . . . . . 0.491 ' N ' ' CG1' ' A' ' 309' ' ' VAL 0.331 55.2 p90 -67.49 -33.14 74.49 Favored 'General case' 0 N--CA 1.452 -0.352 0 N-CA-C 117.584 2.438 . . . . 0.0 117.584 178.89 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 311' ' ' LYS . . . . . 0.626 ' H ' HG22 ' A' ' 308' ' ' ILE . 2.9 ttpm? 46.34 61.29 13.24 Favored Pre-proline 0 C--N 1.315 -0.924 0 C-N-CA 119.136 -1.025 . . . . 0.0 109.508 179.606 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 312' ' ' PRO . . . . . 0.539 ' C ' ' O ' ' A' ' 311' ' ' LYS . 83.8 Cg_exo 24.16 55.25 0.0 OUTLIER 'Trans proline' 0 N--CA 1.486 1.031 0 C-N-CA 120.801 1.001 . . . . 0.0 113.201 -179.209 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 313' ' ' VAL . . . . . 0.526 ' C ' ' O ' ' A' ' 312' ' ' PRO . 4.2 m 2.68 84.11 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 CA-C-N 115.181 -0.918 . . . . 0.0 112.467 -179.743 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 56.1 t0 -55.8 -36.62 67.62 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.956 -0.565 . . . . 0.0 111.146 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 315' ' ' LEU . . . . . . . . . . . . . 62.4 mt -58.82 -33.91 70.93 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.593 -178.976 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 95.3 p -60.43 -28.05 67.98 Favored 'General case' 0 CA--C 1.511 -0.55 0 C-N-CA 120.048 -0.661 . . . . 0.0 111.058 -179.285 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 38.1 mtpt -92.04 137.75 32.11 Favored 'General case' 0 N--CA 1.448 -0.539 0 C-N-CA 119.455 -0.898 . . . . 0.0 109.868 179.434 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 13.7 p -131.69 143.0 41.68 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 CA-C-N 114.977 -1.01 . . . . 0.0 110.765 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 41.6 p . . . . . 0 C--O 1.22 -0.488 0 CA-C-O 118.02 -0.991 . . . . 0.0 110.559 179.989 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 92.3 p . . . . . 0 N--CA 1.463 0.191 0 CA-C-O 120.596 0.236 . . . . 0.0 110.463 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 16.0 mtpp -93.91 149.7 21.0 Favored 'General case' 0 N--CA 1.446 -0.633 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.714 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 295' ' ' ASP . . . . . 0.679 ' OD1' ' N ' ' A' ' 296' ' ' ASN . 49.8 p30 -60.16 -31.94 70.58 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 108.107 -1.071 . . . . 0.0 108.107 178.929 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 296' ' ' ASN . . . . . 0.679 ' N ' ' OD1' ' A' ' 295' ' ' ASP . 17.4 t-20 58.99 44.98 15.54 Favored 'General case' 0 N--CA 1.45 -0.467 0 CA-C-N 115.277 -0.874 . . . . 0.0 109.804 179.63 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 297' ' ' ILE . . . . . 0.781 HG22 ' N ' ' A' ' 298' ' ' LYS . 84.4 mt 36.57 -118.09 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.439 -0.801 . . . . 0.0 110.634 -178.696 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 298' ' ' LYS . . . . . 0.781 ' N ' HG22 ' A' ' 297' ' ' ILE . 83.6 tttt -158.09 -95.86 0.03 OUTLIER 'General case' 0 CA--C 1.538 0.481 0 C-N-CA 119.948 -0.701 . . . . 0.0 111.564 179.499 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 76.3 m80 73.87 88.58 0.09 Allowed 'General case' 0 N--CA 1.476 0.871 0 N-CA-C 113.176 0.806 . . . . 0.0 113.176 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 3.1 m -124.01 77.87 58.78 Favored Pre-proline 0 CA--C 1.537 0.477 0 CA-C-N 115.408 -0.814 . . . . 0.0 109.582 179.125 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 301' ' ' PRO . . . . . 0.664 ' O ' HG23 ' A' ' 306' ' ' VAL . 8.1 Cg_exo -56.51 -24.49 53.42 Favored 'Trans proline' 0 N--CA 1.494 1.529 0 C-N-CA 121.694 1.596 . . . . 0.0 113.1 -178.285 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -73.02 17.54 1.68 Allowed Glycine 0 N--CA 1.463 0.452 0 N-CA-C 109.238 -1.545 . . . . 0.0 109.238 178.338 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 303' ' ' GLY . . . . . 0.622 ' H ' ' C ' ' A' ' 301' ' ' PRO . . . -56.04 -23.58 39.77 Favored Glycine 0 CA--C 1.516 0.147 0 CA-C-N 114.311 -0.944 . . . . 0.0 110.971 -179.814 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 98.1 -4.36 60.69 Favored Glycine 0 CA--C 1.505 -0.59 0 N-CA-C 104.349 -3.5 . . . . 0.0 104.349 -174.776 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 85.2 p -64.69 -20.72 66.48 Favored 'General case' 0 N--CA 1.428 -1.541 0 CA-C-N 111.331 -2.435 . . . . 0.0 106.139 175.649 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 306' ' ' VAL . . . . . 0.664 HG23 ' O ' ' A' ' 301' ' ' PRO . 80.8 t -57.48 -42.09 80.16 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 CA-C-N 113.259 -1.791 . . . . 0.0 110.9 -177.375 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 307' ' ' GLN . . . . . 0.586 ' CB ' ' O ' ' A' ' 306' ' ' VAL . 57.2 tt0 103.92 160.48 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.484 0 O-C-N 124.378 1.049 . . . . 0.0 109.019 179.72 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 308' ' ' ILE . . . . . 0.865 HG22 ' H ' ' A' ' 310' ' ' TYR . 70.2 mt -114.98 129.0 71.91 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.46 0 CA-C-O 121.43 0.634 . . . . 0.0 110.738 178.53 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 1.5 t -86.56 8.63 1.95 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.558 0 CA-C-N 114.648 -1.16 . . . . 0.0 111.763 179.296 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 310' ' ' TYR . . . . . 0.865 ' H ' HG22 ' A' ' 308' ' ' ILE . 0.0 OUTLIER -54.27 -32.43 56.21 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 113.886 1.069 . . . . 0.0 113.886 -174.962 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 311' ' ' LYS . . . . . 0.53 ' N ' ' CD ' ' A' ' 312' ' ' PRO . 12.1 mmmt 57.33 68.16 2.14 Favored Pre-proline 0 N--CA 1.475 0.798 0 CA-C-N 119.732 1.151 . . . . 0.0 112.019 177.345 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 312' ' ' PRO . . . . . 0.594 ' O ' ' N ' ' A' ' 314' ' ' ASP . 86.6 Cg_exo -54.78 148.55 45.22 Favored 'Trans proline' 0 C--N 1.304 -1.808 0 C-N-CA 124.978 3.785 . . . . 0.0 114.761 -179.067 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 17.8 m 38.82 12.28 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 CA-C-N 114.313 -1.312 . . . . 0.0 113.093 -179.337 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 314' ' ' ASP . . . . . 0.594 ' N ' ' O ' ' A' ' 312' ' ' PRO . 20.9 t70 -55.11 -36.64 65.91 Favored 'General case' 0 C--N 1.319 -0.734 0 C-N-CA 120.237 -0.585 . . . . 0.0 109.557 179.126 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 315' ' ' LEU . . . . . 0.62 ' CD2' ' N ' ' A' ' 315' ' ' LEU . 0.2 OUTLIER -61.12 -35.24 76.53 Favored 'General case' 0 CA--C 1.541 0.615 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.027 179.4 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 79.6 p -62.4 -25.93 68.21 Favored 'General case' 0 N--CA 1.471 0.579 0 CA-C-O 121.643 0.735 . . . . 0.0 110.862 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 62.6 mmtt -58.04 -26.29 62.27 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 114.49 -1.232 . . . . 0.0 113.598 -178.432 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 11.6 p -110.22 138.6 37.32 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 CA-C-O 122.142 0.972 . . . . 0.0 111.061 -176.41 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 3.6 m . . . . . 0 C--O 1.219 -0.526 0 CA-C-N 113.335 -1.757 . . . . 0.0 110.203 -178.14 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 98.6 p . . . . . 0 N--CA 1.462 0.173 0 CA-C-O 120.911 0.386 . . . . 0.0 110.215 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 294' ' ' LYS . . . . . 0.459 ' HD2' ' N ' ' A' ' 294' ' ' LYS . 1.0 OUTLIER -85.4 -74.06 0.42 Allowed 'General case' 0 CA--C 1.512 -0.504 0 CA-C-O 121.701 0.762 . . . . 0.0 112.101 -179.296 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 295' ' ' ASP . . . . . 0.47 ' OD1' HD11 ' A' ' 297' ' ' ILE . 50.6 p30 -89.58 6.94 38.92 Favored 'General case' 0 N--CA 1.442 -0.869 0 CA-C-N 114.427 -1.261 . . . . 0.0 109.468 179.879 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 17.3 t-20 58.97 53.53 5.58 Favored 'General case' 0 N--CA 1.473 0.675 0 N-CA-C 114.531 1.308 . . . . 0.0 114.531 176.587 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 297' ' ' ILE . . . . . 0.47 HD11 ' OD1' ' A' ' 295' ' ' ASP . 15.7 mm -73.4 140.94 16.96 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.653 0 C-N-CA 119.524 -0.87 . . . . 0.0 110.172 -179.617 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 298' ' ' LYS . . . . . 0.516 ' NZ ' HG13 ' A' ' 300' ' ' VAL . 14.0 ptmm? -125.22 154.26 41.89 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 114.682 -1.145 . . . . 0.0 111.62 -178.002 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 56.6 t-80 -124.36 129.6 50.99 Favored 'General case' 0 CA--C 1.536 0.409 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 178.265 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 300' ' ' VAL . . . . . 0.516 HG13 ' NZ ' ' A' ' 298' ' ' LYS . 0.2 OUTLIER -124.14 77.35 59.95 Favored Pre-proline 0 N--CA 1.474 0.763 0 N-CA-C 112.406 0.521 . . . . 0.0 112.406 -179.147 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -59.01 -27.63 85.57 Favored 'Trans proline' 0 C--N 1.312 -1.373 0 N-CA-C 109.885 -0.852 . . . . 0.0 109.885 177.969 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -121.66 106.32 1.08 Allowed Glycine 0 CA--C 1.523 0.568 0 CA-C-N 115.039 -0.982 . . . . 0.0 110.788 179.302 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -141.56 33.38 1.98 Allowed Glycine 0 CA--C 1.523 0.579 0 N-CA-C 109.905 -1.278 . . . . 0.0 109.905 179.23 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 95.2 -0.43 63.96 Favored Glycine 0 CA--C 1.521 0.426 0 N-CA-C 107.963 -2.055 . . . . 0.0 107.963 -177.891 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 52.0 p -82.78 -0.14 46.42 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 113.896 -1.152 . . . . 0.0 109.541 178.547 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 306' ' ' VAL . . . . . 0.514 ' O ' ' CB ' ' A' ' 307' ' ' GLN . 92.3 t -58.27 -39.19 72.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.509 -0.769 . . . . 0.0 110.127 -177.633 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 307' ' ' GLN . . . . . 0.627 ' HG2' HG23 ' A' ' 308' ' ' ILE . 57.9 tt0 94.07 139.74 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.727 0 N-CA-C 114.602 1.334 . . . . 0.0 114.602 177.816 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 308' ' ' ILE . . . . . 0.627 HG23 ' HG2' ' A' ' 307' ' ' GLN . 0.8 OUTLIER 16.23 36.76 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.543 0 CA-C-N 112.723 -2.035 . . . . 0.0 115.397 177.99 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 309' ' ' VAL . . . . . 0.614 ' N ' ' O ' ' A' ' 307' ' ' GLN . 62.9 t -55.54 -37.45 45.65 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 N-CA-C 107.943 -1.132 . . . . 0.0 107.943 179.425 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 310' ' ' TYR . . . . . 0.488 ' CE1' ' HD3' ' A' ' 312' ' ' PRO . 33.6 p90 -60.3 -28.04 67.79 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 114.226 1.195 . . . . 0.0 114.226 -179.789 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 311' ' ' LYS . . . . . . . . . . . . . 2.3 tmtp? 68.97 74.32 0.29 Allowed Pre-proline 0 N--CA 1.474 0.75 0 CA-C-N 119.337 0.971 . . . . 0.0 110.512 178.313 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 312' ' ' PRO . . . . . 0.488 ' HD3' ' CE1' ' A' ' 310' ' ' TYR . 13.4 Cg_exo -54.83 -31.07 70.95 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 C-N-CA 122.59 2.193 . . . . 0.0 114.803 -177.014 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 313' ' ' VAL . . . . . 0.641 HG13 ' HB2' ' A' ' 316' ' ' SER . 39.2 t -124.26 134.81 65.63 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.525 0 C-N-CA 120.184 -0.606 . . . . 0.0 111.308 179.765 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 314' ' ' ASP . . . . . 0.499 ' HB3' HD22 ' A' ' 315' ' ' LEU . 61.2 t0 -149.12 -89.42 0.08 Allowed 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.516 -0.765 . . . . 0.0 109.061 178.928 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 315' ' ' LEU . . . . . 0.911 HD22 ' H ' ' A' ' 315' ' ' LEU . 2.0 mm? -59.61 -31.09 69.16 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.065 178.041 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 316' ' ' SER . . . . . 0.641 ' HB2' HG13 ' A' ' 313' ' ' VAL . 25.2 m -55.29 -33.17 63.03 Favored 'General case' 0 N--CA 1.455 -0.197 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.133 -178.025 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 317' ' ' LYS . . . . . 0.581 ' HG3' HG12 ' A' ' 313' ' ' VAL . 65.4 mttm -57.82 -34.1 69.3 Favored 'General case' 0 C--N 1.326 -0.435 0 C-N-CA 120.461 -0.496 . . . . 0.0 110.44 -179.923 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 42.1 t -115.77 135.8 54.71 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-O 120.825 0.345 . . . . 0.0 110.983 -179.449 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 37.4 p . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.333 179.684 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.663 0 N-CA-C 111.123 -0.791 . . . . 0.0 111.123 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 293' ' ' SER . . . . . 0.464 ' O ' ' O ' ' A' ' 294' ' ' LYS . 97.5 p -122.27 153.86 38.34 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 121.119 0.485 . . . . 0.0 111.272 -179.815 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 294' ' ' LYS . . . . . 0.464 ' O ' ' O ' ' A' ' 293' ' ' SER . 57.7 mttp -55.19 -126.1 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.502 -0.772 . . . . 0.0 111.757 179.836 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 295' ' ' ASP . . . . . . . . . . . . . 89.5 m-20 -92.17 7.43 42.57 Favored 'General case' 0 N--CA 1.455 -0.224 0 CA-C-N 114.924 -1.035 . . . . 0.0 111.235 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 49.9 t30 60.26 52.13 5.1 Favored 'General case' 0 C--N 1.333 -0.119 0 C-N-CA 119.68 -0.808 . . . . 0.0 111.567 179.842 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 297' ' ' ILE . . . . . . . . . . . . . 80.9 mt -64.99 135.22 28.6 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 122.396 1.093 . . . . 0.0 111.779 -177.354 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 84.6 tttt -81.76 137.0 35.41 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 112.884 -1.962 . . . . 0.0 112.752 -179.085 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 74.4 t60 -124.53 136.36 53.92 Favored 'General case' 0 CA--C 1.543 0.711 0 N-CA-C 107.914 -1.143 . . . . 0.0 107.914 178.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -124.0 76.72 58.78 Favored Pre-proline 0 N--CA 1.481 1.09 0 N-CA-C 113.336 0.865 . . . . 0.0 113.336 -177.876 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -59.76 -26.1 81.19 Favored 'Trans proline' 0 N--CA 1.493 1.472 0 C-N-CA 121.221 1.28 . . . . 0.0 111.862 178.451 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -167.28 125.1 1.28 Allowed Glycine 0 CA--C 1.527 0.789 0 N-CA-C 110.89 -0.884 . . . . 0.0 110.89 -179.585 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -150.35 37.2 0.92 Allowed Glycine 0 N--CA 1.468 0.803 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 179.732 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 96.7 -4.72 63.85 Favored Glycine 0 C--N 1.317 -0.488 0 N-CA-C 106.262 -2.735 . . . . 0.0 106.262 -177.079 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 24.9 t -59.89 -27.76 66.99 Favored 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 112.827 -1.686 . . . . 0.0 109.121 176.937 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 306' ' ' VAL . . . . . 0.641 ' O ' ' CB ' ' A' ' 307' ' ' GLN . 73.5 t -55.41 -40.08 56.01 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.643 0 CA-C-N 114.081 -1.418 . . . . 0.0 112.038 -175.77 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 307' ' ' GLN . . . . . 0.641 ' CB ' ' O ' ' A' ' 306' ' ' VAL . 63.1 tp60 117.37 84.61 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.529 0 N-CA-C 113.921 1.082 . . . . 0.0 113.921 177.482 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 308' ' ' ILE . . . . . 0.672 HG23 ' O ' ' A' ' 308' ' ' ILE . 18.6 tt 26.46 58.24 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 N-CA-C 113.16 0.8 . . . . 0.0 113.16 176.217 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 54.8 t -56.0 -39.23 56.64 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.605 0 C-N-CA 118.724 -1.19 . . . . 0.0 109.76 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 310' ' ' TYR . . . . . 0.695 ' O ' ' CD1' ' A' ' 310' ' ' TYR . 36.7 p90 -69.83 104.56 2.5 Favored 'General case' 0 N--CA 1.439 -1.0 0 C-N-CA 119.082 -1.047 . . . . 0.0 109.41 178.601 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 311' ' ' LYS . . . . . . . . . . . . . 38.6 mtpt -73.34 128.07 88.02 Favored Pre-proline 0 C--N 1.313 -1.016 0 C-N-CA 119.649 -0.82 . . . . 0.0 110.385 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 312' ' ' PRO . . . . . . . . . . . . . 85.3 Cg_exo -55.96 149.48 51.89 Favored 'Trans proline' 0 C--N 1.306 -1.66 0 N-CA-C 106.122 -2.299 . . . . 0.0 106.122 174.326 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 36.1 t -64.46 126.26 22.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 C-N-CA 116.284 -2.166 . . . . 0.0 110.775 -175.921 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 314' ' ' ASP . . . . . 0.466 ' O ' ' HB3' ' A' ' 317' ' ' LYS . 89.5 m-20 -95.59 -19.22 19.95 Favored 'General case' 0 N--CA 1.444 -0.762 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 175.509 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 315' ' ' LEU . . . . . 0.697 ' O ' HG12 ' A' ' 318' ' ' VAL . 60.5 mt -62.22 -37.47 85.48 Favored 'General case' 0 C--O 1.232 0.141 0 CA-C-N 116.029 -0.532 . . . . 0.0 112.293 -178.324 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 82.9 p -63.03 -30.76 71.85 Favored 'General case' 0 CA--C 1.519 -0.22 0 CA-C-O 121.499 0.666 . . . . 0.0 109.886 179.877 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 317' ' ' LYS . . . . . 0.466 ' HB3' ' O ' ' A' ' 314' ' ' ASP . 18.8 tttt -59.38 -36.89 76.62 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 114.342 -1.299 . . . . 0.0 112.783 -178.824 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 318' ' ' VAL . . . . . 0.697 HG12 ' O ' ' A' ' 315' ' ' LEU . 5.3 p -57.07 -33.98 44.0 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 N-CA-C 112.268 0.47 . . . . 0.0 112.268 -178.148 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 319' ' ' THR . . . . . 0.412 ' OXT' ' O ' ' A' ' 318' ' ' VAL . 1.3 m . . . . . 0 C--O 1.221 -0.443 0 CA-C-O 117.951 -1.023 . . . . 0.0 110.792 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.632 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 23.8 m -57.9 -35.31 70.84 Favored 'General case' 0 C--N 1.332 -0.186 0 C-N-CA 120.77 -0.372 . . . . 0.0 110.137 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -96.27 148.32 22.86 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.716 179.298 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 295' ' ' ASP . . . . . 0.596 ' O ' ' CB ' ' A' ' 296' ' ' ASN . 91.6 m-20 -56.52 -36.4 69.16 Favored 'General case' 0 CA--C 1.492 -1.251 0 N-CA-C 107.382 -1.34 . . . . 0.0 107.382 177.659 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 296' ' ' ASN . . . . . 0.596 ' CB ' ' O ' ' A' ' 295' ' ' ASP . 48.2 t30 118.39 -128.61 0.0 OUTLIER 'General case' 0 CA--C 1.469 -2.16 0 O-C-N 125.581 1.801 . . . . 0.0 110.097 179.51 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 297' ' ' ILE . . . . . 0.651 ' O ' HG23 ' A' ' 297' ' ' ILE . 8.9 tp -122.44 133.35 68.93 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.111 0 CA-C-N 114.499 -1.228 . . . . 0.0 110.497 -178.781 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 43.4 tttm -132.71 120.19 21.35 Favored 'General case' 0 C--N 1.294 -1.84 0 CA-C-N 114.234 -1.348 . . . . 0.0 110.323 174.453 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 299' ' ' HIS . . . . . 0.407 ' CD2' HD11 ' A' ' 297' ' ' ILE . 79.8 m-70 -139.81 145.04 37.65 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.36 -0.836 . . . . 0.0 112.251 174.851 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -124.8 72.71 62.6 Favored Pre-proline 0 C--N 1.322 -0.63 0 CA-C-N 115.473 -0.785 . . . . 0.0 108.952 177.282 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -59.1 -24.67 74.76 Favored 'Trans proline' 0 N--CA 1.492 1.44 0 C-N-CA 121.034 1.156 . . . . 0.0 111.098 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . 150.15 136.51 2.58 Favored Glycine 0 CA--C 1.52 0.365 0 CA-C-N 115.05 -0.977 . . . . 0.0 110.875 179.442 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -84.57 1.52 88.76 Favored Glycine 0 CA--C 1.519 0.311 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 179.009 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 95.74 -2.83 64.81 Favored Glycine 0 CA--C 1.519 0.329 0 N-CA-C 108.936 -1.666 . . . . 0.0 108.936 -179.021 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 73.9 m -84.53 4.28 32.67 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 114.774 -0.713 . . . . 0.0 109.902 178.619 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 306' ' ' VAL . . . . . . . . . . . . . 98.8 t -59.67 -41.78 86.34 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.662 0 CA-C-O 122.235 1.017 . . . . 0.0 111.179 -178.309 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 307' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 -141.84 168.5 19.6 Favored 'General case' 0 C--N 1.31 -1.119 0 CA-C-N 112.896 -1.956 . . . . 0.0 109.0 -177.498 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 308' ' ' ILE . . . . . 0.732 HG22 ' H ' ' A' ' 311' ' ' LYS . 31.8 mm -104.05 117.81 50.19 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 CA-C-N 115.418 -0.81 . . . . 0.0 113.162 -179.152 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 21.0 m -78.53 -30.11 15.09 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.483 0 CA-C-N 114.13 -1.395 . . . . 0.0 108.398 175.592 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 310' ' ' TYR . . . . . 0.611 ' CE2' HG23 ' A' ' 308' ' ' ILE 0.364 51.7 p90 -64.15 -28.29 69.66 Favored 'General case' 0 N--CA 1.447 -0.608 0 N-CA-C 116.311 1.967 . . . . 0.0 116.311 -179.197 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 311' ' ' LYS . . . . . 0.732 ' H ' HG22 ' A' ' 308' ' ' ILE . 37.3 mtpt 53.72 65.65 5.32 Favored Pre-proline 0 C--N 1.318 -0.78 0 C-N-CA 119.875 -0.73 . . . . 0.0 110.958 178.44 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 312' ' ' PRO . . . . . 0.492 ' C ' ' O ' ' A' ' 311' ' ' LYS . 91.0 Cg_exo 3.86 -128.87 0.0 OUTLIER 'Trans proline' 0 N--CA 1.487 1.141 0 C-N-CA 123.092 2.528 . . . . 0.0 115.771 -179.287 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 313' ' ' VAL . . . . . 0.624 HG13 ' O ' ' A' ' 313' ' ' VAL . 4.5 p -113.04 37.06 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.718 0 N-CA-C 112.955 0.724 . . . . 0.0 112.955 -177.234 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 314' ' ' ASP . . . . . 0.402 ' O ' ' HB3' ' A' ' 317' ' ' LYS . 54.6 t0 -54.13 -35.26 62.01 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 112.081 0.4 . . . . 0.0 112.081 -179.614 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 315' ' ' LEU . . . . . 1.012 HD22 ' H ' ' A' ' 315' ' ' LEU . 1.8 mm? -57.15 -35.18 69.21 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 120.299 -0.56 . . . . 0.0 111.074 -178.486 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 316' ' ' SER . . . . . 0.412 ' HB3' HG22 ' A' ' 313' ' ' VAL . 89.8 p -62.37 -23.59 66.89 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 121.135 0.493 . . . . 0.0 110.582 178.65 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 317' ' ' LYS . . . . . 0.402 ' HB3' ' O ' ' A' ' 314' ' ' ASP . 41.8 tttp -56.62 -35.4 68.26 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.137 -0.938 . . . . 0.0 111.855 -177.947 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 13.3 p -129.7 142.75 43.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.045 0.45 . . . . 0.0 110.439 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 117.939 -1.029 . . . . 0.0 110.693 -179.27 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.634 0 N-CA-C 110.786 -0.925 . . . . 0.0 110.786 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 46.5 m -63.39 156.79 24.9 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.159 0.504 . . . . 0.0 110.775 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 11.6 mtpp -81.17 168.9 18.04 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.807 179.476 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 295' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -48.68 -31.88 7.5 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.974 -177.347 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 74.6 m-20 63.81 52.47 2.15 Favored 'General case' 0 CA--C 1.516 -0.355 0 C-N-CA 120.269 -0.572 . . . . 0.0 111.457 -179.923 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 297' ' ' ILE . . . . . . . . . . . . . 82.1 mt -62.98 130.93 28.21 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.249 0 N-CA-C 107.66 -1.237 . . . . 0.0 107.66 -178.976 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 44.4 tttp -81.98 133.69 35.32 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 115.469 1.655 . . . . 0.0 115.469 -175.373 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -121.72 139.17 53.91 Favored 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 106.843 -1.54 . . . . 0.0 106.843 175.812 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 8.0 m -125.75 72.04 68.15 Favored Pre-proline 0 N--CA 1.472 0.651 0 C-N-CA 119.308 -0.957 . . . . 0.0 113.31 -178.917 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 79.3 Cg_exo -62.07 -23.62 75.82 Favored 'Trans proline' 0 C--N 1.302 -1.918 0 C-N-CA 122.281 1.987 . . . . 0.0 110.692 176.266 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -92.97 28.43 9.46 Favored Glycine 0 CA--C 1.526 0.745 0 CA-C-N 114.492 -1.231 . . . . 0.0 112.713 -178.383 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 303' ' ' GLY . . . . . 0.415 ' C ' ' N ' ' A' ' 305' ' ' SER . . . -84.4 -173.28 49.73 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.376 -0.916 . . . . 0.0 111.39 -178.556 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . -50.68 -23.88 7.21 Favored Glycine 0 N--CA 1.453 -0.221 0 N-CA-C 108.31 -1.916 . . . . 0.0 108.31 178.91 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 305' ' ' SER . . . . . 0.415 ' N ' ' C ' ' A' ' 303' ' ' GLY . 22.4 m -55.07 -34.56 63.7 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 114.751 -0.724 . . . . 0.0 111.881 -179.223 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 306' ' ' VAL . . . . . 0.862 ' O ' ' O ' ' A' ' 307' ' ' GLN . 79.0 t -60.88 -39.72 82.9 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.712 0 C-N-CA 121.096 -0.241 . . . . 0.0 110.55 179.772 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 307' ' ' GLN . . . . . 0.862 ' O ' ' O ' ' A' ' 306' ' ' VAL . 13.0 pt20 24.88 166.03 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.471 0 O-C-N 125.222 1.576 . . . . 0.0 113.138 -177.292 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 308' ' ' ILE . . . . . 0.715 ' O ' ' N ' ' A' ' 310' ' ' TYR . 8.5 tt -59.26 -26.86 34.96 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.011 0 CA-C-N 114.192 -1.367 . . . . 0.0 112.753 -176.529 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 309' ' ' VAL . . . . . 0.608 HG23 ' O ' ' A' ' 307' ' ' GLN . 1.0 OUTLIER 51.06 -42.14 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.204 0 N-CA-C 113.0 0.741 . . . . 0.0 113.0 179.454 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 310' ' ' TYR . . . . . 0.715 ' N ' ' O ' ' A' ' 308' ' ' ILE 0.485 52.5 p90 -65.06 -25.48 67.83 Favored 'General case' 0 CA--C 1.564 1.507 0 N-CA-C 119.69 3.219 . . . . 0.0 119.69 -178.074 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 311' ' ' LYS . . . . . 0.461 ' HB2' ' O ' ' A' ' 310' ' ' TYR . 11.3 mttp 74.15 77.25 0.19 Allowed Pre-proline 0 N--CA 1.509 2.516 0 CA-C-N 120.996 1.726 . . . . 0.0 112.13 177.914 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 312' ' ' PRO . . . . . . . . . . . . . 4.7 Cg_endo -54.26 -34.33 79.25 Favored 'Trans proline' 0 N--CA 1.522 3.165 0 C-N-CA 123.524 2.816 . . . . 0.0 117.447 -178.178 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 69.7 t -67.29 -38.64 81.3 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.004 0 N-CA-C 116.155 1.909 . . . . 0.0 116.155 -178.398 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 314' ' ' ASP . . . . . 0.519 ' O ' ' O ' ' A' ' 317' ' ' LYS . 91.1 m-20 -55.47 -39.99 71.08 Favored 'General case' 0 C--N 1.322 -0.62 0 C-N-CA 118.697 -1.201 . . . . 0.0 113.103 -174.074 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 315' ' ' LEU . . . . . 0.841 HD22 ' H ' ' A' ' 315' ' ' LEU . 2.0 mm? -65.22 -36.71 85.01 Favored 'General case' 0 C--N 1.326 -0.423 0 C-N-CA 118.918 -1.113 . . . . 0.0 108.892 176.932 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 22.5 m -60.39 -36.36 77.91 Favored 'General case' 0 CA--C 1.516 -0.364 0 N-CA-C 108.253 -1.017 . . . . 0.0 108.253 178.079 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 317' ' ' LYS . . . . . 0.519 ' O ' ' O ' ' A' ' 314' ' ' ASP . 35.7 ttmt -97.02 117.38 31.06 Favored 'General case' 0 N--CA 1.446 -0.668 0 CA-C-N 114.958 -1.019 . . . . 0.0 111.098 179.71 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 59.5 t -130.92 135.84 59.26 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.333 176.728 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.218 -0.604 0 CA-C-O 117.871 -1.061 . . . . 0.0 110.451 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.728 0 N-CA-C 111.005 -0.838 . . . . 0.0 111.005 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 92.5 p -122.65 156.43 34.34 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.921 0.391 . . . . 0.0 110.531 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 11.9 mtpt -91.8 158.47 16.32 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.702 0.763 . . . . 0.0 112.489 -179.206 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 295' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -53.7 -33.8 56.68 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 114.359 -1.291 . . . . 0.0 110.652 -179.594 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 50.8 t30 64.73 54.34 1.39 Allowed 'General case' 0 CA--C 1.521 -0.14 0 C-N-CA 119.746 -0.782 . . . . 0.0 111.871 -179.817 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 297' ' ' ILE . . . . . . . . . . . . . 75.8 mt -68.05 139.25 21.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.304 -179.024 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 11.5 pttp -77.47 147.71 35.75 Favored 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 114.293 1.22 . . . . 0.0 114.293 -176.391 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 77.3 m80 -120.16 139.32 52.79 Favored 'General case' 0 N--CA 1.454 -0.261 0 CA-C-N 114.032 -1.44 . . . . 0.0 108.455 176.749 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 3.3 m -122.84 73.7 45.49 Favored Pre-proline 0 C--N 1.327 -0.387 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 179.574 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -61.1 -25.15 80.72 Favored 'Trans proline' 0 C--N 1.31 -1.458 0 C-N-CA 122.766 2.311 . . . . 0.0 114.176 -179.353 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -138.14 58.47 0.63 Allowed Glycine 0 CA--C 1.525 0.67 0 C-N-CA 120.597 -0.811 . . . . 0.0 113.363 -177.942 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -57.2 -28.54 58.87 Favored Glycine 0 N--CA 1.445 -0.722 0 N-CA-C 105.901 -2.88 . . . . 0.0 105.901 176.965 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 98.91 -10.45 62.2 Favored Glycine 0 N--CA 1.442 -0.966 0 N-CA-C 104.077 -3.609 . . . . 0.0 104.077 -176.099 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 84.9 p -66.29 -27.74 68.16 Favored 'General case' 0 N--CA 1.432 -1.336 0 CA-C-N 112.024 -2.088 . . . . 0.0 111.875 177.877 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 306' ' ' VAL . . . . . . . . . . . . . 55.8 t -61.1 -46.54 96.45 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.331 0 CA-C-O 122.151 0.977 . . . . 0.0 111.382 -175.385 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 307' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -148.14 164.4 34.02 Favored 'General case' 0 N--CA 1.441 -0.89 0 CA-C-N 113.567 -1.652 . . . . 0.0 110.206 -179.175 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 308' ' ' ILE . . . . . 0.47 HG12 ' CZ ' ' A' ' 310' ' ' TYR . 7.2 tp -122.37 129.72 75.07 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 CA-C-O 122.027 0.918 . . . . 0.0 110.915 176.266 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 69.6 t -67.25 -31.68 54.15 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.494 0 CA-C-N 113.639 -1.619 . . . . 0.0 115.128 179.656 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 310' ' ' TYR . . . . . 0.536 ' HD1' ' N ' ' A' ' 311' ' ' LYS . 0.0 OUTLIER -52.38 -33.84 45.23 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 117.197 2.295 . . . . 0.0 117.197 -171.689 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 311' ' ' LYS . . . . . 0.542 ' O ' ' C ' ' A' ' 312' ' ' PRO . 1.1 mmtt 54.09 64.68 6.15 Favored Pre-proline 0 CA--C 1.549 0.911 0 CA-C-N 121.697 2.044 . . . . 0.0 109.441 -179.974 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 312' ' ' PRO . . . . . 0.542 ' C ' ' O ' ' A' ' 311' ' ' LYS . 81.6 Cg_exo 2.76 64.82 0.0 OUTLIER 'Trans proline' 0 N--CA 1.49 1.321 0 C-N-CA 122.706 2.271 . . . . 0.0 114.794 -179.513 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 313' ' ' VAL . . . . . 0.541 ' N ' ' O ' ' A' ' 311' ' ' LYS . 1.8 m 20.96 54.17 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 CA-C-N 115.46 -0.791 . . . . 0.0 111.973 179.14 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 314' ' ' ASP . . . . . 0.89 ' OD2' HD12 ' A' ' 315' ' ' LEU . 49.6 p30 -60.44 -33.7 72.93 Favored 'General case' 0 C--N 1.322 -0.614 0 C-N-CA 120.611 -0.435 . . . . 0.0 110.858 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 315' ' ' LEU . . . . . 0.89 HD12 ' OD2' ' A' ' 314' ' ' ASP . 6.1 mp -59.16 -37.48 77.41 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 118.833 -1.147 . . . . 0.0 109.591 179.44 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 87.3 p -63.53 -28.04 69.67 Favored 'General case' 0 CA--C 1.509 -0.62 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 177.491 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 15.4 ttpt -82.8 133.14 35.15 Favored 'General case' 0 N--CA 1.446 -0.652 0 CA-C-N 114.434 -1.257 . . . . 0.0 108.828 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 13.3 p -130.55 142.28 44.1 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.751 0 C-N-CA 120.599 -0.441 . . . . 0.0 110.693 -179.761 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.22 -0.491 0 CA-C-O 117.851 -1.071 . . . . 0.0 110.967 -179.696 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.635 0 N-CA-C 110.99 -0.844 . . . . 0.0 110.99 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 74.5 m -82.72 3.7 28.12 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.648 0.261 . . . . 0.0 110.865 -179.813 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 294' ' ' LYS . . . . . 0.452 ' C ' ' H ' ' A' ' 296' ' ' ASN . 68.7 mttm -92.95 148.69 21.79 Favored 'General case' 0 N--CA 1.451 -0.39 0 CA-C-O 121.548 0.689 . . . . 0.0 112.099 -179.355 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 295' ' ' ASP . . . . . 0.478 ' C ' ' OD1' ' A' ' 295' ' ' ASP . 49.4 p30 -88.19 11.55 16.1 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 106.427 -1.694 . . . . 0.0 106.427 177.218 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 296' ' ' ASN . . . . . 0.452 ' H ' ' C ' ' A' ' 294' ' ' LYS . 75.7 m-20 33.88 -115.14 0.07 Allowed 'General case' 0 CA--C 1.49 -1.347 0 CA-C-N 112.878 -1.965 . . . . 0.0 111.934 -177.335 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 297' ' ' ILE . . . . . 0.551 ' O ' HG23 ' A' ' 297' ' ' ILE . 16.9 tt -120.53 133.03 68.54 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.355 0 C-N-CA 118.478 -1.289 . . . . 0.0 110.315 -178.474 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 44.6 tttm -123.97 119.84 30.73 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 113.996 -1.457 . . . . 0.0 111.549 177.271 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 299' ' ' HIS . . . . . 0.503 ' CE1' HD11 ' A' ' 297' ' ' ILE . 71.7 m80 -137.89 145.37 42.05 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 114.504 -1.225 . . . . 0.0 108.464 173.873 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -123.81 68.37 43.48 Favored Pre-proline 0 N--CA 1.468 0.464 0 C-N-CA 119.358 -0.937 . . . . 0.0 111.856 179.231 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -64.35 -23.12 65.75 Favored 'Trans proline' 0 C--N 1.312 -1.353 0 C-N-CA 122.232 1.955 . . . . 0.0 111.044 176.485 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -80.75 25.78 3.35 Favored Glycine 0 N--CA 1.471 0.982 0 CA-C-N 114.794 -1.094 . . . . 0.0 111.297 -178.908 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -56.08 -25.23 46.04 Favored Glycine 0 C--N 1.317 -0.522 0 N-CA-C 110.588 -1.005 . . . . 0.0 110.588 -179.872 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 100.5 -2.77 56.17 Favored Glycine 0 C--N 1.319 -0.401 0 N-CA-C 104.651 -3.379 . . . . 0.0 104.651 -174.339 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 86.9 p -65.49 -17.41 64.53 Favored 'General case' 0 N--CA 1.444 -0.774 0 CA-C-N 111.755 -2.223 . . . . 0.0 107.484 175.325 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 306' ' ' VAL . . . . . 0.527 ' O ' ' CB ' ' A' ' 307' ' ' GLN . 93.9 t -54.98 -41.52 59.0 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.628 0 CA-C-N 113.231 -1.804 . . . . 0.0 109.513 -176.44 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 307' ' ' GLN . . . . . 0.527 ' CB ' ' O ' ' A' ' 306' ' ' VAL . 12.4 pt20 124.39 147.43 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.86 0 O-C-N 124.921 1.388 . . . . 0.0 110.743 177.67 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 308' ' ' ILE . . . . . 0.413 HG12 ' CD1' ' A' ' 310' ' ' TYR . 15.9 tt -61.55 -26.63 40.14 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.045 0 CA-C-N 114.406 -1.27 . . . . 0.0 113.893 -178.483 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 309' ' ' VAL . . . . . 0.443 HG23 ' HG3' ' A' ' 307' ' ' GLN . 75.4 t 57.33 -30.24 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.396 0 N-CA-C 116.346 1.98 . . . . 0.0 116.346 178.903 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 310' ' ' TYR . . . . . 0.442 ' CE1' ' HA ' ' A' ' 312' ' ' PRO . 0.0 OUTLIER -65.79 -14.23 60.99 Favored 'General case' 0 N--CA 1.479 1.001 0 N-CA-C 115.805 1.78 . . . . 0.0 115.805 -175.33 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 311' ' ' LYS . . . . . 0.493 ' O ' ' C ' ' A' ' 312' ' ' PRO . 0.6 OUTLIER 74.46 65.86 0.28 Allowed Pre-proline 0 N--CA 1.473 0.708 0 CA-C-N 118.805 0.73 . . . . 0.0 110.585 -179.909 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 312' ' ' PRO . . . . . 0.493 ' C ' ' O ' ' A' ' 311' ' ' LYS . 12.3 Cg_exo -10.2 -111.4 0.0 OUTLIER 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 123.255 2.636 . . . . 0.0 114.905 179.375 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 17.7 m -111.05 15.69 8.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 N-CA-C 111.954 0.353 . . . . 0.0 111.954 -178.253 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 93.2 m-20 -55.26 -38.76 68.97 Favored 'General case' 0 N--CA 1.451 -0.391 0 C-N-CA 119.436 -0.906 . . . . 0.0 111.096 -178.046 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 315' ' ' LEU . . . . . 0.624 ' O ' HG12 ' A' ' 318' ' ' VAL . 27.8 tp -60.09 -38.72 83.8 Favored 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 119.904 -0.718 . . . . 0.0 110.258 178.475 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 21.2 m -59.57 -33.95 72.08 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 115.508 -0.769 . . . . 0.0 111.596 179.263 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 33.9 tttp -56.78 -36.34 69.73 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.267 -0.879 . . . . 0.0 112.301 -177.346 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 318' ' ' VAL . . . . . 0.624 HG12 ' O ' ' A' ' 315' ' ' LEU . 5.9 p -57.11 -34.35 45.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 C-N-CA 120.067 -0.653 . . . . 0.0 109.888 179.647 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 319' ' ' THR . . . . . 0.445 ' C ' ' O ' ' A' ' 318' ' ' VAL . 2.5 m . . . . . 0 C--O 1.219 -0.546 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.911 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.65 0 N-CA-C 110.983 -0.847 . . . . 0.0 110.983 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 89.4 p -126.03 157.57 37.56 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 121.309 0.576 . . . . 0.0 111.296 -179.521 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 294' ' ' LYS . . . . . 0.409 ' HB3' ' NZ ' ' A' ' 294' ' ' LYS . 9.5 mtpm? -88.35 172.83 9.12 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.45 179.77 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 295' ' ' ASP . . . . . 0.446 ' OD2' ' C ' ' A' ' 295' ' ' ASP . 49.1 p30 -76.76 8.49 3.62 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 112.571 0.582 . . . . 0.0 112.571 -175.629 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 76.7 m-20 61.44 51.68 4.05 Favored 'General case' 0 N--CA 1.468 0.428 0 N-CA-C 115.74 1.755 . . . . 0.0 115.74 175.34 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 297' ' ' ILE . . . . . . . . . . . . . 16.2 mm -70.8 132.51 33.19 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.158 0 N-CA-C 106.975 -1.491 . . . . 0.0 106.975 179.559 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 3.6 ptmt -99.37 144.23 28.73 Favored 'General case' 0 N--CA 1.464 0.264 0 N-CA-C 115.592 1.701 . . . . 0.0 115.592 -175.446 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 299' ' ' HIS . . . . . 0.439 ' CE1' ' CG ' ' A' ' 301' ' ' PRO . 54.8 t-80 -126.75 119.09 26.05 Favored 'General case' 0 CA--C 1.536 0.439 0 N-CA-C 106.022 -1.844 . . . . 0.0 106.022 175.515 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -129.82 77.05 77.49 Favored Pre-proline 0 N--CA 1.477 0.904 0 N-CA-C 114.939 1.459 . . . . 0.0 114.939 -176.944 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 301' ' ' PRO . . . . . 0.499 ' O ' HG23 ' A' ' 306' ' ' VAL . 75.2 Cg_exo -60.29 -22.76 72.0 Favored 'Trans proline' 0 N--CA 1.502 2.005 0 C-N-CA 121.705 1.604 . . . . 0.0 112.446 177.285 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -69.32 20.41 0.45 Allowed Glycine 0 CA--C 1.526 0.732 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.924 -178.757 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 303' ' ' GLY . . . . . 0.495 ' H ' ' C ' ' A' ' 301' ' ' PRO . . . -56.82 -28.16 57.0 Favored Glycine 0 N--CA 1.453 -0.202 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 179.732 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 98.31 -4.71 60.47 Favored Glycine 0 C--N 1.317 -0.486 0 N-CA-C 103.962 -3.655 . . . . 0.0 103.962 -174.603 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 83.8 p -65.88 -18.93 65.67 Favored 'General case' 0 N--CA 1.438 -1.047 0 CA-C-N 111.333 -2.434 . . . . 0.0 108.615 176.591 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 306' ' ' VAL . . . . . 0.499 HG23 ' O ' ' A' ' 301' ' ' PRO . 90.7 t -56.35 -40.77 68.65 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 CA-C-N 113.98 -1.463 . . . . 0.0 110.672 -175.677 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 307' ' ' GLN . . . . . 0.801 ' HG2' ' H ' ' A' ' 308' ' ' ILE . 46.3 tt0 -173.27 -151.02 0.05 Allowed 'General case' 0 CA--C 1.536 0.43 0 N-CA-C 107.691 -1.226 . . . . 0.0 107.691 179.126 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 308' ' ' ILE . . . . . 0.801 ' H ' ' HG2' ' A' ' 307' ' ' GLN . 64.9 mt -114.92 136.69 50.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 179.289 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 71.3 t -60.55 -39.64 81.95 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.089 0 N-CA-C 112.828 0.677 . . . . 0.0 112.828 -178.789 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 310' ' ' TYR . . . . . 0.57 ' N ' ' CD1' ' A' ' 310' ' ' TYR . 0.1 OUTLIER -148.62 23.25 1.01 Allowed 'General case' 0 N--CA 1.477 0.906 0 N-CA-C 115.931 1.826 . . . . 0.0 115.931 -176.623 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 311' ' ' LYS . . . . . 0.471 ' O ' ' C ' ' A' ' 312' ' ' PRO . 0.1 OUTLIER 51.69 67.71 3.89 Favored Pre-proline 0 CA--C 1.546 0.807 0 C-N-CA 117.842 -1.543 . . . . 0.0 107.869 -179.253 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 312' ' ' PRO . . . . . 0.615 ' HD2' HG21 ' A' ' 308' ' ' ILE . 60.3 Cg_exo -6.33 -66.55 0.0 OUTLIER 'Trans proline' 0 N--CA 1.492 1.423 0 C-N-CA 123.109 2.539 . . . . 0.0 116.29 -176.356 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 20.2 m -129.78 156.97 42.43 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.687 0 N-CA-C 113.285 0.846 . . . . 0.0 113.285 -178.429 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 23.1 t70 -142.71 -61.73 0.43 Allowed 'General case' 0 CA--C 1.535 0.382 0 CA-C-N 114.912 -1.04 . . . . 0.0 110.525 178.612 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 315' ' ' LEU . . . . . 0.599 HD12 ' H ' ' A' ' 315' ' ' LEU . 6.6 mp -61.25 -35.1 76.34 Favored 'General case' 0 N--CA 1.47 0.554 0 N-CA-C 112.357 0.503 . . . . 0.0 112.357 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 85.2 p -60.78 -26.06 66.98 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.287 0.565 . . . . 0.0 109.9 -179.446 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 85.9 tttt -57.4 -36.76 71.72 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.355 -0.839 . . . . 0.0 110.362 -179.67 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 318' ' ' VAL . . . . . 0.475 ' O ' ' O ' ' A' ' 315' ' ' LEU . 13.7 p -131.45 142.97 41.91 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.176 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.332 179.67 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 2.0 m . . . . . 0 C--O 1.22 -0.494 0 CA-C-O 118.024 -0.988 . . . . 0.0 110.598 179.986 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.702 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 86.2 p -62.25 -25.99 68.14 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.835 0.35 . . . . 0.0 110.676 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 11.5 mtpp -89.45 162.65 15.63 Favored 'General case' 0 CA--C 1.515 -0.381 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.869 179.89 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 295' ' ' ASP . . . . . 0.653 ' OD1' ' N ' ' A' ' 296' ' ' ASN . 50.0 p30 -57.58 -33.47 68.21 Favored 'General case' 0 N--CA 1.449 -0.524 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.407 -178.501 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 296' ' ' ASN . . . . . 0.653 ' N ' ' OD1' ' A' ' 295' ' ' ASP . 16.4 t-20 58.44 56.54 4.31 Favored 'General case' 0 CA--C 1.516 -0.357 0 C-N-CA 118.38 -1.328 . . . . 0.0 110.558 177.388 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 297' ' ' ILE . . . . . 0.448 HG22 ' H ' ' A' ' 299' ' ' HIS . 21.6 mm -42.63 137.25 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-O 122.659 1.219 . . . . 0.0 109.975 -175.932 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 83.1 tttt -57.38 -36.04 70.74 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 112.354 -2.203 . . . . 0.0 112.939 -176.744 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 299' ' ' HIS . . . . . 0.448 ' H ' HG22 ' A' ' 297' ' ' ILE . 1.2 m80 64.86 112.35 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 120.167 -0.613 . . . . 0.0 109.755 -179.14 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -122.21 78.32 43.51 Favored Pre-proline 0 C--N 1.325 -0.46 0 CA-C-N 115.82 -0.627 . . . . 0.0 109.885 -179.293 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -56.32 -23.65 47.34 Favored 'Trans proline' 0 C--N 1.315 -1.231 0 C-N-CA 120.904 1.069 . . . . 0.0 110.238 -179.426 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 302' ' ' GLY . . . . . 0.451 ' C ' ' H ' ' A' ' 304' ' ' GLY . . . -167.15 127.21 1.54 Allowed Glycine 0 CA--C 1.526 0.721 0 CA-C-N 114.965 -1.016 . . . . 0.0 110.882 179.002 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -78.85 10.87 30.26 Favored Glycine 0 N--CA 1.463 0.459 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 178.811 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 304' ' ' GLY . . . . . 0.451 ' H ' ' C ' ' A' ' 302' ' ' GLY . . . 98.39 -4.2 60.06 Favored Glycine 0 CA--C 1.519 0.334 0 N-CA-C 108.25 -1.94 . . . . 0.0 108.25 -177.483 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 305' ' ' SER . . . . . 0.524 ' O ' ' C ' ' A' ' 306' ' ' VAL . 23.9 m -59.2 -33.14 70.61 Favored 'General case' 0 C--O 1.233 0.193 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 177.259 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 306' ' ' VAL . . . . . 0.571 HG23 ' H ' ' A' ' 307' ' ' GLN . 4.9 m -7.04 -109.7 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 CA-C-N 114.626 -1.17 . . . . 0.0 111.81 -178.881 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 307' ' ' GLN . . . . . 0.571 ' H ' HG23 ' A' ' 306' ' ' VAL . 25.3 pt20 -138.08 154.84 49.22 Favored 'General case' 0 N--CA 1.451 -0.401 0 CA-C-O 121.466 0.65 . . . . 0.0 109.699 178.612 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 308' ' ' ILE . . . . . 1.002 ' O ' ' N ' ' A' ' 310' ' ' TYR . 16.3 pt -78.1 -25.15 14.09 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.779 0 N-CA-C 116.09 1.885 . . . . 0.0 116.09 -177.239 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 309' ' ' VAL . . . . . 0.821 HG12 ' O ' ' A' ' 309' ' ' VAL . 93.7 t 9.4 27.78 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.257 0 N-CA-C 113.989 1.107 . . . . 0.0 113.989 -178.814 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 310' ' ' TYR . . . . . 1.002 ' N ' ' O ' ' A' ' 308' ' ' ILE 0.253 0.4 OUTLIER -71.66 -19.98 62.01 Favored 'General case' 0 C--N 1.332 -0.175 0 N-CA-C 113.158 0.799 . . . . 0.0 113.158 -179.523 . . . . . . . . 4 4 . 1 . 007 nuclear build full ' A' A ' 311' ' ' LYS . . . . . 0.417 ' HE3' ' H ' ' A' ' 311' ' ' LYS . 0.0 OUTLIER 57.08 62.72 5.66 Favored Pre-proline 0 C--N 1.325 -0.49 0 CA-C-O 121.316 0.579 . . . . 0.0 109.786 179.718 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 312' ' ' PRO . . . . . 0.778 ' O ' ' N ' ' A' ' 314' ' ' ASP . 32.7 Cg_endo -58.88 143.54 99.31 Favored 'Trans proline' 0 C--N 1.303 -1.855 0 C-N-CA 122.648 2.232 . . . . 0.0 111.288 179.223 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 313' ' ' VAL . . . . . 0.491 ' O ' ' OG ' ' A' ' 316' ' ' SER . 18.9 m -6.58 59.29 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.645 0 O-C-N 124.224 0.953 . . . . 0.0 113.295 -179.452 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 314' ' ' ASP . . . . . 0.778 ' N ' ' O ' ' A' ' 312' ' ' PRO . 93.2 m-20 -56.89 -36.75 70.5 Favored 'General case' 0 C--O 1.223 -0.308 0 N-CA-C 111.66 0.244 . . . . 0.0 111.66 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 315' ' ' LEU . . . . . . . . . . . . . 61.7 mt -58.81 -36.42 74.46 Favored 'General case' 0 C--N 1.326 -0.424 0 C-N-CA 120.07 -0.652 . . . . 0.0 110.719 -178.609 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 316' ' ' SER . . . . . 0.491 ' OG ' ' O ' ' A' ' 313' ' ' VAL . 86.3 p -63.37 -23.74 67.54 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-O 121.227 0.537 . . . . 0.0 110.756 178.67 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 49.2 tttm -56.75 -35.8 69.03 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.303 -0.862 . . . . 0.0 112.535 -177.489 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 12.5 p -129.7 142.88 42.74 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 C-N-CA 120.263 -0.575 . . . . 0.0 111.829 -179.238 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.221 -0.418 0 CA-C-O 118.137 -0.935 . . . . 0.0 110.813 179.882 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.875 0 N-CA-C 110.974 -0.85 . . . . 0.0 110.974 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 21.2 m -56.98 -33.6 67.26 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.842 0.353 . . . . 0.0 110.688 -179.922 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 67.4 mttt -57.45 -37.77 73.39 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.098 -178.419 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 295' ' ' ASP . . . . . 0.645 ' OD2' ' N ' ' A' ' 296' ' ' ASN . 50.3 p30 175.1 -24.6 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.652 179.401 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 296' ' ' ASN . . . . . 0.645 ' N ' ' OD2' ' A' ' 295' ' ' ASP . 18.7 t-20 56.54 48.22 17.08 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.627 -0.715 . . . . 0.0 111.071 179.751 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 297' ' ' ILE . . . . . 0.672 HG23 ' O ' ' A' ' 297' ' ' ILE . 10.9 tp 15.46 111.04 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 CA-C-O 122.176 0.988 . . . . 0.0 111.602 -178.647 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 298' ' ' LYS . . . . . 0.584 ' O ' ' C ' ' A' ' 299' ' ' HIS . 56.4 tttp -57.86 -36.48 72.4 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 114.488 -1.233 . . . . 0.0 113.285 -178.1 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 299' ' ' HIS . . . . . 0.584 ' C ' ' O ' ' A' ' 298' ' ' LYS . 85.3 t60 1.42 102.25 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.358 0 N-CA-C 112.104 0.409 . . . . 0.0 112.104 -179.265 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.55 75.22 69.68 Favored Pre-proline 0 N--CA 1.469 0.513 0 N-CA-C 111.964 0.357 . . . . 0.0 111.964 -179.17 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -58.94 -21.67 59.23 Favored 'Trans proline' 0 C--N 1.306 -1.693 0 N-CA-C 109.788 -0.889 . . . . 0.0 109.788 177.898 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -79.42 25.21 2.85 Favored Glycine 0 CA--C 1.528 0.892 0 CA-C-N 114.386 -1.279 . . . . 0.0 111.767 -179.848 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -55.93 -26.13 47.3 Favored Glycine 0 CA--C 1.509 -0.296 0 N-CA-C 109.274 -1.53 . . . . 0.0 109.274 179.631 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 98.65 -3.27 59.1 Favored Glycine 0 N--CA 1.442 -0.906 0 N-CA-C 104.686 -3.366 . . . . 0.0 104.686 -175.315 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 305' ' ' SER . . . . . 0.503 ' O ' ' O ' ' A' ' 306' ' ' VAL . 24.7 m -59.46 -33.89 71.86 Favored 'General case' 0 N--CA 1.439 -0.998 0 CA-C-N 112.501 -1.849 . . . . 0.0 108.674 177.157 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 306' ' ' VAL . . . . . 0.552 HG23 ' H ' ' A' ' 307' ' ' GLN . 8.2 m -11.22 -113.37 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.233 0.186 0 CA-C-N 113.438 -1.71 . . . . 0.0 112.835 -178.364 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 307' ' ' GLN . . . . . 0.552 ' H ' HG23 ' A' ' 306' ' ' VAL . 21.7 pt20 -141.56 165.1 28.43 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.429 -0.805 . . . . 0.0 110.803 -178.684 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 308' ' ' ILE . . . . . 0.667 ' O ' HG13 ' A' ' 308' ' ' ILE . 19.9 pt -63.99 100.6 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 122.596 1.189 . . . . 0.0 109.778 179.96 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 81.4 t -63.87 -42.44 95.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 122.005 0.907 . . . . 0.0 109.167 179.829 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 310' ' ' TYR . . . . . 0.405 ' CE1' ' HD3' ' A' ' 312' ' ' PRO 0.321 54.9 p90 -66.21 -32.34 73.71 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 118.082 2.623 . . . . 0.0 118.082 179.542 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 311' ' ' LYS . . . . . 0.615 ' O ' ' N ' ' A' ' 313' ' ' VAL . 14.6 mtpp 51.02 63.99 8.9 Favored Pre-proline 0 C--N 1.313 -0.979 0 C-N-CA 118.633 -1.227 . . . . 0.0 109.781 179.362 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 312' ' ' PRO . . . . . 0.591 ' O ' ' N ' ' A' ' 314' ' ' ASP . 84.0 Cg_exo 6.33 58.26 0.0 OUTLIER 'Trans proline' 0 N--CA 1.492 1.382 0 C-N-CA 122.635 2.223 . . . . 0.0 113.41 -179.586 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 313' ' ' VAL . . . . . 0.748 ' O ' HG13 ' A' ' 313' ' ' VAL . 9.5 p 4.56 62.61 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 O-C-N 124.082 0.864 . . . . 0.0 112.196 -179.704 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 314' ' ' ASP . . . . . 0.591 ' N ' ' O ' ' A' ' 312' ' ' PRO . 92.1 m-20 -56.08 -35.82 67.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.025 -0.989 . . . . 0.0 111.78 -179.369 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 315' ' ' LEU . . . . . 0.743 ' H ' HD12 ' A' ' 315' ' ' LEU . 6.4 mp -57.39 -36.02 70.74 Favored 'General case' 0 C--N 1.326 -0.45 0 C-N-CA 119.854 -0.738 . . . . 0.0 110.027 -178.33 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 316' ' ' SER . . . . . 0.456 ' OG ' HG22 ' A' ' 313' ' ' VAL . 24.4 m -58.45 -34.23 70.61 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 108.396 -0.965 . . . . 0.0 108.396 177.299 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 65.8 tttt -77.05 132.8 39.11 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.084 -0.962 . . . . 0.0 109.714 179.424 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 318' ' ' VAL . . . . . 0.407 ' O ' HG23 ' A' ' 319' ' ' THR . 14.4 p -131.67 142.82 42.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.629 -179.716 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 319' ' ' THR . . . . . 0.407 HG23 ' O ' ' A' ' 318' ' ' VAL . 33.5 p . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 118.049 -0.976 . . . . 0.0 110.845 -179.709 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 292' ' ' GLY . . . . . 0.52 ' O ' ' C ' ' A' ' 293' ' ' SER . . . . . . . . 0 CA--C 1.525 0.665 0 N-CA-C 111.034 -0.827 . . . . 0.0 111.034 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 293' ' ' SER . . . . . 0.52 ' C ' ' O ' ' A' ' 292' ' ' GLY . 1.9 m 21.26 55.82 0.02 OUTLIER 'General case' 0 CA--C 1.535 0.367 0 CA-C-O 120.988 0.423 . . . . 0.0 111.829 -179.568 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 27.8 mttp -91.55 153.51 19.71 Favored 'General case' 0 CA--C 1.515 -0.397 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 178.225 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 295' ' ' ASP . . . . . 0.459 ' C ' ' OD2' ' A' ' 295' ' ' ASP . 48.4 p30 -83.88 8.0 16.36 Favored 'General case' 0 C--N 1.322 -0.626 0 C-N-CA 119.617 -0.833 . . . . 0.0 109.949 -178.988 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 45.5 t30 58.31 56.06 4.67 Favored 'General case' 0 N--CA 1.455 -0.183 0 C-N-CA 119.671 -0.812 . . . . 0.0 112.014 177.102 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 297' ' ' ILE . . . . . 0.451 HG13 ' OD2' ' A' ' 295' ' ' ASP . 70.7 mt -59.82 131.4 24.41 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.165 0 CA-C-O 122.197 0.999 . . . . 0.0 110.103 -175.932 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 2.0 ttmp? -84.15 136.99 33.76 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 113.419 -1.719 . . . . 0.0 113.958 -177.819 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 64.5 m170 -115.88 136.9 52.6 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 106.483 -1.673 . . . . 0.0 106.483 176.08 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 3.9 m -125.08 69.74 59.64 Favored Pre-proline 0 N--CA 1.466 0.349 0 C-N-CA 119.573 -0.851 . . . . 0.0 112.867 -178.566 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -62.46 -19.31 67.11 Favored 'Trans proline' 0 C--N 1.302 -1.892 0 N-CA-C 107.174 -1.894 . . . . 0.0 107.174 174.683 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -165.08 -169.55 28.85 Favored Glycine 0 CA--C 1.531 1.039 0 CA-C-N 112.91 -1.95 . . . . 0.0 110.233 -178.219 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . 126.25 29.59 0.92 Allowed Glycine 0 N--CA 1.466 0.698 0 N-CA-C 109.013 -1.635 . . . . 0.0 109.013 -178.371 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 97.07 -7.45 64.56 Favored Glycine 0 C--N 1.324 -0.116 0 N-CA-C 107.352 -2.299 . . . . 0.0 107.352 -178.493 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 23.2 t -59.96 -30.75 69.3 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 113.146 -1.527 . . . . 0.0 111.157 177.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 306' ' ' VAL . . . . . 0.564 ' O ' ' CB ' ' A' ' 307' ' ' GLN . 88.5 t -56.93 -42.99 79.73 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.48 0 CA-C-N 115.729 -0.669 . . . . 0.0 112.071 -175.373 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 307' ' ' GLN . . . . . 0.564 ' CB ' ' O ' ' A' ' 306' ' ' VAL . 21.3 pt20 125.46 178.49 0.0 OUTLIER 'General case' 0 N--CA 1.469 0.501 0 O-C-N 124.643 1.214 . . . . 0.0 110.201 179.42 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 308' ' ' ILE . . . . . 0.823 ' O ' ' N ' ' A' ' 310' ' ' TYR . 33.3 mm -54.88 -45.16 75.09 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.933 0 CA-C-N 113.952 -1.476 . . . . 0.0 113.852 177.259 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 309' ' ' VAL . . . . . 0.455 ' H ' ' HG3' ' A' ' 307' ' ' GLN . 0.3 OUTLIER 37.2 -0.94 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.693 0 O-C-N 123.939 0.774 . . . . 0.0 113.069 -179.212 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 310' ' ' TYR . . . . . 0.823 ' N ' ' O ' ' A' ' 308' ' ' ILE 0.329 0.0 OUTLIER -67.39 -22.3 65.56 Favored 'General case' 0 CA--C 1.503 -0.85 0 C-N-CA 119.056 -1.057 . . . . 0.0 110.681 -178.763 . . . . . . . . 4 4 . 1 . 009 nuclear build full ' A' A ' 311' ' ' LYS . . . . . 0.583 ' O ' ' C ' ' A' ' 312' ' ' PRO . 32.3 tttp 56.4 63.55 5.61 Favored Pre-proline 0 N--CA 1.447 -0.61 0 CA-C-N 115.028 -0.987 . . . . 0.0 109.916 177.779 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 312' ' ' PRO . . . . . 0.583 ' C ' ' O ' ' A' ' 311' ' ' LYS . 75.8 Cg_exo 12.85 -127.08 0.0 OUTLIER 'Trans proline' 0 N--CA 1.492 1.414 0 C-N-CA 122.337 2.025 . . . . 0.0 110.888 -178.448 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 45.2 t -120.98 126.87 75.73 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.398 0 C-N-CA 118.336 -1.345 . . . . 0.0 109.509 176.193 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -63.93 -38.14 89.98 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.64 0.733 . . . . 0.0 111.282 177.102 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 315' ' ' LEU . . . . . 0.65 ' CD2' ' N ' ' A' ' 315' ' ' LEU . 0.2 OUTLIER -61.07 -36.97 81.04 Favored 'General case' 0 C--O 1.233 0.192 0 CA-C-N 114.453 -1.249 . . . . 0.0 113.29 -176.902 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 68.4 m -79.58 -5.55 55.22 Favored 'General case' 0 C--N 1.327 -0.404 0 C-N-CA 120.166 -0.614 . . . . 0.0 111.026 -179.857 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 57.2 tttp -58.42 -38.0 76.52 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.114 -179.333 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 43.4 t -120.65 135.45 60.83 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 CA-C-N 116.545 -0.298 . . . . 0.0 110.577 179.188 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 6.9 m . . . . . 0 C--O 1.221 -0.399 0 CA-C-O 118.018 -0.991 . . . . 0.0 110.422 179.459 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.636 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 86.6 p -61.79 -27.58 68.85 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.798 0.332 . . . . 0.0 110.498 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 31.0 mttt -93.9 153.37 18.27 Favored 'General case' 0 N--CA 1.448 -0.566 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 178.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 295' ' ' ASP . . . . . 0.474 ' OD1' HG13 ' A' ' 297' ' ' ILE . 49.2 p30 -84.12 7.66 18.1 Favored 'General case' 0 C--N 1.322 -0.591 0 C-N-CA 119.685 -0.806 . . . . 0.0 110.301 -178.653 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 16.6 t-20 58.57 55.91 4.56 Favored 'General case' 0 CA--C 1.535 0.391 0 C-N-CA 119.818 -0.753 . . . . 0.0 112.488 176.629 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 297' ' ' ILE . . . . . 0.474 HG13 ' OD1' ' A' ' 295' ' ' ASP . 71.2 mt -61.8 133.24 27.62 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.52 0 CA-C-O 122.258 1.028 . . . . 0.0 110.906 -175.967 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 15.6 tttt -82.79 137.83 34.21 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-N 113.328 -1.76 . . . . 0.0 114.209 -178.105 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 58.3 t-80 -119.41 132.42 55.82 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 106.75 -1.574 . . . . 0.0 106.75 176.425 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 4.4 m -124.79 79.01 64.25 Favored Pre-proline 0 N--CA 1.472 0.635 0 N-CA-C 113.865 1.061 . . . . 0.0 113.865 -177.033 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -58.53 -24.59 70.42 Favored 'Trans proline' 0 C--N 1.31 -1.471 0 C-N-CA 120.572 0.848 . . . . 0.0 110.963 178.043 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -111.82 48.21 0.96 Allowed Glycine 0 CA--C 1.525 0.694 0 N-CA-C 109.864 -1.294 . . . . 0.0 109.864 179.507 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -81.19 6.85 62.02 Favored Glycine 0 N--CA 1.466 0.638 0 N-CA-C 112.174 -0.37 . . . . 0.0 112.174 -178.398 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 94.52 2.04 63.72 Favored Glycine 0 C--N 1.321 -0.29 0 N-CA-C 107.962 -2.055 . . . . 0.0 107.962 -178.167 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 75.7 m -82.56 6.99 15.77 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 113.851 -1.174 . . . . 0.0 108.229 178.564 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 306' ' ' VAL . . . . . 0.502 ' O ' ' O ' ' A' ' 307' ' ' GLN . 20.7 m -67.25 -22.65 29.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 114.861 -1.063 . . . . 0.0 110.649 -178.845 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 307' ' ' GLN . . . . . 0.536 ' O ' ' O ' ' A' ' 308' ' ' ILE . 21.7 pt20 46.16 118.03 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 122.039 0.924 . . . . 0.0 113.358 179.697 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 308' ' ' ILE . . . . . 0.638 HG23 ' O ' ' A' ' 308' ' ' ILE . 9.7 tp 25.42 120.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.676 0 CA-C-N 113.42 -1.718 . . . . 0.0 114.374 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -149.58 -42.94 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.366 0 CA-C-N 114.599 -1.182 . . . . 0.0 109.072 177.889 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 310' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -61.67 -31.88 72.02 Favored 'General case' 0 CA--C 1.538 0.519 0 N-CA-C 112.938 0.718 . . . . 0.0 112.938 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 311' ' ' LYS . . . . . 0.454 ' HZ2' ' HB3' ' A' ' 311' ' ' LYS . 8.2 mtpp 65.09 73.76 0.42 Allowed Pre-proline 0 N--CA 1.473 0.711 0 N-CA-C 113.116 0.784 . . . . 0.0 113.116 179.114 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 312' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_endo -53.17 -23.76 23.8 Favored 'Trans proline' 0 N--CA 1.498 1.738 0 C-N-CA 120.41 0.74 . . . . 0.0 111.374 179.691 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 313' ' ' VAL . . . . . 0.73 HG13 ' OG ' ' A' ' 316' ' ' SER . 60.3 t -117.16 132.37 67.14 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.273 0 CA-C-O 121.448 0.642 . . . . 0.0 111.589 178.339 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 58.2 t0 -160.17 -60.94 0.06 Allowed 'General case' 0 N--CA 1.449 -0.515 0 CA-C-N 114.98 -1.009 . . . . 0.0 108.921 178.308 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 315' ' ' LEU . . . . . 0.82 ' O ' HG12 ' A' ' 318' ' ' VAL . 61.1 mt -61.65 -35.33 77.63 Favored 'General case' 0 C--O 1.226 -0.167 0 CA-C-N 114.78 -1.1 . . . . 0.0 111.723 179.295 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 316' ' ' SER . . . . . 0.73 ' OG ' HG13 ' A' ' 313' ' ' VAL . 80.2 p -61.21 -28.34 69.08 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.307 0.575 . . . . 0.0 110.241 -179.154 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 29.3 tttm -58.24 -37.2 74.43 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.456 -0.793 . . . . 0.0 111.432 -179.421 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 318' ' ' VAL . . . . . 0.82 HG12 ' O ' ' A' ' 315' ' ' LEU . 5.5 p -57.67 -34.21 46.96 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.152 0 CA-C-O 120.882 0.373 . . . . 0.0 110.62 -179.87 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 319' ' ' THR . . . . . 0.599 ' OG1' HG13 ' A' ' 318' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--O 1.221 -0.447 0 CA-C-O 118.027 -0.987 . . . . 0.0 110.044 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.576 0 N-CA-C 110.969 -0.852 . . . . 0.0 110.969 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 87.0 p -61.68 -27.22 68.53 Favored 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 120.851 -0.34 . . . . 0.0 110.679 -179.845 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 294' ' ' LYS . . . . . 0.405 ' C ' ' H ' ' A' ' 296' ' ' ASN . 41.2 mtpt -95.7 150.94 19.83 Favored 'General case' 0 N--CA 1.452 -0.328 0 CA-C-O 120.907 0.384 . . . . 0.0 111.081 -179.621 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 295' ' ' ASP . . . . . 0.457 ' C ' ' OD2' ' A' ' 295' ' ' ASP . 48.8 p30 -85.98 10.53 13.84 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 107.43 -1.322 . . . . 0.0 107.43 178.709 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 296' ' ' ASN . . . . . 0.405 ' H ' ' C ' ' A' ' 294' ' ' LYS . 79.9 m-20 30.5 -102.09 0.02 OUTLIER 'General case' 0 CA--C 1.511 -0.549 0 CA-C-N 113.301 -1.772 . . . . 0.0 113.294 -179.218 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 297' ' ' ILE . . . . . . . . . . . . . 70.1 mt -113.5 130.31 67.74 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.454 0 CA-C-O 122.297 1.046 . . . . 0.0 113.486 -177.119 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 41.8 tttp -87.5 132.13 34.12 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 113.107 -1.86 . . . . 0.0 108.613 177.037 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 299' ' ' HIS . . . . . 0.557 ' CE1' ' HD3' ' A' ' 301' ' ' PRO . 71.7 t60 -125.09 113.39 17.67 Favored 'General case' 0 N--CA 1.468 0.461 0 N-CA-C 112.676 0.621 . . . . 0.0 112.676 -179.116 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 3.2 m -134.16 73.34 70.07 Favored Pre-proline 0 N--CA 1.471 0.585 0 CA-C-N 116.196 -0.457 . . . . 0.0 112.191 178.075 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 301' ' ' PRO . . . . . 0.557 ' HD3' ' CE1' ' A' ' 299' ' ' HIS . 5.9 Cg_endo -60.56 -23.82 76.56 Favored 'Trans proline' 0 N--CA 1.5 1.901 0 CA-C-N 119.914 1.005 . . . . 0.0 113.067 179.211 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -134.21 -105.29 0.87 Allowed Glycine 0 CA--C 1.525 0.709 0 N-CA-C 111.149 -0.78 . . . . 0.0 111.149 -178.508 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . 86.4 35.64 10.46 Favored Glycine 0 N--CA 1.462 0.386 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 -178.81 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 96.56 -0.25 61.26 Favored Glycine 0 N--CA 1.446 -0.686 0 N-CA-C 108.991 -1.643 . . . . 0.0 108.991 -179.165 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 73.8 m -82.96 1.65 38.68 Favored 'General case' 0 N--CA 1.446 -0.661 0 CA-C-O 121.382 0.611 . . . . 0.0 109.558 178.675 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 306' ' ' VAL . . . . . 0.427 ' O ' ' HB3' ' A' ' 307' ' ' GLN . 73.6 t -61.64 -38.17 79.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 115.06 -0.973 . . . . 0.0 111.253 179.835 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 307' ' ' GLN . . . . . 0.628 ' O ' ' O ' ' A' ' 308' ' ' ILE . 50.3 tt0 79.87 103.03 0.07 Allowed 'General case' 0 CA--C 1.506 -0.729 0 O-C-N 123.6 0.562 . . . . 0.0 112.039 -178.663 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 308' ' ' ILE . . . . . 0.703 HG21 ' HD3' ' A' ' 312' ' ' PRO . 81.7 mt 51.24 149.68 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.443 -0.778 0 CA-C-O 122.256 1.027 . . . . 0.0 109.871 178.506 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 309' ' ' VAL . . . . . 0.673 HG13 ' CD1' ' A' ' 310' ' ' TYR . 6.3 p -56.34 -33.91 39.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 CA-C-N 114.886 -1.052 . . . . 0.0 111.777 -178.576 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 310' ' ' TYR . . . . . 0.808 ' CD1' ' N ' ' A' ' 311' ' ' LYS . 0.0 OUTLIER -161.55 -97.09 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.39 0 CA-C-O 123.896 1.808 . . . . 0.0 112.638 -178.37 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 311' ' ' LYS . . . . . 0.808 ' N ' ' CD1' ' A' ' 310' ' ' TYR . 32.6 mtmm -123.62 103.88 34.32 Favored Pre-proline 0 C--N 1.275 -2.667 0 CA-C-N 109.845 -3.343 . . . . 0.0 108.228 179.181 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 312' ' ' PRO . . . . . 0.703 ' HD3' HG21 ' A' ' 308' ' ' ILE . 9.7 Cg_endo -49.1 151.95 5.51 Favored 'Trans proline' 0 C--N 1.299 -2.038 0 N-CA-C 106.626 -2.106 . . . . 0.0 106.626 179.081 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 313' ' ' VAL . . . . . 0.724 HG12 ' H ' ' A' ' 315' ' ' LEU . 44.3 t -59.53 128.5 20.51 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.585 0 C-N-CA 117.671 -1.611 . . . . 0.0 111.948 -173.434 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 314' ' ' ASP . . . . . 0.497 ' O ' ' HG2' ' A' ' 317' ' ' LYS . 49.2 p30 -97.33 -0.63 46.15 Favored 'General case' 0 N--CA 1.438 -1.058 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 175.897 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 315' ' ' LEU . . . . . 0.724 ' H ' HG12 ' A' ' 313' ' ' VAL . 64.8 mt -64.85 -31.44 72.68 Favored 'General case' 0 N--CA 1.469 0.504 0 O-C-N 123.774 0.671 . . . . 0.0 110.735 178.319 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 89.9 p -58.19 -25.56 61.73 Favored 'General case' 0 N--CA 1.448 -0.545 0 CA-C-N 114.962 -1.017 . . . . 0.0 110.276 -177.453 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 317' ' ' LYS . . . . . 0.497 ' HG2' ' O ' ' A' ' 314' ' ' ASP . 52.2 pttt -59.6 -33.57 71.64 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.349 -0.612 . . . . 0.0 109.349 -179.319 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 318' ' ' VAL . . . . . 0.422 ' N ' ' CG ' ' A' ' 317' ' ' LYS . 74.7 t -60.37 -39.81 82.12 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.132 0 CA-C-N 115.099 -0.955 . . . . 0.0 111.501 -178.807 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 7.1 m . . . . . 0 C--O 1.22 -0.482 0 CA-C-O 117.935 -1.031 . . . . 0.0 110.529 -179.76 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.626 0 N-CA-C 111.038 -0.825 . . . . 0.0 111.038 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 45.3 m -64.02 153.69 36.57 Favored 'General case' 0 C--N 1.333 -0.145 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.857 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 294' ' ' LYS . . . . . 0.458 ' C ' ' H ' ' A' ' 296' ' ' ASN . 88.2 mttt -103.75 145.81 29.54 Favored 'General case' 0 N--CA 1.449 -0.477 0 CA-C-O 121.442 0.639 . . . . 0.0 112.014 -179.156 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 295' ' ' ASP . . . . . 0.47 ' C ' ' OD2' ' A' ' 295' ' ' ASP . 49.2 p30 -89.52 12.76 15.66 Favored 'General case' 0 CA--C 1.49 -1.332 0 N-CA-C 106.35 -1.722 . . . . 0.0 106.35 176.68 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 296' ' ' ASN . . . . . 0.609 ' CG ' ' H ' ' A' ' 297' ' ' ILE . 49.4 t30 36.48 -147.95 0.01 OUTLIER 'General case' 0 N--CA 1.426 -1.626 0 CA-C-N 112.362 -2.199 . . . . 0.0 110.697 -178.717 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 297' ' ' ILE . . . . . 0.609 ' H ' ' CG ' ' A' ' 296' ' ' ASN . 8.8 tp -123.2 132.67 70.98 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 CA-C-O 122.642 1.21 . . . . 0.0 112.809 -177.446 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 75.8 tttt -94.48 130.16 40.97 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-N 112.323 -2.217 . . . . 0.0 109.702 177.014 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 39.0 t-80 -132.18 136.21 46.89 Favored 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 119.701 -0.8 . . . . 0.0 111.784 179.613 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -125.76 74.77 70.57 Favored Pre-proline 0 N--CA 1.477 0.893 0 CA-C-O 120.4 0.143 . . . . 0.0 111.368 178.987 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -59.94 -21.28 63.95 Favored 'Trans proline' 0 N--CA 1.494 1.523 0 C-N-CA 122.529 2.153 . . . . 0.0 112.089 178.734 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . 114.03 130.63 5.1 Favored Glycine 0 CA--C 1.52 0.355 0 N-CA-C 107.418 -2.273 . . . . 0.0 107.418 -177.279 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -96.44 -78.77 1.43 Allowed Glycine 0 CA--C 1.523 0.564 0 C-N-CA 119.457 -1.354 . . . . 0.0 113.219 -177.853 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . -86.16 -35.29 11.14 Favored Glycine 0 CA--C 1.522 0.486 0 C-N-CA 121.201 -0.524 . . . . 0.0 112.589 -179.778 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 305' ' ' SER . . . . . 0.504 ' O ' ' O ' ' A' ' 306' ' ' VAL . 93.9 p -61.63 -30.02 70.43 Favored 'General case' 0 CA--C 1.513 -0.476 0 N-CA-C 114.263 1.209 . . . . 0.0 114.263 -176.756 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 306' ' ' VAL . . . . . 0.504 ' O ' ' O ' ' A' ' 305' ' ' SER . 16.8 t -27.25 -99.88 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 O-C-N 123.57 0.544 . . . . 0.0 112.395 -177.615 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 307' ' ' GLN . . . . . 0.425 ' HG2' ' N ' ' A' ' 308' ' ' ILE . 51.6 tt0 -143.14 158.07 43.95 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.635 179.857 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 308' ' ' ILE . . . . . 0.995 HD11 ' CZ ' ' A' ' 310' ' ' TYR . 5.0 tp -120.96 127.86 76.0 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.673 0 C-N-CA 120.05 -0.66 . . . . 0.0 109.635 177.635 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 73.7 t -67.98 -42.91 85.83 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.565 0 N-CA-C 114.975 1.472 . . . . 0.0 114.975 -179.57 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 310' ' ' TYR . . . . . 0.995 ' CZ ' HD11 ' A' ' 308' ' ' ILE 0.312 2.7 p90 -66.27 -28.14 68.48 Favored 'General case' 0 N--CA 1.469 0.499 0 N-CA-C 116.931 2.197 . . . . 0.0 116.931 -177.019 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 311' ' ' LYS . . . . . 0.536 ' O ' ' O ' ' A' ' 312' ' ' PRO . 10.6 mtpt 56.17 63.23 6.06 Favored Pre-proline 0 C--N 1.307 -1.248 0 C-N-CA 118.74 -1.184 . . . . 0.0 108.534 -178.959 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 312' ' ' PRO . . . . . 0.573 ' O ' ' N ' ' A' ' 314' ' ' ASP . 32.6 Cg_exo 23.62 112.06 0.0 OUTLIER 'Trans proline' 0 C--N 1.316 -1.157 0 C-N-CA 122.752 2.301 . . . . 0.0 115.214 -179.339 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 313' ' ' VAL . . . . . 0.469 ' C ' ' O ' ' A' ' 312' ' ' PRO . 2.1 m 8.15 55.77 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.232 0.141 0 CA-C-N 113.519 -1.673 . . . . 0.0 113.27 179.185 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 314' ' ' ASP . . . . . 0.573 ' N ' ' O ' ' A' ' 312' ' ' PRO . 55.2 t0 -55.37 -36.11 66.0 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 109.962 -0.385 . . . . 0.0 109.962 178.757 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 315' ' ' LEU . . . . . 0.714 ' H ' HD12 ' A' ' 315' ' ' LEU . 6.5 mp -59.27 -35.69 74.19 Favored 'General case' 0 N--CA 1.464 0.254 0 C-N-CA 120.61 -0.436 . . . . 0.0 111.577 -179.344 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 85.4 p -61.71 -27.34 68.64 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.352 0.596 . . . . 0.0 110.038 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 317' ' ' LYS . . . . . 0.42 ' HB3' ' O ' ' A' ' 314' ' ' ASP . 38.9 tttp -57.37 -39.1 75.31 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.265 -0.879 . . . . 0.0 111.112 -178.656 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 70.6 t -63.21 -39.26 84.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 121.128 0.489 . . . . 0.0 110.323 178.747 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 1.9 m . . . . . 0 C--O 1.22 -0.493 0 CA-C-O 118.068 -0.968 . . . . 0.0 110.282 -178.836 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.644 0 N-CA-C 110.929 -0.869 . . . . 0.0 110.929 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 30.8 t -118.98 142.42 47.81 Favored 'General case' 0 N--CA 1.463 0.198 0 CA-C-O 121.098 0.475 . . . . 0.0 111.242 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 25.5 mttm -99.32 152.18 20.22 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.749 179.186 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 295' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -55.29 -37.14 66.94 Favored 'General case' 0 CA--C 1.497 -1.086 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.424 -179.547 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 296' ' ' ASN . . . . . 0.656 ' CG ' ' H ' ' A' ' 297' ' ' ILE . 10.7 p30 175.5 -103.07 0.0 OUTLIER 'General case' 0 C--N 1.308 -1.219 0 CA-C-O 121.97 0.891 . . . . 0.0 111.0 179.907 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 297' ' ' ILE . . . . . 0.807 ' O ' HG23 ' A' ' 297' ' ' ILE . 19.2 tt 137.32 86.92 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 CA-C-N 111.977 -2.374 . . . . 0.0 106.722 -178.124 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 36.0 mttt -83.25 137.23 34.1 Favored 'General case' 0 C--N 1.317 -0.828 0 C-N-CA 119.39 -0.924 . . . . 0.0 112.374 -177.247 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 56.8 t-80 -130.76 117.81 19.94 Favored 'General case' 0 N--CA 1.441 -0.899 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 175.686 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -125.63 77.32 69.55 Favored Pre-proline 0 C--N 1.324 -0.526 0 C-N-CA 120.704 -0.398 . . . . 0.0 111.36 -179.625 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 85.5 Cg_endo -57.79 -23.66 59.75 Favored 'Trans proline' 0 C--N 1.313 -1.308 0 N-CA-C 109.99 -0.812 . . . . 0.0 109.99 179.224 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -173.43 128.15 1.46 Allowed Glycine 0 CA--C 1.523 0.563 0 CA-C-N 114.81 -1.086 . . . . 0.0 110.84 179.193 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -82.05 4.84 74.02 Favored Glycine 0 N--CA 1.462 0.397 0 N-CA-C 108.701 -1.76 . . . . 0.0 108.701 178.414 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 98.4 -8.08 62.14 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 109.845 -1.302 . . . . 0.0 109.845 -179.259 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 305' ' ' SER . . . . . 0.465 ' O ' ' C ' ' A' ' 306' ' ' VAL . 20.3 m -59.9 -34.93 73.83 Favored 'General case' 0 CA--C 1.521 -0.172 0 CA-C-O 121.953 0.882 . . . . 0.0 109.463 177.557 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 306' ' ' VAL . . . . . 0.465 ' C ' ' O ' ' A' ' 305' ' ' SER . 7.7 t -13.61 -104.0 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 CA-C-N 113.475 -1.693 . . . . 0.0 113.697 -177.902 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 307' ' ' GLN . . . . . 0.412 ' H ' ' HB ' ' A' ' 306' ' ' VAL . 21.7 pt20 -145.16 170.71 15.7 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.177 -178.1 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 308' ' ' ILE . . . . . 0.921 HG23 ' CD2' ' A' ' 310' ' ' TYR . 71.8 mt -97.28 116.96 41.02 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.095 0 N-CA-C 115.677 1.732 . . . . 0.0 115.677 -178.529 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 5.9 p -69.86 -32.29 51.3 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.462 0 CA-C-N 113.59 -1.641 . . . . 0.0 108.731 172.751 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 310' ' ' TYR . . . . . 0.921 ' CD2' HG23 ' A' ' 308' ' ' ILE 0.412 51.6 p90 -62.44 -10.71 12.46 Favored 'General case' 0 C--N 1.346 0.435 0 N-CA-C 117.817 2.525 . . . . 0.0 117.817 -177.203 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 311' ' ' LYS . . . . . 0.472 ' O ' ' C ' ' A' ' 312' ' ' PRO . 9.3 mmtt 63.68 67.53 0.98 Allowed Pre-proline 0 N--CA 1.475 0.813 0 CA-C-N 118.853 0.751 . . . . 0.0 112.406 177.235 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 312' ' ' PRO . . . . . 0.602 ' HD3' HG21 ' A' ' 308' ' ' ILE . 61.2 Cg_exo -0.99 -114.3 0.0 OUTLIER 'Trans proline' 0 N--CA 1.489 1.244 0 C-N-CA 123.093 2.529 . . . . 0.0 116.361 179.598 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 16.1 m -111.31 21.03 5.97 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.478 0 N-CA-C 113.071 0.767 . . . . 0.0 113.071 -176.761 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 58.2 t0 -51.33 -36.86 44.75 Favored 'General case' 0 C--N 1.323 -0.568 0 C-N-CA 120.271 -0.572 . . . . 0.0 111.176 -178.105 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 315' ' ' LEU . . . . . 0.635 ' N ' ' CD2' ' A' ' 315' ' ' LEU . 0.2 OUTLIER -60.05 -36.93 78.38 Favored 'General case' 0 C--N 1.33 -0.241 0 C-N-CA 118.983 -1.087 . . . . 0.0 109.496 178.458 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 21.5 t -59.49 -31.36 69.29 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.886 178.36 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 7.7 ttpp -56.17 -35.34 67.1 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.087 -0.961 . . . . 0.0 111.416 -176.879 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 43.0 t -112.27 134.74 53.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 121.017 0.436 . . . . 0.0 110.491 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 1.1 m . . . . . 0 C--O 1.22 -0.457 0 CA-C-O 117.916 -1.04 . . . . 0.0 110.695 -179.671 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.666 0 N-CA-C 110.788 -0.925 . . . . 0.0 110.788 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 74.7 m -82.51 3.37 28.7 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 120.979 -0.288 . . . . 0.0 110.69 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 64.8 mttp -91.65 144.42 25.55 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 179.443 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 295' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -57.93 -39.59 78.37 Favored 'General case' 0 CA--C 1.507 -0.691 0 C-N-CA 120.069 -0.652 . . . . 0.0 111.688 -178.857 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 296' ' ' ASN . . . . . 0.445 ' HB3' ' H ' ' A' ' 297' ' ' ILE . 46.7 t-20 177.92 -94.41 0.0 OUTLIER 'General case' 0 C--N 1.314 -0.978 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 179.1 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 297' ' ' ILE . . . . . 0.445 ' H ' ' HB3' ' A' ' 296' ' ' ASN . 18.1 tt 174.62 3.82 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 113.715 -1.584 . . . . 0.0 109.808 179.431 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 298' ' ' LYS . . . . . 0.428 ' H ' ' H ' ' A' ' 297' ' ' ILE . 29.1 mttt 64.69 47.59 2.76 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-O 120.856 0.36 . . . . 0.0 110.705 -179.693 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 299' ' ' HIS . . . . . 0.401 ' ND1' ' O ' ' A' ' 299' ' ' HIS . 58.4 t-80 -74.07 65.43 1.12 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.139 -179.389 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 4.8 t -124.87 75.13 65.89 Favored Pre-proline 0 N--CA 1.465 0.319 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.323 178.974 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -57.81 -24.74 65.47 Favored 'Trans proline' 0 C--N 1.311 -1.427 0 C-N-CA 121.29 1.327 . . . . 0.0 111.431 -179.385 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -163.05 121.8 1.05 Allowed Glycine 0 CA--C 1.524 0.64 0 C-N-CA 120.624 -0.798 . . . . 0.0 111.656 179.76 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -82.32 1.21 87.88 Favored Glycine 0 CA--C 1.527 0.836 0 N-CA-C 110.264 -1.134 . . . . 0.0 110.264 178.534 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 96.79 -7.62 65.33 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.061 -1.215 . . . . 0.0 110.061 -179.788 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 305' ' ' SER . . . . . 0.455 ' O ' ' C ' ' A' ' 306' ' ' VAL . 25.9 t -60.04 -32.62 71.08 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.537 0.684 . . . . 0.0 109.232 177.07 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 306' ' ' VAL . . . . . 0.458 HG23 ' H ' ' A' ' 307' ' ' GLN . 0.0 OUTLIER -20.45 -90.5 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 CA-C-N 113.999 -1.455 . . . . 0.0 112.962 -177.44 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 307' ' ' GLN . . . . . 0.458 ' H ' HG23 ' A' ' 306' ' ' VAL . 23.4 pt20 -143.22 167.95 20.92 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.341 -0.845 . . . . 0.0 111.067 -177.329 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 308' ' ' ILE . . . . . 0.543 HG23 ' CE2' ' A' ' 310' ' ' TYR . 67.1 mt -107.4 120.89 59.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-O 121.751 0.786 . . . . 0.0 111.075 -179.699 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 309' ' ' VAL . . . . . 0.467 ' CG1' ' N ' ' A' ' 310' ' ' TYR . 8.0 p -66.04 -36.38 77.33 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.847 0 CA-C-O 122.206 1.003 . . . . 0.0 108.914 174.876 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 310' ' ' TYR . . . . . 0.543 ' CE2' HG23 ' A' ' 308' ' ' ILE 0.448 51.1 p90 -64.53 -32.12 73.62 Favored 'General case' 0 N--CA 1.451 -0.407 0 N-CA-C 118.194 2.665 . . . . 0.0 118.194 -177.996 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 311' ' ' LYS . . . . . 0.49 ' C ' ' O ' ' A' ' 310' ' ' TYR . 49.6 mtpt 47.98 72.23 1.33 Allowed Pre-proline 0 C--N 1.317 -0.805 0 C-N-CA 116.942 -1.903 . . . . 0.0 108.74 176.728 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 312' ' ' PRO . . . . . . . . . . . . . 7.0 Cg_endo -42.88 -37.54 6.14 Favored 'Trans proline' 0 N--CA 1.505 2.148 0 N-CA-C 114.364 0.871 . . . . 0.0 114.364 -173.754 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 71.6 t -62.95 -38.23 81.39 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.059 0 N-CA-C 116.417 2.006 . . . . 0.0 116.417 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 60.3 t0 -54.33 -43.84 71.57 Favored 'General case' 0 N--CA 1.467 0.416 0 O-C-N 120.589 -1.32 . . . . 0.0 114.415 -173.899 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 315' ' ' LEU . . . . . 0.651 ' N ' ' CD2' ' A' ' 315' ' ' LEU . 0.3 OUTLIER -66.8 -36.43 82.38 Favored 'General case' 0 C--N 1.319 -0.751 0 C-N-CA 118.308 -1.357 . . . . 0.0 109.068 176.628 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 32.8 m -59.7 -34.88 73.47 Favored 'General case' 0 N--CA 1.45 -0.47 0 CA-C-N 115.091 -0.959 . . . . 0.0 110.719 178.262 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 30.1 ttpt -80.12 125.63 30.06 Favored 'General case' 0 N--CA 1.45 -0.429 0 CA-C-O 121.697 0.761 . . . . 0.0 111.701 -177.25 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 318' ' ' VAL . . . . . 0.445 ' O ' ' OG1' ' A' ' 319' ' ' THR . 13.2 p -134.39 142.45 40.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 114.814 -1.084 . . . . 0.0 109.262 178.468 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 319' ' ' THR . . . . . 0.445 ' OG1' ' O ' ' A' ' 318' ' ' VAL . 0.7 OUTLIER . . . . . 0 C--O 1.219 -0.513 0 CA-C-O 117.962 -1.018 . . . . 0.0 111.227 179.314 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.515 0 N-CA-C 110.931 -0.868 . . . . 0.0 110.931 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 29.9 t -116.65 138.65 51.28 Favored 'General case' 0 C--O 1.232 0.159 0 CA-C-O 121.335 0.588 . . . . 0.0 110.228 179.542 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 1.9 mtpt -133.45 -166.65 1.8 Allowed 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.117 -0.947 . . . . 0.0 111.427 -179.313 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 295' ' ' ASP . . . . . 0.48 ' C ' ' OD1' ' A' ' 295' ' ' ASP . 48.7 p30 -82.92 11.04 6.6 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.19 -0.913 . . . . 0.0 109.203 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 17.6 m120 46.17 -138.34 0.58 Allowed 'General case' 0 CA--C 1.497 -1.074 0 CA-C-N 114.407 -1.27 . . . . 0.0 111.613 179.818 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 297' ' ' ILE . . . . . 0.512 HD11 ' CE1' ' A' ' 299' ' ' HIS . 13.9 tt -121.23 126.79 75.48 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-O 122.357 1.075 . . . . 0.0 111.404 -177.979 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 6.1 mtpm? -61.09 -36.52 79.89 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-N 112.98 -1.918 . . . . 0.0 112.568 179.13 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 299' ' ' HIS . . . . . 0.512 ' CE1' HD11 ' A' ' 297' ' ' ILE . 0.1 OUTLIER 38.21 60.89 1.19 Allowed 'General case' 0 CA--C 1.537 0.473 0 CA-C-O 121.175 0.512 . . . . 0.0 112.266 -179.657 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 300' ' ' VAL . . . . . 0.415 ' C ' ' N ' ' A' ' 302' ' ' GLY . 3.1 m -123.47 72.65 49.81 Favored Pre-proline 0 N--CA 1.464 0.274 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.009 178.658 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 301' ' ' PRO . . . . . 0.401 ' CD ' ' H ' ' A' ' 302' ' ' GLY . 44.5 Cg_endo -58.34 -17.8 35.1 Favored 'Trans proline' 0 C--N 1.317 -1.127 0 N-CA-C 107.96 -1.592 . . . . 0.0 107.96 177.72 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 302' ' ' GLY . . . . . 0.415 ' N ' ' C ' ' A' ' 300' ' ' VAL . . . 116.61 156.13 10.58 Favored Glycine 0 N--CA 1.443 -0.846 0 CA-C-N 112.801 -2.0 . . . . 0.0 109.788 -179.014 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 303' ' ' GLY . . . . . 0.661 ' O ' ' N ' ' A' ' 305' ' ' SER . . . -163.69 -178.96 37.74 Favored Glycine 0 N--CA 1.446 -0.688 0 N-CA-C 108.528 -1.829 . . . . 0.0 108.528 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 59.32 -70.43 0.01 OUTLIER Glycine 0 CA--C 1.529 0.926 0 N-CA-C 109.815 -1.314 . . . . 0.0 109.815 -179.11 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 305' ' ' SER . . . . . 0.661 ' N ' ' O ' ' A' ' 303' ' ' GLY . 23.0 t -58.0 -33.97 69.5 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 121.081 0.467 . . . . 0.0 111.578 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 306' ' ' VAL . . . . . 0.627 HG23 ' H ' ' A' ' 307' ' ' GLN . 2.3 m -36.84 -100.91 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 N-CA-C 114.251 1.204 . . . . 0.0 114.251 -178.256 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 307' ' ' GLN . . . . . 0.627 ' H ' HG23 ' A' ' 306' ' ' VAL . 54.8 mt-30 -113.35 160.3 18.52 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 114.429 -1.26 . . . . 0.0 111.776 -176.376 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 308' ' ' ILE . . . . . 0.875 HG22 ' H ' ' A' ' 311' ' ' LYS . 34.9 mm -103.12 119.11 51.1 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-O 122.006 0.907 . . . . 0.0 112.635 -179.506 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 77.4 t -67.81 -40.27 83.38 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 CA-C-N 113.51 -1.677 . . . . 0.0 107.481 174.549 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 310' ' ' TYR . . . . . 0.641 ' CD2' HG23 ' A' ' 308' ' ' ILE 0.361 51.2 p90 -62.7 -31.05 71.89 Favored 'General case' 0 N--CA 1.446 -0.634 0 N-CA-C 117.467 2.395 . . . . 0.0 117.467 -178.676 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 311' ' ' LYS . . . . . 0.875 ' H ' HG22 ' A' ' 308' ' ' ILE . 19.4 mtpp 52.89 65.57 5.8 Favored Pre-proline 0 C--N 1.319 -0.731 0 CA-C-N 119.815 1.189 . . . . 0.0 110.223 178.773 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 312' ' ' PRO . . . . . 0.45 ' C ' ' O ' ' A' ' 311' ' ' LYS . 78.4 Cg_exo 7.67 -129.04 0.0 OUTLIER 'Trans proline' 0 C--N 1.316 -1.171 0 C-N-CA 123.264 2.643 . . . . 0.0 116.937 -179.216 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 313' ' ' VAL . . . . . 0.47 ' O ' ' OG ' ' A' ' 316' ' ' SER . 17.6 m -112.89 28.77 2.28 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 CA-C-N 114.775 -1.102 . . . . 0.0 113.542 -175.931 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 314' ' ' ASP . . . . . 0.4 ' O ' ' CB ' ' A' ' 317' ' ' LYS . 92.1 m-20 -51.51 -36.46 44.79 Favored 'General case' 0 C--N 1.319 -0.751 0 C-N-CA 119.66 -0.816 . . . . 0.0 111.17 -177.127 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 315' ' ' LEU . . . . . 0.633 ' CD2' ' N ' ' A' ' 315' ' ' LEU . 0.3 OUTLIER -59.81 -35.34 74.5 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 119.819 -0.752 . . . . 0.0 110.414 178.587 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 316' ' ' SER . . . . . 0.47 ' OG ' ' O ' ' A' ' 313' ' ' VAL . 82.6 p -62.44 -21.12 65.17 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-O 121.431 0.634 . . . . 0.0 110.364 179.373 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 317' ' ' LYS . . . . . 0.4 ' CB ' ' O ' ' A' ' 314' ' ' ASP . 82.0 tttt -55.29 -34.53 64.18 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.071 -0.968 . . . . 0.0 111.779 -177.399 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 13.1 p -129.08 142.55 43.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 C-N-CA 120.471 -0.492 . . . . 0.0 110.789 179.657 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.221 -0.439 0 CA-C-O 118.008 -0.996 . . . . 0.0 110.555 -179.644 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.409 0 N-CA-C 110.793 -0.923 . . . . 0.0 110.793 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 97.6 p -120.68 153.07 37.41 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.117 0.484 . . . . 0.0 110.687 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -133.59 170.67 15.19 Favored 'General case' 0 CA--C 1.506 -0.728 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.673 -179.499 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 295' ' ' ASP . . . . . . . . . . . . . 86.0 m-20 -63.12 143.71 57.55 Favored 'General case' 0 N--CA 1.438 -1.063 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 -179.769 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 22.3 t-20 -64.77 130.5 43.74 Favored 'General case' 0 C--N 1.309 -1.174 0 CA-C-N 115.246 -0.888 . . . . 0.0 111.669 -177.595 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 297' ' ' ILE . . . . . . . . . . . . . 71.4 mt -115.18 132.12 65.41 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.09 0 CA-C-N 114.856 -1.065 . . . . 0.0 110.545 -179.762 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 73.1 tttt -105.66 135.62 46.74 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.85 179.184 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 99.3 m-70 -118.94 140.48 49.92 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.089 178.451 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 3.6 m -123.98 78.28 58.44 Favored Pre-proline 0 C--N 1.33 -0.255 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.358 -179.156 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -56.53 145.82 78.3 Favored 'Trans proline' 0 C--N 1.312 -1.371 0 N-CA-C 109.244 -1.099 . . . . 0.0 109.244 178.807 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -49.36 107.52 0.32 Allowed Glycine 0 CA--C 1.52 0.375 0 C-N-CA 118.92 -1.61 . . . . 0.0 109.769 -178.864 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -77.92 -2.13 81.01 Favored Glycine 0 C--N 1.33 0.23 0 N-CA-C 109.798 -1.321 . . . . 0.0 109.798 179.59 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 95.33 -1.93 64.94 Favored Glycine 0 N--CA 1.45 -0.402 0 N-CA-C 108.958 -1.657 . . . . 0.0 108.958 -178.883 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 73.9 m -83.24 1.83 38.85 Favored 'General case' 0 N--CA 1.453 -0.32 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 178.505 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 306' ' ' VAL . . . . . . . . . . . . . 71.6 t -61.08 -39.93 83.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.062 -0.972 . . . . 0.0 110.214 -179.467 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 307' ' ' GLN . . . . . 0.855 ' HG3' ' H ' ' A' ' 308' ' ' ILE . 21.2 pt20 -159.63 -88.24 0.03 OUTLIER 'General case' 0 CA--C 1.542 0.637 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.824 179.065 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 308' ' ' ILE . . . . . 0.855 ' H ' ' HG3' ' A' ' 307' ' ' GLN . 32.0 pt -125.22 160.94 30.24 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 CA-C-N 118.985 0.811 . . . . 0.0 111.305 179.525 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 309' ' ' VAL . . . . . 0.926 HG13 ' H ' ' A' ' 310' ' ' TYR . 3.9 p -136.65 -65.26 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 178.199 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 310' ' ' TYR . . . . . 0.926 ' H ' HG13 ' A' ' 309' ' ' VAL . 0.8 OUTLIER -66.31 -19.47 65.82 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.288 -0.869 . . . . 0.0 112.484 178.461 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 311' ' ' LYS . . . . . 0.534 ' O ' ' C ' ' A' ' 312' ' ' PRO . 43.9 tttt 67.55 65.21 0.66 Allowed Pre-proline 0 C--N 1.326 -0.439 0 C-N-CA 120.791 -0.364 . . . . 0.0 110.674 -179.358 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 312' ' ' PRO . . . . . 0.568 ' O ' ' C ' ' A' ' 313' ' ' VAL . 70.6 Cg_exo 3.9 75.75 0.0 OUTLIER 'Trans proline' 0 N--CA 1.488 1.152 0 C-N-CA 122.924 2.416 . . . . 0.0 114.016 179.812 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 313' ' ' VAL . . . . . 0.601 HG13 ' O ' ' A' ' 313' ' ' VAL . 13.7 p 1.33 71.18 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 O-C-N 124.085 0.866 . . . . 0.0 111.434 179.643 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 314' ' ' ASP . . . . . 0.506 ' N ' ' O ' ' A' ' 312' ' ' PRO . 21.7 t70 -55.18 -36.56 66.02 Favored 'General case' 0 CA--C 1.536 0.416 0 CA-C-N 114.464 -1.244 . . . . 0.0 112.992 -178.586 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 315' ' ' LEU . . . . . 0.635 ' N ' ' CD2' ' A' ' 315' ' ' LEU . 0.2 OUTLIER -58.88 -35.25 72.68 Favored 'General case' 0 N--CA 1.465 0.291 0 C-N-CA 120.585 -0.446 . . . . 0.0 111.258 -178.65 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 316' ' ' SER . . . . . 0.435 ' OG ' HG13 ' A' ' 313' ' ' VAL . 84.1 p -61.83 -26.39 68.09 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.002 0.43 . . . . 0.0 110.91 179.873 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 32.0 mmtm -58.07 -36.18 72.44 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.892 -0.595 . . . . 0.0 111.784 -177.397 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 13.3 p -132.47 143.11 40.81 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.26 0 CA-C-O 120.607 0.241 . . . . 0.0 111.077 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 27.0 p . . . . . 0 C--O 1.221 -0.446 0 CA-C-O 117.83 -1.081 . . . . 0.0 110.422 179.443 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.609 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 74.3 m -82.3 2.3 32.74 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.858 0.361 . . . . 0.0 110.457 -179.94 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 76.9 mttt -96.56 151.52 19.51 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.439 179.699 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 295' ' ' ASP . . . . . 0.469 ' C ' ' OD1' ' A' ' 295' ' ' ASP . 48.9 p30 -86.7 9.86 17.49 Favored 'General case' 0 CA--C 1.503 -0.852 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 178.844 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 296' ' ' ASN . . . . . 0.565 ' CG ' ' H ' ' A' ' 297' ' ' ILE . 37.3 t-20 58.78 -143.17 0.62 Allowed 'General case' 0 CA--C 1.49 -1.341 0 CA-C-N 114.369 -1.287 . . . . 0.0 110.598 179.579 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 297' ' ' ILE . . . . . 0.565 ' H ' ' CG ' ' A' ' 296' ' ' ASN . 14.4 tt -121.4 131.19 73.65 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 CA-C-O 122.482 1.134 . . . . 0.0 112.416 -177.899 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 83.6 tttt -93.88 131.17 39.56 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-N 112.66 -2.064 . . . . 0.0 109.447 177.475 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 49.7 t-80 -128.26 137.05 51.82 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 120.114 -0.635 . . . . 0.0 110.86 179.792 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -124.21 76.55 60.43 Favored Pre-proline 0 N--CA 1.469 0.505 0 CA-C-N 116.804 -0.18 . . . . 0.0 111.065 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 83.6 Cg_endo -58.97 -25.49 77.75 Favored 'Trans proline' 0 N--CA 1.489 1.254 0 C-N-CA 121.126 1.217 . . . . 0.0 111.009 179.193 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . 174.77 133.61 1.75 Allowed Glycine 0 CA--C 1.532 1.125 0 CA-C-N 115.309 -0.86 . . . . 0.0 111.444 179.785 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -117.37 48.16 0.97 Allowed Glycine 0 CA--C 1.533 1.207 0 N-CA-C 110.534 -1.026 . . . . 0.0 110.534 179.565 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 99.1 -7.72 60.53 Favored Glycine 0 N--CA 1.466 0.687 0 N-CA-C 109.01 -1.636 . . . . 0.0 109.01 -178.143 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 27.9 t -83.68 -0.55 51.2 Favored 'General case' 0 CA--C 1.516 -0.327 0 N-CA-C 107.03 -1.47 . . . . 0.0 107.03 175.816 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 306' ' ' VAL . . . . . 0.623 ' O ' ' CB ' ' A' ' 307' ' ' GLN . 99.5 t -58.77 -41.56 82.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 113.569 -1.651 . . . . 0.0 112.193 -175.683 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 307' ' ' GLN . . . . . 0.623 ' CB ' ' O ' ' A' ' 306' ' ' VAL . 63.0 tt0 122.86 172.36 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.792 0 O-C-N 124.631 1.207 . . . . 0.0 108.023 -179.298 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 308' ' ' ILE . . . . . 0.494 ' N ' ' HG2' ' A' ' 307' ' ' GLN . 29.4 pt -121.25 155.24 25.11 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 N-CA-C 110.11 -0.329 . . . . 0.0 110.11 179.384 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 309' ' ' VAL . . . . . 0.59 ' O ' HG12 ' A' ' 309' ' ' VAL . 58.9 t -133.74 -5.62 1.34 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.292 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.611 179.569 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 310' ' ' TYR . . . . . 0.511 ' CD1' ' HD3' ' A' ' 312' ' ' PRO . 2.0 p90 -65.87 -18.29 65.24 Favored 'General case' 0 CA--C 1.517 -0.298 0 N-CA-C 112.508 0.559 . . . . 0.0 112.508 -176.481 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 311' ' ' LYS . . . . . 0.49 ' O ' ' C ' ' A' ' 312' ' ' PRO . 1.9 mtmm 59.38 64.91 2.84 Favored Pre-proline 0 C--N 1.325 -0.461 0 N-CA-C 107.252 -1.388 . . . . 0.0 107.252 -179.411 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 312' ' ' PRO . . . . . 0.511 ' HD3' ' CD1' ' A' ' 310' ' ' TYR . 1.1 Cg_exo -14.06 -62.1 0.01 OUTLIER 'Trans proline' 0 C--N 1.305 -1.731 0 C-N-CA 123.065 2.51 . . . . 0.0 114.536 -178.517 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 313' ' ' VAL . . . . . 0.768 HG22 ' OG ' ' A' ' 316' ' ' SER . 2.6 p -176.18 27.07 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 C-N-CA 120.397 -0.521 . . . . 0.0 111.314 179.621 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 92.9 m-20 -57.85 -37.66 74.29 Favored 'General case' 0 C--N 1.32 -0.705 0 N-CA-C 112.135 0.421 . . . . 0.0 112.135 -179.027 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 315' ' ' LEU . . . . . 0.741 ' O ' HG22 ' A' ' 318' ' ' VAL . 0.1 OUTLIER -56.95 -39.49 74.66 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 120.203 -0.599 . . . . 0.0 109.806 -178.671 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 316' ' ' SER . . . . . 0.768 ' OG ' HG22 ' A' ' 313' ' ' VAL . 86.6 p -63.34 -27.2 69.15 Favored 'General case' 0 N--CA 1.471 0.601 0 O-C-N 122.057 -0.402 . . . . 0.0 111.976 178.595 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 57.2 tttp -58.2 -36.17 72.7 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.156 -0.475 . . . . 0.0 112.114 -177.858 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 318' ' ' VAL . . . . . 0.741 HG22 ' O ' ' A' ' 315' ' ' LEU . 27.9 m -76.0 136.75 24.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-O 121.213 0.53 . . . . 0.0 111.097 -179.21 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 43.6 m . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 118.044 -0.979 . . . . 0.0 110.31 -179.952 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.761 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 46.7 m -63.83 154.32 33.96 Favored 'General case' 0 C--N 1.33 -0.255 0 C-N-CA 121.061 -0.255 . . . . 0.0 110.322 -179.998 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 294' ' ' LYS . . . . . 0.445 ' C ' ' H ' ' A' ' 296' ' ' ASN . 11.5 mtpp -98.99 148.47 23.96 Favored 'General case' 0 N--CA 1.448 -0.569 0 CA-C-O 120.989 0.423 . . . . 0.0 111.188 -179.56 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 295' ' ' ASP . . . . . 0.471 ' OD2' ' C ' ' A' ' 295' ' ' ASP . 49.7 p30 -86.85 10.82 14.88 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 107.079 -1.452 . . . . 0.0 107.079 178.37 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 296' ' ' ASN . . . . . 0.445 ' H ' ' C ' ' A' ' 294' ' ' LYS . 81.1 m-20 29.17 -127.51 0.03 OUTLIER 'General case' 0 CA--C 1.5 -0.953 0 CA-C-N 112.604 -2.089 . . . . 0.0 113.467 -178.348 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 297' ' ' ILE . . . . . 0.448 ' O ' HG23 ' A' ' 297' ' ' ILE . 14.7 tt -121.86 130.47 74.56 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.709 0 CA-C-O 122.473 1.13 . . . . 0.0 113.024 -177.469 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 15.6 ttmm -100.84 127.63 47.21 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-N 112.715 -2.039 . . . . 0.0 109.675 176.933 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 81.4 t60 -136.33 114.33 11.37 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 120.552 -0.459 . . . . 0.0 111.479 179.193 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 3.2 m -133.89 72.87 72.2 Favored Pre-proline 0 N--CA 1.476 0.858 0 N-CA-C 113.953 1.094 . . . . 0.0 113.953 179.269 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 8.4 Cg_endo -61.25 -23.41 77.0 Favored 'Trans proline' 0 N--CA 1.502 2.017 0 CA-C-N 119.978 1.028 . . . . 0.0 112.026 177.732 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -77.01 46.25 2.38 Favored Glycine 0 CA--C 1.528 0.883 0 CA-C-N 115.121 -0.945 . . . . 0.0 113.194 -178.171 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -57.7 -28.53 60.22 Favored Glycine 0 N--CA 1.445 -0.7 0 N-CA-C 107.397 -2.281 . . . . 0.0 107.397 178.122 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 95.94 -0.56 62.62 Favored Glycine 0 N--CA 1.44 -1.038 0 N-CA-C 104.355 -3.498 . . . . 0.0 104.355 -175.594 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 72.8 m -83.06 1.36 40.52 Favored 'General case' 0 N--CA 1.436 -1.155 0 CA-C-N 112.486 -1.857 . . . . 0.0 110.314 179.295 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 306' ' ' VAL . . . . . . . . . . . . . 92.6 t -61.79 -42.63 95.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 115.424 -0.807 . . . . 0.0 112.178 -178.233 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 307' ' ' GLN . . . . . . . . . . . . . 23.2 pt20 173.65 -159.63 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.254 0 O-C-N 123.705 0.628 . . . . 0.0 109.585 -179.312 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 308' ' ' ILE . . . . . 0.626 HG22 ' H ' ' A' ' 311' ' ' LYS . 65.5 mt -114.97 122.95 70.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.546 178.127 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 309' ' ' VAL . . . . . 0.491 ' CG1' ' N ' ' A' ' 310' ' ' TYR . 8.0 p -63.82 -39.6 86.01 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.311 0 C-N-CA 118.859 -1.136 . . . . 0.0 108.442 176.588 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 310' ' ' TYR . . . . . 0.491 ' N ' ' CG1' ' A' ' 309' ' ' VAL 0.331 55.2 p90 -67.49 -33.14 74.49 Favored 'General case' 0 N--CA 1.452 -0.352 0 N-CA-C 117.584 2.438 . . . . 0.0 117.584 178.89 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 311' ' ' LYS . . . . . 0.626 ' H ' HG22 ' A' ' 308' ' ' ILE . 2.9 ttpm? 46.34 61.29 13.24 Favored Pre-proline 0 C--N 1.315 -0.924 0 C-N-CA 119.136 -1.025 . . . . 0.0 109.508 179.606 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 312' ' ' PRO . . . . . 0.539 ' C ' ' O ' ' A' ' 311' ' ' LYS . 83.8 Cg_exo 24.16 55.25 0.0 OUTLIER 'Trans proline' 0 N--CA 1.486 1.031 0 C-N-CA 120.801 1.001 . . . . 0.0 113.201 -179.209 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 313' ' ' VAL . . . . . 0.526 ' C ' ' O ' ' A' ' 312' ' ' PRO . 4.2 m 2.68 84.11 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 CA-C-N 115.181 -0.918 . . . . 0.0 112.467 -179.743 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 56.1 t0 -55.8 -36.62 67.62 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.956 -0.565 . . . . 0.0 111.146 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 315' ' ' LEU . . . . . . . . . . . . . 62.4 mt -58.82 -33.91 70.93 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.593 -178.976 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 95.3 p -60.43 -28.05 67.98 Favored 'General case' 0 CA--C 1.511 -0.55 0 C-N-CA 120.048 -0.661 . . . . 0.0 111.058 -179.285 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 38.1 mtpt -92.04 137.75 32.11 Favored 'General case' 0 N--CA 1.448 -0.539 0 C-N-CA 119.455 -0.898 . . . . 0.0 109.868 179.434 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 13.7 p -131.69 143.0 41.68 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 CA-C-N 114.977 -1.01 . . . . 0.0 110.765 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 41.6 p . . . . . 0 C--O 1.22 -0.488 0 CA-C-O 118.02 -0.991 . . . . 0.0 110.559 179.989 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.737 0 N-CA-C 110.939 -0.864 . . . . 0.0 110.939 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 92.3 p -122.67 155.88 35.49 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.596 0.236 . . . . 0.0 110.463 -179.878 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 16.0 mtpp -93.91 149.7 21.0 Favored 'General case' 0 N--CA 1.446 -0.633 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.714 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 295' ' ' ASP . . . . . 0.679 ' OD1' ' N ' ' A' ' 296' ' ' ASN . 49.8 p30 -60.16 -31.94 70.58 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 108.107 -1.071 . . . . 0.0 108.107 178.929 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 296' ' ' ASN . . . . . 0.679 ' N ' ' OD1' ' A' ' 295' ' ' ASP . 17.4 t-20 58.99 44.98 15.54 Favored 'General case' 0 N--CA 1.45 -0.467 0 CA-C-N 115.277 -0.874 . . . . 0.0 109.804 179.63 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 297' ' ' ILE . . . . . 0.781 HG22 ' N ' ' A' ' 298' ' ' LYS . 84.4 mt 36.57 -118.09 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.439 -0.801 . . . . 0.0 110.634 -178.696 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 298' ' ' LYS . . . . . 0.781 ' N ' HG22 ' A' ' 297' ' ' ILE . 83.6 tttt -158.09 -95.86 0.03 OUTLIER 'General case' 0 CA--C 1.538 0.481 0 C-N-CA 119.948 -0.701 . . . . 0.0 111.564 179.499 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 76.3 m80 73.87 88.58 0.09 Allowed 'General case' 0 N--CA 1.476 0.871 0 N-CA-C 113.176 0.806 . . . . 0.0 113.176 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 3.1 m -124.01 77.87 58.78 Favored Pre-proline 0 CA--C 1.537 0.477 0 CA-C-N 115.408 -0.814 . . . . 0.0 109.582 179.125 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 301' ' ' PRO . . . . . 0.664 ' O ' HG23 ' A' ' 306' ' ' VAL . 8.1 Cg_exo -56.51 -24.49 53.42 Favored 'Trans proline' 0 N--CA 1.494 1.529 0 C-N-CA 121.694 1.596 . . . . 0.0 113.1 -178.285 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -73.02 17.54 1.68 Allowed Glycine 0 N--CA 1.463 0.452 0 N-CA-C 109.238 -1.545 . . . . 0.0 109.238 178.338 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 303' ' ' GLY . . . . . 0.622 ' H ' ' C ' ' A' ' 301' ' ' PRO . . . -56.04 -23.58 39.77 Favored Glycine 0 CA--C 1.516 0.147 0 CA-C-N 114.311 -0.944 . . . . 0.0 110.971 -179.814 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 98.1 -4.36 60.69 Favored Glycine 0 CA--C 1.505 -0.59 0 N-CA-C 104.349 -3.5 . . . . 0.0 104.349 -174.776 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 85.2 p -64.69 -20.72 66.48 Favored 'General case' 0 N--CA 1.428 -1.541 0 CA-C-N 111.331 -2.435 . . . . 0.0 106.139 175.649 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 306' ' ' VAL . . . . . 0.664 HG23 ' O ' ' A' ' 301' ' ' PRO . 80.8 t -57.48 -42.09 80.16 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 CA-C-N 113.259 -1.791 . . . . 0.0 110.9 -177.375 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 307' ' ' GLN . . . . . 0.586 ' CB ' ' O ' ' A' ' 306' ' ' VAL . 57.2 tt0 103.92 160.48 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.484 0 O-C-N 124.378 1.049 . . . . 0.0 109.019 179.72 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 308' ' ' ILE . . . . . 0.865 HG22 ' H ' ' A' ' 310' ' ' TYR . 70.2 mt -114.98 129.0 71.91 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.46 0 CA-C-O 121.43 0.634 . . . . 0.0 110.738 178.53 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 1.5 t -86.56 8.63 1.95 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.558 0 CA-C-N 114.648 -1.16 . . . . 0.0 111.763 179.296 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 310' ' ' TYR . . . . . 0.865 ' H ' HG22 ' A' ' 308' ' ' ILE . 0.0 OUTLIER -54.27 -32.43 56.21 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 113.886 1.069 . . . . 0.0 113.886 -174.962 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 311' ' ' LYS . . . . . 0.53 ' N ' ' CD ' ' A' ' 312' ' ' PRO . 12.1 mmmt 57.33 68.16 2.14 Favored Pre-proline 0 N--CA 1.475 0.798 0 CA-C-N 119.732 1.151 . . . . 0.0 112.019 177.345 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 312' ' ' PRO . . . . . 0.594 ' O ' ' N ' ' A' ' 314' ' ' ASP . 86.6 Cg_exo -54.78 148.55 45.22 Favored 'Trans proline' 0 C--N 1.304 -1.808 0 C-N-CA 124.978 3.785 . . . . 0.0 114.761 -179.067 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 17.8 m 38.82 12.28 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 CA-C-N 114.313 -1.312 . . . . 0.0 113.093 -179.337 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 314' ' ' ASP . . . . . 0.594 ' N ' ' O ' ' A' ' 312' ' ' PRO . 20.9 t70 -55.11 -36.64 65.91 Favored 'General case' 0 C--N 1.319 -0.734 0 C-N-CA 120.237 -0.585 . . . . 0.0 109.557 179.126 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 315' ' ' LEU . . . . . 0.62 ' CD2' ' N ' ' A' ' 315' ' ' LEU . 0.2 OUTLIER -61.12 -35.24 76.53 Favored 'General case' 0 CA--C 1.541 0.615 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.027 179.4 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 79.6 p -62.4 -25.93 68.21 Favored 'General case' 0 N--CA 1.471 0.579 0 CA-C-O 121.643 0.735 . . . . 0.0 110.862 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 62.6 mmtt -58.04 -26.29 62.27 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 114.49 -1.232 . . . . 0.0 113.598 -178.432 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 11.6 p -110.22 138.6 37.32 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 CA-C-O 122.142 0.972 . . . . 0.0 111.061 -176.41 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 3.6 m . . . . . 0 C--O 1.219 -0.526 0 CA-C-N 113.335 -1.757 . . . . 0.0 110.203 -178.14 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.642 0 N-CA-C 111.05 -0.82 . . . . 0.0 111.05 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 98.6 p -120.25 152.75 37.31 Favored 'General case' 0 N--CA 1.462 0.173 0 CA-C-O 120.911 0.386 . . . . 0.0 110.215 179.654 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 294' ' ' LYS . . . . . 0.459 ' HD2' ' N ' ' A' ' 294' ' ' LYS . 1.0 OUTLIER -85.4 -74.06 0.42 Allowed 'General case' 0 CA--C 1.512 -0.504 0 CA-C-O 121.701 0.762 . . . . 0.0 112.101 -179.296 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 295' ' ' ASP . . . . . 0.47 ' OD1' HD11 ' A' ' 297' ' ' ILE . 50.6 p30 -89.58 6.94 38.92 Favored 'General case' 0 N--CA 1.442 -0.869 0 CA-C-N 114.427 -1.261 . . . . 0.0 109.468 179.879 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 17.3 t-20 58.97 53.53 5.58 Favored 'General case' 0 N--CA 1.473 0.675 0 N-CA-C 114.531 1.308 . . . . 0.0 114.531 176.587 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 297' ' ' ILE . . . . . 0.47 HD11 ' OD1' ' A' ' 295' ' ' ASP . 15.7 mm -73.4 140.94 16.96 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.653 0 C-N-CA 119.524 -0.87 . . . . 0.0 110.172 -179.617 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 298' ' ' LYS . . . . . 0.516 ' NZ ' HG13 ' A' ' 300' ' ' VAL . 14.0 ptmm? -125.22 154.26 41.89 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 114.682 -1.145 . . . . 0.0 111.62 -178.002 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 56.6 t-80 -124.36 129.6 50.99 Favored 'General case' 0 CA--C 1.536 0.409 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 178.265 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 300' ' ' VAL . . . . . 0.516 HG13 ' NZ ' ' A' ' 298' ' ' LYS . 0.2 OUTLIER -124.14 77.35 59.95 Favored Pre-proline 0 N--CA 1.474 0.763 0 N-CA-C 112.406 0.521 . . . . 0.0 112.406 -179.147 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -59.01 -27.63 85.57 Favored 'Trans proline' 0 C--N 1.312 -1.373 0 N-CA-C 109.885 -0.852 . . . . 0.0 109.885 177.969 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -121.66 106.32 1.08 Allowed Glycine 0 CA--C 1.523 0.568 0 CA-C-N 115.039 -0.982 . . . . 0.0 110.788 179.302 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -141.56 33.38 1.98 Allowed Glycine 0 CA--C 1.523 0.579 0 N-CA-C 109.905 -1.278 . . . . 0.0 109.905 179.23 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 95.2 -0.43 63.96 Favored Glycine 0 CA--C 1.521 0.426 0 N-CA-C 107.963 -2.055 . . . . 0.0 107.963 -177.891 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 52.0 p -82.78 -0.14 46.42 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 113.896 -1.152 . . . . 0.0 109.541 178.547 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 306' ' ' VAL . . . . . 0.514 ' O ' ' CB ' ' A' ' 307' ' ' GLN . 92.3 t -58.27 -39.19 72.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.509 -0.769 . . . . 0.0 110.127 -177.633 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 307' ' ' GLN . . . . . 0.627 ' HG2' HG23 ' A' ' 308' ' ' ILE . 57.9 tt0 94.07 139.74 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.727 0 N-CA-C 114.602 1.334 . . . . 0.0 114.602 177.816 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 308' ' ' ILE . . . . . 0.627 HG23 ' HG2' ' A' ' 307' ' ' GLN . 0.8 OUTLIER 16.23 36.76 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.543 0 CA-C-N 112.723 -2.035 . . . . 0.0 115.397 177.99 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 309' ' ' VAL . . . . . 0.614 ' N ' ' O ' ' A' ' 307' ' ' GLN . 62.9 t -55.54 -37.45 45.65 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 N-CA-C 107.943 -1.132 . . . . 0.0 107.943 179.425 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 310' ' ' TYR . . . . . 0.488 ' CE1' ' HD3' ' A' ' 312' ' ' PRO . 33.6 p90 -60.3 -28.04 67.79 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 114.226 1.195 . . . . 0.0 114.226 -179.789 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 311' ' ' LYS . . . . . . . . . . . . . 2.3 tmtp? 68.97 74.32 0.29 Allowed Pre-proline 0 N--CA 1.474 0.75 0 CA-C-N 119.337 0.971 . . . . 0.0 110.512 178.313 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 312' ' ' PRO . . . . . 0.488 ' HD3' ' CE1' ' A' ' 310' ' ' TYR . 13.4 Cg_exo -54.83 -31.07 70.95 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 C-N-CA 122.59 2.193 . . . . 0.0 114.803 -177.014 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 313' ' ' VAL . . . . . 0.641 HG13 ' HB2' ' A' ' 316' ' ' SER . 39.2 t -124.26 134.81 65.63 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.525 0 C-N-CA 120.184 -0.606 . . . . 0.0 111.308 179.765 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 314' ' ' ASP . . . . . 0.499 ' HB3' HD22 ' A' ' 315' ' ' LEU . 61.2 t0 -149.12 -89.42 0.08 Allowed 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.516 -0.765 . . . . 0.0 109.061 178.928 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 315' ' ' LEU . . . . . 0.911 HD22 ' H ' ' A' ' 315' ' ' LEU . 2.0 mm? -59.61 -31.09 69.16 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.065 178.041 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 316' ' ' SER . . . . . 0.641 ' HB2' HG13 ' A' ' 313' ' ' VAL . 25.2 m -55.29 -33.17 63.03 Favored 'General case' 0 N--CA 1.455 -0.197 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.133 -178.025 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 317' ' ' LYS . . . . . 0.581 ' HG3' HG12 ' A' ' 313' ' ' VAL . 65.4 mttm -57.82 -34.1 69.3 Favored 'General case' 0 C--N 1.326 -0.435 0 C-N-CA 120.461 -0.496 . . . . 0.0 110.44 -179.923 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 42.1 t -115.77 135.8 54.71 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-O 120.825 0.345 . . . . 0.0 110.983 -179.449 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 37.4 p . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.333 179.684 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . 0.464 ' O ' ' O ' ' A' ' 294' ' ' LYS . 97.5 p . . . . . 0 N--CA 1.461 0.115 0 CA-C-O 121.119 0.485 . . . . 0.0 111.272 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 294' ' ' LYS . . . . . 0.464 ' O ' ' O ' ' A' ' 293' ' ' SER . 57.7 mttp -55.19 -126.1 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.502 -0.772 . . . . 0.0 111.757 179.836 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 295' ' ' ASP . . . . . . . . . . . . . 89.5 m-20 -92.17 7.43 42.57 Favored 'General case' 0 N--CA 1.455 -0.224 0 CA-C-N 114.924 -1.035 . . . . 0.0 111.235 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 49.9 t30 60.26 52.13 5.1 Favored 'General case' 0 C--N 1.333 -0.119 0 C-N-CA 119.68 -0.808 . . . . 0.0 111.567 179.842 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 297' ' ' ILE . . . . . . . . . . . . . 80.9 mt -64.99 135.22 28.6 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 122.396 1.093 . . . . 0.0 111.779 -177.354 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 84.6 tttt -81.76 137.0 35.41 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 112.884 -1.962 . . . . 0.0 112.752 -179.085 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 74.4 t60 -124.53 136.36 53.92 Favored 'General case' 0 CA--C 1.543 0.711 0 N-CA-C 107.914 -1.143 . . . . 0.0 107.914 178.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -124.0 76.72 58.78 Favored Pre-proline 0 N--CA 1.481 1.09 0 N-CA-C 113.336 0.865 . . . . 0.0 113.336 -177.876 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -59.76 -26.1 81.19 Favored 'Trans proline' 0 N--CA 1.493 1.472 0 C-N-CA 121.221 1.28 . . . . 0.0 111.862 178.451 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -167.28 125.1 1.28 Allowed Glycine 0 CA--C 1.527 0.789 0 N-CA-C 110.89 -0.884 . . . . 0.0 110.89 -179.585 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -150.35 37.2 0.92 Allowed Glycine 0 N--CA 1.468 0.803 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 179.732 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 96.7 -4.72 63.85 Favored Glycine 0 C--N 1.317 -0.488 0 N-CA-C 106.262 -2.735 . . . . 0.0 106.262 -177.079 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 24.9 t -59.89 -27.76 66.99 Favored 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 112.827 -1.686 . . . . 0.0 109.121 176.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 306' ' ' VAL . . . . . 0.641 ' O ' ' CB ' ' A' ' 307' ' ' GLN . 73.5 t -55.41 -40.08 56.01 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.643 0 CA-C-N 114.081 -1.418 . . . . 0.0 112.038 -175.77 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 307' ' ' GLN . . . . . 0.641 ' CB ' ' O ' ' A' ' 306' ' ' VAL . 63.1 tp60 117.37 84.61 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.529 0 N-CA-C 113.921 1.082 . . . . 0.0 113.921 177.482 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 308' ' ' ILE . . . . . 0.672 HG23 ' O ' ' A' ' 308' ' ' ILE . 18.6 tt 26.46 58.24 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 N-CA-C 113.16 0.8 . . . . 0.0 113.16 176.217 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 54.8 t -56.0 -39.23 56.64 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.605 0 C-N-CA 118.724 -1.19 . . . . 0.0 109.76 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 310' ' ' TYR . . . . . 0.695 ' O ' ' CD1' ' A' ' 310' ' ' TYR . 36.7 p90 -69.83 104.56 2.5 Favored 'General case' 0 N--CA 1.439 -1.0 0 C-N-CA 119.082 -1.047 . . . . 0.0 109.41 178.601 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 311' ' ' LYS . . . . . . . . . . . . . 38.6 mtpt -73.34 128.07 88.02 Favored Pre-proline 0 C--N 1.313 -1.016 0 C-N-CA 119.649 -0.82 . . . . 0.0 110.385 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 312' ' ' PRO . . . . . . . . . . . . . 85.3 Cg_exo -55.96 149.48 51.89 Favored 'Trans proline' 0 C--N 1.306 -1.66 0 N-CA-C 106.122 -2.299 . . . . 0.0 106.122 174.326 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 36.1 t -64.46 126.26 22.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 C-N-CA 116.284 -2.166 . . . . 0.0 110.775 -175.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 314' ' ' ASP . . . . . 0.466 ' O ' ' HB3' ' A' ' 317' ' ' LYS . 89.5 m-20 -95.59 -19.22 19.95 Favored 'General case' 0 N--CA 1.444 -0.762 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 175.509 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 315' ' ' LEU . . . . . 0.697 ' O ' HG12 ' A' ' 318' ' ' VAL . 60.5 mt -62.22 -37.47 85.48 Favored 'General case' 0 C--O 1.232 0.141 0 CA-C-N 116.029 -0.532 . . . . 0.0 112.293 -178.324 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 82.9 p -63.03 -30.76 71.85 Favored 'General case' 0 CA--C 1.519 -0.22 0 CA-C-O 121.499 0.666 . . . . 0.0 109.886 179.877 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 317' ' ' LYS . . . . . 0.466 ' HB3' ' O ' ' A' ' 314' ' ' ASP . 18.8 tttt -59.38 -36.89 76.62 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 114.342 -1.299 . . . . 0.0 112.783 -178.824 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 318' ' ' VAL . . . . . 0.697 HG12 ' O ' ' A' ' 315' ' ' LEU . 5.3 p -57.07 -33.98 44.0 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 N-CA-C 112.268 0.47 . . . . 0.0 112.268 -178.148 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 319' ' ' THR . . . . . 0.412 ' OXT' ' O ' ' A' ' 318' ' ' VAL . 1.3 m . . . . . 0 C--O 1.221 -0.443 0 CA-C-O 117.951 -1.023 . . . . 0.0 110.792 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 23.8 m . . . . . 0 C--O 1.231 0.121 0 CA-C-O 120.862 0.363 . . . . 0.0 110.137 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -96.27 148.32 22.86 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.716 179.298 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 295' ' ' ASP . . . . . 0.596 ' O ' ' CB ' ' A' ' 296' ' ' ASN . 91.6 m-20 -56.52 -36.4 69.16 Favored 'General case' 0 CA--C 1.492 -1.251 0 N-CA-C 107.382 -1.34 . . . . 0.0 107.382 177.659 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 296' ' ' ASN . . . . . 0.596 ' CB ' ' O ' ' A' ' 295' ' ' ASP . 48.2 t30 118.39 -128.61 0.0 OUTLIER 'General case' 0 CA--C 1.469 -2.16 0 O-C-N 125.581 1.801 . . . . 0.0 110.097 179.51 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 297' ' ' ILE . . . . . 0.651 ' O ' HG23 ' A' ' 297' ' ' ILE . 8.9 tp -122.44 133.35 68.93 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.111 0 CA-C-N 114.499 -1.228 . . . . 0.0 110.497 -178.781 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 43.4 tttm -132.71 120.19 21.35 Favored 'General case' 0 C--N 1.294 -1.84 0 CA-C-N 114.234 -1.348 . . . . 0.0 110.323 174.453 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 299' ' ' HIS . . . . . 0.407 ' CD2' HD11 ' A' ' 297' ' ' ILE . 79.8 m-70 -139.81 145.04 37.65 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.36 -0.836 . . . . 0.0 112.251 174.851 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -124.8 72.71 62.6 Favored Pre-proline 0 C--N 1.322 -0.63 0 CA-C-N 115.473 -0.785 . . . . 0.0 108.952 177.282 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -59.1 -24.67 74.76 Favored 'Trans proline' 0 N--CA 1.492 1.44 0 C-N-CA 121.034 1.156 . . . . 0.0 111.098 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . 150.15 136.51 2.58 Favored Glycine 0 CA--C 1.52 0.365 0 CA-C-N 115.05 -0.977 . . . . 0.0 110.875 179.442 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -84.57 1.52 88.76 Favored Glycine 0 CA--C 1.519 0.311 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 179.009 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 95.74 -2.83 64.81 Favored Glycine 0 CA--C 1.519 0.329 0 N-CA-C 108.936 -1.666 . . . . 0.0 108.936 -179.021 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 73.9 m -84.53 4.28 32.67 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 114.774 -0.713 . . . . 0.0 109.902 178.619 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 306' ' ' VAL . . . . . . . . . . . . . 98.8 t -59.67 -41.78 86.34 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.662 0 CA-C-O 122.235 1.017 . . . . 0.0 111.179 -178.309 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 307' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 -141.84 168.5 19.6 Favored 'General case' 0 C--N 1.31 -1.119 0 CA-C-N 112.896 -1.956 . . . . 0.0 109.0 -177.498 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 308' ' ' ILE . . . . . 0.732 HG22 ' H ' ' A' ' 311' ' ' LYS . 31.8 mm -104.05 117.81 50.19 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 CA-C-N 115.418 -0.81 . . . . 0.0 113.162 -179.152 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 21.0 m -78.53 -30.11 15.09 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.483 0 CA-C-N 114.13 -1.395 . . . . 0.0 108.398 175.592 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 310' ' ' TYR . . . . . 0.611 ' CE2' HG23 ' A' ' 308' ' ' ILE 0.364 51.7 p90 -64.15 -28.29 69.66 Favored 'General case' 0 N--CA 1.447 -0.608 0 N-CA-C 116.311 1.967 . . . . 0.0 116.311 -179.197 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 311' ' ' LYS . . . . . 0.732 ' H ' HG22 ' A' ' 308' ' ' ILE . 37.3 mtpt 53.72 65.65 5.32 Favored Pre-proline 0 C--N 1.318 -0.78 0 C-N-CA 119.875 -0.73 . . . . 0.0 110.958 178.44 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 312' ' ' PRO . . . . . 0.492 ' C ' ' O ' ' A' ' 311' ' ' LYS . 91.0 Cg_exo 3.86 -128.87 0.0 OUTLIER 'Trans proline' 0 N--CA 1.487 1.141 0 C-N-CA 123.092 2.528 . . . . 0.0 115.771 -179.287 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 313' ' ' VAL . . . . . 0.624 HG13 ' O ' ' A' ' 313' ' ' VAL . 4.5 p -113.04 37.06 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.718 0 N-CA-C 112.955 0.724 . . . . 0.0 112.955 -177.234 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 314' ' ' ASP . . . . . 0.402 ' O ' ' HB3' ' A' ' 317' ' ' LYS . 54.6 t0 -54.13 -35.26 62.01 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 112.081 0.4 . . . . 0.0 112.081 -179.614 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 315' ' ' LEU . . . . . 1.012 HD22 ' H ' ' A' ' 315' ' ' LEU . 1.8 mm? -57.15 -35.18 69.21 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 120.299 -0.56 . . . . 0.0 111.074 -178.486 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . 0.412 ' HB3' HG22 ' A' ' 313' ' ' VAL . 89.8 p -62.37 -23.59 66.89 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 121.135 0.493 . . . . 0.0 110.582 178.65 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 317' ' ' LYS . . . . . 0.402 ' HB3' ' O ' ' A' ' 314' ' ' ASP . 41.8 tttp -56.62 -35.4 68.26 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.137 -0.938 . . . . 0.0 111.855 -177.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 13.3 p -129.7 142.75 43.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.045 0.45 . . . . 0.0 110.439 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 117.939 -1.029 . . . . 0.0 110.693 -179.27 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 46.5 m . . . . . 0 N--CA 1.455 -0.222 0 CA-C-O 121.159 0.504 . . . . 0.0 110.775 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 11.6 mtpp -81.17 168.9 18.04 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.807 179.476 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 295' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -48.68 -31.88 7.5 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.974 -177.347 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 74.6 m-20 63.81 52.47 2.15 Favored 'General case' 0 CA--C 1.516 -0.355 0 C-N-CA 120.269 -0.572 . . . . 0.0 111.457 -179.923 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 297' ' ' ILE . . . . . . . . . . . . . 82.1 mt -62.98 130.93 28.21 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.249 0 N-CA-C 107.66 -1.237 . . . . 0.0 107.66 -178.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 44.4 tttp -81.98 133.69 35.32 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 115.469 1.655 . . . . 0.0 115.469 -175.373 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -121.72 139.17 53.91 Favored 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 106.843 -1.54 . . . . 0.0 106.843 175.812 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 8.0 m -125.75 72.04 68.15 Favored Pre-proline 0 N--CA 1.472 0.651 0 C-N-CA 119.308 -0.957 . . . . 0.0 113.31 -178.917 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 79.3 Cg_exo -62.07 -23.62 75.82 Favored 'Trans proline' 0 C--N 1.302 -1.918 0 C-N-CA 122.281 1.987 . . . . 0.0 110.692 176.266 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -92.97 28.43 9.46 Favored Glycine 0 CA--C 1.526 0.745 0 CA-C-N 114.492 -1.231 . . . . 0.0 112.713 -178.383 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 303' ' ' GLY . . . . . 0.415 ' C ' ' N ' ' A' ' 305' ' ' SER . . . -84.4 -173.28 49.73 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.376 -0.916 . . . . 0.0 111.39 -178.556 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . -50.68 -23.88 7.21 Favored Glycine 0 N--CA 1.453 -0.221 0 N-CA-C 108.31 -1.916 . . . . 0.0 108.31 178.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 305' ' ' SER . . . . . 0.415 ' N ' ' C ' ' A' ' 303' ' ' GLY . 22.4 m -55.07 -34.56 63.7 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 114.751 -0.724 . . . . 0.0 111.881 -179.223 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 306' ' ' VAL . . . . . 0.862 ' O ' ' O ' ' A' ' 307' ' ' GLN . 79.0 t -60.88 -39.72 82.9 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.712 0 C-N-CA 121.096 -0.241 . . . . 0.0 110.55 179.772 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 307' ' ' GLN . . . . . 0.862 ' O ' ' O ' ' A' ' 306' ' ' VAL . 13.0 pt20 24.88 166.03 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.471 0 O-C-N 125.222 1.576 . . . . 0.0 113.138 -177.292 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 308' ' ' ILE . . . . . 0.715 ' O ' ' N ' ' A' ' 310' ' ' TYR . 8.5 tt -59.26 -26.86 34.96 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.011 0 CA-C-N 114.192 -1.367 . . . . 0.0 112.753 -176.529 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . 0.608 HG23 ' O ' ' A' ' 307' ' ' GLN . 1.0 OUTLIER 51.06 -42.14 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.204 0 N-CA-C 113.0 0.741 . . . . 0.0 113.0 179.454 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 310' ' ' TYR . . . . . 0.715 ' N ' ' O ' ' A' ' 308' ' ' ILE 0.485 52.5 p90 -65.06 -25.48 67.83 Favored 'General case' 0 CA--C 1.564 1.507 0 N-CA-C 119.69 3.219 . . . . 0.0 119.69 -178.074 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 311' ' ' LYS . . . . . 0.461 ' HB2' ' O ' ' A' ' 310' ' ' TYR . 11.3 mttp 74.15 77.25 0.19 Allowed Pre-proline 0 N--CA 1.509 2.516 0 CA-C-N 120.996 1.726 . . . . 0.0 112.13 177.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 312' ' ' PRO . . . . . . . . . . . . . 4.7 Cg_endo -54.26 -34.33 79.25 Favored 'Trans proline' 0 N--CA 1.522 3.165 0 C-N-CA 123.524 2.816 . . . . 0.0 117.447 -178.178 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 69.7 t -67.29 -38.64 81.3 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.004 0 N-CA-C 116.155 1.909 . . . . 0.0 116.155 -178.398 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 314' ' ' ASP . . . . . 0.519 ' O ' ' O ' ' A' ' 317' ' ' LYS . 91.1 m-20 -55.47 -39.99 71.08 Favored 'General case' 0 C--N 1.322 -0.62 0 C-N-CA 118.697 -1.201 . . . . 0.0 113.103 -174.074 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 315' ' ' LEU . . . . . 0.841 HD22 ' H ' ' A' ' 315' ' ' LEU . 2.0 mm? -65.22 -36.71 85.01 Favored 'General case' 0 C--N 1.326 -0.423 0 C-N-CA 118.918 -1.113 . . . . 0.0 108.892 176.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 22.5 m -60.39 -36.36 77.91 Favored 'General case' 0 CA--C 1.516 -0.364 0 N-CA-C 108.253 -1.017 . . . . 0.0 108.253 178.079 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 317' ' ' LYS . . . . . 0.519 ' O ' ' O ' ' A' ' 314' ' ' ASP . 35.7 ttmt -97.02 117.38 31.06 Favored 'General case' 0 N--CA 1.446 -0.668 0 CA-C-N 114.958 -1.019 . . . . 0.0 111.098 179.71 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 59.5 t -130.92 135.84 59.26 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.333 176.728 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.218 -0.604 0 CA-C-O 117.871 -1.061 . . . . 0.0 110.451 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 92.5 p . . . . . 0 N--CA 1.461 0.121 0 CA-C-O 120.921 0.391 . . . . 0.0 110.531 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 11.9 mtpt -91.8 158.47 16.32 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.702 0.763 . . . . 0.0 112.489 -179.206 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 295' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -53.7 -33.8 56.68 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 114.359 -1.291 . . . . 0.0 110.652 -179.594 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 50.8 t30 64.73 54.34 1.39 Allowed 'General case' 0 CA--C 1.521 -0.14 0 C-N-CA 119.746 -0.782 . . . . 0.0 111.871 -179.817 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 297' ' ' ILE . . . . . . . . . . . . . 75.8 mt -68.05 139.25 21.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.304 -179.024 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 11.5 pttp -77.47 147.71 35.75 Favored 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 114.293 1.22 . . . . 0.0 114.293 -176.391 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 77.3 m80 -120.16 139.32 52.79 Favored 'General case' 0 N--CA 1.454 -0.261 0 CA-C-N 114.032 -1.44 . . . . 0.0 108.455 176.749 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 3.3 m -122.84 73.7 45.49 Favored Pre-proline 0 C--N 1.327 -0.387 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 179.574 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -61.1 -25.15 80.72 Favored 'Trans proline' 0 C--N 1.31 -1.458 0 C-N-CA 122.766 2.311 . . . . 0.0 114.176 -179.353 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -138.14 58.47 0.63 Allowed Glycine 0 CA--C 1.525 0.67 0 C-N-CA 120.597 -0.811 . . . . 0.0 113.363 -177.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -57.2 -28.54 58.87 Favored Glycine 0 N--CA 1.445 -0.722 0 N-CA-C 105.901 -2.88 . . . . 0.0 105.901 176.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 98.91 -10.45 62.2 Favored Glycine 0 N--CA 1.442 -0.966 0 N-CA-C 104.077 -3.609 . . . . 0.0 104.077 -176.099 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 84.9 p -66.29 -27.74 68.16 Favored 'General case' 0 N--CA 1.432 -1.336 0 CA-C-N 112.024 -2.088 . . . . 0.0 111.875 177.877 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 306' ' ' VAL . . . . . . . . . . . . . 55.8 t -61.1 -46.54 96.45 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.331 0 CA-C-O 122.151 0.977 . . . . 0.0 111.382 -175.385 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 307' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -148.14 164.4 34.02 Favored 'General case' 0 N--CA 1.441 -0.89 0 CA-C-N 113.567 -1.652 . . . . 0.0 110.206 -179.175 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 308' ' ' ILE . . . . . 0.47 HG12 ' CZ ' ' A' ' 310' ' ' TYR . 7.2 tp -122.37 129.72 75.07 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 CA-C-O 122.027 0.918 . . . . 0.0 110.915 176.266 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 69.6 t -67.25 -31.68 54.15 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.494 0 CA-C-N 113.639 -1.619 . . . . 0.0 115.128 179.656 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 310' ' ' TYR . . . . . 0.536 ' HD1' ' N ' ' A' ' 311' ' ' LYS . 0.0 OUTLIER -52.38 -33.84 45.23 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 117.197 2.295 . . . . 0.0 117.197 -171.689 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 311' ' ' LYS . . . . . 0.542 ' O ' ' C ' ' A' ' 312' ' ' PRO . 1.1 mmtt 54.09 64.68 6.15 Favored Pre-proline 0 CA--C 1.549 0.911 0 CA-C-N 121.697 2.044 . . . . 0.0 109.441 -179.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 312' ' ' PRO . . . . . 0.542 ' C ' ' O ' ' A' ' 311' ' ' LYS . 81.6 Cg_exo 2.76 64.82 0.0 OUTLIER 'Trans proline' 0 N--CA 1.49 1.321 0 C-N-CA 122.706 2.271 . . . . 0.0 114.794 -179.513 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 313' ' ' VAL . . . . . 0.541 ' N ' ' O ' ' A' ' 311' ' ' LYS . 1.8 m 20.96 54.17 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 CA-C-N 115.46 -0.791 . . . . 0.0 111.973 179.14 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 314' ' ' ASP . . . . . 0.89 ' OD2' HD12 ' A' ' 315' ' ' LEU . 49.6 p30 -60.44 -33.7 72.93 Favored 'General case' 0 C--N 1.322 -0.614 0 C-N-CA 120.611 -0.435 . . . . 0.0 110.858 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 315' ' ' LEU . . . . . 0.89 HD12 ' OD2' ' A' ' 314' ' ' ASP . 6.1 mp -59.16 -37.48 77.41 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 118.833 -1.147 . . . . 0.0 109.591 179.44 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 87.3 p -63.53 -28.04 69.67 Favored 'General case' 0 CA--C 1.509 -0.62 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 177.491 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 15.4 ttpt -82.8 133.14 35.15 Favored 'General case' 0 N--CA 1.446 -0.652 0 CA-C-N 114.434 -1.257 . . . . 0.0 108.828 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 13.3 p -130.55 142.28 44.1 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.751 0 C-N-CA 120.599 -0.441 . . . . 0.0 110.693 -179.761 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.22 -0.491 0 CA-C-O 117.851 -1.071 . . . . 0.0 110.967 -179.696 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 74.5 m . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.648 0.261 . . . . 0.0 110.865 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 294' ' ' LYS . . . . . 0.452 ' C ' ' H ' ' A' ' 296' ' ' ASN . 68.7 mttm -92.95 148.69 21.79 Favored 'General case' 0 N--CA 1.451 -0.39 0 CA-C-O 121.548 0.689 . . . . 0.0 112.099 -179.355 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 295' ' ' ASP . . . . . 0.478 ' C ' ' OD1' ' A' ' 295' ' ' ASP . 49.4 p30 -88.19 11.55 16.1 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 106.427 -1.694 . . . . 0.0 106.427 177.218 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 296' ' ' ASN . . . . . 0.452 ' H ' ' C ' ' A' ' 294' ' ' LYS . 21.1 m120 33.88 -115.14 0.07 Allowed 'General case' 0 CA--C 1.49 -1.347 0 CA-C-N 112.878 -1.965 . . . . 0.0 111.934 -177.335 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 297' ' ' ILE . . . . . 0.551 ' O ' HG23 ' A' ' 297' ' ' ILE . 16.9 tt -120.53 133.03 68.54 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.355 0 C-N-CA 118.478 -1.289 . . . . 0.0 110.315 -178.474 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 44.6 tttm -123.97 119.84 30.73 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 113.996 -1.457 . . . . 0.0 111.549 177.271 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 299' ' ' HIS . . . . . 0.503 ' CE1' HD11 ' A' ' 297' ' ' ILE . 71.7 m80 -137.89 145.37 42.05 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 114.504 -1.225 . . . . 0.0 108.464 173.873 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -123.81 68.37 43.48 Favored Pre-proline 0 N--CA 1.468 0.464 0 C-N-CA 119.358 -0.937 . . . . 0.0 111.856 179.231 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -64.35 -23.12 65.75 Favored 'Trans proline' 0 C--N 1.312 -1.353 0 C-N-CA 122.232 1.955 . . . . 0.0 111.044 176.485 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -80.75 25.78 3.35 Favored Glycine 0 N--CA 1.471 0.982 0 CA-C-N 114.794 -1.094 . . . . 0.0 111.297 -178.908 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -56.08 -25.23 46.04 Favored Glycine 0 C--N 1.317 -0.522 0 N-CA-C 110.588 -1.005 . . . . 0.0 110.588 -179.872 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 100.5 -2.77 56.17 Favored Glycine 0 C--N 1.319 -0.401 0 N-CA-C 104.651 -3.379 . . . . 0.0 104.651 -174.339 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 86.9 p -65.49 -17.41 64.53 Favored 'General case' 0 N--CA 1.444 -0.774 0 CA-C-N 111.755 -2.223 . . . . 0.0 107.484 175.325 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 306' ' ' VAL . . . . . 0.527 ' O ' ' CB ' ' A' ' 307' ' ' GLN . 93.9 t -54.98 -41.52 59.0 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.628 0 CA-C-N 113.231 -1.804 . . . . 0.0 109.513 -176.44 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 307' ' ' GLN . . . . . 0.527 ' CB ' ' O ' ' A' ' 306' ' ' VAL . 12.4 pt20 124.39 147.43 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.86 0 O-C-N 124.921 1.388 . . . . 0.0 110.743 177.67 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 308' ' ' ILE . . . . . 0.413 HG12 ' CD1' ' A' ' 310' ' ' TYR . 15.9 tt -61.55 -26.63 40.14 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.045 0 CA-C-N 114.406 -1.27 . . . . 0.0 113.893 -178.483 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . 0.443 HG23 ' HG3' ' A' ' 307' ' ' GLN . 75.4 t 57.33 -30.24 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.396 0 N-CA-C 116.346 1.98 . . . . 0.0 116.346 178.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 310' ' ' TYR . . . . . 0.442 ' CE1' ' HA ' ' A' ' 312' ' ' PRO . 0.0 OUTLIER -65.79 -14.23 60.99 Favored 'General case' 0 N--CA 1.479 1.001 0 N-CA-C 115.805 1.78 . . . . 0.0 115.805 -175.33 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 311' ' ' LYS . . . . . 0.493 ' O ' ' C ' ' A' ' 312' ' ' PRO . 0.6 OUTLIER 74.46 65.86 0.28 Allowed Pre-proline 0 N--CA 1.473 0.708 0 CA-C-N 118.805 0.73 . . . . 0.0 110.585 -179.909 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 312' ' ' PRO . . . . . 0.493 ' C ' ' O ' ' A' ' 311' ' ' LYS . 12.3 Cg_exo -10.2 -111.4 0.0 OUTLIER 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 123.255 2.636 . . . . 0.0 114.905 179.375 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 17.7 m -111.05 15.69 8.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 N-CA-C 111.954 0.353 . . . . 0.0 111.954 -178.253 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 93.2 m-20 -55.26 -38.76 68.97 Favored 'General case' 0 N--CA 1.451 -0.391 0 C-N-CA 119.436 -0.906 . . . . 0.0 111.096 -178.046 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 315' ' ' LEU . . . . . 0.624 ' O ' HG12 ' A' ' 318' ' ' VAL . 27.8 tp -60.09 -38.72 83.8 Favored 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 119.904 -0.718 . . . . 0.0 110.258 178.475 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 21.2 m -59.57 -33.95 72.08 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 115.508 -0.769 . . . . 0.0 111.596 179.263 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 33.9 tttp -56.78 -36.34 69.73 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.267 -0.879 . . . . 0.0 112.301 -177.346 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 318' ' ' VAL . . . . . 0.624 HG12 ' O ' ' A' ' 315' ' ' LEU . 5.9 p -57.11 -34.35 45.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 C-N-CA 120.067 -0.653 . . . . 0.0 109.888 179.647 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 319' ' ' THR . . . . . 0.445 ' C ' ' O ' ' A' ' 318' ' ' VAL . 2.5 m . . . . . 0 C--O 1.219 -0.546 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.911 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 89.4 p . . . . . 0 N--CA 1.462 0.159 0 CA-C-O 121.309 0.576 . . . . 0.0 111.296 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 294' ' ' LYS . . . . . 0.409 ' HB3' ' NZ ' ' A' ' 294' ' ' LYS . 9.5 mtpm? -88.35 172.83 9.12 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.45 179.77 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 295' ' ' ASP . . . . . 0.446 ' OD2' ' C ' ' A' ' 295' ' ' ASP . 49.1 p30 -76.76 8.49 3.62 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 112.571 0.582 . . . . 0.0 112.571 -175.629 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 76.7 m-20 61.44 51.68 4.05 Favored 'General case' 0 N--CA 1.468 0.428 0 N-CA-C 115.74 1.755 . . . . 0.0 115.74 175.34 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 297' ' ' ILE . . . . . . . . . . . . . 16.2 mm -70.8 132.51 33.19 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.158 0 N-CA-C 106.975 -1.491 . . . . 0.0 106.975 179.559 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 3.6 ptmt -99.37 144.23 28.73 Favored 'General case' 0 N--CA 1.464 0.264 0 N-CA-C 115.592 1.701 . . . . 0.0 115.592 -175.446 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 299' ' ' HIS . . . . . 0.439 ' CE1' ' CG ' ' A' ' 301' ' ' PRO . 54.8 t-80 -126.75 119.09 26.05 Favored 'General case' 0 CA--C 1.536 0.439 0 N-CA-C 106.022 -1.844 . . . . 0.0 106.022 175.515 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -129.82 77.05 77.49 Favored Pre-proline 0 N--CA 1.477 0.904 0 N-CA-C 114.939 1.459 . . . . 0.0 114.939 -176.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 301' ' ' PRO . . . . . 0.499 ' O ' HG23 ' A' ' 306' ' ' VAL . 75.2 Cg_exo -60.29 -22.76 72.0 Favored 'Trans proline' 0 N--CA 1.502 2.005 0 C-N-CA 121.705 1.604 . . . . 0.0 112.446 177.285 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -69.32 20.41 0.45 Allowed Glycine 0 CA--C 1.526 0.732 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.924 -178.757 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 303' ' ' GLY . . . . . 0.495 ' H ' ' C ' ' A' ' 301' ' ' PRO . . . -56.82 -28.16 57.0 Favored Glycine 0 N--CA 1.453 -0.202 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 179.732 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 98.31 -4.71 60.47 Favored Glycine 0 C--N 1.317 -0.486 0 N-CA-C 103.962 -3.655 . . . . 0.0 103.962 -174.603 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 83.8 p -65.88 -18.93 65.67 Favored 'General case' 0 N--CA 1.438 -1.047 0 CA-C-N 111.333 -2.434 . . . . 0.0 108.615 176.591 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 306' ' ' VAL . . . . . 0.499 HG23 ' O ' ' A' ' 301' ' ' PRO . 90.7 t -56.35 -40.77 68.65 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 CA-C-N 113.98 -1.463 . . . . 0.0 110.672 -175.677 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 307' ' ' GLN . . . . . 0.801 ' HG2' ' H ' ' A' ' 308' ' ' ILE . 6.2 tt0 -173.27 -151.02 0.05 Allowed 'General case' 0 CA--C 1.536 0.43 0 N-CA-C 107.691 -1.226 . . . . 0.0 107.691 179.126 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 308' ' ' ILE . . . . . 0.801 ' H ' ' HG2' ' A' ' 307' ' ' GLN . 64.9 mt -114.92 136.69 50.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 179.289 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 71.3 t -60.55 -39.64 81.95 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.089 0 N-CA-C 112.828 0.677 . . . . 0.0 112.828 -178.789 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 310' ' ' TYR . . . . . 0.57 ' N ' ' CD1' ' A' ' 310' ' ' TYR . 0.1 OUTLIER -148.62 23.25 1.01 Allowed 'General case' 0 N--CA 1.477 0.906 0 N-CA-C 115.931 1.826 . . . . 0.0 115.931 -176.623 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 311' ' ' LYS . . . . . 0.471 ' O ' ' C ' ' A' ' 312' ' ' PRO . 0.1 OUTLIER 51.69 67.71 3.89 Favored Pre-proline 0 CA--C 1.546 0.807 0 C-N-CA 117.842 -1.543 . . . . 0.0 107.869 -179.253 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 312' ' ' PRO . . . . . 0.615 ' HD2' HG21 ' A' ' 308' ' ' ILE . 60.3 Cg_exo -6.33 -66.55 0.0 OUTLIER 'Trans proline' 0 N--CA 1.492 1.423 0 C-N-CA 123.109 2.539 . . . . 0.0 116.29 -176.356 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 20.2 m -129.78 156.97 42.43 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.687 0 N-CA-C 113.285 0.846 . . . . 0.0 113.285 -178.429 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 23.1 t70 -142.71 -61.73 0.43 Allowed 'General case' 0 CA--C 1.535 0.382 0 CA-C-N 114.912 -1.04 . . . . 0.0 110.525 178.612 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 315' ' ' LEU . . . . . 0.599 HD12 ' H ' ' A' ' 315' ' ' LEU . 6.6 mp -61.25 -35.1 76.34 Favored 'General case' 0 N--CA 1.47 0.554 0 N-CA-C 112.357 0.503 . . . . 0.0 112.357 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 85.2 p -60.78 -26.06 66.98 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.287 0.565 . . . . 0.0 109.9 -179.446 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 85.9 tttt -57.4 -36.76 71.72 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.355 -0.839 . . . . 0.0 110.362 -179.67 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 318' ' ' VAL . . . . . 0.475 ' O ' ' O ' ' A' ' 315' ' ' LEU . 13.7 p -131.45 142.97 41.91 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.176 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.332 179.67 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 2.0 m . . . . . 0 C--O 1.22 -0.494 0 CA-C-O 118.024 -0.988 . . . . 0.0 110.598 179.986 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 86.2 p . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.835 0.35 . . . . 0.0 110.676 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 11.5 mtpp -89.45 162.65 15.63 Favored 'General case' 0 CA--C 1.515 -0.381 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.869 179.89 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 295' ' ' ASP . . . . . 0.653 ' OD1' ' N ' ' A' ' 296' ' ' ASN . 50.0 p30 -57.58 -33.47 68.21 Favored 'General case' 0 N--CA 1.449 -0.524 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.407 -178.501 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 296' ' ' ASN . . . . . 0.653 ' N ' ' OD1' ' A' ' 295' ' ' ASP . 16.4 t-20 58.44 56.54 4.31 Favored 'General case' 0 CA--C 1.516 -0.357 0 C-N-CA 118.38 -1.328 . . . . 0.0 110.558 177.388 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 297' ' ' ILE . . . . . 0.448 HG22 ' H ' ' A' ' 299' ' ' HIS . 21.6 mm -42.63 137.25 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-O 122.659 1.219 . . . . 0.0 109.975 -175.932 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 83.1 tttt -57.38 -36.04 70.74 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 112.354 -2.203 . . . . 0.0 112.939 -176.744 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 299' ' ' HIS . . . . . 0.448 ' H ' HG22 ' A' ' 297' ' ' ILE . 1.2 m80 64.86 112.35 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 120.167 -0.613 . . . . 0.0 109.755 -179.14 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -122.21 78.32 43.51 Favored Pre-proline 0 C--N 1.325 -0.46 0 CA-C-N 115.82 -0.627 . . . . 0.0 109.885 -179.293 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -56.32 -23.65 47.34 Favored 'Trans proline' 0 C--N 1.315 -1.231 0 C-N-CA 120.904 1.069 . . . . 0.0 110.238 -179.426 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 302' ' ' GLY . . . . . 0.451 ' C ' ' H ' ' A' ' 304' ' ' GLY . . . -167.15 127.21 1.54 Allowed Glycine 0 CA--C 1.526 0.721 0 CA-C-N 114.965 -1.016 . . . . 0.0 110.882 179.002 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -78.85 10.87 30.26 Favored Glycine 0 N--CA 1.463 0.459 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 178.811 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 304' ' ' GLY . . . . . 0.451 ' H ' ' C ' ' A' ' 302' ' ' GLY . . . 98.39 -4.2 60.06 Favored Glycine 0 CA--C 1.519 0.334 0 N-CA-C 108.25 -1.94 . . . . 0.0 108.25 -177.483 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 305' ' ' SER . . . . . 0.524 ' O ' ' C ' ' A' ' 306' ' ' VAL . 23.9 m -59.2 -33.14 70.61 Favored 'General case' 0 C--O 1.233 0.193 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 177.259 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 306' ' ' VAL . . . . . 0.571 HG23 ' H ' ' A' ' 307' ' ' GLN . 4.9 m -7.04 -109.7 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 CA-C-N 114.626 -1.17 . . . . 0.0 111.81 -178.881 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 307' ' ' GLN . . . . . 0.571 ' H ' HG23 ' A' ' 306' ' ' VAL . 25.3 pt20 -138.08 154.84 49.22 Favored 'General case' 0 N--CA 1.451 -0.401 0 CA-C-O 121.466 0.65 . . . . 0.0 109.699 178.612 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 308' ' ' ILE . . . . . 1.002 ' O ' ' N ' ' A' ' 310' ' ' TYR . 16.3 pt -78.1 -25.15 14.09 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.779 0 N-CA-C 116.09 1.885 . . . . 0.0 116.09 -177.239 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . 0.821 HG12 ' O ' ' A' ' 309' ' ' VAL . 93.7 t 9.4 27.78 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.257 0 N-CA-C 113.989 1.107 . . . . 0.0 113.989 -178.814 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 310' ' ' TYR . . . . . 1.002 ' N ' ' O ' ' A' ' 308' ' ' ILE 0.253 0.4 OUTLIER -71.66 -19.98 62.01 Favored 'General case' 0 C--N 1.332 -0.175 0 N-CA-C 113.158 0.799 . . . . 0.0 113.158 -179.523 . . . . . . . . 4 4 . 1 . 007 nuclear nobuild core ' A' A ' 311' ' ' LYS . . . . . 0.417 ' HE3' ' H ' ' A' ' 311' ' ' LYS . 0.0 OUTLIER 57.08 62.72 5.66 Favored Pre-proline 0 C--N 1.325 -0.49 0 CA-C-O 121.316 0.579 . . . . 0.0 109.786 179.718 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 312' ' ' PRO . . . . . 0.778 ' O ' ' N ' ' A' ' 314' ' ' ASP . 32.7 Cg_endo -58.88 143.54 99.31 Favored 'Trans proline' 0 C--N 1.303 -1.855 0 C-N-CA 122.648 2.232 . . . . 0.0 111.288 179.223 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 313' ' ' VAL . . . . . 0.491 ' O ' ' OG ' ' A' ' 316' ' ' SER . 18.9 m -6.58 59.29 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.645 0 O-C-N 124.224 0.953 . . . . 0.0 113.295 -179.452 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 314' ' ' ASP . . . . . 0.778 ' N ' ' O ' ' A' ' 312' ' ' PRO . 93.2 m-20 -56.89 -36.75 70.5 Favored 'General case' 0 C--O 1.223 -0.308 0 N-CA-C 111.66 0.244 . . . . 0.0 111.66 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 315' ' ' LEU . . . . . . . . . . . . . 61.7 mt -58.81 -36.42 74.46 Favored 'General case' 0 C--N 1.326 -0.424 0 C-N-CA 120.07 -0.652 . . . . 0.0 110.719 -178.609 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . 0.491 ' OG ' ' O ' ' A' ' 313' ' ' VAL . 86.3 p -63.37 -23.74 67.54 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-O 121.227 0.537 . . . . 0.0 110.756 178.67 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 49.2 tttm -56.75 -35.8 69.03 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.303 -0.862 . . . . 0.0 112.535 -177.489 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 12.5 p -129.7 142.88 42.74 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 C-N-CA 120.263 -0.575 . . . . 0.0 111.829 -179.238 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.221 -0.418 0 CA-C-O 118.137 -0.935 . . . . 0.0 110.813 179.882 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 21.2 m . . . . . 0 C--O 1.232 0.153 0 CA-C-O 120.842 0.353 . . . . 0.0 110.688 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 67.4 mttt -57.45 -37.77 73.39 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.098 -178.419 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 295' ' ' ASP . . . . . 0.645 ' OD2' ' N ' ' A' ' 296' ' ' ASN . 50.3 p30 175.1 -24.6 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.652 179.401 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 296' ' ' ASN . . . . . 0.645 ' N ' ' OD2' ' A' ' 295' ' ' ASP . 18.7 t-20 56.54 48.22 17.08 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.627 -0.715 . . . . 0.0 111.071 179.751 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 297' ' ' ILE . . . . . 0.672 HG23 ' O ' ' A' ' 297' ' ' ILE . 10.9 tp 15.46 111.04 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 CA-C-O 122.176 0.988 . . . . 0.0 111.602 -178.647 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 298' ' ' LYS . . . . . 0.584 ' O ' ' C ' ' A' ' 299' ' ' HIS . 56.4 tttp -57.86 -36.48 72.4 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 114.488 -1.233 . . . . 0.0 113.285 -178.1 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 299' ' ' HIS . . . . . 0.584 ' C ' ' O ' ' A' ' 298' ' ' LYS . 85.3 t60 1.42 102.25 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.358 0 N-CA-C 112.104 0.409 . . . . 0.0 112.104 -179.265 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.55 75.22 69.68 Favored Pre-proline 0 N--CA 1.469 0.513 0 N-CA-C 111.964 0.357 . . . . 0.0 111.964 -179.17 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -58.94 -21.67 59.23 Favored 'Trans proline' 0 C--N 1.306 -1.693 0 N-CA-C 109.788 -0.889 . . . . 0.0 109.788 177.898 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -79.42 25.21 2.85 Favored Glycine 0 CA--C 1.528 0.892 0 CA-C-N 114.386 -1.279 . . . . 0.0 111.767 -179.848 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -55.93 -26.13 47.3 Favored Glycine 0 CA--C 1.509 -0.296 0 N-CA-C 109.274 -1.53 . . . . 0.0 109.274 179.631 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 98.65 -3.27 59.1 Favored Glycine 0 N--CA 1.442 -0.906 0 N-CA-C 104.686 -3.366 . . . . 0.0 104.686 -175.315 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 305' ' ' SER . . . . . 0.503 ' O ' ' O ' ' A' ' 306' ' ' VAL . 24.7 m -59.46 -33.89 71.86 Favored 'General case' 0 N--CA 1.439 -0.998 0 CA-C-N 112.501 -1.849 . . . . 0.0 108.674 177.157 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 306' ' ' VAL . . . . . 0.552 HG23 ' H ' ' A' ' 307' ' ' GLN . 8.2 m -11.22 -113.37 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.233 0.186 0 CA-C-N 113.438 -1.71 . . . . 0.0 112.835 -178.364 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 307' ' ' GLN . . . . . 0.552 ' H ' HG23 ' A' ' 306' ' ' VAL . 21.7 pt20 -141.56 165.1 28.43 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.429 -0.805 . . . . 0.0 110.803 -178.684 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 308' ' ' ILE . . . . . 0.667 ' O ' HG13 ' A' ' 308' ' ' ILE . 19.9 pt -63.99 100.6 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 122.596 1.189 . . . . 0.0 109.778 179.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 81.4 t -63.87 -42.44 95.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 122.005 0.907 . . . . 0.0 109.167 179.829 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 310' ' ' TYR . . . . . 0.405 ' CE1' ' HD3' ' A' ' 312' ' ' PRO 0.321 54.9 p90 -66.21 -32.34 73.71 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 118.082 2.623 . . . . 0.0 118.082 179.542 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 311' ' ' LYS . . . . . 0.615 ' O ' ' N ' ' A' ' 313' ' ' VAL . 14.6 mtpp 51.02 63.99 8.9 Favored Pre-proline 0 C--N 1.313 -0.979 0 C-N-CA 118.633 -1.227 . . . . 0.0 109.781 179.362 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 312' ' ' PRO . . . . . 0.591 ' O ' ' N ' ' A' ' 314' ' ' ASP . 84.0 Cg_exo 6.33 58.26 0.0 OUTLIER 'Trans proline' 0 N--CA 1.492 1.382 0 C-N-CA 122.635 2.223 . . . . 0.0 113.41 -179.586 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 313' ' ' VAL . . . . . 0.748 ' O ' HG13 ' A' ' 313' ' ' VAL . 9.5 p 4.56 62.61 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 O-C-N 124.082 0.864 . . . . 0.0 112.196 -179.704 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 314' ' ' ASP . . . . . 0.591 ' N ' ' O ' ' A' ' 312' ' ' PRO . 92.1 m-20 -56.08 -35.82 67.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.025 -0.989 . . . . 0.0 111.78 -179.369 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 315' ' ' LEU . . . . . 0.743 ' H ' HD12 ' A' ' 315' ' ' LEU . 6.4 mp -57.39 -36.02 70.74 Favored 'General case' 0 C--N 1.326 -0.45 0 C-N-CA 119.854 -0.738 . . . . 0.0 110.027 -178.33 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . 0.456 ' OG ' HG22 ' A' ' 313' ' ' VAL . 24.4 m -58.45 -34.23 70.61 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 108.396 -0.965 . . . . 0.0 108.396 177.299 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 65.8 tttt -77.05 132.8 39.11 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.084 -0.962 . . . . 0.0 109.714 179.424 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 318' ' ' VAL . . . . . 0.407 ' O ' HG23 ' A' ' 319' ' ' THR . 14.4 p -131.67 142.82 42.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.629 -179.716 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 319' ' ' THR . . . . . 0.407 HG23 ' O ' ' A' ' 318' ' ' VAL . 33.5 p . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 118.049 -0.976 . . . . 0.0 110.845 -179.709 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 1.9 m . . . . . 0 CA--C 1.535 0.367 0 CA-C-O 120.988 0.423 . . . . 0.0 111.829 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 27.8 mttp -91.55 153.51 19.71 Favored 'General case' 0 CA--C 1.515 -0.397 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 178.225 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 295' ' ' ASP . . . . . 0.459 ' OD2' ' C ' ' A' ' 295' ' ' ASP . 48.4 p30 -83.88 8.0 16.36 Favored 'General case' 0 C--N 1.322 -0.626 0 C-N-CA 119.617 -0.833 . . . . 0.0 109.949 -178.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 45.5 t30 58.31 56.06 4.67 Favored 'General case' 0 N--CA 1.455 -0.183 0 C-N-CA 119.671 -0.812 . . . . 0.0 112.014 177.102 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 297' ' ' ILE . . . . . 0.451 HG13 ' OD2' ' A' ' 295' ' ' ASP . 70.7 mt -59.82 131.4 24.41 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.165 0 CA-C-O 122.197 0.999 . . . . 0.0 110.103 -175.932 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 2.0 ttmp? -84.15 136.99 33.76 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 113.419 -1.719 . . . . 0.0 113.958 -177.819 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 64.5 m170 -115.88 136.9 52.6 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 106.483 -1.673 . . . . 0.0 106.483 176.08 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 3.9 m -125.08 69.74 59.64 Favored Pre-proline 0 N--CA 1.466 0.349 0 C-N-CA 119.573 -0.851 . . . . 0.0 112.867 -178.566 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -62.46 -19.31 67.11 Favored 'Trans proline' 0 C--N 1.302 -1.892 0 N-CA-C 107.174 -1.894 . . . . 0.0 107.174 174.683 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -165.08 -169.55 28.85 Favored Glycine 0 CA--C 1.531 1.039 0 CA-C-N 112.91 -1.95 . . . . 0.0 110.233 -178.219 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . 126.25 29.59 0.92 Allowed Glycine 0 N--CA 1.466 0.698 0 N-CA-C 109.013 -1.635 . . . . 0.0 109.013 -178.371 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 97.07 -7.45 64.56 Favored Glycine 0 C--N 1.324 -0.116 0 N-CA-C 107.352 -2.299 . . . . 0.0 107.352 -178.493 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 23.2 t -59.96 -30.75 69.3 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 113.146 -1.527 . . . . 0.0 111.157 177.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 306' ' ' VAL . . . . . 0.564 ' O ' ' CB ' ' A' ' 307' ' ' GLN . 88.5 t -56.93 -42.99 79.73 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.48 0 CA-C-N 115.729 -0.669 . . . . 0.0 112.071 -175.373 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 307' ' ' GLN . . . . . 0.564 ' CB ' ' O ' ' A' ' 306' ' ' VAL . 21.3 pt20 125.46 178.49 0.0 OUTLIER 'General case' 0 N--CA 1.469 0.501 0 O-C-N 124.643 1.214 . . . . 0.0 110.201 179.42 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 308' ' ' ILE . . . . . 0.823 ' O ' ' N ' ' A' ' 310' ' ' TYR . 33.3 mm -54.88 -45.16 75.09 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.933 0 CA-C-N 113.952 -1.476 . . . . 0.0 113.852 177.259 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . 0.455 ' H ' ' HG3' ' A' ' 307' ' ' GLN . 0.3 OUTLIER 37.2 -0.94 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.693 0 O-C-N 123.939 0.774 . . . . 0.0 113.069 -179.212 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 310' ' ' TYR . . . . . 0.823 ' N ' ' O ' ' A' ' 308' ' ' ILE 0.329 0.0 OUTLIER -67.39 -22.3 65.56 Favored 'General case' 0 CA--C 1.503 -0.85 0 C-N-CA 119.056 -1.057 . . . . 0.0 110.681 -178.763 . . . . . . . . 4 4 . 1 . 009 nuclear nobuild core ' A' A ' 311' ' ' LYS . . . . . 0.583 ' O ' ' C ' ' A' ' 312' ' ' PRO . 32.3 tttp 56.4 63.55 5.61 Favored Pre-proline 0 N--CA 1.447 -0.61 0 CA-C-N 115.028 -0.987 . . . . 0.0 109.916 177.779 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 312' ' ' PRO . . . . . 0.583 ' C ' ' O ' ' A' ' 311' ' ' LYS . 75.8 Cg_exo 12.85 -127.08 0.0 OUTLIER 'Trans proline' 0 N--CA 1.492 1.414 0 C-N-CA 122.337 2.025 . . . . 0.0 110.888 -178.448 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 45.2 t -120.98 126.87 75.73 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.398 0 C-N-CA 118.336 -1.345 . . . . 0.0 109.509 176.193 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -63.93 -38.14 89.98 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.64 0.733 . . . . 0.0 111.282 177.102 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 315' ' ' LEU . . . . . 0.65 ' N ' ' CD2' ' A' ' 315' ' ' LEU . 0.2 OUTLIER -61.07 -36.97 81.04 Favored 'General case' 0 C--O 1.233 0.192 0 CA-C-N 114.453 -1.249 . . . . 0.0 113.29 -176.902 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 68.4 m -79.58 -5.55 55.22 Favored 'General case' 0 C--N 1.327 -0.404 0 C-N-CA 120.166 -0.614 . . . . 0.0 111.026 -179.857 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 57.2 tttp -58.42 -38.0 76.52 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.114 -179.333 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 43.4 t -120.65 135.45 60.83 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 CA-C-N 116.545 -0.298 . . . . 0.0 110.577 179.188 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 6.9 m . . . . . 0 C--O 1.221 -0.399 0 CA-C-O 118.018 -0.991 . . . . 0.0 110.422 179.459 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 86.6 p . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.798 0.332 . . . . 0.0 110.498 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 31.0 mttt -93.9 153.37 18.27 Favored 'General case' 0 N--CA 1.448 -0.566 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 178.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 295' ' ' ASP . . . . . 0.474 ' OD1' HG13 ' A' ' 297' ' ' ILE . 49.2 p30 -84.12 7.66 18.1 Favored 'General case' 0 C--N 1.322 -0.591 0 C-N-CA 119.685 -0.806 . . . . 0.0 110.301 -178.653 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 16.6 t-20 58.57 55.91 4.56 Favored 'General case' 0 CA--C 1.535 0.391 0 C-N-CA 119.818 -0.753 . . . . 0.0 112.488 176.629 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 297' ' ' ILE . . . . . 0.474 HG13 ' OD1' ' A' ' 295' ' ' ASP . 71.2 mt -61.8 133.24 27.62 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.52 0 CA-C-O 122.258 1.028 . . . . 0.0 110.906 -175.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 15.6 tttt -82.79 137.83 34.21 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-N 113.328 -1.76 . . . . 0.0 114.209 -178.105 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 58.3 t-80 -119.41 132.42 55.82 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 106.75 -1.574 . . . . 0.0 106.75 176.425 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 4.4 m -124.79 79.01 64.25 Favored Pre-proline 0 N--CA 1.472 0.635 0 N-CA-C 113.865 1.061 . . . . 0.0 113.865 -177.033 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -58.53 -24.59 70.42 Favored 'Trans proline' 0 C--N 1.31 -1.471 0 C-N-CA 120.572 0.848 . . . . 0.0 110.963 178.043 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -111.82 48.21 0.96 Allowed Glycine 0 CA--C 1.525 0.694 0 N-CA-C 109.864 -1.294 . . . . 0.0 109.864 179.507 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -81.19 6.85 62.02 Favored Glycine 0 N--CA 1.466 0.638 0 N-CA-C 112.174 -0.37 . . . . 0.0 112.174 -178.398 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 94.52 2.04 63.72 Favored Glycine 0 C--N 1.321 -0.29 0 N-CA-C 107.962 -2.055 . . . . 0.0 107.962 -178.167 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 75.7 m -82.56 6.99 15.77 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 113.851 -1.174 . . . . 0.0 108.229 178.564 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 306' ' ' VAL . . . . . 0.502 ' O ' ' O ' ' A' ' 307' ' ' GLN . 20.7 m -67.25 -22.65 29.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 114.861 -1.063 . . . . 0.0 110.649 -178.845 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 307' ' ' GLN . . . . . 0.536 ' O ' ' O ' ' A' ' 308' ' ' ILE . 21.7 pt20 46.16 118.03 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 122.039 0.924 . . . . 0.0 113.358 179.697 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 308' ' ' ILE . . . . . 0.638 HG23 ' O ' ' A' ' 308' ' ' ILE . 9.7 tp 25.42 120.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.676 0 CA-C-N 113.42 -1.718 . . . . 0.0 114.374 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -149.58 -42.94 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.366 0 CA-C-N 114.599 -1.182 . . . . 0.0 109.072 177.889 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 310' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -61.67 -31.88 72.02 Favored 'General case' 0 CA--C 1.538 0.519 0 N-CA-C 112.938 0.718 . . . . 0.0 112.938 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 311' ' ' LYS . . . . . 0.454 ' HZ2' ' HB3' ' A' ' 311' ' ' LYS . 8.2 mtpp 65.09 73.76 0.42 Allowed Pre-proline 0 N--CA 1.473 0.711 0 N-CA-C 113.116 0.784 . . . . 0.0 113.116 179.114 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 312' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_endo -53.17 -23.76 23.8 Favored 'Trans proline' 0 N--CA 1.498 1.738 0 C-N-CA 120.41 0.74 . . . . 0.0 111.374 179.691 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 313' ' ' VAL . . . . . 0.73 HG13 ' OG ' ' A' ' 316' ' ' SER . 60.3 t -117.16 132.37 67.14 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.273 0 CA-C-O 121.448 0.642 . . . . 0.0 111.589 178.339 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 58.2 t0 -160.17 -60.94 0.06 Allowed 'General case' 0 N--CA 1.449 -0.515 0 CA-C-N 114.98 -1.009 . . . . 0.0 108.921 178.308 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 315' ' ' LEU . . . . . 0.82 ' O ' HG12 ' A' ' 318' ' ' VAL . 61.1 mt -61.65 -35.33 77.63 Favored 'General case' 0 C--O 1.226 -0.167 0 CA-C-N 114.78 -1.1 . . . . 0.0 111.723 179.295 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . 0.73 ' OG ' HG13 ' A' ' 313' ' ' VAL . 80.2 p -61.21 -28.34 69.08 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.307 0.575 . . . . 0.0 110.241 -179.154 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 29.3 tttm -58.24 -37.2 74.43 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.456 -0.793 . . . . 0.0 111.432 -179.421 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 318' ' ' VAL . . . . . 0.82 HG12 ' O ' ' A' ' 315' ' ' LEU . 5.5 p -57.67 -34.21 46.96 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.152 0 CA-C-O 120.882 0.373 . . . . 0.0 110.62 -179.87 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 319' ' ' THR . . . . . 0.599 ' OG1' HG13 ' A' ' 318' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--O 1.221 -0.447 0 CA-C-O 118.027 -0.987 . . . . 0.0 110.044 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 87.0 p . . . . . 0 N--CA 1.456 -0.141 0 CA-C-O 120.662 0.268 . . . . 0.0 110.679 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 294' ' ' LYS . . . . . 0.405 ' C ' ' H ' ' A' ' 296' ' ' ASN . 41.2 mtpt -95.7 150.94 19.83 Favored 'General case' 0 N--CA 1.452 -0.328 0 CA-C-O 120.907 0.384 . . . . 0.0 111.081 -179.621 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 295' ' ' ASP . . . . . 0.457 ' C ' ' OD2' ' A' ' 295' ' ' ASP . 48.8 p30 -85.98 10.53 13.84 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 107.43 -1.322 . . . . 0.0 107.43 178.709 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 296' ' ' ASN . . . . . 0.405 ' H ' ' C ' ' A' ' 294' ' ' LYS . 23.6 m120 30.5 -102.09 0.02 OUTLIER 'General case' 0 CA--C 1.511 -0.549 0 CA-C-N 113.301 -1.772 . . . . 0.0 113.294 -179.218 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 297' ' ' ILE . . . . . . . . . . . . . 70.1 mt -113.5 130.31 67.74 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.454 0 CA-C-O 122.297 1.046 . . . . 0.0 113.486 -177.119 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 41.8 tttp -87.5 132.13 34.12 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 113.107 -1.86 . . . . 0.0 108.613 177.037 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 299' ' ' HIS . . . . . 0.575 ' CE1' ' CD ' ' A' ' 301' ' ' PRO . 37.4 t-80 -125.09 113.39 17.67 Favored 'General case' 0 N--CA 1.468 0.461 0 N-CA-C 112.676 0.621 . . . . 0.0 112.676 -179.116 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 3.2 m -134.16 73.34 70.07 Favored Pre-proline 0 N--CA 1.471 0.585 0 CA-C-N 116.196 -0.457 . . . . 0.0 112.191 178.075 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 301' ' ' PRO . . . . . 0.575 ' CD ' ' CE1' ' A' ' 299' ' ' HIS . 5.9 Cg_endo -60.56 -23.82 76.56 Favored 'Trans proline' 0 N--CA 1.5 1.901 0 CA-C-N 119.914 1.005 . . . . 0.0 113.067 179.211 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -134.21 -105.29 0.87 Allowed Glycine 0 CA--C 1.525 0.709 0 N-CA-C 111.149 -0.78 . . . . 0.0 111.149 -178.508 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . 86.4 35.64 10.46 Favored Glycine 0 N--CA 1.462 0.386 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 -178.81 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 96.56 -0.25 61.26 Favored Glycine 0 N--CA 1.446 -0.686 0 N-CA-C 108.991 -1.643 . . . . 0.0 108.991 -179.165 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 73.8 m -82.96 1.65 38.68 Favored 'General case' 0 N--CA 1.446 -0.661 0 CA-C-O 121.382 0.611 . . . . 0.0 109.558 178.675 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 306' ' ' VAL . . . . . 0.427 ' O ' ' HB3' ' A' ' 307' ' ' GLN . 73.6 t -61.64 -38.17 79.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 115.06 -0.973 . . . . 0.0 111.253 179.835 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 307' ' ' GLN . . . . . 0.628 ' O ' ' O ' ' A' ' 308' ' ' ILE . 50.3 tt0 79.87 103.03 0.07 Allowed 'General case' 0 CA--C 1.506 -0.729 0 O-C-N 123.6 0.562 . . . . 0.0 112.039 -178.663 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 308' ' ' ILE . . . . . 0.703 HG21 ' HD3' ' A' ' 312' ' ' PRO . 81.7 mt 51.24 149.68 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.443 -0.778 0 CA-C-O 122.256 1.027 . . . . 0.0 109.871 178.506 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . 0.673 HG13 ' CD1' ' A' ' 310' ' ' TYR . 6.3 p -56.34 -33.91 39.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 CA-C-N 114.886 -1.052 . . . . 0.0 111.777 -178.576 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 310' ' ' TYR . . . . . 0.808 ' CD1' ' N ' ' A' ' 311' ' ' LYS . 0.0 OUTLIER -161.55 -97.09 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.39 0 CA-C-O 123.896 1.808 . . . . 0.0 112.638 -178.37 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 311' ' ' LYS . . . . . 0.808 ' N ' ' CD1' ' A' ' 310' ' ' TYR . 32.6 mtmm -123.62 103.88 34.32 Favored Pre-proline 0 C--N 1.275 -2.667 0 CA-C-N 109.845 -3.343 . . . . 0.0 108.228 179.181 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 312' ' ' PRO . . . . . 0.703 ' HD3' HG21 ' A' ' 308' ' ' ILE . 9.7 Cg_endo -49.1 151.95 5.51 Favored 'Trans proline' 0 C--N 1.299 -2.038 0 N-CA-C 106.626 -2.106 . . . . 0.0 106.626 179.081 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 313' ' ' VAL . . . . . 0.724 HG12 ' H ' ' A' ' 315' ' ' LEU . 44.3 t -59.53 128.5 20.51 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.585 0 C-N-CA 117.671 -1.611 . . . . 0.0 111.948 -173.434 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 314' ' ' ASP . . . . . 0.497 ' O ' ' HG2' ' A' ' 317' ' ' LYS . 49.2 p30 -97.33 -0.63 46.15 Favored 'General case' 0 N--CA 1.438 -1.058 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 175.897 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 315' ' ' LEU . . . . . 0.724 ' H ' HG12 ' A' ' 313' ' ' VAL . 64.8 mt -64.85 -31.44 72.68 Favored 'General case' 0 N--CA 1.469 0.504 0 O-C-N 123.774 0.671 . . . . 0.0 110.735 178.319 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 89.9 p -58.19 -25.56 61.73 Favored 'General case' 0 N--CA 1.448 -0.545 0 CA-C-N 114.962 -1.017 . . . . 0.0 110.276 -177.453 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 317' ' ' LYS . . . . . 0.497 ' HG2' ' O ' ' A' ' 314' ' ' ASP . 52.2 pttt -59.6 -33.57 71.64 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.349 -0.612 . . . . 0.0 109.349 -179.319 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 318' ' ' VAL . . . . . 0.422 ' N ' ' CG ' ' A' ' 317' ' ' LYS . 74.7 t -60.37 -39.81 82.12 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.132 0 CA-C-N 115.099 -0.955 . . . . 0.0 111.501 -178.807 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 7.1 m . . . . . 0 C--O 1.22 -0.482 0 CA-C-O 117.935 -1.031 . . . . 0.0 110.529 -179.76 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 45.3 m . . . . . 0 N--CA 1.461 0.088 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 294' ' ' LYS . . . . . 0.458 ' C ' ' H ' ' A' ' 296' ' ' ASN . 88.2 mttt -103.75 145.81 29.54 Favored 'General case' 0 N--CA 1.449 -0.477 0 CA-C-O 121.442 0.639 . . . . 0.0 112.014 -179.156 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 295' ' ' ASP . . . . . 0.47 ' C ' ' OD2' ' A' ' 295' ' ' ASP . 49.2 p30 -89.52 12.76 15.66 Favored 'General case' 0 CA--C 1.49 -1.332 0 N-CA-C 106.35 -1.722 . . . . 0.0 106.35 176.68 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 296' ' ' ASN . . . . . 0.609 ' CG ' ' H ' ' A' ' 297' ' ' ILE . 49.4 t30 36.48 -147.95 0.01 OUTLIER 'General case' 0 N--CA 1.426 -1.626 0 CA-C-N 112.362 -2.199 . . . . 0.0 110.697 -178.717 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 297' ' ' ILE . . . . . 0.609 ' H ' ' CG ' ' A' ' 296' ' ' ASN . 8.8 tp -123.2 132.67 70.98 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 CA-C-O 122.642 1.21 . . . . 0.0 112.809 -177.446 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 75.8 tttt -94.48 130.16 40.97 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-N 112.323 -2.217 . . . . 0.0 109.702 177.014 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 39.0 t-80 -132.18 136.21 46.89 Favored 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 119.701 -0.8 . . . . 0.0 111.784 179.613 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -125.76 74.77 70.57 Favored Pre-proline 0 N--CA 1.477 0.893 0 CA-C-O 120.4 0.143 . . . . 0.0 111.368 178.987 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -59.94 -21.28 63.95 Favored 'Trans proline' 0 N--CA 1.494 1.523 0 C-N-CA 122.529 2.153 . . . . 0.0 112.089 178.734 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . 114.03 130.63 5.1 Favored Glycine 0 CA--C 1.52 0.355 0 N-CA-C 107.418 -2.273 . . . . 0.0 107.418 -177.279 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -96.44 -78.77 1.43 Allowed Glycine 0 CA--C 1.523 0.564 0 C-N-CA 119.457 -1.354 . . . . 0.0 113.219 -177.853 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . -86.16 -35.29 11.14 Favored Glycine 0 CA--C 1.522 0.486 0 C-N-CA 121.201 -0.524 . . . . 0.0 112.589 -179.778 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 305' ' ' SER . . . . . 0.504 ' O ' ' O ' ' A' ' 306' ' ' VAL . 93.9 p -61.63 -30.02 70.43 Favored 'General case' 0 CA--C 1.513 -0.476 0 N-CA-C 114.263 1.209 . . . . 0.0 114.263 -176.756 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 306' ' ' VAL . . . . . 0.504 ' O ' ' O ' ' A' ' 305' ' ' SER . 16.8 t -27.25 -99.88 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 O-C-N 123.57 0.544 . . . . 0.0 112.395 -177.615 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 307' ' ' GLN . . . . . 0.425 ' HG2' ' N ' ' A' ' 308' ' ' ILE . 51.6 tt0 -143.14 158.07 43.95 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.635 179.857 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 308' ' ' ILE . . . . . 0.995 HD11 ' CZ ' ' A' ' 310' ' ' TYR . 5.0 tp -120.96 127.86 76.0 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.673 0 C-N-CA 120.05 -0.66 . . . . 0.0 109.635 177.635 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 73.7 t -67.98 -42.91 85.83 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.565 0 N-CA-C 114.975 1.472 . . . . 0.0 114.975 -179.57 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 310' ' ' TYR . . . . . 0.995 ' CZ ' HD11 ' A' ' 308' ' ' ILE 0.312 2.7 p90 -66.27 -28.14 68.48 Favored 'General case' 0 N--CA 1.469 0.499 0 N-CA-C 116.931 2.197 . . . . 0.0 116.931 -177.019 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 311' ' ' LYS . . . . . 0.536 ' O ' ' O ' ' A' ' 312' ' ' PRO . 10.6 mtpt 56.17 63.23 6.06 Favored Pre-proline 0 C--N 1.307 -1.248 0 C-N-CA 118.74 -1.184 . . . . 0.0 108.534 -178.959 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 312' ' ' PRO . . . . . 0.573 ' O ' ' N ' ' A' ' 314' ' ' ASP . 32.6 Cg_exo 23.62 112.06 0.0 OUTLIER 'Trans proline' 0 C--N 1.316 -1.157 0 C-N-CA 122.752 2.301 . . . . 0.0 115.214 -179.339 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 313' ' ' VAL . . . . . 0.469 ' C ' ' O ' ' A' ' 312' ' ' PRO . 2.1 m 8.15 55.77 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.232 0.141 0 CA-C-N 113.519 -1.673 . . . . 0.0 113.27 179.185 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 314' ' ' ASP . . . . . 0.573 ' N ' ' O ' ' A' ' 312' ' ' PRO . 55.2 t0 -55.37 -36.11 66.0 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 109.962 -0.385 . . . . 0.0 109.962 178.757 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 315' ' ' LEU . . . . . 0.714 ' H ' HD12 ' A' ' 315' ' ' LEU . 6.5 mp -59.27 -35.69 74.19 Favored 'General case' 0 N--CA 1.464 0.254 0 C-N-CA 120.61 -0.436 . . . . 0.0 111.577 -179.344 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 85.4 p -61.71 -27.34 68.64 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.352 0.596 . . . . 0.0 110.038 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 317' ' ' LYS . . . . . 0.42 ' HB3' ' O ' ' A' ' 314' ' ' ASP . 38.9 tttp -57.37 -39.1 75.31 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.265 -0.879 . . . . 0.0 111.112 -178.656 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 70.6 t -63.21 -39.26 84.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 121.128 0.489 . . . . 0.0 110.323 178.747 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 1.9 m . . . . . 0 C--O 1.22 -0.493 0 CA-C-O 118.068 -0.968 . . . . 0.0 110.282 -178.836 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 30.8 t . . . . . 0 N--CA 1.463 0.198 0 CA-C-O 121.098 0.475 . . . . 0.0 111.242 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 25.5 mttm -99.32 152.18 20.22 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.749 179.186 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 295' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -55.29 -37.14 66.94 Favored 'General case' 0 CA--C 1.497 -1.086 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.424 -179.547 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 296' ' ' ASN . . . . . 0.727 HD22 ' N ' ' A' ' 296' ' ' ASN . 0.0 OUTLIER 175.5 -103.07 0.0 OUTLIER 'General case' 0 C--N 1.308 -1.219 0 CA-C-O 121.97 0.891 . . . . 0.0 111.0 179.907 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 297' ' ' ILE . . . . . 0.807 ' O ' HG23 ' A' ' 297' ' ' ILE . 19.2 tt 137.32 86.92 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 CA-C-N 111.977 -2.374 . . . . 0.0 106.722 -178.124 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 36.0 mttt -83.25 137.23 34.1 Favored 'General case' 0 C--N 1.317 -0.828 0 C-N-CA 119.39 -0.924 . . . . 0.0 112.374 -177.247 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 56.8 t-80 -130.76 117.81 19.94 Favored 'General case' 0 N--CA 1.441 -0.899 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 175.686 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -125.63 77.32 69.55 Favored Pre-proline 0 C--N 1.324 -0.526 0 C-N-CA 120.704 -0.398 . . . . 0.0 111.36 -179.625 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 85.5 Cg_endo -57.79 -23.66 59.75 Favored 'Trans proline' 0 C--N 1.313 -1.308 0 N-CA-C 109.99 -0.812 . . . . 0.0 109.99 179.224 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -173.43 128.15 1.46 Allowed Glycine 0 CA--C 1.523 0.563 0 CA-C-N 114.81 -1.086 . . . . 0.0 110.84 179.193 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -82.05 4.84 74.02 Favored Glycine 0 N--CA 1.462 0.397 0 N-CA-C 108.701 -1.76 . . . . 0.0 108.701 178.414 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 98.4 -8.08 62.14 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 109.845 -1.302 . . . . 0.0 109.845 -179.259 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 305' ' ' SER . . . . . 0.465 ' O ' ' C ' ' A' ' 306' ' ' VAL . 20.3 m -59.9 -34.93 73.83 Favored 'General case' 0 CA--C 1.521 -0.172 0 CA-C-O 121.953 0.882 . . . . 0.0 109.463 177.557 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 306' ' ' VAL . . . . . 0.465 ' C ' ' O ' ' A' ' 305' ' ' SER . 7.7 t -13.61 -104.0 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 CA-C-N 113.475 -1.693 . . . . 0.0 113.697 -177.902 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 307' ' ' GLN . . . . . 0.412 ' H ' ' HB ' ' A' ' 306' ' ' VAL . 21.7 pt20 -145.16 170.71 15.7 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.177 -178.1 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 308' ' ' ILE . . . . . 0.921 HG23 ' CD2' ' A' ' 310' ' ' TYR . 71.8 mt -97.28 116.96 41.02 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.095 0 N-CA-C 115.677 1.732 . . . . 0.0 115.677 -178.529 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 5.9 p -69.86 -32.29 51.3 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.462 0 CA-C-N 113.59 -1.641 . . . . 0.0 108.731 172.751 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 310' ' ' TYR . . . . . 0.921 ' CD2' HG23 ' A' ' 308' ' ' ILE 0.412 51.6 p90 -62.44 -10.71 12.46 Favored 'General case' 0 C--N 1.346 0.435 0 N-CA-C 117.817 2.525 . . . . 0.0 117.817 -177.203 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 311' ' ' LYS . . . . . 0.472 ' O ' ' C ' ' A' ' 312' ' ' PRO . 9.3 mmtt 63.68 67.53 0.98 Allowed Pre-proline 0 N--CA 1.475 0.813 0 CA-C-N 118.853 0.751 . . . . 0.0 112.406 177.235 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 312' ' ' PRO . . . . . 0.602 ' HD3' HG21 ' A' ' 308' ' ' ILE . 61.2 Cg_exo -0.99 -114.3 0.0 OUTLIER 'Trans proline' 0 N--CA 1.489 1.244 0 C-N-CA 123.093 2.529 . . . . 0.0 116.361 179.598 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 16.1 m -111.31 21.03 5.97 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.478 0 N-CA-C 113.071 0.767 . . . . 0.0 113.071 -176.761 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 58.2 t0 -51.33 -36.86 44.75 Favored 'General case' 0 C--N 1.323 -0.568 0 C-N-CA 120.271 -0.572 . . . . 0.0 111.176 -178.105 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 315' ' ' LEU . . . . . 0.635 ' N ' ' CD2' ' A' ' 315' ' ' LEU . 0.2 OUTLIER -60.05 -36.93 78.38 Favored 'General case' 0 C--N 1.33 -0.241 0 C-N-CA 118.983 -1.087 . . . . 0.0 109.496 178.458 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 21.5 t -59.49 -31.36 69.29 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.886 178.36 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 7.7 ttpp -56.17 -35.34 67.1 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.087 -0.961 . . . . 0.0 111.416 -176.879 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 43.0 t -112.27 134.74 53.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 121.017 0.436 . . . . 0.0 110.491 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 1.1 m . . . . . 0 C--O 1.22 -0.457 0 CA-C-O 117.916 -1.04 . . . . 0.0 110.695 -179.671 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 74.7 m . . . . . 0 CA--C 1.527 0.081 0 CA-C-O 120.647 0.26 . . . . 0.0 110.69 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 64.8 mttp -91.65 144.42 25.55 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 179.443 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 295' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -57.93 -39.59 78.37 Favored 'General case' 0 CA--C 1.507 -0.691 0 C-N-CA 120.069 -0.652 . . . . 0.0 111.688 -178.857 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 296' ' ' ASN . . . . . 0.445 ' HB3' ' H ' ' A' ' 297' ' ' ILE . 46.7 t-20 177.92 -94.41 0.0 OUTLIER 'General case' 0 C--N 1.314 -0.978 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 179.1 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 297' ' ' ILE . . . . . 0.445 ' H ' ' HB3' ' A' ' 296' ' ' ASN . 18.1 tt 174.62 3.82 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 113.715 -1.584 . . . . 0.0 109.808 179.431 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 298' ' ' LYS . . . . . 0.428 ' H ' ' H ' ' A' ' 297' ' ' ILE . 29.1 mttt 64.69 47.59 2.76 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-O 120.856 0.36 . . . . 0.0 110.705 -179.693 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 299' ' ' HIS . . . . . 0.401 ' ND1' ' O ' ' A' ' 299' ' ' HIS . 58.4 t-80 -74.07 65.43 1.12 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.139 -179.389 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 4.8 t -124.87 75.13 65.89 Favored Pre-proline 0 N--CA 1.465 0.319 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.323 178.974 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -57.81 -24.74 65.47 Favored 'Trans proline' 0 C--N 1.311 -1.427 0 C-N-CA 121.29 1.327 . . . . 0.0 111.431 -179.385 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -163.05 121.8 1.05 Allowed Glycine 0 CA--C 1.524 0.64 0 C-N-CA 120.624 -0.798 . . . . 0.0 111.656 179.76 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -82.32 1.21 87.88 Favored Glycine 0 CA--C 1.527 0.836 0 N-CA-C 110.264 -1.134 . . . . 0.0 110.264 178.534 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 96.79 -7.62 65.33 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.061 -1.215 . . . . 0.0 110.061 -179.788 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 305' ' ' SER . . . . . 0.455 ' O ' ' C ' ' A' ' 306' ' ' VAL . 25.9 t -60.04 -32.62 71.08 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.537 0.684 . . . . 0.0 109.232 177.07 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 306' ' ' VAL . . . . . 0.458 HG23 ' H ' ' A' ' 307' ' ' GLN . 0.0 OUTLIER -20.45 -90.5 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 CA-C-N 113.999 -1.455 . . . . 0.0 112.962 -177.44 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 307' ' ' GLN . . . . . 0.458 ' H ' HG23 ' A' ' 306' ' ' VAL . 2.6 pt20 -143.22 167.95 20.92 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.341 -0.845 . . . . 0.0 111.067 -177.329 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 308' ' ' ILE . . . . . 0.543 HG23 ' CE2' ' A' ' 310' ' ' TYR . 67.1 mt -107.4 120.89 59.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-O 121.751 0.786 . . . . 0.0 111.075 -179.699 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . 0.467 ' CG1' ' N ' ' A' ' 310' ' ' TYR . 8.0 p -66.04 -36.38 77.33 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.847 0 CA-C-O 122.206 1.003 . . . . 0.0 108.914 174.876 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 310' ' ' TYR . . . . . 0.543 ' CE2' HG23 ' A' ' 308' ' ' ILE 0.448 51.1 p90 -64.53 -32.12 73.62 Favored 'General case' 0 N--CA 1.451 -0.407 0 N-CA-C 118.194 2.665 . . . . 0.0 118.194 -177.996 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 311' ' ' LYS . . . . . 0.49 ' C ' ' O ' ' A' ' 310' ' ' TYR . 49.6 mtpt 47.98 72.23 1.33 Allowed Pre-proline 0 C--N 1.317 -0.805 0 C-N-CA 116.942 -1.903 . . . . 0.0 108.74 176.728 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 312' ' ' PRO . . . . . . . . . . . . . 7.0 Cg_endo -42.88 -37.54 6.14 Favored 'Trans proline' 0 N--CA 1.505 2.148 0 N-CA-C 114.364 0.871 . . . . 0.0 114.364 -173.754 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 71.6 t -62.95 -38.23 81.39 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.059 0 N-CA-C 116.417 2.006 . . . . 0.0 116.417 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 60.3 t0 -54.33 -43.84 71.57 Favored 'General case' 0 N--CA 1.467 0.416 0 O-C-N 120.589 -1.32 . . . . 0.0 114.415 -173.899 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 315' ' ' LEU . . . . . 0.651 ' N ' ' CD2' ' A' ' 315' ' ' LEU . 0.3 OUTLIER -66.8 -36.43 82.38 Favored 'General case' 0 C--N 1.319 -0.751 0 C-N-CA 118.308 -1.357 . . . . 0.0 109.068 176.628 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 32.8 m -59.7 -34.88 73.47 Favored 'General case' 0 N--CA 1.45 -0.47 0 CA-C-N 115.091 -0.959 . . . . 0.0 110.719 178.262 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 30.1 ttpt -80.12 125.63 30.06 Favored 'General case' 0 N--CA 1.45 -0.429 0 CA-C-O 121.697 0.761 . . . . 0.0 111.701 -177.25 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 318' ' ' VAL . . . . . 0.445 ' O ' ' OG1' ' A' ' 319' ' ' THR . 13.2 p -134.39 142.45 40.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 114.814 -1.084 . . . . 0.0 109.262 178.468 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 319' ' ' THR . . . . . 0.445 ' OG1' ' O ' ' A' ' 318' ' ' VAL . 0.7 OUTLIER . . . . . 0 C--O 1.219 -0.513 0 CA-C-O 117.962 -1.018 . . . . 0.0 111.227 179.314 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 29.9 t . . . . . 0 C--O 1.232 0.159 0 CA-C-O 121.335 0.588 . . . . 0.0 110.228 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 1.9 mtpt -133.45 -166.65 1.8 Allowed 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.117 -0.947 . . . . 0.0 111.427 -179.313 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 295' ' ' ASP . . . . . 0.48 ' C ' ' OD1' ' A' ' 295' ' ' ASP . 48.7 p30 -82.92 11.04 6.6 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.19 -0.913 . . . . 0.0 109.203 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 17.6 m120 46.17 -138.34 0.58 Allowed 'General case' 0 CA--C 1.497 -1.074 0 CA-C-N 114.407 -1.27 . . . . 0.0 111.613 179.818 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 297' ' ' ILE . . . . . 0.6 HD11 ' CD2' ' A' ' 299' ' ' HIS . 13.9 tt -121.23 126.79 75.48 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-O 122.357 1.075 . . . . 0.0 111.404 -177.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 6.1 mtpm? -61.09 -36.52 79.89 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-N 112.98 -1.918 . . . . 0.0 112.568 179.13 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 299' ' ' HIS . . . . . 0.6 ' CD2' HD11 ' A' ' 297' ' ' ILE . 1.4 m170 38.21 60.89 1.19 Allowed 'General case' 0 CA--C 1.537 0.473 0 CA-C-O 121.175 0.512 . . . . 0.0 112.266 -179.657 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . 0.415 ' C ' ' N ' ' A' ' 302' ' ' GLY . 3.1 m -123.47 72.65 49.81 Favored Pre-proline 0 N--CA 1.464 0.274 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.009 178.658 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 301' ' ' PRO . . . . . 0.401 ' CD ' ' H ' ' A' ' 302' ' ' GLY . 44.5 Cg_endo -58.34 -17.8 35.1 Favored 'Trans proline' 0 C--N 1.317 -1.127 0 N-CA-C 107.96 -1.592 . . . . 0.0 107.96 177.72 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 302' ' ' GLY . . . . . 0.415 ' N ' ' C ' ' A' ' 300' ' ' VAL . . . 116.61 156.13 10.58 Favored Glycine 0 N--CA 1.443 -0.846 0 CA-C-N 112.801 -2.0 . . . . 0.0 109.788 -179.014 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 303' ' ' GLY . . . . . 0.661 ' O ' ' N ' ' A' ' 305' ' ' SER . . . -163.69 -178.96 37.74 Favored Glycine 0 N--CA 1.446 -0.688 0 N-CA-C 108.528 -1.829 . . . . 0.0 108.528 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 59.32 -70.43 0.01 OUTLIER Glycine 0 CA--C 1.529 0.926 0 N-CA-C 109.815 -1.314 . . . . 0.0 109.815 -179.11 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 305' ' ' SER . . . . . 0.661 ' N ' ' O ' ' A' ' 303' ' ' GLY . 23.0 t -58.0 -33.97 69.5 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 121.081 0.467 . . . . 0.0 111.578 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 306' ' ' VAL . . . . . 0.627 HG23 ' H ' ' A' ' 307' ' ' GLN . 2.3 m -36.84 -100.91 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 N-CA-C 114.251 1.204 . . . . 0.0 114.251 -178.256 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 307' ' ' GLN . . . . . 0.627 ' H ' HG23 ' A' ' 306' ' ' VAL . 54.8 mt-30 -113.35 160.3 18.52 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 114.429 -1.26 . . . . 0.0 111.776 -176.376 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 308' ' ' ILE . . . . . 0.875 HG22 ' H ' ' A' ' 311' ' ' LYS . 34.9 mm -103.12 119.11 51.1 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-O 122.006 0.907 . . . . 0.0 112.635 -179.506 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 77.4 t -67.81 -40.27 83.38 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 CA-C-N 113.51 -1.677 . . . . 0.0 107.481 174.549 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 310' ' ' TYR . . . . . 0.641 ' CD2' HG23 ' A' ' 308' ' ' ILE 0.361 51.2 p90 -62.7 -31.05 71.89 Favored 'General case' 0 N--CA 1.446 -0.634 0 N-CA-C 117.467 2.395 . . . . 0.0 117.467 -178.676 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 311' ' ' LYS . . . . . 0.875 ' H ' HG22 ' A' ' 308' ' ' ILE . 19.4 mtpp 52.89 65.57 5.8 Favored Pre-proline 0 C--N 1.319 -0.731 0 CA-C-N 119.815 1.189 . . . . 0.0 110.223 178.773 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 312' ' ' PRO . . . . . 0.45 ' C ' ' O ' ' A' ' 311' ' ' LYS . 78.4 Cg_exo 7.67 -129.04 0.0 OUTLIER 'Trans proline' 0 C--N 1.316 -1.171 0 C-N-CA 123.264 2.643 . . . . 0.0 116.937 -179.216 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 313' ' ' VAL . . . . . 0.47 ' O ' ' OG ' ' A' ' 316' ' ' SER . 17.6 m -112.89 28.77 2.28 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 CA-C-N 114.775 -1.102 . . . . 0.0 113.542 -175.931 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 314' ' ' ASP . . . . . 0.4 ' O ' ' CB ' ' A' ' 317' ' ' LYS . 92.1 m-20 -51.51 -36.46 44.79 Favored 'General case' 0 C--N 1.319 -0.751 0 C-N-CA 119.66 -0.816 . . . . 0.0 111.17 -177.127 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 315' ' ' LEU . . . . . 0.633 ' CD2' ' N ' ' A' ' 315' ' ' LEU . 0.3 OUTLIER -59.81 -35.34 74.5 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 119.819 -0.752 . . . . 0.0 110.414 178.587 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . 0.47 ' OG ' ' O ' ' A' ' 313' ' ' VAL . 82.6 p -62.44 -21.12 65.17 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-O 121.431 0.634 . . . . 0.0 110.364 179.373 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 317' ' ' LYS . . . . . 0.4 ' CB ' ' O ' ' A' ' 314' ' ' ASP . 82.0 tttt -55.29 -34.53 64.18 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.071 -0.968 . . . . 0.0 111.779 -177.399 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 13.1 p -129.08 142.55 43.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 C-N-CA 120.471 -0.492 . . . . 0.0 110.789 179.657 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.221 -0.439 0 CA-C-O 118.008 -0.996 . . . . 0.0 110.555 -179.644 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 97.6 p . . . . . 0 C--O 1.231 0.116 0 CA-C-O 121.117 0.484 . . . . 0.0 110.687 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -133.59 170.67 15.19 Favored 'General case' 0 CA--C 1.506 -0.728 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.673 -179.499 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 295' ' ' ASP . . . . . . . . . . . . . 86.0 m-20 -63.12 143.71 57.55 Favored 'General case' 0 N--CA 1.438 -1.063 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 -179.769 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 22.3 t-20 -64.77 130.5 43.74 Favored 'General case' 0 C--N 1.309 -1.174 0 CA-C-N 115.246 -0.888 . . . . 0.0 111.669 -177.595 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 297' ' ' ILE . . . . . . . . . . . . . 71.4 mt -115.18 132.12 65.41 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.09 0 CA-C-N 114.856 -1.065 . . . . 0.0 110.545 -179.762 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 73.1 tttt -105.66 135.62 46.74 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.85 179.184 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 99.3 m-70 -118.94 140.48 49.92 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.089 178.451 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 3.6 m -123.98 78.28 58.44 Favored Pre-proline 0 C--N 1.33 -0.255 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.358 -179.156 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -56.53 145.82 78.3 Favored 'Trans proline' 0 C--N 1.312 -1.371 0 N-CA-C 109.244 -1.099 . . . . 0.0 109.244 178.807 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -49.36 107.52 0.32 Allowed Glycine 0 CA--C 1.52 0.375 0 C-N-CA 118.92 -1.61 . . . . 0.0 109.769 -178.864 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -77.92 -2.13 81.01 Favored Glycine 0 C--N 1.33 0.23 0 N-CA-C 109.798 -1.321 . . . . 0.0 109.798 179.59 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 95.33 -1.93 64.94 Favored Glycine 0 N--CA 1.45 -0.402 0 N-CA-C 108.958 -1.657 . . . . 0.0 108.958 -178.883 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 73.9 m -83.24 1.83 38.85 Favored 'General case' 0 N--CA 1.453 -0.32 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 178.505 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 306' ' ' VAL . . . . . . . . . . . . . 71.6 t -61.08 -39.93 83.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.062 -0.972 . . . . 0.0 110.214 -179.467 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 307' ' ' GLN . . . . . 0.855 ' HG3' ' H ' ' A' ' 308' ' ' ILE . 21.2 pt20 -159.63 -88.24 0.03 OUTLIER 'General case' 0 CA--C 1.542 0.637 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.824 179.065 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 308' ' ' ILE . . . . . 0.855 ' H ' ' HG3' ' A' ' 307' ' ' GLN . 32.0 pt -125.22 160.94 30.24 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 CA-C-N 118.985 0.811 . . . . 0.0 111.305 179.525 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . 0.926 HG13 ' H ' ' A' ' 310' ' ' TYR . 3.9 p -136.65 -65.26 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 178.199 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 310' ' ' TYR . . . . . 0.926 ' H ' HG13 ' A' ' 309' ' ' VAL . 0.8 OUTLIER -66.31 -19.47 65.82 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.288 -0.869 . . . . 0.0 112.484 178.461 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 311' ' ' LYS . . . . . 0.534 ' O ' ' C ' ' A' ' 312' ' ' PRO . 43.9 tttt 67.55 65.21 0.66 Allowed Pre-proline 0 C--N 1.326 -0.439 0 C-N-CA 120.791 -0.364 . . . . 0.0 110.674 -179.358 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 312' ' ' PRO . . . . . 0.568 ' O ' ' C ' ' A' ' 313' ' ' VAL . 70.6 Cg_exo 3.9 75.75 0.0 OUTLIER 'Trans proline' 0 N--CA 1.488 1.152 0 C-N-CA 122.924 2.416 . . . . 0.0 114.016 179.812 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 313' ' ' VAL . . . . . 0.601 HG13 ' O ' ' A' ' 313' ' ' VAL . 13.7 p 1.33 71.18 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 O-C-N 124.085 0.866 . . . . 0.0 111.434 179.643 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 314' ' ' ASP . . . . . 0.506 ' N ' ' O ' ' A' ' 312' ' ' PRO . 21.7 t70 -55.18 -36.56 66.02 Favored 'General case' 0 CA--C 1.536 0.416 0 CA-C-N 114.464 -1.244 . . . . 0.0 112.992 -178.586 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 315' ' ' LEU . . . . . 0.635 ' N ' ' CD2' ' A' ' 315' ' ' LEU . 0.2 OUTLIER -58.88 -35.25 72.68 Favored 'General case' 0 N--CA 1.465 0.291 0 C-N-CA 120.585 -0.446 . . . . 0.0 111.258 -178.65 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . 0.435 ' OG ' HG13 ' A' ' 313' ' ' VAL . 84.1 p -61.83 -26.39 68.09 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.002 0.43 . . . . 0.0 110.91 179.873 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 32.0 mmtm -58.07 -36.18 72.44 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.892 -0.595 . . . . 0.0 111.784 -177.397 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 13.3 p -132.47 143.11 40.81 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.26 0 CA-C-O 120.607 0.241 . . . . 0.0 111.077 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 27.0 p . . . . . 0 C--O 1.221 -0.446 0 CA-C-O 117.83 -1.081 . . . . 0.0 110.422 179.443 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 74.3 m . . . . . 0 C--O 1.231 0.108 0 CA-C-O 120.858 0.361 . . . . 0.0 110.457 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 76.9 mttt -96.56 151.52 19.51 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.439 179.699 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 295' ' ' ASP . . . . . 0.469 ' C ' ' OD1' ' A' ' 295' ' ' ASP . 48.9 p30 -86.7 9.86 17.49 Favored 'General case' 0 CA--C 1.503 -0.852 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 178.844 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 296' ' ' ASN . . . . . 0.565 ' CG ' ' H ' ' A' ' 297' ' ' ILE . 37.3 t-20 58.78 -143.17 0.62 Allowed 'General case' 0 CA--C 1.49 -1.341 0 CA-C-N 114.369 -1.287 . . . . 0.0 110.598 179.579 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 297' ' ' ILE . . . . . 0.565 ' H ' ' CG ' ' A' ' 296' ' ' ASN . 14.4 tt -121.4 131.19 73.65 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 CA-C-O 122.482 1.134 . . . . 0.0 112.416 -177.899 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 83.6 tttt -93.88 131.17 39.56 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-N 112.66 -2.064 . . . . 0.0 109.447 177.475 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 49.7 t-80 -128.26 137.05 51.82 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 120.114 -0.635 . . . . 0.0 110.86 179.792 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -124.21 76.55 60.43 Favored Pre-proline 0 N--CA 1.469 0.505 0 CA-C-N 116.804 -0.18 . . . . 0.0 111.065 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 83.6 Cg_endo -58.97 -25.49 77.75 Favored 'Trans proline' 0 N--CA 1.489 1.254 0 C-N-CA 121.126 1.217 . . . . 0.0 111.009 179.193 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . 174.77 133.61 1.75 Allowed Glycine 0 CA--C 1.532 1.125 0 CA-C-N 115.309 -0.86 . . . . 0.0 111.444 179.785 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -117.37 48.16 0.97 Allowed Glycine 0 CA--C 1.533 1.207 0 N-CA-C 110.534 -1.026 . . . . 0.0 110.534 179.565 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 99.1 -7.72 60.53 Favored Glycine 0 N--CA 1.466 0.687 0 N-CA-C 109.01 -1.636 . . . . 0.0 109.01 -178.143 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 27.9 t -83.68 -0.55 51.2 Favored 'General case' 0 CA--C 1.516 -0.327 0 N-CA-C 107.03 -1.47 . . . . 0.0 107.03 175.816 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 306' ' ' VAL . . . . . 0.623 ' O ' ' CB ' ' A' ' 307' ' ' GLN . 99.5 t -58.77 -41.56 82.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 113.569 -1.651 . . . . 0.0 112.193 -175.683 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 307' ' ' GLN . . . . . 0.623 ' CB ' ' O ' ' A' ' 306' ' ' VAL . 63.0 tt0 122.86 172.36 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.792 0 O-C-N 124.631 1.207 . . . . 0.0 108.023 -179.298 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 308' ' ' ILE . . . . . 0.494 ' N ' ' HG2' ' A' ' 307' ' ' GLN . 29.4 pt -121.25 155.24 25.11 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 N-CA-C 110.11 -0.329 . . . . 0.0 110.11 179.384 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . 0.59 ' O ' HG12 ' A' ' 309' ' ' VAL . 58.9 t -133.74 -5.62 1.34 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.292 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.611 179.569 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 310' ' ' TYR . . . . . 0.511 ' CD1' ' HD3' ' A' ' 312' ' ' PRO . 2.0 p90 -65.87 -18.29 65.24 Favored 'General case' 0 CA--C 1.517 -0.298 0 N-CA-C 112.508 0.559 . . . . 0.0 112.508 -176.481 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 311' ' ' LYS . . . . . 0.49 ' O ' ' C ' ' A' ' 312' ' ' PRO . 1.9 mtmm 59.38 64.91 2.84 Favored Pre-proline 0 C--N 1.325 -0.461 0 N-CA-C 107.252 -1.388 . . . . 0.0 107.252 -179.411 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 312' ' ' PRO . . . . . 0.511 ' HD3' ' CD1' ' A' ' 310' ' ' TYR . 1.1 Cg_exo -14.06 -62.1 0.01 OUTLIER 'Trans proline' 0 C--N 1.305 -1.731 0 C-N-CA 123.065 2.51 . . . . 0.0 114.536 -178.517 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 313' ' ' VAL . . . . . 0.768 HG22 ' OG ' ' A' ' 316' ' ' SER . 2.6 p -176.18 27.07 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 C-N-CA 120.397 -0.521 . . . . 0.0 111.314 179.621 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 92.9 m-20 -57.85 -37.66 74.29 Favored 'General case' 0 C--N 1.32 -0.705 0 N-CA-C 112.135 0.421 . . . . 0.0 112.135 -179.027 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 315' ' ' LEU . . . . . 0.741 ' O ' HG22 ' A' ' 318' ' ' VAL . 0.1 OUTLIER -56.95 -39.49 74.66 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 120.203 -0.599 . . . . 0.0 109.806 -178.671 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . 0.768 ' OG ' HG22 ' A' ' 313' ' ' VAL . 86.6 p -63.34 -27.2 69.15 Favored 'General case' 0 N--CA 1.471 0.601 0 O-C-N 122.057 -0.402 . . . . 0.0 111.976 178.595 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 57.2 tttp -58.2 -36.17 72.7 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.156 -0.475 . . . . 0.0 112.114 -177.858 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 318' ' ' VAL . . . . . 0.741 HG22 ' O ' ' A' ' 315' ' ' LEU . 27.9 m -76.0 136.75 24.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-O 121.213 0.53 . . . . 0.0 111.097 -179.21 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 43.6 m . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 118.044 -0.979 . . . . 0.0 110.31 -179.952 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 46.7 m . . . . . 0 N--CA 1.46 0.074 0 N-CA-C 110.322 -0.251 . . . . 0.0 110.322 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 294' ' ' LYS . . . . . 0.445 ' C ' ' H ' ' A' ' 296' ' ' ASN . 11.5 mtpp -98.99 148.47 23.96 Favored 'General case' 0 N--CA 1.448 -0.569 0 CA-C-O 120.989 0.423 . . . . 0.0 111.188 -179.56 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 295' ' ' ASP . . . . . 0.471 ' OD2' ' C ' ' A' ' 295' ' ' ASP . 49.7 p30 -86.85 10.82 14.88 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 107.079 -1.452 . . . . 0.0 107.079 178.37 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 296' ' ' ASN . . . . . 0.445 ' H ' ' C ' ' A' ' 294' ' ' LYS . 81.1 m-20 29.17 -127.51 0.03 OUTLIER 'General case' 0 CA--C 1.5 -0.953 0 CA-C-N 112.604 -2.089 . . . . 0.0 113.467 -178.348 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 297' ' ' ILE . . . . . 0.448 ' O ' HG23 ' A' ' 297' ' ' ILE . 14.7 tt -121.86 130.47 74.56 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.709 0 CA-C-O 122.473 1.13 . . . . 0.0 113.024 -177.469 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 15.6 ttmm -100.84 127.63 47.21 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-N 112.715 -2.039 . . . . 0.0 109.675 176.933 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 50.6 t-80 -136.33 114.33 11.37 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 120.552 -0.459 . . . . 0.0 111.479 179.193 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 3.2 m -133.89 72.87 72.2 Favored Pre-proline 0 N--CA 1.476 0.858 0 N-CA-C 113.953 1.094 . . . . 0.0 113.953 179.269 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 8.4 Cg_endo -61.25 -23.41 77.0 Favored 'Trans proline' 0 N--CA 1.502 2.017 0 CA-C-N 119.978 1.028 . . . . 0.0 112.026 177.732 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -77.01 46.25 2.38 Favored Glycine 0 CA--C 1.528 0.883 0 CA-C-N 115.121 -0.945 . . . . 0.0 113.194 -178.171 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -57.7 -28.53 60.22 Favored Glycine 0 N--CA 1.445 -0.7 0 N-CA-C 107.397 -2.281 . . . . 0.0 107.397 178.122 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 95.94 -0.56 62.62 Favored Glycine 0 N--CA 1.44 -1.038 0 N-CA-C 104.355 -3.498 . . . . 0.0 104.355 -175.594 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 72.8 m -83.06 1.36 40.52 Favored 'General case' 0 N--CA 1.436 -1.155 0 CA-C-N 112.486 -1.857 . . . . 0.0 110.314 179.295 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 306' ' ' VAL . . . . . . . . . . . . . 92.6 t -61.79 -42.63 95.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 115.424 -0.807 . . . . 0.0 112.178 -178.233 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 307' ' ' GLN . . . . . . . . . . . . . 2.5 pt20 173.65 -159.63 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.254 0 O-C-N 123.705 0.628 . . . . 0.0 109.585 -179.312 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 308' ' ' ILE . . . . . 0.626 HG22 ' H ' ' A' ' 311' ' ' LYS . 65.5 mt -114.97 122.95 70.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.546 178.127 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . 0.491 ' CG1' ' N ' ' A' ' 310' ' ' TYR . 8.0 p -63.82 -39.6 86.01 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.311 0 C-N-CA 118.859 -1.136 . . . . 0.0 108.442 176.588 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 310' ' ' TYR . . . . . 0.491 ' N ' ' CG1' ' A' ' 309' ' ' VAL 0.331 55.2 p90 -67.49 -33.14 74.49 Favored 'General case' 0 N--CA 1.452 -0.352 0 N-CA-C 117.584 2.438 . . . . 0.0 117.584 178.89 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 311' ' ' LYS . . . . . 0.626 ' H ' HG22 ' A' ' 308' ' ' ILE . 2.9 ttpm? 46.34 61.29 13.24 Favored Pre-proline 0 C--N 1.315 -0.924 0 C-N-CA 119.136 -1.025 . . . . 0.0 109.508 179.606 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 312' ' ' PRO . . . . . 0.539 ' C ' ' O ' ' A' ' 311' ' ' LYS . 83.8 Cg_exo 24.16 55.25 0.0 OUTLIER 'Trans proline' 0 N--CA 1.486 1.031 0 C-N-CA 120.801 1.001 . . . . 0.0 113.201 -179.209 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 313' ' ' VAL . . . . . 0.526 ' C ' ' O ' ' A' ' 312' ' ' PRO . 4.2 m 2.68 84.11 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 CA-C-N 115.181 -0.918 . . . . 0.0 112.467 -179.743 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 56.1 t0 -55.8 -36.62 67.62 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.956 -0.565 . . . . 0.0 111.146 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 315' ' ' LEU . . . . . . . . . . . . . 62.4 mt -58.82 -33.91 70.93 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.593 -178.976 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 95.3 p -60.43 -28.05 67.98 Favored 'General case' 0 CA--C 1.511 -0.55 0 C-N-CA 120.048 -0.661 . . . . 0.0 111.058 -179.285 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 38.1 mtpt -92.04 137.75 32.11 Favored 'General case' 0 N--CA 1.448 -0.539 0 C-N-CA 119.455 -0.898 . . . . 0.0 109.868 179.434 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 13.7 p -131.69 143.0 41.68 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 CA-C-N 114.977 -1.01 . . . . 0.0 110.765 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 41.6 p . . . . . 0 C--O 1.22 -0.488 0 CA-C-O 118.02 -0.991 . . . . 0.0 110.559 179.989 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 92.3 p . . . . . 0 N--CA 1.463 0.191 0 CA-C-O 120.596 0.236 . . . . 0.0 110.463 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 16.0 mtpp -93.91 149.7 21.0 Favored 'General case' 0 N--CA 1.446 -0.633 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.714 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 295' ' ' ASP . . . . . 0.679 ' OD1' ' N ' ' A' ' 296' ' ' ASN . 49.8 p30 -60.16 -31.94 70.58 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 108.107 -1.071 . . . . 0.0 108.107 178.929 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 296' ' ' ASN . . . . . 0.679 ' N ' ' OD1' ' A' ' 295' ' ' ASP . 0.4 OUTLIER 58.99 44.98 15.54 Favored 'General case' 0 N--CA 1.45 -0.467 0 CA-C-N 115.277 -0.874 . . . . 0.0 109.804 179.63 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 297' ' ' ILE . . . . . 0.781 HG22 ' N ' ' A' ' 298' ' ' LYS . 84.4 mt 36.57 -118.09 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.439 -0.801 . . . . 0.0 110.634 -178.696 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 298' ' ' LYS . . . . . 0.781 ' N ' HG22 ' A' ' 297' ' ' ILE . 83.6 tttt -158.09 -95.86 0.03 OUTLIER 'General case' 0 CA--C 1.538 0.481 0 C-N-CA 119.948 -0.701 . . . . 0.0 111.564 179.499 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 76.3 m80 73.87 88.58 0.09 Allowed 'General case' 0 N--CA 1.476 0.871 0 N-CA-C 113.176 0.806 . . . . 0.0 113.176 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 3.1 m -124.01 77.87 58.78 Favored Pre-proline 0 CA--C 1.537 0.477 0 CA-C-N 115.408 -0.814 . . . . 0.0 109.582 179.125 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 301' ' ' PRO . . . . . 0.664 ' O ' HG23 ' A' ' 306' ' ' VAL . 8.1 Cg_exo -56.51 -24.49 53.42 Favored 'Trans proline' 0 N--CA 1.494 1.529 0 C-N-CA 121.694 1.596 . . . . 0.0 113.1 -178.285 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -73.02 17.54 1.68 Allowed Glycine 0 N--CA 1.463 0.452 0 N-CA-C 109.238 -1.545 . . . . 0.0 109.238 178.338 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 303' ' ' GLY . . . . . 0.622 ' H ' ' C ' ' A' ' 301' ' ' PRO . . . -56.04 -23.58 39.77 Favored Glycine 0 CA--C 1.516 0.147 0 CA-C-N 114.311 -0.944 . . . . 0.0 110.971 -179.814 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 98.1 -4.36 60.69 Favored Glycine 0 CA--C 1.505 -0.59 0 N-CA-C 104.349 -3.5 . . . . 0.0 104.349 -174.776 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 85.2 p -64.69 -20.72 66.48 Favored 'General case' 0 N--CA 1.428 -1.541 0 CA-C-N 111.331 -2.435 . . . . 0.0 106.139 175.649 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 306' ' ' VAL . . . . . 0.664 HG23 ' O ' ' A' ' 301' ' ' PRO . 80.8 t -57.48 -42.09 80.16 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 CA-C-N 113.259 -1.791 . . . . 0.0 110.9 -177.375 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 307' ' ' GLN . . . . . 0.586 ' CB ' ' O ' ' A' ' 306' ' ' VAL . 57.2 tt0 103.92 160.48 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.484 0 O-C-N 124.378 1.049 . . . . 0.0 109.019 179.72 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 308' ' ' ILE . . . . . 0.865 HG22 ' H ' ' A' ' 310' ' ' TYR . 70.2 mt -114.98 129.0 71.91 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.46 0 CA-C-O 121.43 0.634 . . . . 0.0 110.738 178.53 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 1.5 t -86.56 8.63 1.95 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.558 0 CA-C-N 114.648 -1.16 . . . . 0.0 111.763 179.296 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 310' ' ' TYR . . . . . 0.865 ' H ' HG22 ' A' ' 308' ' ' ILE . 0.0 OUTLIER -54.27 -32.43 56.21 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 113.886 1.069 . . . . 0.0 113.886 -174.962 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 311' ' ' LYS . . . . . 0.53 ' N ' ' CD ' ' A' ' 312' ' ' PRO . 12.1 mmmt 57.33 68.16 2.14 Favored Pre-proline 0 N--CA 1.475 0.798 0 CA-C-N 119.732 1.151 . . . . 0.0 112.019 177.345 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 312' ' ' PRO . . . . . 0.594 ' O ' ' N ' ' A' ' 314' ' ' ASP . 86.6 Cg_exo -54.78 148.55 45.22 Favored 'Trans proline' 0 C--N 1.304 -1.808 0 C-N-CA 124.978 3.785 . . . . 0.0 114.761 -179.067 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 17.8 m 38.82 12.28 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 CA-C-N 114.313 -1.312 . . . . 0.0 113.093 -179.337 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 314' ' ' ASP . . . . . 0.594 ' N ' ' O ' ' A' ' 312' ' ' PRO . 20.9 t70 -55.11 -36.64 65.91 Favored 'General case' 0 C--N 1.319 -0.734 0 C-N-CA 120.237 -0.585 . . . . 0.0 109.557 179.126 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 315' ' ' LEU . . . . . 0.62 ' CD2' ' N ' ' A' ' 315' ' ' LEU . 0.2 OUTLIER -61.12 -35.24 76.53 Favored 'General case' 0 CA--C 1.541 0.615 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.027 179.4 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 79.6 p -62.4 -25.93 68.21 Favored 'General case' 0 N--CA 1.471 0.579 0 CA-C-O 121.643 0.735 . . . . 0.0 110.862 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 62.6 mmtt -58.04 -26.29 62.27 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 114.49 -1.232 . . . . 0.0 113.598 -178.432 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 11.6 p -110.22 138.6 37.32 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 CA-C-O 122.142 0.972 . . . . 0.0 111.061 -176.41 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 3.6 m . . . . . 0 C--O 1.219 -0.526 0 CA-C-N 113.335 -1.757 . . . . 0.0 110.203 -178.14 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 98.6 p . . . . . 0 N--CA 1.462 0.173 0 CA-C-O 120.911 0.386 . . . . 0.0 110.215 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 294' ' ' LYS . . . . . 0.459 ' HD2' ' N ' ' A' ' 294' ' ' LYS . 1.0 OUTLIER -85.4 -74.06 0.42 Allowed 'General case' 0 CA--C 1.512 -0.504 0 CA-C-O 121.701 0.762 . . . . 0.0 112.101 -179.296 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 295' ' ' ASP . . . . . 0.47 ' OD1' HD11 ' A' ' 297' ' ' ILE . 50.6 p30 -89.58 6.94 38.92 Favored 'General case' 0 N--CA 1.442 -0.869 0 CA-C-N 114.427 -1.261 . . . . 0.0 109.468 179.879 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 17.3 t-20 58.97 53.53 5.58 Favored 'General case' 0 N--CA 1.473 0.675 0 N-CA-C 114.531 1.308 . . . . 0.0 114.531 176.587 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 297' ' ' ILE . . . . . 0.47 HD11 ' OD1' ' A' ' 295' ' ' ASP . 15.7 mm -73.4 140.94 16.96 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.653 0 C-N-CA 119.524 -0.87 . . . . 0.0 110.172 -179.617 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 298' ' ' LYS . . . . . 0.516 ' NZ ' HG13 ' A' ' 300' ' ' VAL . 14.0 ptmm? -125.22 154.26 41.89 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 114.682 -1.145 . . . . 0.0 111.62 -178.002 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 56.6 t-80 -124.36 129.6 50.99 Favored 'General case' 0 CA--C 1.536 0.409 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 178.265 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 300' ' ' VAL . . . . . 0.516 HG13 ' NZ ' ' A' ' 298' ' ' LYS . 0.2 OUTLIER -124.14 77.35 59.95 Favored Pre-proline 0 N--CA 1.474 0.763 0 N-CA-C 112.406 0.521 . . . . 0.0 112.406 -179.147 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -59.01 -27.63 85.57 Favored 'Trans proline' 0 C--N 1.312 -1.373 0 N-CA-C 109.885 -0.852 . . . . 0.0 109.885 177.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -121.66 106.32 1.08 Allowed Glycine 0 CA--C 1.523 0.568 0 CA-C-N 115.039 -0.982 . . . . 0.0 110.788 179.302 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -141.56 33.38 1.98 Allowed Glycine 0 CA--C 1.523 0.579 0 N-CA-C 109.905 -1.278 . . . . 0.0 109.905 179.23 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 95.2 -0.43 63.96 Favored Glycine 0 CA--C 1.521 0.426 0 N-CA-C 107.963 -2.055 . . . . 0.0 107.963 -177.891 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 52.0 p -82.78 -0.14 46.42 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 113.896 -1.152 . . . . 0.0 109.541 178.547 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 306' ' ' VAL . . . . . 0.514 ' O ' ' CB ' ' A' ' 307' ' ' GLN . 92.3 t -58.27 -39.19 72.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.509 -0.769 . . . . 0.0 110.127 -177.633 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 307' ' ' GLN . . . . . 0.627 ' HG2' HG23 ' A' ' 308' ' ' ILE . 57.9 tt0 94.07 139.74 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.727 0 N-CA-C 114.602 1.334 . . . . 0.0 114.602 177.816 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 308' ' ' ILE . . . . . 0.627 HG23 ' HG2' ' A' ' 307' ' ' GLN . 0.8 OUTLIER 16.23 36.76 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.543 0 CA-C-N 112.723 -2.035 . . . . 0.0 115.397 177.99 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 309' ' ' VAL . . . . . 0.614 ' N ' ' O ' ' A' ' 307' ' ' GLN . 62.9 t -55.54 -37.45 45.65 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 N-CA-C 107.943 -1.132 . . . . 0.0 107.943 179.425 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 310' ' ' TYR . . . . . 0.488 ' CE1' ' HD3' ' A' ' 312' ' ' PRO . 33.6 p90 -60.3 -28.04 67.79 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 114.226 1.195 . . . . 0.0 114.226 -179.789 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 311' ' ' LYS . . . . . . . . . . . . . 2.3 tmtp? 68.97 74.32 0.29 Allowed Pre-proline 0 N--CA 1.474 0.75 0 CA-C-N 119.337 0.971 . . . . 0.0 110.512 178.313 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 312' ' ' PRO . . . . . 0.488 ' HD3' ' CE1' ' A' ' 310' ' ' TYR . 13.4 Cg_exo -54.83 -31.07 70.95 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 C-N-CA 122.59 2.193 . . . . 0.0 114.803 -177.014 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 313' ' ' VAL . . . . . 0.641 HG13 ' HB2' ' A' ' 316' ' ' SER . 39.2 t -124.26 134.81 65.63 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.525 0 C-N-CA 120.184 -0.606 . . . . 0.0 111.308 179.765 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 314' ' ' ASP . . . . . 0.499 ' HB3' HD22 ' A' ' 315' ' ' LEU . 61.2 t0 -149.12 -89.42 0.08 Allowed 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.516 -0.765 . . . . 0.0 109.061 178.928 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 315' ' ' LEU . . . . . 0.911 HD22 ' H ' ' A' ' 315' ' ' LEU . 2.0 mm? -59.61 -31.09 69.16 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.065 178.041 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 316' ' ' SER . . . . . 0.641 ' HB2' HG13 ' A' ' 313' ' ' VAL . 25.2 m -55.29 -33.17 63.03 Favored 'General case' 0 N--CA 1.455 -0.197 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.133 -178.025 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 317' ' ' LYS . . . . . 0.581 ' HG3' HG12 ' A' ' 313' ' ' VAL . 65.4 mttm -57.82 -34.1 69.3 Favored 'General case' 0 C--N 1.326 -0.435 0 C-N-CA 120.461 -0.496 . . . . 0.0 110.44 -179.923 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 42.1 t -115.77 135.8 54.71 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-O 120.825 0.345 . . . . 0.0 110.983 -179.449 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 37.4 p . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.333 179.684 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.663 0 N-CA-C 111.123 -0.791 . . . . 0.0 111.123 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . 0.464 ' O ' ' O ' ' A' ' 294' ' ' LYS . 97.5 p -122.27 153.86 38.34 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 121.119 0.485 . . . . 0.0 111.272 -179.815 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 294' ' ' LYS . . . . . 0.464 ' O ' ' O ' ' A' ' 293' ' ' SER . 57.7 mttp -55.19 -126.1 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.502 -0.772 . . . . 0.0 111.757 179.836 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 295' ' ' ASP . . . . . . . . . . . . . 89.5 m-20 -92.17 7.43 42.57 Favored 'General case' 0 N--CA 1.455 -0.224 0 CA-C-N 114.924 -1.035 . . . . 0.0 111.235 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 49.9 t30 60.26 52.13 5.1 Favored 'General case' 0 C--N 1.333 -0.119 0 C-N-CA 119.68 -0.808 . . . . 0.0 111.567 179.842 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 297' ' ' ILE . . . . . . . . . . . . . 80.9 mt -64.99 135.22 28.6 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 122.396 1.093 . . . . 0.0 111.779 -177.354 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 84.6 tttt -81.76 137.0 35.41 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 112.884 -1.962 . . . . 0.0 112.752 -179.085 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 74.4 t60 -124.53 136.36 53.92 Favored 'General case' 0 CA--C 1.543 0.711 0 N-CA-C 107.914 -1.143 . . . . 0.0 107.914 178.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -124.0 76.72 58.78 Favored Pre-proline 0 N--CA 1.481 1.09 0 N-CA-C 113.336 0.865 . . . . 0.0 113.336 -177.876 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -59.76 -26.1 81.19 Favored 'Trans proline' 0 N--CA 1.493 1.472 0 C-N-CA 121.221 1.28 . . . . 0.0 111.862 178.451 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -167.28 125.1 1.28 Allowed Glycine 0 CA--C 1.527 0.789 0 N-CA-C 110.89 -0.884 . . . . 0.0 110.89 -179.585 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -150.35 37.2 0.92 Allowed Glycine 0 N--CA 1.468 0.803 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 179.732 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 96.7 -4.72 63.85 Favored Glycine 0 C--N 1.317 -0.488 0 N-CA-C 106.262 -2.735 . . . . 0.0 106.262 -177.079 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 24.9 t -59.89 -27.76 66.99 Favored 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 112.827 -1.686 . . . . 0.0 109.121 176.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 306' ' ' VAL . . . . . 0.641 ' O ' ' CB ' ' A' ' 307' ' ' GLN . 73.5 t -55.41 -40.08 56.01 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.643 0 CA-C-N 114.081 -1.418 . . . . 0.0 112.038 -175.77 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 307' ' ' GLN . . . . . 0.641 ' CB ' ' O ' ' A' ' 306' ' ' VAL . 63.1 tp60 117.37 84.61 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.529 0 N-CA-C 113.921 1.082 . . . . 0.0 113.921 177.482 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 308' ' ' ILE . . . . . 0.672 HG23 ' O ' ' A' ' 308' ' ' ILE . 18.6 tt 26.46 58.24 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 N-CA-C 113.16 0.8 . . . . 0.0 113.16 176.217 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 54.8 t -56.0 -39.23 56.64 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.605 0 C-N-CA 118.724 -1.19 . . . . 0.0 109.76 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 310' ' ' TYR . . . . . 0.695 ' O ' ' CD1' ' A' ' 310' ' ' TYR . 36.7 p90 -69.83 104.56 2.5 Favored 'General case' 0 N--CA 1.439 -1.0 0 C-N-CA 119.082 -1.047 . . . . 0.0 109.41 178.601 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 311' ' ' LYS . . . . . . . . . . . . . 38.6 mtpt -73.34 128.07 88.02 Favored Pre-proline 0 C--N 1.313 -1.016 0 C-N-CA 119.649 -0.82 . . . . 0.0 110.385 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 312' ' ' PRO . . . . . . . . . . . . . 85.3 Cg_exo -55.96 149.48 51.89 Favored 'Trans proline' 0 C--N 1.306 -1.66 0 N-CA-C 106.122 -2.299 . . . . 0.0 106.122 174.326 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 36.1 t -64.46 126.26 22.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 C-N-CA 116.284 -2.166 . . . . 0.0 110.775 -175.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 314' ' ' ASP . . . . . 0.466 ' O ' ' HB3' ' A' ' 317' ' ' LYS . 89.5 m-20 -95.59 -19.22 19.95 Favored 'General case' 0 N--CA 1.444 -0.762 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 175.509 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 315' ' ' LEU . . . . . 0.697 ' O ' HG12 ' A' ' 318' ' ' VAL . 60.5 mt -62.22 -37.47 85.48 Favored 'General case' 0 C--O 1.232 0.141 0 CA-C-N 116.029 -0.532 . . . . 0.0 112.293 -178.324 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 82.9 p -63.03 -30.76 71.85 Favored 'General case' 0 CA--C 1.519 -0.22 0 CA-C-O 121.499 0.666 . . . . 0.0 109.886 179.877 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 317' ' ' LYS . . . . . 0.466 ' HB3' ' O ' ' A' ' 314' ' ' ASP . 18.8 tttt -59.38 -36.89 76.62 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 114.342 -1.299 . . . . 0.0 112.783 -178.824 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 318' ' ' VAL . . . . . 0.697 HG12 ' O ' ' A' ' 315' ' ' LEU . 5.3 p -57.07 -33.98 44.0 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 N-CA-C 112.268 0.47 . . . . 0.0 112.268 -178.148 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 319' ' ' THR . . . . . 0.412 ' OXT' ' O ' ' A' ' 318' ' ' VAL . 1.3 m . . . . . 0 C--O 1.221 -0.443 0 CA-C-O 117.951 -1.023 . . . . 0.0 110.792 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.632 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 23.8 m -57.9 -35.31 70.84 Favored 'General case' 0 C--N 1.332 -0.186 0 C-N-CA 120.77 -0.372 . . . . 0.0 110.137 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -96.27 148.32 22.86 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.716 179.298 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 295' ' ' ASP . . . . . 0.596 ' O ' ' CB ' ' A' ' 296' ' ' ASN . 91.6 m-20 -56.52 -36.4 69.16 Favored 'General case' 0 CA--C 1.492 -1.251 0 N-CA-C 107.382 -1.34 . . . . 0.0 107.382 177.659 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 296' ' ' ASN . . . . . 0.596 ' CB ' ' O ' ' A' ' 295' ' ' ASP . 48.2 t30 118.39 -128.61 0.0 OUTLIER 'General case' 0 CA--C 1.469 -2.16 0 O-C-N 125.581 1.801 . . . . 0.0 110.097 179.51 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 297' ' ' ILE . . . . . 0.651 ' O ' HG23 ' A' ' 297' ' ' ILE . 8.9 tp -122.44 133.35 68.93 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.111 0 CA-C-N 114.499 -1.228 . . . . 0.0 110.497 -178.781 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 43.4 tttm -132.71 120.19 21.35 Favored 'General case' 0 C--N 1.294 -1.84 0 CA-C-N 114.234 -1.348 . . . . 0.0 110.323 174.453 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 299' ' ' HIS . . . . . 0.407 ' CD2' HD11 ' A' ' 297' ' ' ILE . 79.8 m-70 -139.81 145.04 37.65 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.36 -0.836 . . . . 0.0 112.251 174.851 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -124.8 72.71 62.6 Favored Pre-proline 0 C--N 1.322 -0.63 0 CA-C-N 115.473 -0.785 . . . . 0.0 108.952 177.282 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -59.1 -24.67 74.76 Favored 'Trans proline' 0 N--CA 1.492 1.44 0 C-N-CA 121.034 1.156 . . . . 0.0 111.098 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . 150.15 136.51 2.58 Favored Glycine 0 CA--C 1.52 0.365 0 CA-C-N 115.05 -0.977 . . . . 0.0 110.875 179.442 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -84.57 1.52 88.76 Favored Glycine 0 CA--C 1.519 0.311 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 179.009 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 95.74 -2.83 64.81 Favored Glycine 0 CA--C 1.519 0.329 0 N-CA-C 108.936 -1.666 . . . . 0.0 108.936 -179.021 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 73.9 m -84.53 4.28 32.67 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 114.774 -0.713 . . . . 0.0 109.902 178.619 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 306' ' ' VAL . . . . . . . . . . . . . 98.8 t -59.67 -41.78 86.34 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.662 0 CA-C-O 122.235 1.017 . . . . 0.0 111.179 -178.309 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 307' ' ' GLN . . . . . . . . . . . . . 14.5 pt20 -141.84 168.5 19.6 Favored 'General case' 0 C--N 1.31 -1.119 0 CA-C-N 112.896 -1.956 . . . . 0.0 109.0 -177.498 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 308' ' ' ILE . . . . . 0.732 HG22 ' H ' ' A' ' 311' ' ' LYS . 31.8 mm -104.05 117.81 50.19 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 CA-C-N 115.418 -0.81 . . . . 0.0 113.162 -179.152 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 21.0 m -78.53 -30.11 15.09 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.483 0 CA-C-N 114.13 -1.395 . . . . 0.0 108.398 175.592 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 310' ' ' TYR . . . . . 0.611 ' CE2' HG23 ' A' ' 308' ' ' ILE 0.364 51.7 p90 -64.15 -28.29 69.66 Favored 'General case' 0 N--CA 1.447 -0.608 0 N-CA-C 116.311 1.967 . . . . 0.0 116.311 -179.197 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 311' ' ' LYS . . . . . 0.732 ' H ' HG22 ' A' ' 308' ' ' ILE . 37.3 mtpt 53.72 65.65 5.32 Favored Pre-proline 0 C--N 1.318 -0.78 0 C-N-CA 119.875 -0.73 . . . . 0.0 110.958 178.44 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 312' ' ' PRO . . . . . 0.492 ' C ' ' O ' ' A' ' 311' ' ' LYS . 91.0 Cg_exo 3.86 -128.87 0.0 OUTLIER 'Trans proline' 0 N--CA 1.487 1.141 0 C-N-CA 123.092 2.528 . . . . 0.0 115.771 -179.287 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 313' ' ' VAL . . . . . 0.624 HG13 ' O ' ' A' ' 313' ' ' VAL . 4.5 p -113.04 37.06 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.718 0 N-CA-C 112.955 0.724 . . . . 0.0 112.955 -177.234 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 314' ' ' ASP . . . . . 0.402 ' O ' ' HB3' ' A' ' 317' ' ' LYS . 54.6 t0 -54.13 -35.26 62.01 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 112.081 0.4 . . . . 0.0 112.081 -179.614 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 315' ' ' LEU . . . . . 1.012 HD22 ' H ' ' A' ' 315' ' ' LEU . 1.8 mm? -57.15 -35.18 69.21 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 120.299 -0.56 . . . . 0.0 111.074 -178.486 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . 0.412 ' HB3' HG22 ' A' ' 313' ' ' VAL . 89.8 p -62.37 -23.59 66.89 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 121.135 0.493 . . . . 0.0 110.582 178.65 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 317' ' ' LYS . . . . . 0.402 ' HB3' ' O ' ' A' ' 314' ' ' ASP . 41.8 tttp -56.62 -35.4 68.26 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.137 -0.938 . . . . 0.0 111.855 -177.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 13.3 p -129.7 142.75 43.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.045 0.45 . . . . 0.0 110.439 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 117.939 -1.029 . . . . 0.0 110.693 -179.27 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.634 0 N-CA-C 110.786 -0.925 . . . . 0.0 110.786 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 46.5 m -63.39 156.79 24.9 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.159 0.504 . . . . 0.0 110.775 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 11.6 mtpp -81.17 168.9 18.04 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.807 179.476 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 295' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -48.68 -31.88 7.5 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.974 -177.347 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 74.6 m-20 63.81 52.47 2.15 Favored 'General case' 0 CA--C 1.516 -0.355 0 C-N-CA 120.269 -0.572 . . . . 0.0 111.457 -179.923 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 297' ' ' ILE . . . . . . . . . . . . . 82.1 mt -62.98 130.93 28.21 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.249 0 N-CA-C 107.66 -1.237 . . . . 0.0 107.66 -178.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 44.4 tttp -81.98 133.69 35.32 Favored 'General case' 0 C--N 1.324 -0.526 0 N-CA-C 115.469 1.655 . . . . 0.0 115.469 -175.373 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -121.72 139.17 53.91 Favored 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 106.843 -1.54 . . . . 0.0 106.843 175.812 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 8.0 m -125.75 72.04 68.15 Favored Pre-proline 0 N--CA 1.472 0.651 0 C-N-CA 119.308 -0.957 . . . . 0.0 113.31 -178.917 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 79.3 Cg_exo -62.07 -23.62 75.82 Favored 'Trans proline' 0 C--N 1.302 -1.918 0 C-N-CA 122.281 1.987 . . . . 0.0 110.692 176.266 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -92.97 28.43 9.46 Favored Glycine 0 CA--C 1.526 0.745 0 CA-C-N 114.492 -1.231 . . . . 0.0 112.713 -178.383 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 303' ' ' GLY . . . . . 0.415 ' C ' ' N ' ' A' ' 305' ' ' SER . . . -84.4 -173.28 49.73 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.376 -0.916 . . . . 0.0 111.39 -178.556 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . -50.68 -23.88 7.21 Favored Glycine 0 N--CA 1.453 -0.221 0 N-CA-C 108.31 -1.916 . . . . 0.0 108.31 178.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . 0.415 ' N ' ' C ' ' A' ' 303' ' ' GLY . 22.4 m -55.07 -34.56 63.7 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 114.751 -0.724 . . . . 0.0 111.881 -179.223 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 306' ' ' VAL . . . . . 0.862 ' O ' ' O ' ' A' ' 307' ' ' GLN . 79.0 t -60.88 -39.72 82.9 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.712 0 C-N-CA 121.096 -0.241 . . . . 0.0 110.55 179.772 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 307' ' ' GLN . . . . . 0.862 ' O ' ' O ' ' A' ' 306' ' ' VAL . 13.0 pt20 24.88 166.03 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.471 0 O-C-N 125.222 1.576 . . . . 0.0 113.138 -177.292 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 308' ' ' ILE . . . . . 0.715 ' O ' ' N ' ' A' ' 310' ' ' TYR . 8.5 tt -59.26 -26.86 34.96 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.011 0 CA-C-N 114.192 -1.367 . . . . 0.0 112.753 -176.529 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . 0.608 HG23 ' O ' ' A' ' 307' ' ' GLN . 1.0 OUTLIER 51.06 -42.14 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.204 0 N-CA-C 113.0 0.741 . . . . 0.0 113.0 179.454 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 310' ' ' TYR . . . . . 0.715 ' N ' ' O ' ' A' ' 308' ' ' ILE 0.485 52.5 p90 -65.06 -25.48 67.83 Favored 'General case' 0 CA--C 1.564 1.507 0 N-CA-C 119.69 3.219 . . . . 0.0 119.69 -178.074 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 311' ' ' LYS . . . . . 0.461 ' HB2' ' O ' ' A' ' 310' ' ' TYR . 11.3 mttp 74.15 77.25 0.19 Allowed Pre-proline 0 N--CA 1.509 2.516 0 CA-C-N 120.996 1.726 . . . . 0.0 112.13 177.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 312' ' ' PRO . . . . . . . . . . . . . 4.7 Cg_endo -54.26 -34.33 79.25 Favored 'Trans proline' 0 N--CA 1.522 3.165 0 C-N-CA 123.524 2.816 . . . . 0.0 117.447 -178.178 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 69.7 t -67.29 -38.64 81.3 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.004 0 N-CA-C 116.155 1.909 . . . . 0.0 116.155 -178.398 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 314' ' ' ASP . . . . . 0.519 ' O ' ' O ' ' A' ' 317' ' ' LYS . 91.1 m-20 -55.47 -39.99 71.08 Favored 'General case' 0 C--N 1.322 -0.62 0 C-N-CA 118.697 -1.201 . . . . 0.0 113.103 -174.074 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 315' ' ' LEU . . . . . 0.841 HD22 ' H ' ' A' ' 315' ' ' LEU . 2.0 mm? -65.22 -36.71 85.01 Favored 'General case' 0 C--N 1.326 -0.423 0 C-N-CA 118.918 -1.113 . . . . 0.0 108.892 176.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 22.5 m -60.39 -36.36 77.91 Favored 'General case' 0 CA--C 1.516 -0.364 0 N-CA-C 108.253 -1.017 . . . . 0.0 108.253 178.079 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 317' ' ' LYS . . . . . 0.519 ' O ' ' O ' ' A' ' 314' ' ' ASP . 35.7 ttmt -97.02 117.38 31.06 Favored 'General case' 0 N--CA 1.446 -0.668 0 CA-C-N 114.958 -1.019 . . . . 0.0 111.098 179.71 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 59.5 t -130.92 135.84 59.26 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.333 176.728 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.218 -0.604 0 CA-C-O 117.871 -1.061 . . . . 0.0 110.451 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.728 0 N-CA-C 111.005 -0.838 . . . . 0.0 111.005 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 92.5 p -122.65 156.43 34.34 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 120.921 0.391 . . . . 0.0 110.531 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 11.9 mtpt -91.8 158.47 16.32 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.702 0.763 . . . . 0.0 112.489 -179.206 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 295' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -53.7 -33.8 56.68 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 114.359 -1.291 . . . . 0.0 110.652 -179.594 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 50.8 t30 64.73 54.34 1.39 Allowed 'General case' 0 CA--C 1.521 -0.14 0 C-N-CA 119.746 -0.782 . . . . 0.0 111.871 -179.817 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 297' ' ' ILE . . . . . . . . . . . . . 75.8 mt -68.05 139.25 21.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.304 -179.024 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 11.5 pttp -77.47 147.71 35.75 Favored 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 114.293 1.22 . . . . 0.0 114.293 -176.391 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 77.3 m80 -120.16 139.32 52.79 Favored 'General case' 0 N--CA 1.454 -0.261 0 CA-C-N 114.032 -1.44 . . . . 0.0 108.455 176.749 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 3.3 m -122.84 73.7 45.49 Favored Pre-proline 0 C--N 1.327 -0.387 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 179.574 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -61.1 -25.15 80.72 Favored 'Trans proline' 0 C--N 1.31 -1.458 0 C-N-CA 122.766 2.311 . . . . 0.0 114.176 -179.353 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -138.14 58.47 0.63 Allowed Glycine 0 CA--C 1.525 0.67 0 C-N-CA 120.597 -0.811 . . . . 0.0 113.363 -177.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -57.2 -28.54 58.87 Favored Glycine 0 N--CA 1.445 -0.722 0 N-CA-C 105.901 -2.88 . . . . 0.0 105.901 176.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 98.91 -10.45 62.2 Favored Glycine 0 N--CA 1.442 -0.966 0 N-CA-C 104.077 -3.609 . . . . 0.0 104.077 -176.099 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 84.9 p -66.29 -27.74 68.16 Favored 'General case' 0 N--CA 1.432 -1.336 0 CA-C-N 112.024 -2.088 . . . . 0.0 111.875 177.877 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 306' ' ' VAL . . . . . . . . . . . . . 55.8 t -61.1 -46.54 96.45 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.331 0 CA-C-O 122.151 0.977 . . . . 0.0 111.382 -175.385 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 307' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 -148.14 164.4 34.02 Favored 'General case' 0 N--CA 1.441 -0.89 0 CA-C-N 113.567 -1.652 . . . . 0.0 110.206 -179.175 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 308' ' ' ILE . . . . . 0.47 HG12 ' CZ ' ' A' ' 310' ' ' TYR . 7.2 tp -122.37 129.72 75.07 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 CA-C-O 122.027 0.918 . . . . 0.0 110.915 176.266 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 69.6 t -67.25 -31.68 54.15 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.494 0 CA-C-N 113.639 -1.619 . . . . 0.0 115.128 179.656 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 310' ' ' TYR . . . . . 0.536 ' HD1' ' N ' ' A' ' 311' ' ' LYS . 0.0 OUTLIER -52.38 -33.84 45.23 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 117.197 2.295 . . . . 0.0 117.197 -171.689 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 311' ' ' LYS . . . . . 0.542 ' O ' ' C ' ' A' ' 312' ' ' PRO . 1.1 mmtt 54.09 64.68 6.15 Favored Pre-proline 0 CA--C 1.549 0.911 0 CA-C-N 121.697 2.044 . . . . 0.0 109.441 -179.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 312' ' ' PRO . . . . . 0.542 ' C ' ' O ' ' A' ' 311' ' ' LYS . 81.6 Cg_exo 2.76 64.82 0.0 OUTLIER 'Trans proline' 0 N--CA 1.49 1.321 0 C-N-CA 122.706 2.271 . . . . 0.0 114.794 -179.513 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 313' ' ' VAL . . . . . 0.541 ' N ' ' O ' ' A' ' 311' ' ' LYS . 1.8 m 20.96 54.17 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 CA-C-N 115.46 -0.791 . . . . 0.0 111.973 179.14 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 314' ' ' ASP . . . . . 0.89 ' OD2' HD12 ' A' ' 315' ' ' LEU . 49.6 p30 -60.44 -33.7 72.93 Favored 'General case' 0 C--N 1.322 -0.614 0 C-N-CA 120.611 -0.435 . . . . 0.0 110.858 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 315' ' ' LEU . . . . . 0.89 HD12 ' OD2' ' A' ' 314' ' ' ASP . 6.1 mp -59.16 -37.48 77.41 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 118.833 -1.147 . . . . 0.0 109.591 179.44 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 87.3 p -63.53 -28.04 69.67 Favored 'General case' 0 CA--C 1.509 -0.62 0 N-CA-C 108.696 -0.853 . . . . 0.0 108.696 177.491 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 15.4 ttpt -82.8 133.14 35.15 Favored 'General case' 0 N--CA 1.446 -0.652 0 CA-C-N 114.434 -1.257 . . . . 0.0 108.828 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 13.3 p -130.55 142.28 44.1 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.751 0 C-N-CA 120.599 -0.441 . . . . 0.0 110.693 -179.761 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.22 -0.491 0 CA-C-O 117.851 -1.071 . . . . 0.0 110.967 -179.696 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.635 0 N-CA-C 110.99 -0.844 . . . . 0.0 110.99 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 74.5 m -82.72 3.7 28.12 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.648 0.261 . . . . 0.0 110.865 -179.813 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 294' ' ' LYS . . . . . 0.452 ' C ' ' H ' ' A' ' 296' ' ' ASN . 68.7 mttm -92.95 148.69 21.79 Favored 'General case' 0 N--CA 1.451 -0.39 0 CA-C-O 121.548 0.689 . . . . 0.0 112.099 -179.355 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 295' ' ' ASP . . . . . 0.478 ' C ' ' OD1' ' A' ' 295' ' ' ASP . 49.4 p30 -88.19 11.55 16.1 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 106.427 -1.694 . . . . 0.0 106.427 177.218 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 296' ' ' ASN . . . . . 0.452 ' H ' ' C ' ' A' ' 294' ' ' LYS . 21.1 m120 33.88 -115.14 0.07 Allowed 'General case' 0 CA--C 1.49 -1.347 0 CA-C-N 112.878 -1.965 . . . . 0.0 111.934 -177.335 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 297' ' ' ILE . . . . . 0.551 ' O ' HG23 ' A' ' 297' ' ' ILE . 16.9 tt -120.53 133.03 68.54 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.355 0 C-N-CA 118.478 -1.289 . . . . 0.0 110.315 -178.474 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 44.6 tttm -123.97 119.84 30.73 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 113.996 -1.457 . . . . 0.0 111.549 177.271 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 299' ' ' HIS . . . . . 0.503 ' CE1' HD11 ' A' ' 297' ' ' ILE . 71.7 m80 -137.89 145.37 42.05 Favored 'General case' 0 C--N 1.317 -0.809 0 CA-C-N 114.504 -1.225 . . . . 0.0 108.464 173.873 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -123.81 68.37 43.48 Favored Pre-proline 0 N--CA 1.468 0.464 0 C-N-CA 119.358 -0.937 . . . . 0.0 111.856 179.231 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -64.35 -23.12 65.75 Favored 'Trans proline' 0 C--N 1.312 -1.353 0 C-N-CA 122.232 1.955 . . . . 0.0 111.044 176.485 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -80.75 25.78 3.35 Favored Glycine 0 N--CA 1.471 0.982 0 CA-C-N 114.794 -1.094 . . . . 0.0 111.297 -178.908 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -56.08 -25.23 46.04 Favored Glycine 0 C--N 1.317 -0.522 0 N-CA-C 110.588 -1.005 . . . . 0.0 110.588 -179.872 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 100.5 -2.77 56.17 Favored Glycine 0 C--N 1.319 -0.401 0 N-CA-C 104.651 -3.379 . . . . 0.0 104.651 -174.339 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 86.9 p -65.49 -17.41 64.53 Favored 'General case' 0 N--CA 1.444 -0.774 0 CA-C-N 111.755 -2.223 . . . . 0.0 107.484 175.325 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 306' ' ' VAL . . . . . 0.527 ' O ' ' CB ' ' A' ' 307' ' ' GLN . 93.9 t -54.98 -41.52 59.0 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.628 0 CA-C-N 113.231 -1.804 . . . . 0.0 109.513 -176.44 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 307' ' ' GLN . . . . . 0.527 ' CB ' ' O ' ' A' ' 306' ' ' VAL . 12.4 pt20 124.39 147.43 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.86 0 O-C-N 124.921 1.388 . . . . 0.0 110.743 177.67 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 308' ' ' ILE . . . . . 0.413 HG12 ' CD1' ' A' ' 310' ' ' TYR . 15.9 tt -61.55 -26.63 40.14 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.045 0 CA-C-N 114.406 -1.27 . . . . 0.0 113.893 -178.483 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . 0.443 HG23 ' HG3' ' A' ' 307' ' ' GLN . 75.4 t 57.33 -30.24 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.396 0 N-CA-C 116.346 1.98 . . . . 0.0 116.346 178.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 310' ' ' TYR . . . . . 0.442 ' CE1' ' HA ' ' A' ' 312' ' ' PRO . 0.0 OUTLIER -65.79 -14.23 60.99 Favored 'General case' 0 N--CA 1.479 1.001 0 N-CA-C 115.805 1.78 . . . . 0.0 115.805 -175.33 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 311' ' ' LYS . . . . . 0.493 ' O ' ' C ' ' A' ' 312' ' ' PRO . 0.6 OUTLIER 74.46 65.86 0.28 Allowed Pre-proline 0 N--CA 1.473 0.708 0 CA-C-N 118.805 0.73 . . . . 0.0 110.585 -179.909 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 312' ' ' PRO . . . . . 0.493 ' C ' ' O ' ' A' ' 311' ' ' LYS . 12.3 Cg_exo -10.2 -111.4 0.0 OUTLIER 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 123.255 2.636 . . . . 0.0 114.905 179.375 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 17.7 m -111.05 15.69 8.21 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 N-CA-C 111.954 0.353 . . . . 0.0 111.954 -178.253 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 93.2 m-20 -55.26 -38.76 68.97 Favored 'General case' 0 N--CA 1.451 -0.391 0 C-N-CA 119.436 -0.906 . . . . 0.0 111.096 -178.046 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 315' ' ' LEU . . . . . 0.624 ' O ' HG12 ' A' ' 318' ' ' VAL . 27.8 tp -60.09 -38.72 83.8 Favored 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 119.904 -0.718 . . . . 0.0 110.258 178.475 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 21.2 m -59.57 -33.95 72.08 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 115.508 -0.769 . . . . 0.0 111.596 179.263 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 33.9 tttp -56.78 -36.34 69.73 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.267 -0.879 . . . . 0.0 112.301 -177.346 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 318' ' ' VAL . . . . . 0.624 HG12 ' O ' ' A' ' 315' ' ' LEU . 5.9 p -57.11 -34.35 45.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 C-N-CA 120.067 -0.653 . . . . 0.0 109.888 179.647 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 319' ' ' THR . . . . . 0.445 ' C ' ' O ' ' A' ' 318' ' ' VAL . 2.5 m . . . . . 0 C--O 1.219 -0.546 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.911 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.65 0 N-CA-C 110.983 -0.847 . . . . 0.0 110.983 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 89.4 p -126.03 157.57 37.56 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 121.309 0.576 . . . . 0.0 111.296 -179.521 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 294' ' ' LYS . . . . . 0.409 ' HB3' ' NZ ' ' A' ' 294' ' ' LYS . 9.5 mtpm? -88.35 172.83 9.12 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.45 179.77 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 295' ' ' ASP . . . . . 0.446 ' OD2' ' C ' ' A' ' 295' ' ' ASP . 49.1 p30 -76.76 8.49 3.62 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 112.571 0.582 . . . . 0.0 112.571 -175.629 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 76.7 m-20 61.44 51.68 4.05 Favored 'General case' 0 N--CA 1.468 0.428 0 N-CA-C 115.74 1.755 . . . . 0.0 115.74 175.34 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 297' ' ' ILE . . . . . . . . . . . . . 16.2 mm -70.8 132.51 33.19 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.158 0 N-CA-C 106.975 -1.491 . . . . 0.0 106.975 179.559 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 3.6 ptmt -99.37 144.23 28.73 Favored 'General case' 0 N--CA 1.464 0.264 0 N-CA-C 115.592 1.701 . . . . 0.0 115.592 -175.446 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 299' ' ' HIS . . . . . 0.439 ' CE1' ' CG ' ' A' ' 301' ' ' PRO . 54.8 t-80 -126.75 119.09 26.05 Favored 'General case' 0 CA--C 1.536 0.439 0 N-CA-C 106.022 -1.844 . . . . 0.0 106.022 175.515 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -129.82 77.05 77.49 Favored Pre-proline 0 N--CA 1.477 0.904 0 N-CA-C 114.939 1.459 . . . . 0.0 114.939 -176.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 301' ' ' PRO . . . . . 0.499 ' O ' HG23 ' A' ' 306' ' ' VAL . 75.2 Cg_exo -60.29 -22.76 72.0 Favored 'Trans proline' 0 N--CA 1.502 2.005 0 C-N-CA 121.705 1.604 . . . . 0.0 112.446 177.285 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -69.32 20.41 0.45 Allowed Glycine 0 CA--C 1.526 0.732 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.924 -178.757 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 303' ' ' GLY . . . . . 0.495 ' H ' ' C ' ' A' ' 301' ' ' PRO . . . -56.82 -28.16 57.0 Favored Glycine 0 N--CA 1.453 -0.202 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 179.732 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 98.31 -4.71 60.47 Favored Glycine 0 C--N 1.317 -0.486 0 N-CA-C 103.962 -3.655 . . . . 0.0 103.962 -174.603 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 83.8 p -65.88 -18.93 65.67 Favored 'General case' 0 N--CA 1.438 -1.047 0 CA-C-N 111.333 -2.434 . . . . 0.0 108.615 176.591 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 306' ' ' VAL . . . . . 0.499 HG23 ' O ' ' A' ' 301' ' ' PRO . 90.7 t -56.35 -40.77 68.65 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.55 0 CA-C-N 113.98 -1.463 . . . . 0.0 110.672 -175.677 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 307' ' ' GLN . . . . . 0.801 ' HG2' ' H ' ' A' ' 308' ' ' ILE . 6.2 tt0 -173.27 -151.02 0.05 Allowed 'General case' 0 CA--C 1.536 0.43 0 N-CA-C 107.691 -1.226 . . . . 0.0 107.691 179.126 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 308' ' ' ILE . . . . . 0.801 ' H ' ' HG2' ' A' ' 307' ' ' GLN . 64.9 mt -114.92 136.69 50.79 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 179.289 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 71.3 t -60.55 -39.64 81.95 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.089 0 N-CA-C 112.828 0.677 . . . . 0.0 112.828 -178.789 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 310' ' ' TYR . . . . . 0.57 ' N ' ' CD1' ' A' ' 310' ' ' TYR . 0.1 OUTLIER -148.62 23.25 1.01 Allowed 'General case' 0 N--CA 1.477 0.906 0 N-CA-C 115.931 1.826 . . . . 0.0 115.931 -176.623 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 311' ' ' LYS . . . . . 0.471 ' O ' ' C ' ' A' ' 312' ' ' PRO . 0.1 OUTLIER 51.69 67.71 3.89 Favored Pre-proline 0 CA--C 1.546 0.807 0 C-N-CA 117.842 -1.543 . . . . 0.0 107.869 -179.253 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 312' ' ' PRO . . . . . 0.615 ' HD2' HG21 ' A' ' 308' ' ' ILE . 60.3 Cg_exo -6.33 -66.55 0.0 OUTLIER 'Trans proline' 0 N--CA 1.492 1.423 0 C-N-CA 123.109 2.539 . . . . 0.0 116.29 -176.356 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 20.2 m -129.78 156.97 42.43 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.687 0 N-CA-C 113.285 0.846 . . . . 0.0 113.285 -178.429 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 23.1 t70 -142.71 -61.73 0.43 Allowed 'General case' 0 CA--C 1.535 0.382 0 CA-C-N 114.912 -1.04 . . . . 0.0 110.525 178.612 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 315' ' ' LEU . . . . . 0.599 HD12 ' H ' ' A' ' 315' ' ' LEU . 6.6 mp -61.25 -35.1 76.34 Favored 'General case' 0 N--CA 1.47 0.554 0 N-CA-C 112.357 0.503 . . . . 0.0 112.357 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 85.2 p -60.78 -26.06 66.98 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.287 0.565 . . . . 0.0 109.9 -179.446 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 85.9 tttt -57.4 -36.76 71.72 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.355 -0.839 . . . . 0.0 110.362 -179.67 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 318' ' ' VAL . . . . . 0.475 ' O ' ' O ' ' A' ' 315' ' ' LEU . 13.7 p -131.45 142.97 41.91 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.176 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.332 179.67 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 2.0 m . . . . . 0 C--O 1.22 -0.494 0 CA-C-O 118.024 -0.988 . . . . 0.0 110.598 179.986 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.702 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 86.2 p -62.25 -25.99 68.14 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.835 0.35 . . . . 0.0 110.676 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 11.5 mtpp -89.45 162.65 15.63 Favored 'General case' 0 CA--C 1.515 -0.381 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.869 179.89 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 295' ' ' ASP . . . . . 0.653 ' OD1' ' N ' ' A' ' 296' ' ' ASN . 50.0 p30 -57.58 -33.47 68.21 Favored 'General case' 0 N--CA 1.449 -0.524 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.407 -178.501 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 296' ' ' ASN . . . . . 0.653 ' N ' ' OD1' ' A' ' 295' ' ' ASP . 16.4 t-20 58.44 56.54 4.31 Favored 'General case' 0 CA--C 1.516 -0.357 0 C-N-CA 118.38 -1.328 . . . . 0.0 110.558 177.388 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 297' ' ' ILE . . . . . 0.448 HG22 ' H ' ' A' ' 299' ' ' HIS . 21.6 mm -42.63 137.25 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-O 122.659 1.219 . . . . 0.0 109.975 -175.932 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 83.1 tttt -57.38 -36.04 70.74 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 112.354 -2.203 . . . . 0.0 112.939 -176.744 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 299' ' ' HIS . . . . . 0.448 ' H ' HG22 ' A' ' 297' ' ' ILE . 1.2 m80 64.86 112.35 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 C-N-CA 120.167 -0.613 . . . . 0.0 109.755 -179.14 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -122.21 78.32 43.51 Favored Pre-proline 0 C--N 1.325 -0.46 0 CA-C-N 115.82 -0.627 . . . . 0.0 109.885 -179.293 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -56.32 -23.65 47.34 Favored 'Trans proline' 0 C--N 1.315 -1.231 0 C-N-CA 120.904 1.069 . . . . 0.0 110.238 -179.426 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 302' ' ' GLY . . . . . 0.451 ' C ' ' H ' ' A' ' 304' ' ' GLY . . . -167.15 127.21 1.54 Allowed Glycine 0 CA--C 1.526 0.721 0 CA-C-N 114.965 -1.016 . . . . 0.0 110.882 179.002 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -78.85 10.87 30.26 Favored Glycine 0 N--CA 1.463 0.459 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 178.811 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 304' ' ' GLY . . . . . 0.451 ' H ' ' C ' ' A' ' 302' ' ' GLY . . . 98.39 -4.2 60.06 Favored Glycine 0 CA--C 1.519 0.334 0 N-CA-C 108.25 -1.94 . . . . 0.0 108.25 -177.483 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . 0.524 ' O ' ' C ' ' A' ' 306' ' ' VAL . 23.9 m -59.2 -33.14 70.61 Favored 'General case' 0 C--O 1.233 0.193 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 177.259 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 306' ' ' VAL . . . . . 0.571 HG23 ' H ' ' A' ' 307' ' ' GLN . 4.9 m -7.04 -109.7 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 CA-C-N 114.626 -1.17 . . . . 0.0 111.81 -178.881 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 307' ' ' GLN . . . . . 0.571 ' H ' HG23 ' A' ' 306' ' ' VAL . 25.3 pt20 -138.08 154.84 49.22 Favored 'General case' 0 N--CA 1.451 -0.401 0 CA-C-O 121.466 0.65 . . . . 0.0 109.699 178.612 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 308' ' ' ILE . . . . . 1.002 ' O ' ' N ' ' A' ' 310' ' ' TYR . 16.3 pt -78.1 -25.15 14.09 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.779 0 N-CA-C 116.09 1.885 . . . . 0.0 116.09 -177.239 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . 0.821 HG12 ' O ' ' A' ' 309' ' ' VAL . 93.7 t 9.4 27.78 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.257 0 N-CA-C 113.989 1.107 . . . . 0.0 113.989 -178.814 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 310' ' ' TYR . . . . . 1.002 ' N ' ' O ' ' A' ' 308' ' ' ILE 0.253 0.4 OUTLIER -71.66 -19.98 62.01 Favored 'General case' 0 C--N 1.332 -0.175 0 N-CA-C 113.158 0.799 . . . . 0.0 113.158 -179.523 . . . . . . . . 4 4 . 1 . 007 nuclear nobuild full ' A' A ' 311' ' ' LYS . . . . . 0.417 ' HE3' ' H ' ' A' ' 311' ' ' LYS . 0.0 OUTLIER 57.08 62.72 5.66 Favored Pre-proline 0 C--N 1.325 -0.49 0 CA-C-O 121.316 0.579 . . . . 0.0 109.786 179.718 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 312' ' ' PRO . . . . . 0.778 ' O ' ' N ' ' A' ' 314' ' ' ASP . 32.7 Cg_endo -58.88 143.54 99.31 Favored 'Trans proline' 0 C--N 1.303 -1.855 0 C-N-CA 122.648 2.232 . . . . 0.0 111.288 179.223 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 313' ' ' VAL . . . . . 0.491 ' O ' ' OG ' ' A' ' 316' ' ' SER . 18.9 m -6.58 59.29 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.645 0 O-C-N 124.224 0.953 . . . . 0.0 113.295 -179.452 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 314' ' ' ASP . . . . . 0.778 ' N ' ' O ' ' A' ' 312' ' ' PRO . 93.2 m-20 -56.89 -36.75 70.5 Favored 'General case' 0 C--O 1.223 -0.308 0 N-CA-C 111.66 0.244 . . . . 0.0 111.66 -179.992 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 315' ' ' LEU . . . . . . . . . . . . . 61.7 mt -58.81 -36.42 74.46 Favored 'General case' 0 C--N 1.326 -0.424 0 C-N-CA 120.07 -0.652 . . . . 0.0 110.719 -178.609 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . 0.491 ' OG ' ' O ' ' A' ' 313' ' ' VAL . 86.3 p -63.37 -23.74 67.54 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-O 121.227 0.537 . . . . 0.0 110.756 178.67 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 49.2 tttm -56.75 -35.8 69.03 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.303 -0.862 . . . . 0.0 112.535 -177.489 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 12.5 p -129.7 142.88 42.74 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 C-N-CA 120.263 -0.575 . . . . 0.0 111.829 -179.238 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.221 -0.418 0 CA-C-O 118.137 -0.935 . . . . 0.0 110.813 179.882 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.528 0.875 0 N-CA-C 110.974 -0.85 . . . . 0.0 110.974 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 21.2 m -56.98 -33.6 67.26 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.842 0.353 . . . . 0.0 110.688 -179.922 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 67.4 mttt -57.45 -37.77 73.39 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.098 -178.419 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 295' ' ' ASP . . . . . 0.645 ' OD2' ' N ' ' A' ' 296' ' ' ASN . 50.3 p30 175.1 -24.6 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 115.913 -0.585 . . . . 0.0 109.652 179.401 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 296' ' ' ASN . . . . . 0.645 ' N ' ' OD2' ' A' ' 295' ' ' ASP . 18.7 t-20 56.54 48.22 17.08 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.627 -0.715 . . . . 0.0 111.071 179.751 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 297' ' ' ILE . . . . . 0.672 HG23 ' O ' ' A' ' 297' ' ' ILE . 10.9 tp 15.46 111.04 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 CA-C-O 122.176 0.988 . . . . 0.0 111.602 -178.647 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 298' ' ' LYS . . . . . 0.584 ' O ' ' C ' ' A' ' 299' ' ' HIS . 56.4 tttp -57.86 -36.48 72.4 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 114.488 -1.233 . . . . 0.0 113.285 -178.1 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 299' ' ' HIS . . . . . 0.584 ' C ' ' O ' ' A' ' 298' ' ' LYS . 85.3 t60 1.42 102.25 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.358 0 N-CA-C 112.104 0.409 . . . . 0.0 112.104 -179.265 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.55 75.22 69.68 Favored Pre-proline 0 N--CA 1.469 0.513 0 N-CA-C 111.964 0.357 . . . . 0.0 111.964 -179.17 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -58.94 -21.67 59.23 Favored 'Trans proline' 0 C--N 1.306 -1.693 0 N-CA-C 109.788 -0.889 . . . . 0.0 109.788 177.898 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -79.42 25.21 2.85 Favored Glycine 0 CA--C 1.528 0.892 0 CA-C-N 114.386 -1.279 . . . . 0.0 111.767 -179.848 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -55.93 -26.13 47.3 Favored Glycine 0 CA--C 1.509 -0.296 0 N-CA-C 109.274 -1.53 . . . . 0.0 109.274 179.631 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 98.65 -3.27 59.1 Favored Glycine 0 N--CA 1.442 -0.906 0 N-CA-C 104.686 -3.366 . . . . 0.0 104.686 -175.315 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . 0.503 ' O ' ' O ' ' A' ' 306' ' ' VAL . 24.7 m -59.46 -33.89 71.86 Favored 'General case' 0 N--CA 1.439 -0.998 0 CA-C-N 112.501 -1.849 . . . . 0.0 108.674 177.157 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 306' ' ' VAL . . . . . 0.552 HG23 ' H ' ' A' ' 307' ' ' GLN . 8.2 m -11.22 -113.37 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.233 0.186 0 CA-C-N 113.438 -1.71 . . . . 0.0 112.835 -178.364 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 307' ' ' GLN . . . . . 0.552 ' H ' HG23 ' A' ' 306' ' ' VAL . 21.7 pt20 -141.56 165.1 28.43 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.429 -0.805 . . . . 0.0 110.803 -178.684 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 308' ' ' ILE . . . . . 0.667 ' O ' HG13 ' A' ' 308' ' ' ILE . 19.9 pt -63.99 100.6 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-O 122.596 1.189 . . . . 0.0 109.778 179.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 81.4 t -63.87 -42.44 95.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 122.005 0.907 . . . . 0.0 109.167 179.829 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 310' ' ' TYR . . . . . 0.405 ' CE1' ' HD3' ' A' ' 312' ' ' PRO 0.321 54.9 p90 -66.21 -32.34 73.71 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 118.082 2.623 . . . . 0.0 118.082 179.542 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 311' ' ' LYS . . . . . 0.615 ' O ' ' N ' ' A' ' 313' ' ' VAL . 14.6 mtpp 51.02 63.99 8.9 Favored Pre-proline 0 C--N 1.313 -0.979 0 C-N-CA 118.633 -1.227 . . . . 0.0 109.781 179.362 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 312' ' ' PRO . . . . . 0.591 ' O ' ' N ' ' A' ' 314' ' ' ASP . 84.0 Cg_exo 6.33 58.26 0.0 OUTLIER 'Trans proline' 0 N--CA 1.492 1.382 0 C-N-CA 122.635 2.223 . . . . 0.0 113.41 -179.586 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 313' ' ' VAL . . . . . 0.748 ' O ' HG13 ' A' ' 313' ' ' VAL . 9.5 p 4.56 62.61 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 O-C-N 124.082 0.864 . . . . 0.0 112.196 -179.704 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 314' ' ' ASP . . . . . 0.591 ' N ' ' O ' ' A' ' 312' ' ' PRO . 92.1 m-20 -56.08 -35.82 67.41 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.025 -0.989 . . . . 0.0 111.78 -179.369 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 315' ' ' LEU . . . . . 0.743 ' H ' HD12 ' A' ' 315' ' ' LEU . 6.4 mp -57.39 -36.02 70.74 Favored 'General case' 0 C--N 1.326 -0.45 0 C-N-CA 119.854 -0.738 . . . . 0.0 110.027 -178.33 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . 0.456 ' OG ' HG22 ' A' ' 313' ' ' VAL . 24.4 m -58.45 -34.23 70.61 Favored 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 108.396 -0.965 . . . . 0.0 108.396 177.299 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 65.8 tttt -77.05 132.8 39.11 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.084 -0.962 . . . . 0.0 109.714 179.424 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 318' ' ' VAL . . . . . 0.407 ' O ' HG23 ' A' ' 319' ' ' THR . 14.4 p -131.67 142.82 42.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.629 -179.716 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 319' ' ' THR . . . . . 0.407 HG23 ' O ' ' A' ' 318' ' ' VAL . 33.5 p . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 118.049 -0.976 . . . . 0.0 110.845 -179.709 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 292' ' ' GLY . . . . . 0.52 ' O ' ' C ' ' A' ' 293' ' ' SER . . . . . . . . 0 CA--C 1.525 0.665 0 N-CA-C 111.034 -0.827 . . . . 0.0 111.034 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . 0.52 ' C ' ' O ' ' A' ' 292' ' ' GLY . 1.9 m 21.26 55.82 0.02 OUTLIER 'General case' 0 CA--C 1.535 0.367 0 CA-C-O 120.988 0.423 . . . . 0.0 111.829 -179.568 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 27.8 mttp -91.55 153.51 19.71 Favored 'General case' 0 CA--C 1.515 -0.397 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 178.225 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 295' ' ' ASP . . . . . 0.459 ' C ' ' OD2' ' A' ' 295' ' ' ASP . 48.4 p30 -83.88 8.0 16.36 Favored 'General case' 0 C--N 1.322 -0.626 0 C-N-CA 119.617 -0.833 . . . . 0.0 109.949 -178.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 45.5 t30 58.31 56.06 4.67 Favored 'General case' 0 N--CA 1.455 -0.183 0 C-N-CA 119.671 -0.812 . . . . 0.0 112.014 177.102 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 297' ' ' ILE . . . . . 0.451 HG13 ' OD2' ' A' ' 295' ' ' ASP . 70.7 mt -59.82 131.4 24.41 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.165 0 CA-C-O 122.197 0.999 . . . . 0.0 110.103 -175.932 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 2.0 ttmp? -84.15 136.99 33.76 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 113.419 -1.719 . . . . 0.0 113.958 -177.819 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 64.5 m170 -115.88 136.9 52.6 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 106.483 -1.673 . . . . 0.0 106.483 176.08 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 3.9 m -125.08 69.74 59.64 Favored Pre-proline 0 N--CA 1.466 0.349 0 C-N-CA 119.573 -0.851 . . . . 0.0 112.867 -178.566 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -62.46 -19.31 67.11 Favored 'Trans proline' 0 C--N 1.302 -1.892 0 N-CA-C 107.174 -1.894 . . . . 0.0 107.174 174.683 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -165.08 -169.55 28.85 Favored Glycine 0 CA--C 1.531 1.039 0 CA-C-N 112.91 -1.95 . . . . 0.0 110.233 -178.219 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . 126.25 29.59 0.92 Allowed Glycine 0 N--CA 1.466 0.698 0 N-CA-C 109.013 -1.635 . . . . 0.0 109.013 -178.371 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 97.07 -7.45 64.56 Favored Glycine 0 C--N 1.324 -0.116 0 N-CA-C 107.352 -2.299 . . . . 0.0 107.352 -178.493 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 23.2 t -59.96 -30.75 69.3 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 113.146 -1.527 . . . . 0.0 111.157 177.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 306' ' ' VAL . . . . . 0.564 ' O ' ' CB ' ' A' ' 307' ' ' GLN . 88.5 t -56.93 -42.99 79.73 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.48 0 CA-C-N 115.729 -0.669 . . . . 0.0 112.071 -175.373 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 307' ' ' GLN . . . . . 0.564 ' CB ' ' O ' ' A' ' 306' ' ' VAL . 21.3 pt20 125.46 178.49 0.0 OUTLIER 'General case' 0 N--CA 1.469 0.501 0 O-C-N 124.643 1.214 . . . . 0.0 110.201 179.42 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 308' ' ' ILE . . . . . 0.823 ' O ' ' N ' ' A' ' 310' ' ' TYR . 33.3 mm -54.88 -45.16 75.09 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.933 0 CA-C-N 113.952 -1.476 . . . . 0.0 113.852 177.259 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . 0.455 ' H ' ' HG3' ' A' ' 307' ' ' GLN . 0.3 OUTLIER 37.2 -0.94 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.693 0 O-C-N 123.939 0.774 . . . . 0.0 113.069 -179.212 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 310' ' ' TYR . . . . . 0.823 ' N ' ' O ' ' A' ' 308' ' ' ILE 0.329 0.0 OUTLIER -67.39 -22.3 65.56 Favored 'General case' 0 CA--C 1.503 -0.85 0 C-N-CA 119.056 -1.057 . . . . 0.0 110.681 -178.763 . . . . . . . . 4 4 . 1 . 009 nuclear nobuild full ' A' A ' 311' ' ' LYS . . . . . 0.583 ' O ' ' C ' ' A' ' 312' ' ' PRO . 32.3 tttp 56.4 63.55 5.61 Favored Pre-proline 0 N--CA 1.447 -0.61 0 CA-C-N 115.028 -0.987 . . . . 0.0 109.916 177.779 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 312' ' ' PRO . . . . . 0.583 ' C ' ' O ' ' A' ' 311' ' ' LYS . 75.8 Cg_exo 12.85 -127.08 0.0 OUTLIER 'Trans proline' 0 N--CA 1.492 1.414 0 C-N-CA 122.337 2.025 . . . . 0.0 110.888 -178.448 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 45.2 t -120.98 126.87 75.73 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.398 0 C-N-CA 118.336 -1.345 . . . . 0.0 109.509 176.193 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -63.93 -38.14 89.98 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.64 0.733 . . . . 0.0 111.282 177.102 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 315' ' ' LEU . . . . . 0.65 ' CD2' ' N ' ' A' ' 315' ' ' LEU . 0.2 OUTLIER -61.07 -36.97 81.04 Favored 'General case' 0 C--O 1.233 0.192 0 CA-C-N 114.453 -1.249 . . . . 0.0 113.29 -176.902 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 68.4 m -79.58 -5.55 55.22 Favored 'General case' 0 C--N 1.327 -0.404 0 C-N-CA 120.166 -0.614 . . . . 0.0 111.026 -179.857 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 57.2 tttp -58.42 -38.0 76.52 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.114 -179.333 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 43.4 t -120.65 135.45 60.83 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 CA-C-N 116.545 -0.298 . . . . 0.0 110.577 179.188 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 6.9 m . . . . . 0 C--O 1.221 -0.399 0 CA-C-O 118.018 -0.991 . . . . 0.0 110.422 179.459 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.636 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 86.6 p -61.79 -27.58 68.85 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.798 0.332 . . . . 0.0 110.498 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 31.0 mttt -93.9 153.37 18.27 Favored 'General case' 0 N--CA 1.448 -0.566 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 178.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 295' ' ' ASP . . . . . 0.474 ' OD1' HG13 ' A' ' 297' ' ' ILE . 49.2 p30 -84.12 7.66 18.1 Favored 'General case' 0 C--N 1.322 -0.591 0 C-N-CA 119.685 -0.806 . . . . 0.0 110.301 -178.653 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 16.6 t-20 58.57 55.91 4.56 Favored 'General case' 0 CA--C 1.535 0.391 0 C-N-CA 119.818 -0.753 . . . . 0.0 112.488 176.629 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 297' ' ' ILE . . . . . 0.474 HG13 ' OD1' ' A' ' 295' ' ' ASP . 71.2 mt -61.8 133.24 27.62 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.52 0 CA-C-O 122.258 1.028 . . . . 0.0 110.906 -175.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 15.6 tttt -82.79 137.83 34.21 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-N 113.328 -1.76 . . . . 0.0 114.209 -178.105 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 58.3 t-80 -119.41 132.42 55.82 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 106.75 -1.574 . . . . 0.0 106.75 176.425 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 4.4 m -124.79 79.01 64.25 Favored Pre-proline 0 N--CA 1.472 0.635 0 N-CA-C 113.865 1.061 . . . . 0.0 113.865 -177.033 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -58.53 -24.59 70.42 Favored 'Trans proline' 0 C--N 1.31 -1.471 0 C-N-CA 120.572 0.848 . . . . 0.0 110.963 178.043 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -111.82 48.21 0.96 Allowed Glycine 0 CA--C 1.525 0.694 0 N-CA-C 109.864 -1.294 . . . . 0.0 109.864 179.507 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -81.19 6.85 62.02 Favored Glycine 0 N--CA 1.466 0.638 0 N-CA-C 112.174 -0.37 . . . . 0.0 112.174 -178.398 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 94.52 2.04 63.72 Favored Glycine 0 C--N 1.321 -0.29 0 N-CA-C 107.962 -2.055 . . . . 0.0 107.962 -178.167 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 75.7 m -82.56 6.99 15.77 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 113.851 -1.174 . . . . 0.0 108.229 178.564 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 306' ' ' VAL . . . . . 0.502 ' O ' ' O ' ' A' ' 307' ' ' GLN . 20.7 m -67.25 -22.65 29.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 114.861 -1.063 . . . . 0.0 110.649 -178.845 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 307' ' ' GLN . . . . . 0.536 ' O ' ' O ' ' A' ' 308' ' ' ILE . 21.7 pt20 46.16 118.03 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 122.039 0.924 . . . . 0.0 113.358 179.697 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 308' ' ' ILE . . . . . 0.638 HG23 ' O ' ' A' ' 308' ' ' ILE . 9.7 tp 25.42 120.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.676 0 CA-C-N 113.42 -1.718 . . . . 0.0 114.374 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -149.58 -42.94 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.366 0 CA-C-N 114.599 -1.182 . . . . 0.0 109.072 177.889 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 310' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -61.67 -31.88 72.02 Favored 'General case' 0 CA--C 1.538 0.519 0 N-CA-C 112.938 0.718 . . . . 0.0 112.938 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 311' ' ' LYS . . . . . 0.454 ' HZ2' ' HB3' ' A' ' 311' ' ' LYS . 8.2 mtpp 65.09 73.76 0.42 Allowed Pre-proline 0 N--CA 1.473 0.711 0 N-CA-C 113.116 0.784 . . . . 0.0 113.116 179.114 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 312' ' ' PRO . . . . . . . . . . . . . 6.3 Cg_endo -53.17 -23.76 23.8 Favored 'Trans proline' 0 N--CA 1.498 1.738 0 C-N-CA 120.41 0.74 . . . . 0.0 111.374 179.691 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 313' ' ' VAL . . . . . 0.73 HG13 ' OG ' ' A' ' 316' ' ' SER . 60.3 t -117.16 132.37 67.14 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.273 0 CA-C-O 121.448 0.642 . . . . 0.0 111.589 178.339 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 58.2 t0 -160.17 -60.94 0.06 Allowed 'General case' 0 N--CA 1.449 -0.515 0 CA-C-N 114.98 -1.009 . . . . 0.0 108.921 178.308 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 315' ' ' LEU . . . . . 0.82 ' O ' HG12 ' A' ' 318' ' ' VAL . 61.1 mt -61.65 -35.33 77.63 Favored 'General case' 0 C--O 1.226 -0.167 0 CA-C-N 114.78 -1.1 . . . . 0.0 111.723 179.295 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . 0.73 ' OG ' HG13 ' A' ' 313' ' ' VAL . 80.2 p -61.21 -28.34 69.08 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.307 0.575 . . . . 0.0 110.241 -179.154 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 29.3 tttm -58.24 -37.2 74.43 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.456 -0.793 . . . . 0.0 111.432 -179.421 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 318' ' ' VAL . . . . . 0.82 HG12 ' O ' ' A' ' 315' ' ' LEU . 5.5 p -57.67 -34.21 46.96 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.152 0 CA-C-O 120.882 0.373 . . . . 0.0 110.62 -179.87 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 319' ' ' THR . . . . . 0.599 ' OG1' HG13 ' A' ' 318' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--O 1.221 -0.447 0 CA-C-O 118.027 -0.987 . . . . 0.0 110.044 -179.937 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.576 0 N-CA-C 110.969 -0.852 . . . . 0.0 110.969 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 87.0 p -61.68 -27.22 68.53 Favored 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 120.851 -0.34 . . . . 0.0 110.679 -179.845 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 294' ' ' LYS . . . . . 0.405 ' C ' ' H ' ' A' ' 296' ' ' ASN . 41.2 mtpt -95.7 150.94 19.83 Favored 'General case' 0 N--CA 1.452 -0.328 0 CA-C-O 120.907 0.384 . . . . 0.0 111.081 -179.621 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 295' ' ' ASP . . . . . 0.457 ' C ' ' OD2' ' A' ' 295' ' ' ASP . 48.8 p30 -85.98 10.53 13.84 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 107.43 -1.322 . . . . 0.0 107.43 178.709 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 296' ' ' ASN . . . . . 0.405 ' H ' ' C ' ' A' ' 294' ' ' LYS . 23.6 m120 30.5 -102.09 0.02 OUTLIER 'General case' 0 CA--C 1.511 -0.549 0 CA-C-N 113.301 -1.772 . . . . 0.0 113.294 -179.218 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 297' ' ' ILE . . . . . . . . . . . . . 70.1 mt -113.5 130.31 67.74 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.454 0 CA-C-O 122.297 1.046 . . . . 0.0 113.486 -177.119 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 41.8 tttp -87.5 132.13 34.12 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 113.107 -1.86 . . . . 0.0 108.613 177.037 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 299' ' ' HIS . . . . . 0.575 ' CE1' ' CD ' ' A' ' 301' ' ' PRO . 37.4 t-80 -125.09 113.39 17.67 Favored 'General case' 0 N--CA 1.468 0.461 0 N-CA-C 112.676 0.621 . . . . 0.0 112.676 -179.116 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 3.2 m -134.16 73.34 70.07 Favored Pre-proline 0 N--CA 1.471 0.585 0 CA-C-N 116.196 -0.457 . . . . 0.0 112.191 178.075 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 301' ' ' PRO . . . . . 0.575 ' CD ' ' CE1' ' A' ' 299' ' ' HIS . 5.9 Cg_endo -60.56 -23.82 76.56 Favored 'Trans proline' 0 N--CA 1.5 1.901 0 CA-C-N 119.914 1.005 . . . . 0.0 113.067 179.211 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -134.21 -105.29 0.87 Allowed Glycine 0 CA--C 1.525 0.709 0 N-CA-C 111.149 -0.78 . . . . 0.0 111.149 -178.508 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . 86.4 35.64 10.46 Favored Glycine 0 N--CA 1.462 0.386 0 N-CA-C 109.957 -1.257 . . . . 0.0 109.957 -178.81 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 96.56 -0.25 61.26 Favored Glycine 0 N--CA 1.446 -0.686 0 N-CA-C 108.991 -1.643 . . . . 0.0 108.991 -179.165 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 73.8 m -82.96 1.65 38.68 Favored 'General case' 0 N--CA 1.446 -0.661 0 CA-C-O 121.382 0.611 . . . . 0.0 109.558 178.675 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 306' ' ' VAL . . . . . 0.427 ' O ' ' HB3' ' A' ' 307' ' ' GLN . 73.6 t -61.64 -38.17 79.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 115.06 -0.973 . . . . 0.0 111.253 179.835 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 307' ' ' GLN . . . . . 0.628 ' O ' ' O ' ' A' ' 308' ' ' ILE . 50.3 tt0 79.87 103.03 0.07 Allowed 'General case' 0 CA--C 1.506 -0.729 0 O-C-N 123.6 0.562 . . . . 0.0 112.039 -178.663 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 308' ' ' ILE . . . . . 0.703 HG21 ' HD3' ' A' ' 312' ' ' PRO . 81.7 mt 51.24 149.68 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.443 -0.778 0 CA-C-O 122.256 1.027 . . . . 0.0 109.871 178.506 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . 0.673 HG13 ' CD1' ' A' ' 310' ' ' TYR . 6.3 p -56.34 -33.91 39.15 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 CA-C-N 114.886 -1.052 . . . . 0.0 111.777 -178.576 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 310' ' ' TYR . . . . . 0.808 ' CD1' ' N ' ' A' ' 311' ' ' LYS . 0.0 OUTLIER -161.55 -97.09 0.02 OUTLIER 'General case' 0 C--N 1.304 -1.39 0 CA-C-O 123.896 1.808 . . . . 0.0 112.638 -178.37 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 311' ' ' LYS . . . . . 0.808 ' N ' ' CD1' ' A' ' 310' ' ' TYR . 32.6 mtmm -123.62 103.88 34.32 Favored Pre-proline 0 C--N 1.275 -2.667 0 CA-C-N 109.845 -3.343 . . . . 0.0 108.228 179.181 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 312' ' ' PRO . . . . . 0.703 ' HD3' HG21 ' A' ' 308' ' ' ILE . 9.7 Cg_endo -49.1 151.95 5.51 Favored 'Trans proline' 0 C--N 1.299 -2.038 0 N-CA-C 106.626 -2.106 . . . . 0.0 106.626 179.081 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 313' ' ' VAL . . . . . 0.724 HG12 ' H ' ' A' ' 315' ' ' LEU . 44.3 t -59.53 128.5 20.51 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.585 0 C-N-CA 117.671 -1.611 . . . . 0.0 111.948 -173.434 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 314' ' ' ASP . . . . . 0.497 ' O ' ' HG2' ' A' ' 317' ' ' LYS . 49.2 p30 -97.33 -0.63 46.15 Favored 'General case' 0 N--CA 1.438 -1.058 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 175.897 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 315' ' ' LEU . . . . . 0.724 ' H ' HG12 ' A' ' 313' ' ' VAL . 64.8 mt -64.85 -31.44 72.68 Favored 'General case' 0 N--CA 1.469 0.504 0 O-C-N 123.774 0.671 . . . . 0.0 110.735 178.319 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 89.9 p -58.19 -25.56 61.73 Favored 'General case' 0 N--CA 1.448 -0.545 0 CA-C-N 114.962 -1.017 . . . . 0.0 110.276 -177.453 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 317' ' ' LYS . . . . . 0.497 ' HG2' ' O ' ' A' ' 314' ' ' ASP . 52.2 pttt -59.6 -33.57 71.64 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.349 -0.612 . . . . 0.0 109.349 -179.319 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 318' ' ' VAL . . . . . 0.422 ' N ' ' CG ' ' A' ' 317' ' ' LYS . 74.7 t -60.37 -39.81 82.12 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.132 0 CA-C-N 115.099 -0.955 . . . . 0.0 111.501 -178.807 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 7.1 m . . . . . 0 C--O 1.22 -0.482 0 CA-C-O 117.935 -1.031 . . . . 0.0 110.529 -179.76 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.626 0 N-CA-C 111.038 -0.825 . . . . 0.0 111.038 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 45.3 m -64.02 153.69 36.57 Favored 'General case' 0 C--N 1.333 -0.145 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 179.857 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 294' ' ' LYS . . . . . 0.458 ' C ' ' H ' ' A' ' 296' ' ' ASN . 88.2 mttt -103.75 145.81 29.54 Favored 'General case' 0 N--CA 1.449 -0.477 0 CA-C-O 121.442 0.639 . . . . 0.0 112.014 -179.156 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 295' ' ' ASP . . . . . 0.47 ' C ' ' OD2' ' A' ' 295' ' ' ASP . 49.2 p30 -89.52 12.76 15.66 Favored 'General case' 0 CA--C 1.49 -1.332 0 N-CA-C 106.35 -1.722 . . . . 0.0 106.35 176.68 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 296' ' ' ASN . . . . . 0.609 ' CG ' ' H ' ' A' ' 297' ' ' ILE . 49.4 t30 36.48 -147.95 0.01 OUTLIER 'General case' 0 N--CA 1.426 -1.626 0 CA-C-N 112.362 -2.199 . . . . 0.0 110.697 -178.717 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 297' ' ' ILE . . . . . 0.609 ' H ' ' CG ' ' A' ' 296' ' ' ASN . 8.8 tp -123.2 132.67 70.98 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 CA-C-O 122.642 1.21 . . . . 0.0 112.809 -177.446 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 75.8 tttt -94.48 130.16 40.97 Favored 'General case' 0 C--N 1.302 -1.48 0 CA-C-N 112.323 -2.217 . . . . 0.0 109.702 177.014 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 39.0 t-80 -132.18 136.21 46.89 Favored 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 119.701 -0.8 . . . . 0.0 111.784 179.613 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -125.76 74.77 70.57 Favored Pre-proline 0 N--CA 1.477 0.893 0 CA-C-O 120.4 0.143 . . . . 0.0 111.368 178.987 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -59.94 -21.28 63.95 Favored 'Trans proline' 0 N--CA 1.494 1.523 0 C-N-CA 122.529 2.153 . . . . 0.0 112.089 178.734 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . 114.03 130.63 5.1 Favored Glycine 0 CA--C 1.52 0.355 0 N-CA-C 107.418 -2.273 . . . . 0.0 107.418 -177.279 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -96.44 -78.77 1.43 Allowed Glycine 0 CA--C 1.523 0.564 0 C-N-CA 119.457 -1.354 . . . . 0.0 113.219 -177.853 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . -86.16 -35.29 11.14 Favored Glycine 0 CA--C 1.522 0.486 0 C-N-CA 121.201 -0.524 . . . . 0.0 112.589 -179.778 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . 0.504 ' O ' ' O ' ' A' ' 306' ' ' VAL . 93.9 p -61.63 -30.02 70.43 Favored 'General case' 0 CA--C 1.513 -0.476 0 N-CA-C 114.263 1.209 . . . . 0.0 114.263 -176.756 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 306' ' ' VAL . . . . . 0.504 ' O ' ' O ' ' A' ' 305' ' ' SER . 16.8 t -27.25 -99.88 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 O-C-N 123.57 0.544 . . . . 0.0 112.395 -177.615 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 307' ' ' GLN . . . . . 0.425 ' HG2' ' N ' ' A' ' 308' ' ' ILE . 51.6 tt0 -143.14 158.07 43.95 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.635 179.857 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 308' ' ' ILE . . . . . 0.995 HD11 ' CZ ' ' A' ' 310' ' ' TYR . 5.0 tp -120.96 127.86 76.0 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.673 0 C-N-CA 120.05 -0.66 . . . . 0.0 109.635 177.635 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 73.7 t -67.98 -42.91 85.83 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.565 0 N-CA-C 114.975 1.472 . . . . 0.0 114.975 -179.57 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 310' ' ' TYR . . . . . 0.995 ' CZ ' HD11 ' A' ' 308' ' ' ILE 0.312 2.7 p90 -66.27 -28.14 68.48 Favored 'General case' 0 N--CA 1.469 0.499 0 N-CA-C 116.931 2.197 . . . . 0.0 116.931 -177.019 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 311' ' ' LYS . . . . . 0.536 ' O ' ' O ' ' A' ' 312' ' ' PRO . 10.6 mtpt 56.17 63.23 6.06 Favored Pre-proline 0 C--N 1.307 -1.248 0 C-N-CA 118.74 -1.184 . . . . 0.0 108.534 -178.959 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 312' ' ' PRO . . . . . 0.573 ' O ' ' N ' ' A' ' 314' ' ' ASP . 32.6 Cg_exo 23.62 112.06 0.0 OUTLIER 'Trans proline' 0 C--N 1.316 -1.157 0 C-N-CA 122.752 2.301 . . . . 0.0 115.214 -179.339 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 313' ' ' VAL . . . . . 0.469 ' C ' ' O ' ' A' ' 312' ' ' PRO . 2.1 m 8.15 55.77 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.232 0.141 0 CA-C-N 113.519 -1.673 . . . . 0.0 113.27 179.185 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 314' ' ' ASP . . . . . 0.573 ' N ' ' O ' ' A' ' 312' ' ' PRO . 55.2 t0 -55.37 -36.11 66.0 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 109.962 -0.385 . . . . 0.0 109.962 178.757 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 315' ' ' LEU . . . . . 0.714 ' H ' HD12 ' A' ' 315' ' ' LEU . 6.5 mp -59.27 -35.69 74.19 Favored 'General case' 0 N--CA 1.464 0.254 0 C-N-CA 120.61 -0.436 . . . . 0.0 111.577 -179.344 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 85.4 p -61.71 -27.34 68.64 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 121.352 0.596 . . . . 0.0 110.038 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 317' ' ' LYS . . . . . 0.42 ' HB3' ' O ' ' A' ' 314' ' ' ASP . 38.9 tttp -57.37 -39.1 75.31 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.265 -0.879 . . . . 0.0 111.112 -178.656 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 70.6 t -63.21 -39.26 84.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-O 121.128 0.489 . . . . 0.0 110.323 178.747 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 1.9 m . . . . . 0 C--O 1.22 -0.493 0 CA-C-O 118.068 -0.968 . . . . 0.0 110.282 -178.836 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.644 0 N-CA-C 110.929 -0.869 . . . . 0.0 110.929 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 30.8 t -118.98 142.42 47.81 Favored 'General case' 0 N--CA 1.463 0.198 0 CA-C-O 121.098 0.475 . . . . 0.0 111.242 -179.93 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 25.5 mttm -99.32 152.18 20.22 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.749 179.186 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 295' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -55.29 -37.14 66.94 Favored 'General case' 0 CA--C 1.497 -1.086 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.424 -179.547 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 296' ' ' ASN . . . . . 0.727 HD22 ' N ' ' A' ' 296' ' ' ASN . 0.0 OUTLIER 175.5 -103.07 0.0 OUTLIER 'General case' 0 C--N 1.308 -1.219 0 CA-C-O 121.97 0.891 . . . . 0.0 111.0 179.907 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 297' ' ' ILE . . . . . 0.807 ' O ' HG23 ' A' ' 297' ' ' ILE . 19.2 tt 137.32 86.92 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 CA-C-N 111.977 -2.374 . . . . 0.0 106.722 -178.124 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 36.0 mttt -83.25 137.23 34.1 Favored 'General case' 0 C--N 1.317 -0.828 0 C-N-CA 119.39 -0.924 . . . . 0.0 112.374 -177.247 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 56.8 t-80 -130.76 117.81 19.94 Favored 'General case' 0 N--CA 1.441 -0.899 0 N-CA-C 107.625 -1.25 . . . . 0.0 107.625 175.686 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -125.63 77.32 69.55 Favored Pre-proline 0 C--N 1.324 -0.526 0 C-N-CA 120.704 -0.398 . . . . 0.0 111.36 -179.625 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 85.5 Cg_endo -57.79 -23.66 59.75 Favored 'Trans proline' 0 C--N 1.313 -1.308 0 N-CA-C 109.99 -0.812 . . . . 0.0 109.99 179.224 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -173.43 128.15 1.46 Allowed Glycine 0 CA--C 1.523 0.563 0 CA-C-N 114.81 -1.086 . . . . 0.0 110.84 179.193 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -82.05 4.84 74.02 Favored Glycine 0 N--CA 1.462 0.397 0 N-CA-C 108.701 -1.76 . . . . 0.0 108.701 178.414 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 98.4 -8.08 62.14 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 109.845 -1.302 . . . . 0.0 109.845 -179.259 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . 0.465 ' O ' ' C ' ' A' ' 306' ' ' VAL . 20.3 m -59.9 -34.93 73.83 Favored 'General case' 0 CA--C 1.521 -0.172 0 CA-C-O 121.953 0.882 . . . . 0.0 109.463 177.557 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 306' ' ' VAL . . . . . 0.465 ' C ' ' O ' ' A' ' 305' ' ' SER . 7.7 t -13.61 -104.0 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 CA-C-N 113.475 -1.693 . . . . 0.0 113.697 -177.902 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 307' ' ' GLN . . . . . 0.412 ' H ' ' HB ' ' A' ' 306' ' ' VAL . 21.7 pt20 -145.16 170.71 15.7 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.03 -0.532 . . . . 0.0 111.177 -178.1 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 308' ' ' ILE . . . . . 0.921 HG23 ' CD2' ' A' ' 310' ' ' TYR . 71.8 mt -97.28 116.96 41.02 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.095 0 N-CA-C 115.677 1.732 . . . . 0.0 115.677 -178.529 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 5.9 p -69.86 -32.29 51.3 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.462 0 CA-C-N 113.59 -1.641 . . . . 0.0 108.731 172.751 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 310' ' ' TYR . . . . . 0.921 ' CD2' HG23 ' A' ' 308' ' ' ILE 0.412 51.6 p90 -62.44 -10.71 12.46 Favored 'General case' 0 C--N 1.346 0.435 0 N-CA-C 117.817 2.525 . . . . 0.0 117.817 -177.203 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 311' ' ' LYS . . . . . 0.472 ' O ' ' C ' ' A' ' 312' ' ' PRO . 9.3 mmtt 63.68 67.53 0.98 Allowed Pre-proline 0 N--CA 1.475 0.813 0 CA-C-N 118.853 0.751 . . . . 0.0 112.406 177.235 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 312' ' ' PRO . . . . . 0.602 ' HD3' HG21 ' A' ' 308' ' ' ILE . 61.2 Cg_exo -0.99 -114.3 0.0 OUTLIER 'Trans proline' 0 N--CA 1.489 1.244 0 C-N-CA 123.093 2.529 . . . . 0.0 116.361 179.598 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 16.1 m -111.31 21.03 5.97 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.478 0 N-CA-C 113.071 0.767 . . . . 0.0 113.071 -176.761 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 58.2 t0 -51.33 -36.86 44.75 Favored 'General case' 0 C--N 1.323 -0.568 0 C-N-CA 120.271 -0.572 . . . . 0.0 111.176 -178.105 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 315' ' ' LEU . . . . . 0.635 ' N ' ' CD2' ' A' ' 315' ' ' LEU . 0.2 OUTLIER -60.05 -36.93 78.38 Favored 'General case' 0 C--N 1.33 -0.241 0 C-N-CA 118.983 -1.087 . . . . 0.0 109.496 178.458 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 21.5 t -59.49 -31.36 69.29 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.886 178.36 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 7.7 ttpp -56.17 -35.34 67.1 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.087 -0.961 . . . . 0.0 111.416 -176.879 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 43.0 t -112.27 134.74 53.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 121.017 0.436 . . . . 0.0 110.491 -179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 1.1 m . . . . . 0 C--O 1.22 -0.457 0 CA-C-O 117.916 -1.04 . . . . 0.0 110.695 -179.671 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.666 0 N-CA-C 110.788 -0.925 . . . . 0.0 110.788 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 74.7 m -82.51 3.37 28.7 Favored 'General case' 0 C--N 1.329 -0.32 0 C-N-CA 120.979 -0.288 . . . . 0.0 110.69 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 64.8 mttp -91.65 144.42 25.55 Favored 'General case' 0 C--N 1.331 -0.227 0 N-CA-C 109.476 -0.564 . . . . 0.0 109.476 179.443 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 295' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -57.93 -39.59 78.37 Favored 'General case' 0 CA--C 1.507 -0.691 0 C-N-CA 120.069 -0.652 . . . . 0.0 111.688 -178.857 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 296' ' ' ASN . . . . . 0.445 ' HB3' ' H ' ' A' ' 297' ' ' ILE . 46.7 t-20 177.92 -94.41 0.0 OUTLIER 'General case' 0 C--N 1.314 -0.978 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 179.1 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 297' ' ' ILE . . . . . 0.445 ' H ' ' HB3' ' A' ' 296' ' ' ASN . 18.1 tt 174.62 3.82 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 113.715 -1.584 . . . . 0.0 109.808 179.431 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 298' ' ' LYS . . . . . 0.428 ' H ' ' H ' ' A' ' 297' ' ' ILE . 29.1 mttt 64.69 47.59 2.76 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-O 120.856 0.36 . . . . 0.0 110.705 -179.693 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 299' ' ' HIS . . . . . 0.401 ' ND1' ' O ' ' A' ' 299' ' ' HIS . 58.4 t-80 -74.07 65.43 1.12 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.139 -179.389 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 4.8 t -124.87 75.13 65.89 Favored Pre-proline 0 N--CA 1.465 0.319 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.323 178.974 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 66.1 Cg_endo -57.81 -24.74 65.47 Favored 'Trans proline' 0 C--N 1.311 -1.427 0 C-N-CA 121.29 1.327 . . . . 0.0 111.431 -179.385 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -163.05 121.8 1.05 Allowed Glycine 0 CA--C 1.524 0.64 0 C-N-CA 120.624 -0.798 . . . . 0.0 111.656 179.76 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -82.32 1.21 87.88 Favored Glycine 0 CA--C 1.527 0.836 0 N-CA-C 110.264 -1.134 . . . . 0.0 110.264 178.534 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 96.79 -7.62 65.33 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.061 -1.215 . . . . 0.0 110.061 -179.788 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . 0.455 ' O ' ' C ' ' A' ' 306' ' ' VAL . 25.9 t -60.04 -32.62 71.08 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.537 0.684 . . . . 0.0 109.232 177.07 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 306' ' ' VAL . . . . . 0.458 HG23 ' H ' ' A' ' 307' ' ' GLN . 0.0 OUTLIER -20.45 -90.5 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 CA-C-N 113.999 -1.455 . . . . 0.0 112.962 -177.44 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 307' ' ' GLN . . . . . 0.458 ' H ' HG23 ' A' ' 306' ' ' VAL . 2.6 pt20 -143.22 167.95 20.92 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.341 -0.845 . . . . 0.0 111.067 -177.329 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 308' ' ' ILE . . . . . 0.543 HG23 ' CE2' ' A' ' 310' ' ' TYR . 67.1 mt -107.4 120.89 59.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-O 121.751 0.786 . . . . 0.0 111.075 -179.699 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . 0.467 ' CG1' ' N ' ' A' ' 310' ' ' TYR . 8.0 p -66.04 -36.38 77.33 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.847 0 CA-C-O 122.206 1.003 . . . . 0.0 108.914 174.876 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 310' ' ' TYR . . . . . 0.543 ' CE2' HG23 ' A' ' 308' ' ' ILE 0.448 51.1 p90 -64.53 -32.12 73.62 Favored 'General case' 0 N--CA 1.451 -0.407 0 N-CA-C 118.194 2.665 . . . . 0.0 118.194 -177.996 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 311' ' ' LYS . . . . . 0.49 ' C ' ' O ' ' A' ' 310' ' ' TYR . 49.6 mtpt 47.98 72.23 1.33 Allowed Pre-proline 0 C--N 1.317 -0.805 0 C-N-CA 116.942 -1.903 . . . . 0.0 108.74 176.728 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 312' ' ' PRO . . . . . . . . . . . . . 7.0 Cg_endo -42.88 -37.54 6.14 Favored 'Trans proline' 0 N--CA 1.505 2.148 0 N-CA-C 114.364 0.871 . . . . 0.0 114.364 -173.754 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 71.6 t -62.95 -38.23 81.39 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.059 0 N-CA-C 116.417 2.006 . . . . 0.0 116.417 -179.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 60.3 t0 -54.33 -43.84 71.57 Favored 'General case' 0 N--CA 1.467 0.416 0 O-C-N 120.589 -1.32 . . . . 0.0 114.415 -173.899 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 315' ' ' LEU . . . . . 0.651 ' N ' ' CD2' ' A' ' 315' ' ' LEU . 0.3 OUTLIER -66.8 -36.43 82.38 Favored 'General case' 0 C--N 1.319 -0.751 0 C-N-CA 118.308 -1.357 . . . . 0.0 109.068 176.628 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 32.8 m -59.7 -34.88 73.47 Favored 'General case' 0 N--CA 1.45 -0.47 0 CA-C-N 115.091 -0.959 . . . . 0.0 110.719 178.262 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 30.1 ttpt -80.12 125.63 30.06 Favored 'General case' 0 N--CA 1.45 -0.429 0 CA-C-O 121.697 0.761 . . . . 0.0 111.701 -177.25 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 318' ' ' VAL . . . . . 0.445 ' O ' ' OG1' ' A' ' 319' ' ' THR . 13.2 p -134.39 142.45 40.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 114.814 -1.084 . . . . 0.0 109.262 178.468 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 319' ' ' THR . . . . . 0.445 ' OG1' ' O ' ' A' ' 318' ' ' VAL . 0.7 OUTLIER . . . . . 0 C--O 1.219 -0.513 0 CA-C-O 117.962 -1.018 . . . . 0.0 111.227 179.314 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.515 0 N-CA-C 110.931 -0.868 . . . . 0.0 110.931 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 29.9 t -116.65 138.65 51.28 Favored 'General case' 0 C--O 1.232 0.159 0 CA-C-O 121.335 0.588 . . . . 0.0 110.228 179.542 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 1.9 mtpt -133.45 -166.65 1.8 Allowed 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.117 -0.947 . . . . 0.0 111.427 -179.313 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 295' ' ' ASP . . . . . 0.48 ' C ' ' OD1' ' A' ' 295' ' ' ASP . 48.7 p30 -82.92 11.04 6.6 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.19 -0.913 . . . . 0.0 109.203 179.946 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 17.6 m120 46.17 -138.34 0.58 Allowed 'General case' 0 CA--C 1.497 -1.074 0 CA-C-N 114.407 -1.27 . . . . 0.0 111.613 179.818 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 297' ' ' ILE . . . . . 0.6 HD11 ' CD2' ' A' ' 299' ' ' HIS . 13.9 tt -121.23 126.79 75.48 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-O 122.357 1.075 . . . . 0.0 111.404 -177.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 6.1 mtpm? -61.09 -36.52 79.89 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-N 112.98 -1.918 . . . . 0.0 112.568 179.13 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 299' ' ' HIS . . . . . 0.6 ' CD2' HD11 ' A' ' 297' ' ' ILE . 1.4 m170 38.21 60.89 1.19 Allowed 'General case' 0 CA--C 1.537 0.473 0 CA-C-O 121.175 0.512 . . . . 0.0 112.266 -179.657 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . 0.415 ' C ' ' N ' ' A' ' 302' ' ' GLY . 3.1 m -123.47 72.65 49.81 Favored Pre-proline 0 N--CA 1.464 0.274 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.009 178.658 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 301' ' ' PRO . . . . . 0.401 ' CD ' ' H ' ' A' ' 302' ' ' GLY . 44.5 Cg_endo -58.34 -17.8 35.1 Favored 'Trans proline' 0 C--N 1.317 -1.127 0 N-CA-C 107.96 -1.592 . . . . 0.0 107.96 177.72 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 302' ' ' GLY . . . . . 0.415 ' N ' ' C ' ' A' ' 300' ' ' VAL . . . 116.61 156.13 10.58 Favored Glycine 0 N--CA 1.443 -0.846 0 CA-C-N 112.801 -2.0 . . . . 0.0 109.788 -179.014 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 303' ' ' GLY . . . . . 0.661 ' O ' ' N ' ' A' ' 305' ' ' SER . . . -163.69 -178.96 37.74 Favored Glycine 0 N--CA 1.446 -0.688 0 N-CA-C 108.528 -1.829 . . . . 0.0 108.528 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 59.32 -70.43 0.01 OUTLIER Glycine 0 CA--C 1.529 0.926 0 N-CA-C 109.815 -1.314 . . . . 0.0 109.815 -179.11 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . 0.661 ' N ' ' O ' ' A' ' 303' ' ' GLY . 23.0 t -58.0 -33.97 69.5 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 121.081 0.467 . . . . 0.0 111.578 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 306' ' ' VAL . . . . . 0.627 HG23 ' H ' ' A' ' 307' ' ' GLN . 2.3 m -36.84 -100.91 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 N-CA-C 114.251 1.204 . . . . 0.0 114.251 -178.256 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 307' ' ' GLN . . . . . 0.627 ' H ' HG23 ' A' ' 306' ' ' VAL . 54.8 mt-30 -113.35 160.3 18.52 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 114.429 -1.26 . . . . 0.0 111.776 -176.376 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 308' ' ' ILE . . . . . 0.875 HG22 ' H ' ' A' ' 311' ' ' LYS . 34.9 mm -103.12 119.11 51.1 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-O 122.006 0.907 . . . . 0.0 112.635 -179.506 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 77.4 t -67.81 -40.27 83.38 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 CA-C-N 113.51 -1.677 . . . . 0.0 107.481 174.549 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 310' ' ' TYR . . . . . 0.641 ' CD2' HG23 ' A' ' 308' ' ' ILE 0.361 51.2 p90 -62.7 -31.05 71.89 Favored 'General case' 0 N--CA 1.446 -0.634 0 N-CA-C 117.467 2.395 . . . . 0.0 117.467 -178.676 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 311' ' ' LYS . . . . . 0.875 ' H ' HG22 ' A' ' 308' ' ' ILE . 19.4 mtpp 52.89 65.57 5.8 Favored Pre-proline 0 C--N 1.319 -0.731 0 CA-C-N 119.815 1.189 . . . . 0.0 110.223 178.773 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 312' ' ' PRO . . . . . 0.45 ' C ' ' O ' ' A' ' 311' ' ' LYS . 78.4 Cg_exo 7.67 -129.04 0.0 OUTLIER 'Trans proline' 0 C--N 1.316 -1.171 0 C-N-CA 123.264 2.643 . . . . 0.0 116.937 -179.216 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 313' ' ' VAL . . . . . 0.47 ' O ' ' OG ' ' A' ' 316' ' ' SER . 17.6 m -112.89 28.77 2.28 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 CA-C-N 114.775 -1.102 . . . . 0.0 113.542 -175.931 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 314' ' ' ASP . . . . . 0.4 ' O ' ' CB ' ' A' ' 317' ' ' LYS . 92.1 m-20 -51.51 -36.46 44.79 Favored 'General case' 0 C--N 1.319 -0.751 0 C-N-CA 119.66 -0.816 . . . . 0.0 111.17 -177.127 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 315' ' ' LEU . . . . . 0.633 ' CD2' ' N ' ' A' ' 315' ' ' LEU . 0.3 OUTLIER -59.81 -35.34 74.5 Favored 'General case' 0 CA--C 1.537 0.457 0 C-N-CA 119.819 -0.752 . . . . 0.0 110.414 178.587 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . 0.47 ' OG ' ' O ' ' A' ' 313' ' ' VAL . 82.6 p -62.44 -21.12 65.17 Favored 'General case' 0 N--CA 1.469 0.511 0 CA-C-O 121.431 0.634 . . . . 0.0 110.364 179.373 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 317' ' ' LYS . . . . . 0.4 ' CB ' ' O ' ' A' ' 314' ' ' ASP . 82.0 tttt -55.29 -34.53 64.18 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.071 -0.968 . . . . 0.0 111.779 -177.399 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 13.1 p -129.08 142.55 43.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 C-N-CA 120.471 -0.492 . . . . 0.0 110.789 179.657 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.221 -0.439 0 CA-C-O 118.008 -0.996 . . . . 0.0 110.555 -179.644 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 0.409 0 N-CA-C 110.793 -0.923 . . . . 0.0 110.793 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 97.6 p -120.68 153.07 37.41 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.117 0.484 . . . . 0.0 110.687 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -133.59 170.67 15.19 Favored 'General case' 0 CA--C 1.506 -0.728 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.673 -179.499 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 295' ' ' ASP . . . . . . . . . . . . . 86.0 m-20 -63.12 143.71 57.55 Favored 'General case' 0 N--CA 1.438 -1.063 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 -179.769 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 22.3 t-20 -64.77 130.5 43.74 Favored 'General case' 0 C--N 1.309 -1.174 0 CA-C-N 115.246 -0.888 . . . . 0.0 111.669 -177.595 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 297' ' ' ILE . . . . . . . . . . . . . 71.4 mt -115.18 132.12 65.41 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.09 0 CA-C-N 114.856 -1.065 . . . . 0.0 110.545 -179.762 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 73.1 tttt -105.66 135.62 46.74 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.85 179.184 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 99.3 m-70 -118.94 140.48 49.92 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.089 178.451 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 3.6 m -123.98 78.28 58.44 Favored Pre-proline 0 C--N 1.33 -0.255 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.358 -179.156 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -56.53 145.82 78.3 Favored 'Trans proline' 0 C--N 1.312 -1.371 0 N-CA-C 109.244 -1.099 . . . . 0.0 109.244 178.807 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -49.36 107.52 0.32 Allowed Glycine 0 CA--C 1.52 0.375 0 C-N-CA 118.92 -1.61 . . . . 0.0 109.769 -178.864 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -77.92 -2.13 81.01 Favored Glycine 0 C--N 1.33 0.23 0 N-CA-C 109.798 -1.321 . . . . 0.0 109.798 179.59 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 95.33 -1.93 64.94 Favored Glycine 0 N--CA 1.45 -0.402 0 N-CA-C 108.958 -1.657 . . . . 0.0 108.958 -178.883 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 73.9 m -83.24 1.83 38.85 Favored 'General case' 0 N--CA 1.453 -0.32 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 178.505 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 306' ' ' VAL . . . . . . . . . . . . . 71.6 t -61.08 -39.93 83.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 CA-C-N 115.062 -0.972 . . . . 0.0 110.214 -179.467 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 307' ' ' GLN . . . . . 0.855 ' HG3' ' H ' ' A' ' 308' ' ' ILE . 21.2 pt20 -159.63 -88.24 0.03 OUTLIER 'General case' 0 CA--C 1.542 0.637 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.824 179.065 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 308' ' ' ILE . . . . . 0.855 ' H ' ' HG3' ' A' ' 307' ' ' GLN . 32.0 pt -125.22 160.94 30.24 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 CA-C-N 118.985 0.811 . . . . 0.0 111.305 179.525 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . 0.926 HG13 ' H ' ' A' ' 310' ' ' TYR . 3.9 p -136.65 -65.26 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 178.199 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 310' ' ' TYR . . . . . 0.926 ' H ' HG13 ' A' ' 309' ' ' VAL . 0.8 OUTLIER -66.31 -19.47 65.82 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.288 -0.869 . . . . 0.0 112.484 178.461 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 311' ' ' LYS . . . . . 0.534 ' O ' ' C ' ' A' ' 312' ' ' PRO . 43.9 tttt 67.55 65.21 0.66 Allowed Pre-proline 0 C--N 1.326 -0.439 0 C-N-CA 120.791 -0.364 . . . . 0.0 110.674 -179.358 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 312' ' ' PRO . . . . . 0.568 ' O ' ' C ' ' A' ' 313' ' ' VAL . 70.6 Cg_exo 3.9 75.75 0.0 OUTLIER 'Trans proline' 0 N--CA 1.488 1.152 0 C-N-CA 122.924 2.416 . . . . 0.0 114.016 179.812 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 313' ' ' VAL . . . . . 0.601 HG13 ' O ' ' A' ' 313' ' ' VAL . 13.7 p 1.33 71.18 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 O-C-N 124.085 0.866 . . . . 0.0 111.434 179.643 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 314' ' ' ASP . . . . . 0.506 ' N ' ' O ' ' A' ' 312' ' ' PRO . 21.7 t70 -55.18 -36.56 66.02 Favored 'General case' 0 CA--C 1.536 0.416 0 CA-C-N 114.464 -1.244 . . . . 0.0 112.992 -178.586 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 315' ' ' LEU . . . . . 0.635 ' N ' ' CD2' ' A' ' 315' ' ' LEU . 0.2 OUTLIER -58.88 -35.25 72.68 Favored 'General case' 0 N--CA 1.465 0.291 0 C-N-CA 120.585 -0.446 . . . . 0.0 111.258 -178.65 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . 0.435 ' OG ' HG13 ' A' ' 313' ' ' VAL . 84.1 p -61.83 -26.39 68.09 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.002 0.43 . . . . 0.0 110.91 179.873 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 32.0 mmtm -58.07 -36.18 72.44 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.892 -0.595 . . . . 0.0 111.784 -177.397 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 13.3 p -132.47 143.11 40.81 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.26 0 CA-C-O 120.607 0.241 . . . . 0.0 111.077 -179.901 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 27.0 p . . . . . 0 C--O 1.221 -0.446 0 CA-C-O 117.83 -1.081 . . . . 0.0 110.422 179.443 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.609 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 74.3 m -82.3 2.3 32.74 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.858 0.361 . . . . 0.0 110.457 -179.94 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 76.9 mttt -96.56 151.52 19.51 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.439 179.699 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 295' ' ' ASP . . . . . 0.469 ' C ' ' OD1' ' A' ' 295' ' ' ASP . 48.9 p30 -86.7 9.86 17.49 Favored 'General case' 0 CA--C 1.503 -0.852 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 178.844 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 296' ' ' ASN . . . . . 0.565 ' CG ' ' H ' ' A' ' 297' ' ' ILE . 37.3 t-20 58.78 -143.17 0.62 Allowed 'General case' 0 CA--C 1.49 -1.341 0 CA-C-N 114.369 -1.287 . . . . 0.0 110.598 179.579 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 297' ' ' ILE . . . . . 0.565 ' H ' ' CG ' ' A' ' 296' ' ' ASN . 14.4 tt -121.4 131.19 73.65 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 CA-C-O 122.482 1.134 . . . . 0.0 112.416 -177.899 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 83.6 tttt -93.88 131.17 39.56 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-N 112.66 -2.064 . . . . 0.0 109.447 177.475 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 49.7 t-80 -128.26 137.05 51.82 Favored 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 120.114 -0.635 . . . . 0.0 110.86 179.792 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -124.21 76.55 60.43 Favored Pre-proline 0 N--CA 1.469 0.505 0 CA-C-N 116.804 -0.18 . . . . 0.0 111.065 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 83.6 Cg_endo -58.97 -25.49 77.75 Favored 'Trans proline' 0 N--CA 1.489 1.254 0 C-N-CA 121.126 1.217 . . . . 0.0 111.009 179.193 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . 174.77 133.61 1.75 Allowed Glycine 0 CA--C 1.532 1.125 0 CA-C-N 115.309 -0.86 . . . . 0.0 111.444 179.785 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -117.37 48.16 0.97 Allowed Glycine 0 CA--C 1.533 1.207 0 N-CA-C 110.534 -1.026 . . . . 0.0 110.534 179.565 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 99.1 -7.72 60.53 Favored Glycine 0 N--CA 1.466 0.687 0 N-CA-C 109.01 -1.636 . . . . 0.0 109.01 -178.143 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 27.9 t -83.68 -0.55 51.2 Favored 'General case' 0 CA--C 1.516 -0.327 0 N-CA-C 107.03 -1.47 . . . . 0.0 107.03 175.816 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 306' ' ' VAL . . . . . 0.623 ' O ' ' CB ' ' A' ' 307' ' ' GLN . 99.5 t -58.77 -41.56 82.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 113.569 -1.651 . . . . 0.0 112.193 -175.683 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 307' ' ' GLN . . . . . 0.623 ' CB ' ' O ' ' A' ' 306' ' ' VAL . 63.0 tt0 122.86 172.36 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.792 0 O-C-N 124.631 1.207 . . . . 0.0 108.023 -179.298 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 308' ' ' ILE . . . . . 0.494 ' N ' ' HG2' ' A' ' 307' ' ' GLN . 29.4 pt -121.25 155.24 25.11 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 N-CA-C 110.11 -0.329 . . . . 0.0 110.11 179.384 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . 0.59 ' O ' HG12 ' A' ' 309' ' ' VAL . 58.9 t -133.74 -5.62 1.34 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.292 0 CA-C-N 116.315 -0.402 . . . . 0.0 111.611 179.569 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 310' ' ' TYR . . . . . 0.511 ' CD1' ' HD3' ' A' ' 312' ' ' PRO . 2.0 p90 -65.87 -18.29 65.24 Favored 'General case' 0 CA--C 1.517 -0.298 0 N-CA-C 112.508 0.559 . . . . 0.0 112.508 -176.481 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 311' ' ' LYS . . . . . 0.49 ' O ' ' C ' ' A' ' 312' ' ' PRO . 1.9 mtmm 59.38 64.91 2.84 Favored Pre-proline 0 C--N 1.325 -0.461 0 N-CA-C 107.252 -1.388 . . . . 0.0 107.252 -179.411 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 312' ' ' PRO . . . . . 0.511 ' HD3' ' CD1' ' A' ' 310' ' ' TYR . 1.1 Cg_exo -14.06 -62.1 0.01 OUTLIER 'Trans proline' 0 C--N 1.305 -1.731 0 C-N-CA 123.065 2.51 . . . . 0.0 114.536 -178.517 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 313' ' ' VAL . . . . . 0.768 HG22 ' OG ' ' A' ' 316' ' ' SER . 2.6 p -176.18 27.07 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 C-N-CA 120.397 -0.521 . . . . 0.0 111.314 179.621 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 92.9 m-20 -57.85 -37.66 74.29 Favored 'General case' 0 C--N 1.32 -0.705 0 N-CA-C 112.135 0.421 . . . . 0.0 112.135 -179.027 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 315' ' ' LEU . . . . . 0.741 ' O ' HG22 ' A' ' 318' ' ' VAL . 0.1 OUTLIER -56.95 -39.49 74.66 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 120.203 -0.599 . . . . 0.0 109.806 -178.671 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . 0.768 ' OG ' HG22 ' A' ' 313' ' ' VAL . 86.6 p -63.34 -27.2 69.15 Favored 'General case' 0 N--CA 1.471 0.601 0 O-C-N 122.057 -0.402 . . . . 0.0 111.976 178.595 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 57.2 tttp -58.2 -36.17 72.7 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.156 -0.475 . . . . 0.0 112.114 -177.858 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 318' ' ' VAL . . . . . 0.741 HG22 ' O ' ' A' ' 315' ' ' LEU . 27.9 m -76.0 136.75 24.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-O 121.213 0.53 . . . . 0.0 111.097 -179.21 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 43.6 m . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 118.044 -0.979 . . . . 0.0 110.31 -179.952 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.761 0 N-CA-C 110.903 -0.879 . . . . 0.0 110.903 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 46.7 m -63.83 154.32 33.96 Favored 'General case' 0 C--N 1.33 -0.255 0 C-N-CA 121.061 -0.255 . . . . 0.0 110.322 -179.998 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 294' ' ' LYS . . . . . 0.445 ' C ' ' H ' ' A' ' 296' ' ' ASN . 11.5 mtpp -98.99 148.47 23.96 Favored 'General case' 0 N--CA 1.448 -0.569 0 CA-C-O 120.989 0.423 . . . . 0.0 111.188 -179.56 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 295' ' ' ASP . . . . . 0.471 ' OD2' ' C ' ' A' ' 295' ' ' ASP . 49.7 p30 -86.85 10.82 14.88 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 107.079 -1.452 . . . . 0.0 107.079 178.37 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 296' ' ' ASN . . . . . 0.445 ' H ' ' C ' ' A' ' 294' ' ' LYS . 81.1 m-20 29.17 -127.51 0.03 OUTLIER 'General case' 0 CA--C 1.5 -0.953 0 CA-C-N 112.604 -2.089 . . . . 0.0 113.467 -178.348 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 297' ' ' ILE . . . . . 0.448 ' O ' HG23 ' A' ' 297' ' ' ILE . 14.7 tt -121.86 130.47 74.56 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.709 0 CA-C-O 122.473 1.13 . . . . 0.0 113.024 -177.469 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 298' ' ' LYS . . . . . . . . . . . . . 15.6 ttmm -100.84 127.63 47.21 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-N 112.715 -2.039 . . . . 0.0 109.675 176.933 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 50.6 t-80 -136.33 114.33 11.37 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 120.552 -0.459 . . . . 0.0 111.479 179.193 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 3.2 m -133.89 72.87 72.2 Favored Pre-proline 0 N--CA 1.476 0.858 0 N-CA-C 113.953 1.094 . . . . 0.0 113.953 179.269 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 8.4 Cg_endo -61.25 -23.41 77.0 Favored 'Trans proline' 0 N--CA 1.502 2.017 0 CA-C-N 119.978 1.028 . . . . 0.0 112.026 177.732 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -77.01 46.25 2.38 Favored Glycine 0 CA--C 1.528 0.883 0 CA-C-N 115.121 -0.945 . . . . 0.0 113.194 -178.171 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -57.7 -28.53 60.22 Favored Glycine 0 N--CA 1.445 -0.7 0 N-CA-C 107.397 -2.281 . . . . 0.0 107.397 178.122 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 95.94 -0.56 62.62 Favored Glycine 0 N--CA 1.44 -1.038 0 N-CA-C 104.355 -3.498 . . . . 0.0 104.355 -175.594 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 72.8 m -83.06 1.36 40.52 Favored 'General case' 0 N--CA 1.436 -1.155 0 CA-C-N 112.486 -1.857 . . . . 0.0 110.314 179.295 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 306' ' ' VAL . . . . . . . . . . . . . 92.6 t -61.79 -42.63 95.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 115.424 -0.807 . . . . 0.0 112.178 -178.233 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 307' ' ' GLN . . . . . . . . . . . . . 2.5 pt20 173.65 -159.63 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.254 0 O-C-N 123.705 0.628 . . . . 0.0 109.585 -179.312 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 308' ' ' ILE . . . . . 0.626 HG22 ' H ' ' A' ' 311' ' ' LYS . 65.5 mt -114.97 122.95 70.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.546 178.127 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . 0.491 ' CG1' ' N ' ' A' ' 310' ' ' TYR . 8.0 p -63.82 -39.6 86.01 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.311 0 C-N-CA 118.859 -1.136 . . . . 0.0 108.442 176.588 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 310' ' ' TYR . . . . . 0.491 ' N ' ' CG1' ' A' ' 309' ' ' VAL 0.331 55.2 p90 -67.49 -33.14 74.49 Favored 'General case' 0 N--CA 1.452 -0.352 0 N-CA-C 117.584 2.438 . . . . 0.0 117.584 178.89 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 311' ' ' LYS . . . . . 0.626 ' H ' HG22 ' A' ' 308' ' ' ILE . 2.9 ttpm? 46.34 61.29 13.24 Favored Pre-proline 0 C--N 1.315 -0.924 0 C-N-CA 119.136 -1.025 . . . . 0.0 109.508 179.606 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 312' ' ' PRO . . . . . 0.539 ' C ' ' O ' ' A' ' 311' ' ' LYS . 83.8 Cg_exo 24.16 55.25 0.0 OUTLIER 'Trans proline' 0 N--CA 1.486 1.031 0 C-N-CA 120.801 1.001 . . . . 0.0 113.201 -179.209 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 313' ' ' VAL . . . . . 0.526 ' C ' ' O ' ' A' ' 312' ' ' PRO . 4.2 m 2.68 84.11 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 CA-C-N 115.181 -0.918 . . . . 0.0 112.467 -179.743 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 314' ' ' ASP . . . . . . . . . . . . . 56.1 t0 -55.8 -36.62 67.62 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.956 -0.565 . . . . 0.0 111.146 179.978 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 315' ' ' LEU . . . . . . . . . . . . . 62.4 mt -58.82 -33.91 70.93 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.593 -178.976 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 95.3 p -60.43 -28.05 67.98 Favored 'General case' 0 CA--C 1.511 -0.55 0 C-N-CA 120.048 -0.661 . . . . 0.0 111.058 -179.285 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 38.1 mtpt -92.04 137.75 32.11 Favored 'General case' 0 N--CA 1.448 -0.539 0 C-N-CA 119.455 -0.898 . . . . 0.0 109.868 179.434 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 13.7 p -131.69 143.0 41.68 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 CA-C-N 114.977 -1.01 . . . . 0.0 110.765 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 41.6 p . . . . . 0 C--O 1.22 -0.488 0 CA-C-O 118.02 -0.991 . . . . 0.0 110.559 179.989 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.737 0 N-CA-C 110.939 -0.864 . . . . 0.0 110.939 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 92.3 p -122.67 155.88 35.49 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.596 0.236 . . . . 0.0 110.463 -179.878 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 294' ' ' LYS . . . . . . . . . . . . . 16.0 mtpp -93.91 149.7 21.0 Favored 'General case' 0 N--CA 1.446 -0.633 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.714 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 295' ' ' ASP . . . . . 0.679 ' OD1' ' N ' ' A' ' 296' ' ' ASN . 49.8 p30 -60.16 -31.94 70.58 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 108.107 -1.071 . . . . 0.0 108.107 178.929 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 296' ' ' ASN . . . . . 0.679 ' N ' ' OD1' ' A' ' 295' ' ' ASP . 0.4 OUTLIER 58.99 44.98 15.54 Favored 'General case' 0 N--CA 1.45 -0.467 0 CA-C-N 115.277 -0.874 . . . . 0.0 109.804 179.63 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 297' ' ' ILE . . . . . 0.781 HG22 ' N ' ' A' ' 298' ' ' LYS . 84.4 mt 36.57 -118.09 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.439 -0.801 . . . . 0.0 110.634 -178.696 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 298' ' ' LYS . . . . . 0.781 ' N ' HG22 ' A' ' 297' ' ' ILE . 83.6 tttt -158.09 -95.86 0.03 OUTLIER 'General case' 0 CA--C 1.538 0.481 0 C-N-CA 119.948 -0.701 . . . . 0.0 111.564 179.499 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 76.3 m80 73.87 88.58 0.09 Allowed 'General case' 0 N--CA 1.476 0.871 0 N-CA-C 113.176 0.806 . . . . 0.0 113.176 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . . . . . . . . . 3.1 m -124.01 77.87 58.78 Favored Pre-proline 0 CA--C 1.537 0.477 0 CA-C-N 115.408 -0.814 . . . . 0.0 109.582 179.125 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 301' ' ' PRO . . . . . 0.664 ' O ' HG23 ' A' ' 306' ' ' VAL . 8.1 Cg_exo -56.51 -24.49 53.42 Favored 'Trans proline' 0 N--CA 1.494 1.529 0 C-N-CA 121.694 1.596 . . . . 0.0 113.1 -178.285 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -73.02 17.54 1.68 Allowed Glycine 0 N--CA 1.463 0.452 0 N-CA-C 109.238 -1.545 . . . . 0.0 109.238 178.338 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 303' ' ' GLY . . . . . 0.622 ' H ' ' C ' ' A' ' 301' ' ' PRO . . . -56.04 -23.58 39.77 Favored Glycine 0 CA--C 1.516 0.147 0 CA-C-N 114.311 -0.944 . . . . 0.0 110.971 -179.814 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 98.1 -4.36 60.69 Favored Glycine 0 CA--C 1.505 -0.59 0 N-CA-C 104.349 -3.5 . . . . 0.0 104.349 -174.776 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 85.2 p -64.69 -20.72 66.48 Favored 'General case' 0 N--CA 1.428 -1.541 0 CA-C-N 111.331 -2.435 . . . . 0.0 106.139 175.649 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 306' ' ' VAL . . . . . 0.664 HG23 ' O ' ' A' ' 301' ' ' PRO . 80.8 t -57.48 -42.09 80.16 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 CA-C-N 113.259 -1.791 . . . . 0.0 110.9 -177.375 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 307' ' ' GLN . . . . . 0.586 ' CB ' ' O ' ' A' ' 306' ' ' VAL . 57.2 tt0 103.92 160.48 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.484 0 O-C-N 124.378 1.049 . . . . 0.0 109.019 179.72 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 308' ' ' ILE . . . . . 0.865 HG22 ' H ' ' A' ' 310' ' ' TYR . 70.2 mt -114.98 129.0 71.91 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.46 0 CA-C-O 121.43 0.634 . . . . 0.0 110.738 178.53 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . . . . . . . . . 1.5 t -86.56 8.63 1.95 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.558 0 CA-C-N 114.648 -1.16 . . . . 0.0 111.763 179.296 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 310' ' ' TYR . . . . . 0.865 ' H ' HG22 ' A' ' 308' ' ' ILE . 0.0 OUTLIER -54.27 -32.43 56.21 Favored 'General case' 0 CA--C 1.544 0.733 0 N-CA-C 113.886 1.069 . . . . 0.0 113.886 -174.962 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 311' ' ' LYS . . . . . 0.53 ' N ' ' CD ' ' A' ' 312' ' ' PRO . 12.1 mmmt 57.33 68.16 2.14 Favored Pre-proline 0 N--CA 1.475 0.798 0 CA-C-N 119.732 1.151 . . . . 0.0 112.019 177.345 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 312' ' ' PRO . . . . . 0.594 ' O ' ' N ' ' A' ' 314' ' ' ASP . 86.6 Cg_exo -54.78 148.55 45.22 Favored 'Trans proline' 0 C--N 1.304 -1.808 0 C-N-CA 124.978 3.785 . . . . 0.0 114.761 -179.067 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 313' ' ' VAL . . . . . . . . . . . . . 17.8 m 38.82 12.28 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 CA-C-N 114.313 -1.312 . . . . 0.0 113.093 -179.337 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 314' ' ' ASP . . . . . 0.594 ' N ' ' O ' ' A' ' 312' ' ' PRO . 20.9 t70 -55.11 -36.64 65.91 Favored 'General case' 0 C--N 1.319 -0.734 0 C-N-CA 120.237 -0.585 . . . . 0.0 109.557 179.126 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 315' ' ' LEU . . . . . 0.62 ' CD2' ' N ' ' A' ' 315' ' ' LEU . 0.2 OUTLIER -61.12 -35.24 76.53 Favored 'General case' 0 CA--C 1.541 0.615 0 CA-C-N 116.277 -0.419 . . . . 0.0 111.027 179.4 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . . . . . . . . . 79.6 p -62.4 -25.93 68.21 Favored 'General case' 0 N--CA 1.471 0.579 0 CA-C-O 121.643 0.735 . . . . 0.0 110.862 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 317' ' ' LYS . . . . . . . . . . . . . 62.6 mmtt -58.04 -26.29 62.27 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 114.49 -1.232 . . . . 0.0 113.598 -178.432 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 11.6 p -110.22 138.6 37.32 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 CA-C-O 122.142 0.972 . . . . 0.0 111.061 -176.41 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 3.6 m . . . . . 0 C--O 1.219 -0.526 0 CA-C-N 113.335 -1.757 . . . . 0.0 110.203 -178.14 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 292' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.524 0.642 0 N-CA-C 111.05 -0.82 . . . . 0.0 111.05 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 293' ' ' SER . . . . . . . . . . . . . 98.6 p -120.25 152.75 37.31 Favored 'General case' 0 N--CA 1.462 0.173 0 CA-C-O 120.911 0.386 . . . . 0.0 110.215 179.654 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 294' ' ' LYS . . . . . 0.459 ' HD2' ' N ' ' A' ' 294' ' ' LYS . 1.0 OUTLIER -85.4 -74.06 0.42 Allowed 'General case' 0 CA--C 1.512 -0.504 0 CA-C-O 121.701 0.762 . . . . 0.0 112.101 -179.296 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 295' ' ' ASP . . . . . 0.47 ' OD1' HD11 ' A' ' 297' ' ' ILE . 50.6 p30 -89.58 6.94 38.92 Favored 'General case' 0 N--CA 1.442 -0.869 0 CA-C-N 114.427 -1.261 . . . . 0.0 109.468 179.879 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 296' ' ' ASN . . . . . . . . . . . . . 17.3 t-20 58.97 53.53 5.58 Favored 'General case' 0 N--CA 1.473 0.675 0 N-CA-C 114.531 1.308 . . . . 0.0 114.531 176.587 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 297' ' ' ILE . . . . . 0.47 HD11 ' OD1' ' A' ' 295' ' ' ASP . 15.7 mm -73.4 140.94 16.96 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.653 0 C-N-CA 119.524 -0.87 . . . . 0.0 110.172 -179.617 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 298' ' ' LYS . . . . . 0.516 ' NZ ' HG13 ' A' ' 300' ' ' VAL . 14.0 ptmm? -125.22 154.26 41.89 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 114.682 -1.145 . . . . 0.0 111.62 -178.002 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 299' ' ' HIS . . . . . . . . . . . . . 56.6 t-80 -124.36 129.6 50.99 Favored 'General case' 0 CA--C 1.536 0.409 0 N-CA-C 109.027 -0.731 . . . . 0.0 109.027 178.265 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 300' ' ' VAL . . . . . 0.516 HG13 ' NZ ' ' A' ' 298' ' ' LYS . 0.2 OUTLIER -124.14 77.35 59.95 Favored Pre-proline 0 N--CA 1.474 0.763 0 N-CA-C 112.406 0.521 . . . . 0.0 112.406 -179.147 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 301' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -59.01 -27.63 85.57 Favored 'Trans proline' 0 C--N 1.312 -1.373 0 N-CA-C 109.885 -0.852 . . . . 0.0 109.885 177.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 302' ' ' GLY . . . . . . . . . . . . . . . -121.66 106.32 1.08 Allowed Glycine 0 CA--C 1.523 0.568 0 CA-C-N 115.039 -0.982 . . . . 0.0 110.788 179.302 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 303' ' ' GLY . . . . . . . . . . . . . . . -141.56 33.38 1.98 Allowed Glycine 0 CA--C 1.523 0.579 0 N-CA-C 109.905 -1.278 . . . . 0.0 109.905 179.23 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 304' ' ' GLY . . . . . . . . . . . . . . . 95.2 -0.43 63.96 Favored Glycine 0 CA--C 1.521 0.426 0 N-CA-C 107.963 -2.055 . . . . 0.0 107.963 -177.891 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 305' ' ' SER . . . . . . . . . . . . . 52.0 p -82.78 -0.14 46.42 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 113.896 -1.152 . . . . 0.0 109.541 178.547 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 306' ' ' VAL . . . . . 0.514 ' O ' ' CB ' ' A' ' 307' ' ' GLN . 92.3 t -58.27 -39.19 72.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.509 -0.769 . . . . 0.0 110.127 -177.633 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 307' ' ' GLN . . . . . 0.627 ' HG2' HG23 ' A' ' 308' ' ' ILE . 57.9 tt0 94.07 139.74 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.727 0 N-CA-C 114.602 1.334 . . . . 0.0 114.602 177.816 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 308' ' ' ILE . . . . . 0.627 HG23 ' HG2' ' A' ' 307' ' ' GLN . 0.8 OUTLIER 16.23 36.76 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.543 0 CA-C-N 112.723 -2.035 . . . . 0.0 115.397 177.99 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 309' ' ' VAL . . . . . 0.614 ' N ' ' O ' ' A' ' 307' ' ' GLN . 62.9 t -55.54 -37.45 45.65 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 N-CA-C 107.943 -1.132 . . . . 0.0 107.943 179.425 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 310' ' ' TYR . . . . . 0.488 ' CE1' ' HD3' ' A' ' 312' ' ' PRO . 33.6 p90 -60.3 -28.04 67.79 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 114.226 1.195 . . . . 0.0 114.226 -179.789 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 311' ' ' LYS . . . . . . . . . . . . . 2.3 tmtp? 68.97 74.32 0.29 Allowed Pre-proline 0 N--CA 1.474 0.75 0 CA-C-N 119.337 0.971 . . . . 0.0 110.512 178.313 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 312' ' ' PRO . . . . . 0.488 ' HD3' ' CE1' ' A' ' 310' ' ' TYR . 13.4 Cg_exo -54.83 -31.07 70.95 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 C-N-CA 122.59 2.193 . . . . 0.0 114.803 -177.014 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 313' ' ' VAL . . . . . 0.641 HG13 ' HB2' ' A' ' 316' ' ' SER . 39.2 t -124.26 134.81 65.63 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.525 0 C-N-CA 120.184 -0.606 . . . . 0.0 111.308 179.765 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 314' ' ' ASP . . . . . 0.499 ' HB3' HD22 ' A' ' 315' ' ' LEU . 61.2 t0 -149.12 -89.42 0.08 Allowed 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.516 -0.765 . . . . 0.0 109.061 178.928 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 315' ' ' LEU . . . . . 0.911 HD22 ' H ' ' A' ' 315' ' ' LEU . 2.0 mm? -59.61 -31.09 69.16 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.065 178.041 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 316' ' ' SER . . . . . 0.641 ' HB2' HG13 ' A' ' 313' ' ' VAL . 25.2 m -55.29 -33.17 63.03 Favored 'General case' 0 N--CA 1.455 -0.197 0 CA-C-N 116.433 -0.349 . . . . 0.0 111.133 -178.025 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 317' ' ' LYS . . . . . 0.581 ' HG3' HG12 ' A' ' 313' ' ' VAL . 65.4 mttm -57.82 -34.1 69.3 Favored 'General case' 0 C--N 1.326 -0.435 0 C-N-CA 120.461 -0.496 . . . . 0.0 110.44 -179.923 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 42.1 t -115.77 135.8 54.71 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-O 120.825 0.345 . . . . 0.0 110.983 -179.449 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 319' ' ' THR . . . . . . . . . . . . . 37.4 p . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.333 179.684 . . . . . . . . 0 0 . 1 stop_ save_